#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Prefrontal cortical responses in children with prenatal alcohol-related neurodevelopmental impairment: A functional near-infrared spectroscopy study
#Text=Objective
#Text=Disruption in the neural activation of the prefrontal cortex (PFC) in modulating arousal was explored in children with heavy prenatal alcohol exposure (PAE), who have known neurobehavioral impairment.
1-1	0-10	Prefrontal	_	
1-2	11-19	cortical	_	
1-3	20-29	responses	_	
1-4	30-32	in	_	
1-5	33-41	children	_	
1-6	42-46	with	_	
1-7	47-55	prenatal	_	
1-8	56-71	alcohol-related	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[1]	
1-9	72-90	neurodevelopmental	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[1]	
1-10	91-101	impairment	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[1]	
1-11	101-102	:	_	
1-12	103-104	A	_	
1-13	105-115	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
1-14	116-129	near-infrared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
1-15	130-142	spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
1-16	143-148	study	_	
1-17	149-158	Objective	_	
1-18	159-169	Disruption	_	
1-19	170-172	in	_	
1-20	173-176	the	_	
1-21	177-183	neural	_	
1-22	184-194	activation	_	
1-23	195-197	of	_	
1-24	198-201	the	_	
1-25	202-212	prefrontal	_	
1-26	213-219	cortex	_	
1-27	220-221	(	_	
1-28	221-224	PFC	_	
1-29	224-225	)	_	
1-30	226-228	in	_	
1-31	229-239	modulating	_	
1-32	240-247	arousal	_	
1-33	248-251	was	_	
1-34	252-260	explored	_	
1-35	261-263	in	_	
1-36	264-272	children	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-37	273-277	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-38	278-283	heavy	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-39	284-292	prenatal	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-40	293-300	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-41	301-309	exposure	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-42	310-311	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-43	311-314	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-44	314-315	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-45	315-316	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-46	317-320	who	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-47	321-325	have	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-48	326-331	known	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-49	332-347	neurobehavioral	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-50	348-358	impairment	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	
1-51	358-359	.	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[3]	

#Text=Methods
#Text=During a task that elicits frustration, functional near-infrared spectroscopy (fNIRS) was used to measure PFC activation, specifically levels of oxygenated (HBO) and deoxygenated (HBR) hemoglobin, in children with PAE (n=18) relative to typically developing Controls (n=12) and a Clinical Contrast group with other neurodevelopmental or behavioral problems (n=14).
2-1	360-367	Methods	_	
2-2	368-374	During	_	
2-3	375-376	a	_	
2-4	377-381	task	_	
2-5	382-386	that	_	
2-6	387-394	elicits	_	
2-7	395-406	frustration	_	
2-8	406-407	,	_	
2-9	408-418	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[4]	
2-10	419-432	near-infrared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[4]	
2-11	433-445	spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[4]	
2-12	446-447	(	_	
2-13	447-452	fNIRS	_	
2-14	452-453	)	_	
2-15	454-457	was	_	
2-16	458-462	used	_	
2-17	463-465	to	_	
2-18	466-473	measure	_	
2-19	474-477	PFC	_	
2-20	478-488	activation	_	
2-21	488-489	,	_	
2-22	490-502	specifically	_	
2-23	503-509	levels	_	
2-24	510-512	of	_	
2-25	513-523	oxygenated	_	
2-26	524-525	(	_	
2-27	525-528	HBO	_	
2-28	528-529	)	_	
2-29	530-533	and	_	
2-30	534-546	deoxygenated	_	
2-31	547-548	(	_	
2-32	548-551	HBR	_	
2-33	551-552	)	_	
2-34	553-563	hemoglobin	_	
2-35	563-564	,	_	
2-36	565-567	in	_	
2-37	568-576	children	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[5]	
2-38	577-581	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[5]	
2-39	582-585	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[5]	
2-40	586-587	(	_	
2-41	587-588	n	_	
2-42	588-589	=	_	
2-43	589-591	18	_	
2-44	591-592	)	_	
2-45	593-601	relative	_	
2-46	602-604	to	_	
2-47	605-614	typically	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
2-48	615-625	developing	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
2-49	626-634	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
2-50	635-636	(	_	
2-51	636-637	n	_	
2-52	637-638	=	_	
2-53	638-640	12	_	
2-54	640-641	)	_	
2-55	642-645	and	_	
2-56	646-647	a	_	
2-57	648-656	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-58	657-665	Contrast	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-59	666-671	group	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-60	672-676	with	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-61	677-682	other	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-62	683-701	neurodevelopmental	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-63	702-704	or	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-64	705-715	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-65	716-724	problems	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[7]	
2-66	725-726	(	_	
2-67	726-727	n	_	
2-68	727-728	=	_	
2-69	728-730	14	_	
2-70	730-731	)	_	
2-71	731-732	.	_	

#Text=Results
#Text=Children with PAE had less activation during conditions with positive emotional arousal, as indicated by lower levels of HBO in the medial areas of the PFC and higher levels of HBR in all areas of the PFC sampled relative to both other groups.
3-1	733-740	Results	_	
3-2	741-749	Children	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[8]	
3-3	750-754	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[8]	
3-4	755-758	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[8]	
3-5	759-762	had	_	
3-6	763-767	less	_	
3-7	768-778	activation	_	
3-8	779-785	during	_	
3-9	786-796	conditions	_	
3-10	797-801	with	_	
3-11	802-810	positive	_	
3-12	811-820	emotional	_	
3-13	821-828	arousal	_	
3-14	828-829	,	_	
3-15	830-832	as	_	
3-16	833-842	indicated	_	
3-17	843-845	by	_	
3-18	846-851	lower	_	
3-19	852-858	levels	_	
3-20	859-861	of	_	
3-21	862-865	HBO	_	
3-22	866-868	in	_	
3-23	869-872	the	_	
3-24	873-879	medial	_	
3-25	880-885	areas	_	
3-26	886-888	of	_	
3-27	889-892	the	_	
3-28	893-896	PFC	_	
3-29	897-900	and	_	
3-30	901-907	higher	_	
3-31	908-914	levels	_	
3-32	915-917	of	_	
3-33	918-921	HBR	_	
3-34	922-924	in	_	
3-35	925-928	all	_	
3-36	929-934	areas	_	
3-37	935-937	of	_	
3-38	938-941	the	_	
3-39	942-945	PFC	_	
3-40	946-953	sampled	_	
3-41	954-962	relative	_	
3-42	963-965	to	_	
3-43	966-970	both	_	
3-44	971-976	other	_	
3-45	977-983	groups	_	
3-46	983-984	.	_	

#Text=Children in the Control group demonstrated greater differentiation of PFC activity than did children with PAE.
4-1	985-993	Children	_	
4-2	994-996	in	_	
4-3	997-1000	the	_	
4-4	1001-1008	Control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
4-5	1009-1014	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
4-6	1015-1027	demonstrated	_	
4-7	1028-1035	greater	_	
4-8	1036-1051	differentiation	_	
4-9	1052-1054	of	_	
4-10	1055-1058	PFC	_	
4-11	1059-1067	activity	_	
4-12	1068-1072	than	_	
4-13	1073-1076	did	_	
4-14	1077-1085	children	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[10]	
4-15	1086-1090	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[10]	
4-16	1091-1094	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[10]	
4-17	1094-1095	.	_	

#Text=Children in the Clinical Contrast group demonstrated the greatest differences in PFC activity between valences of task conditions.
5-1	1096-1104	Children	_	
5-2	1105-1107	in	_	
5-3	1108-1111	the	_	
5-4	1112-1120	Clinical	_	
5-5	1121-1129	Contrast	_	
5-6	1130-1135	group	_	
5-7	1136-1148	demonstrated	_	
5-8	1149-1152	the	_	
5-9	1153-1161	greatest	_	
5-10	1162-1173	differences	_	
5-11	1174-1176	in	_	
5-12	1177-1180	PFC	_	
5-13	1181-1189	activity	_	
5-14	1190-1197	between	_	
5-15	1198-1206	valences	_	
5-16	1207-1209	of	_	
5-17	1210-1214	task	_	
5-18	1215-1225	conditions	_	
5-19	1225-1226	.	_	

#Text=Conclusions: Specific patterns of PFC activation differentiated children with PAE from typically developing children and children with other clinical problems.
6-1	1227-1238	Conclusions	_	
6-2	1238-1239	:	_	
6-3	1240-1248	Specific	_	
6-4	1249-1257	patterns	_	
6-5	1258-1260	of	_	
6-6	1261-1264	PFC	_	
6-7	1265-1275	activation	_	
6-8	1276-1290	differentiated	_	
6-9	1291-1299	children	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[11]	
6-10	1300-1304	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[11]	
6-11	1305-1308	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[11]	
6-12	1309-1313	from	_	
6-13	1314-1323	typically	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-14	1324-1334	developing	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-15	1335-1343	children	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-16	1344-1347	and	_	
6-17	1348-1356	children	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[13]	
6-18	1357-1361	with	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[13]	
6-19	1362-1367	other	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[13]	
6-20	1368-1376	clinical	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[13]	
6-21	1377-1385	problems	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[13]	
6-22	1385-1386	.	_	

#Text=Significance
#Text=FNIRS assessments of PFC activity provide new insights regarding the mechanisms of commonly seen neurobehavioral dysfunction in children with PAE.
#Text=1.
7-1	1387-1399	Significance	_	
7-2	1400-1405	FNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
7-3	1406-1417	assessments	_	
7-4	1418-1420	of	_	
7-5	1421-1424	PFC	_	
7-6	1425-1433	activity	_	
7-7	1434-1441	provide	_	
7-8	1442-1445	new	_	
7-9	1446-1454	insights	_	
7-10	1455-1464	regarding	_	
7-11	1465-1468	the	_	
7-12	1469-1479	mechanisms	_	
7-13	1480-1482	of	_	
7-14	1483-1491	commonly	_	
7-15	1492-1496	seen	_	
7-16	1497-1512	neurobehavioral	_	
7-17	1513-1524	dysfunction	_	
7-18	1525-1527	in	_	
7-19	1528-1536	children	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[14]	
7-20	1537-1541	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[14]	
7-21	1542-1545	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[14]	
7-22	1545-1546	.	_	
7-23	1547-1548	1	_	
7-24	1548-1549	.	_	

#Text=Introduction
#Text=Fetal Alcohol Spectrum Disorders (FASDS) is a term that refers to a cluster of physical and neurobehavioral abnormalities, including facial dysmorphology, growth retardation, and disruption to brain development, that have been investigated for over four decades in human and animal model studies of prenatal alcohol exposure (PAE).
8-1	1550-1562	Introduction	_	
8-2	1563-1568	Fetal	_	
8-3	1569-1576	Alcohol	_	
8-4	1577-1585	Spectrum	_	
8-5	1586-1595	Disorders	_	
8-6	1596-1597	(	_	
8-7	1597-1602	FASDS	_	
8-8	1602-1603	)	_	
8-9	1604-1606	is	_	
8-10	1607-1608	a	_	
8-11	1609-1613	term	_	
8-12	1614-1618	that	_	
8-13	1619-1625	refers	_	
8-14	1626-1628	to	_	
8-15	1629-1630	a	_	
8-16	1631-1638	cluster	_	
8-17	1639-1641	of	_	
8-18	1642-1650	physical	_	
8-19	1651-1654	and	_	
8-20	1655-1670	neurobehavioral	_	
8-21	1671-1684	abnormalities	_	
8-22	1684-1685	,	_	
8-23	1686-1695	including	_	
8-24	1696-1702	facial	_	
8-25	1703-1716	dysmorphology	_	
8-26	1716-1717	,	_	
8-27	1718-1724	growth	_	
8-28	1725-1736	retardation	_	
8-29	1736-1737	,	_	
8-30	1738-1741	and	_	
8-31	1742-1752	disruption	_	
8-32	1753-1755	to	_	
8-33	1756-1761	brain	_	
8-34	1762-1773	development	_	
8-35	1773-1774	,	_	
8-36	1775-1779	that	_	
8-37	1780-1784	have	_	
8-38	1785-1789	been	_	
8-39	1790-1802	investigated	_	
8-40	1803-1806	for	_	
8-41	1807-1811	over	_	
8-42	1812-1816	four	_	
8-43	1817-1824	decades	_	
8-44	1825-1827	in	_	
8-45	1828-1833	human	_	
8-46	1834-1837	and	_	
8-47	1838-1844	animal	_	
8-48	1845-1850	model	_	
8-49	1851-1858	studies	_	
8-50	1859-1861	of	_	
8-51	1862-1870	prenatal	_	
8-52	1871-1878	alcohol	_	
8-53	1879-1887	exposure	_	
8-54	1888-1889	(	_	
8-55	1889-1892	PAE	_	
8-56	1892-1893	)	_	
8-57	1893-1894	.	_	

#Text=Although public health awareness and prevention efforts have increased as a result of these findings, recent estimates of the prevalence of Fetal Alcohol Syndrome (FAS), the most severe FASD condition, have ranged from .6 to .9 percent of live births with the full range of FASDs estimated to fall between 2.4 to 4.8 percent.
9-1	1895-1903	Although	_	
9-2	1904-1910	public	_	
9-3	1911-1917	health	_	
9-4	1918-1927	awareness	_	
9-5	1928-1931	and	_	
9-6	1932-1942	prevention	_	
9-7	1943-1950	efforts	_	
9-8	1951-1955	have	_	
9-9	1956-1965	increased	_	
9-10	1966-1968	as	_	
9-11	1969-1970	a	_	
9-12	1971-1977	result	_	
9-13	1978-1980	of	_	
9-14	1981-1986	these	_	
9-15	1987-1995	findings	_	
9-16	1995-1996	,	_	
9-17	1997-2003	recent	_	
9-18	2004-2013	estimates	_	
9-19	2014-2016	of	_	
9-20	2017-2020	the	_	
9-21	2021-2031	prevalence	_	
9-22	2032-2034	of	_	
9-23	2035-2040	Fetal	_	
9-24	2041-2048	Alcohol	_	
9-25	2049-2057	Syndrome	_	
9-26	2058-2059	(	_	
9-27	2059-2062	FAS	_	
9-28	2062-2063	)	_	
9-29	2063-2064	,	_	
9-30	2065-2068	the	_	
9-31	2069-2073	most	_	
9-32	2074-2080	severe	_	
9-33	2081-2085	FASD	_	
9-34	2086-2095	condition	_	
9-35	2095-2096	,	_	
9-36	2097-2101	have	_	
9-37	2102-2108	ranged	_	
9-38	2109-2113	from	_	
9-39	2114-2116	.6	_	
9-40	2117-2119	to	_	
9-41	2120-2122	.9	_	
9-42	2123-2130	percent	_	
9-43	2131-2133	of	_	
9-44	2134-2138	live	_	
9-45	2139-2145	births	_	
9-46	2146-2150	with	_	
9-47	2151-2154	the	_	
9-48	2155-2159	full	_	
9-49	2160-2165	range	_	
9-50	2166-2168	of	_	
9-51	2169-2174	FASDs	_	
9-52	2175-2184	estimated	_	
9-53	2185-2187	to	_	
9-54	2188-2192	fall	_	
9-55	2193-2200	between	_	
9-56	2201-2204	2.4	_	
9-57	2205-2207	to	_	
9-58	2208-2211	4.8	_	
9-59	2212-2219	percent	_	
9-60	2219-2220	.	_	

#Text=Despite the fairly high prevalence rates, most children with FASDs are misdiagnosed.
10-1	2221-2228	Despite	_	
10-2	2229-2232	the	_	
10-3	2233-2239	fairly	_	
10-4	2240-2244	high	_	
10-5	2245-2255	prevalence	_	
10-6	2256-2261	rates	_	
10-7	2261-2262	,	_	
10-8	2263-2267	most	_	
10-9	2268-2276	children	_	
10-10	2277-2281	with	_	
10-11	2282-2287	FASDs	_	
10-12	2288-2291	are	_	
10-13	2292-2304	misdiagnosed	_	
10-14	2304-2305	.	_	

#Text=Improved methods of identifying alcohol-affected children are needed, including the development of biomarkers of the neural damage caused by PAE.
11-1	2306-2314	Improved	_	
11-2	2315-2322	methods	_	
11-3	2323-2325	of	_	
11-4	2326-2337	identifying	_	
11-5	2338-2354	alcohol-affected	_	
11-6	2355-2363	children	_	
11-7	2364-2367	are	_	
11-8	2368-2374	needed	_	
11-9	2374-2375	,	_	
11-10	2376-2385	including	_	
11-11	2386-2389	the	_	
11-12	2390-2401	development	_	
11-13	2402-2404	of	_	
11-14	2405-2415	biomarkers	_	
11-15	2416-2418	of	_	
11-16	2419-2422	the	_	
11-17	2423-2429	neural	_	
11-18	2430-2436	damage	_	
11-19	2437-2443	caused	_	
11-20	2444-2446	by	_	
11-21	2447-2450	PAE	_	
11-22	2450-2451	.	_	

#Text=Although much attention was initially devoted to understanding the deficits in general cognitive functioning associated with a history of PAE, many individuals who are exposed do not meet criteria for an intellectual disability but still demonstrate a complex array of neurobehavioral problems.
12-1	2452-2460	Although	_	
12-2	2461-2465	much	_	
12-3	2466-2475	attention	_	
12-4	2476-2479	was	_	
12-5	2480-2489	initially	_	
12-6	2490-2497	devoted	_	
12-7	2498-2500	to	_	
12-8	2501-2514	understanding	_	
12-9	2515-2518	the	_	
12-10	2519-2527	deficits	_	
12-11	2528-2530	in	_	
12-12	2531-2538	general	_	
12-13	2539-2548	cognitive	_	
12-14	2549-2560	functioning	_	
12-15	2561-2571	associated	_	
12-16	2572-2576	with	_	
12-17	2577-2578	a	_	
12-18	2579-2586	history	_	
12-19	2587-2589	of	_	
12-20	2590-2593	PAE	_	
12-21	2593-2594	,	_	
12-22	2595-2599	many	_	
12-23	2600-2611	individuals	_	
12-24	2612-2615	who	_	
12-25	2616-2619	are	_	
12-26	2620-2627	exposed	_	
12-27	2628-2630	do	_	
12-28	2631-2634	not	_	
12-29	2635-2639	meet	_	
12-30	2640-2648	criteria	_	
12-31	2649-2652	for	_	
12-32	2653-2655	an	_	
12-33	2656-2668	intellectual	_	
12-34	2669-2679	disability	_	
12-35	2680-2683	but	_	
12-36	2684-2689	still	_	
12-37	2690-2701	demonstrate	_	
12-38	2702-2703	a	_	
12-39	2704-2711	complex	_	
12-40	2712-2717	array	_	
12-41	2718-2720	of	_	
12-42	2721-2736	neurobehavioral	_	
12-43	2737-2745	problems	_	
12-44	2745-2746	.	_	

#Text=Among the most significant problems are the persistent and wide-ranging difficulties in a set of cognitive skills known as executive functions (EF), particularly in planning, organization, and problem-solving.
13-1	2747-2752	Among	_	
13-2	2753-2756	the	_	
13-3	2757-2761	most	_	
13-4	2762-2773	significant	_	
13-5	2774-2782	problems	_	
13-6	2783-2786	are	_	
13-7	2787-2790	the	_	
13-8	2791-2801	persistent	_	
13-9	2802-2805	and	_	
13-10	2806-2818	wide-ranging	_	
13-11	2819-2831	difficulties	_	
13-12	2832-2834	in	_	
13-13	2835-2836	a	_	
13-14	2837-2840	set	_	
13-15	2841-2843	of	_	
13-16	2844-2853	cognitive	_	
13-17	2854-2860	skills	_	
13-18	2861-2866	known	_	
13-19	2867-2869	as	_	
13-20	2870-2879	executive	_	
13-21	2880-2889	functions	_	
13-22	2890-2891	(	_	
13-23	2891-2893	EF	_	
13-24	2893-2894	)	_	
13-25	2894-2895	,	_	
13-26	2896-2908	particularly	_	
13-27	2909-2911	in	_	
13-28	2912-2920	planning	_	
13-29	2920-2921	,	_	
13-30	2922-2934	organization	_	
13-31	2934-2935	,	_	
13-32	2936-2939	and	_	
13-33	2940-2955	problem-solving	_	
13-34	2955-2956	.	_	

#Text=Evidence from the Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) neurobehavioral study of children, 8 to 17 years, indicated that assessment of executive functioning differentiated individuals with FASD from other clinical groups (i.e.
14-1	2957-2965	Evidence	_	
14-2	2966-2970	from	_	
14-3	2971-2974	the	_	
14-4	2975-2988	Collaborative	_	
14-5	2989-2999	Initiative	_	
14-6	3000-3002	on	_	
14-7	3003-3008	Fetal	_	
14-8	3009-3016	Alcohol	_	
14-9	3017-3025	Spectrum	_	
14-10	3026-3035	Disorders	_	
14-11	3036-3037	(	_	
14-12	3037-3043	CIFASD	_	
14-13	3043-3044	)	_	
14-14	3045-3060	neurobehavioral	_	
14-15	3061-3066	study	_	
14-16	3067-3069	of	_	
14-17	3070-3078	children	_	
14-18	3078-3079	,	_	
14-19	3080-3081	8	_	
14-20	3082-3084	to	_	
14-21	3085-3087	17	_	
14-22	3088-3093	years	_	
14-23	3093-3094	,	_	
14-24	3095-3104	indicated	_	
14-25	3105-3109	that	_	
14-26	3110-3120	assessment	_	
14-27	3121-3123	of	_	
14-28	3124-3133	executive	_	
14-29	3134-3145	functioning	_	
14-30	3146-3160	differentiated	_	
14-31	3161-3172	individuals	_	
14-32	3173-3177	with	_	
14-33	3178-3182	FASD	_	
14-34	3183-3187	from	_	
14-35	3188-3193	other	_	
14-36	3194-3202	clinical	_	
14-37	3203-3209	groups	_	
14-38	3210-3211	(	_	
14-39	3211-3214	i.e	_	
14-40	3214-3215	.	_	

#Text=ADHD).
15-1	3216-3220	ADHD	_	
15-2	3220-3221	)	_	
15-3	3221-3222	.	_	

#Text=EF problems are expressed in multiple ways in everyday functioning of children with FASD.
16-1	3223-3225	EF	_	
16-2	3226-3234	problems	_	
16-3	3235-3238	are	_	
16-4	3239-3248	expressed	_	
16-5	3249-3251	in	_	
16-6	3252-3260	multiple	_	
16-7	3261-3265	ways	_	
16-8	3266-3268	in	_	
16-9	3269-3277	everyday	_	
16-10	3278-3289	functioning	_	
16-11	3290-3292	of	_	
16-12	3293-3301	children	_	
16-13	3302-3306	with	_	
16-14	3307-3311	FASD	_	
16-15	3311-3312	.	_	

#Text=Difficulties with incorporating environmental feedback to correct a response are suggested by deficits in overall performance on progressive planning tasks and by more repetition errors on learning tasks.
17-1	3313-3325	Difficulties	_	
17-2	3326-3330	with	_	
17-3	3331-3344	incorporating	_	
17-4	3345-3358	environmental	_	
17-5	3359-3367	feedback	_	
17-6	3368-3370	to	_	
17-7	3371-3378	correct	_	
17-8	3379-3380	a	_	
17-9	3381-3389	response	_	
17-10	3390-3393	are	_	
17-11	3394-3403	suggested	_	
17-12	3404-3406	by	_	
17-13	3407-3415	deficits	_	
17-14	3416-3418	in	_	
17-15	3419-3426	overall	_	
17-16	3427-3438	performance	_	
17-17	3439-3441	on	_	
17-18	3442-3453	progressive	_	
17-19	3454-3462	planning	_	
17-20	3463-3468	tasks	_	
17-21	3469-3472	and	_	
17-22	3473-3475	by	_	
17-23	3476-3480	more	_	
17-24	3481-3491	repetition	_	
17-25	3492-3498	errors	_	
17-26	3499-3501	on	_	
17-27	3502-3510	learning	_	
17-28	3511-3516	tasks	_	
17-29	3516-3517	.	_	

#Text=Making shifts in cognitive sets while learning has also been found to be impaired in individuals with PAE, specifically reversal shifts.
18-1	3518-3524	Making	_	
18-2	3525-3531	shifts	_	
18-3	3532-3534	in	_	
18-4	3535-3544	cognitive	_	
18-5	3545-3549	sets	_	
18-6	3550-3555	while	_	
18-7	3556-3564	learning	_	
18-8	3565-3568	has	_	
18-9	3569-3573	also	_	
18-10	3574-3578	been	_	
18-11	3579-3584	found	_	
18-12	3585-3587	to	_	
18-13	3588-3590	be	_	
18-14	3591-3599	impaired	_	
18-15	3600-3602	in	_	
18-16	3603-3614	individuals	_	
18-17	3615-3619	with	_	
18-18	3620-3623	PAE	_	
18-19	3623-3624	,	_	
18-20	3625-3637	specifically	_	
18-21	3638-3646	reversal	_	
18-22	3647-3653	shifts	_	
18-23	3653-3654	.	_	

#Text=Impairments in verbal fluency and working memory skills have also been reported.
19-1	3655-3666	Impairments	_	
19-2	3667-3669	in	_	
19-3	3670-3676	verbal	_	
19-4	3677-3684	fluency	_	
19-5	3685-3688	and	_	
19-6	3689-3696	working	_	
19-7	3697-3703	memory	_	
19-8	3704-3710	skills	_	
19-9	3711-3715	have	_	
19-10	3716-3720	also	_	
19-11	3721-3725	been	_	
19-12	3726-3734	reported	_	
19-13	3734-3735	.	_	

#Text=Children with PAE have been found to have problems in sustaining attention and the appropriate mental effort needed to complete tasks while inhibiting impulses.
20-1	3736-3744	Children	_	
20-2	3745-3749	with	_	
20-3	3750-3753	PAE	_	
20-4	3754-3758	have	_	
20-5	3759-3763	been	_	
20-6	3764-3769	found	_	
20-7	3770-3772	to	_	
20-8	3773-3777	have	_	
20-9	3778-3786	problems	_	
20-10	3787-3789	in	_	
20-11	3790-3800	sustaining	_	
20-12	3801-3810	attention	_	
20-13	3811-3814	and	_	
20-14	3815-3818	the	_	
20-15	3819-3830	appropriate	_	
20-16	3831-3837	mental	_	
20-17	3838-3844	effort	_	
20-18	3845-3851	needed	_	
20-19	3852-3854	to	_	
20-20	3855-3863	complete	_	
20-21	3864-3869	tasks	_	
20-22	3870-3875	while	_	
20-23	3876-3886	inhibiting	_	
20-24	3887-3895	impulses	_	
20-25	3895-3896	.	_	

#Text=Finally, behavioral and emotional control problems are commonly reported by caregivers of children with FASDs.
21-1	3897-3904	Finally	_	
21-2	3904-3905	,	_	
21-3	3906-3916	behavioral	_	
21-4	3917-3920	and	_	
21-5	3921-3930	emotional	_	
21-6	3931-3938	control	_	
21-7	3939-3947	problems	_	
21-8	3948-3951	are	_	
21-9	3952-3960	commonly	_	
21-10	3961-3969	reported	_	
21-11	3970-3972	by	_	
21-12	3973-3983	caregivers	_	
21-13	3984-3986	of	_	
21-14	3987-3995	children	_	
21-15	3996-4000	with	_	
21-16	4001-4006	FASDs	_	
21-17	4006-4007	.	_	

#Text=Evidence suggests that the prefrontal cortex (PFC) and the connectivity of the PFC to other brain regions is adversely impacted by PAE and may be the neural substrate from which the deficits in EF skills arise.
22-1	4008-4016	Evidence	_	
22-2	4017-4025	suggests	_	
22-3	4026-4030	that	_	
22-4	4031-4034	the	_	
22-5	4035-4045	prefrontal	_	
22-6	4046-4052	cortex	_	
22-7	4053-4054	(	_	
22-8	4054-4057	PFC	_	
22-9	4057-4058	)	_	
22-10	4059-4062	and	_	
22-11	4063-4066	the	_	
22-12	4067-4079	connectivity	_	
22-13	4080-4082	of	_	
22-14	4083-4086	the	_	
22-15	4087-4090	PFC	_	
22-16	4091-4093	to	_	
22-17	4094-4099	other	_	
22-18	4100-4105	brain	_	
22-19	4106-4113	regions	_	
22-20	4114-4116	is	_	
22-21	4117-4126	adversely	_	
22-22	4127-4135	impacted	_	
22-23	4136-4138	by	_	
22-24	4139-4142	PAE	_	
22-25	4143-4146	and	_	
22-26	4147-4150	may	_	
22-27	4151-4153	be	_	
22-28	4154-4157	the	_	
22-29	4158-4164	neural	_	
22-30	4165-4174	substrate	_	
22-31	4175-4179	from	_	
22-32	4180-4185	which	_	
22-33	4186-4189	the	_	
22-34	4190-4198	deficits	_	
22-35	4199-4201	in	_	
22-36	4202-4204	EF	_	
22-37	4205-4211	skills	_	
22-38	4212-4217	arise	_	
22-39	4217-4218	.	_	

#Text=Frontal lobe deficits are thought to underlie difficulties with response inhibition, poor behavioral regulation, and other EF skill deficits noted in alcohol-exposed individuals.
23-1	4219-4226	Frontal	_	
23-2	4227-4231	lobe	_	
23-3	4232-4240	deficits	_	
23-4	4241-4244	are	_	
23-5	4245-4252	thought	_	
23-6	4253-4255	to	_	
23-7	4256-4264	underlie	_	
23-8	4265-4277	difficulties	_	
23-9	4278-4282	with	_	
23-10	4283-4291	response	_	
23-11	4292-4302	inhibition	_	
23-12	4302-4303	,	_	
23-13	4304-4308	poor	_	
23-14	4309-4319	behavioral	_	
23-15	4320-4330	regulation	_	
23-16	4330-4331	,	_	
23-17	4332-4335	and	_	
23-18	4336-4341	other	_	
23-19	4342-4344	EF	_	
23-20	4345-4350	skill	_	
23-21	4351-4359	deficits	_	
23-22	4360-4365	noted	_	
23-23	4366-4368	in	_	
23-24	4369-4384	alcohol-exposed	_	
23-25	4385-4396	individuals	_	
23-26	4396-4397	.	_	

#Text=Further, deficits in both EF and social functioning have been related to the metabolic composition of the frontal lobes, leading many to theorize that disruption to PFC activity may also help to explain impairments in interpersonal relationships and social skills commonly seen among individuals affected by PAE.
24-1	4398-4405	Further	_	
24-2	4405-4406	,	_	
24-3	4407-4415	deficits	_	
24-4	4416-4418	in	_	
24-5	4419-4423	both	_	
24-6	4424-4426	EF	_	
24-7	4427-4430	and	_	
24-8	4431-4437	social	_	
24-9	4438-4449	functioning	_	
24-10	4450-4454	have	_	
24-11	4455-4459	been	_	
24-12	4460-4467	related	_	
24-13	4468-4470	to	_	
24-14	4471-4474	the	_	
24-15	4475-4484	metabolic	_	
24-16	4485-4496	composition	_	
24-17	4497-4499	of	_	
24-18	4500-4503	the	_	
24-19	4504-4511	frontal	_	
24-20	4512-4517	lobes	_	
24-21	4517-4518	,	_	
24-22	4519-4526	leading	_	
24-23	4527-4531	many	_	
24-24	4532-4534	to	_	
24-25	4535-4543	theorize	_	
24-26	4544-4548	that	_	
24-27	4549-4559	disruption	_	
24-28	4560-4562	to	_	
24-29	4563-4566	PFC	_	
24-30	4567-4575	activity	_	
24-31	4576-4579	may	_	
24-32	4580-4584	also	_	
24-33	4585-4589	help	_	
24-34	4590-4592	to	_	
24-35	4593-4600	explain	_	
24-36	4601-4612	impairments	_	
24-37	4613-4615	in	_	
24-38	4616-4629	interpersonal	_	
24-39	4630-4643	relationships	_	
24-40	4644-4647	and	_	
24-41	4648-4654	social	_	
24-42	4655-4661	skills	_	
24-43	4662-4670	commonly	_	
24-44	4671-4675	seen	_	
24-45	4676-4681	among	_	
24-46	4682-4693	individuals	_	
24-47	4694-4702	affected	_	
24-48	4703-4705	by	_	
24-49	4706-4709	PAE	_	
24-50	4709-4710	.	_	

#Text=Evidence suggests identification of EF skills and PFC activity that supports these skills may be effective in diagnosing individuals affected by PAE and in need of intervention services.
25-1	4711-4719	Evidence	_	
25-2	4720-4728	suggests	_	
25-3	4729-4743	identification	_	
25-4	4744-4746	of	_	
25-5	4747-4749	EF	_	
25-6	4750-4756	skills	_	
25-7	4757-4760	and	_	
25-8	4761-4764	PFC	_	
25-9	4765-4773	activity	_	
25-10	4774-4778	that	_	
25-11	4779-4787	supports	_	
25-12	4788-4793	these	_	
25-13	4794-4800	skills	_	
25-14	4801-4804	may	_	
25-15	4805-4807	be	_	
25-16	4808-4817	effective	_	
25-17	4818-4820	in	_	
25-18	4821-4831	diagnosing	_	
25-19	4832-4843	individuals	_	
25-20	4844-4852	affected	_	
25-21	4853-4855	by	_	
25-22	4856-4859	PAE	_	
25-23	4860-4863	and	_	
25-24	4864-4866	in	_	
25-25	4867-4871	need	_	
25-26	4872-4874	of	_	
25-27	4875-4887	intervention	_	
25-28	4888-4896	services	_	
25-29	4896-4897	.	_	

#Text=An alternative to traditional neuroimaging methods (functional magnetic resonance imaging (fMRI) and positron emission tomography (PET)) is functional near-infrared spectroscopy (fNIRS), which has been used to assess local hemodynamic changes in PFC activity and has the advantage of reducing movement-artifact errors and anxiety, particularly in younger children, related to the equipment used with traditional neuroimaging assessments.
26-1	4898-4900	An	_	
26-2	4901-4912	alternative	_	
26-3	4913-4915	to	_	
26-4	4916-4927	traditional	_	
26-5	4928-4940	neuroimaging	_	
26-6	4941-4948	methods	_	
26-7	4949-4950	(	_	
26-8	4950-4960	functional	_	
26-9	4961-4969	magnetic	_	
26-10	4970-4979	resonance	_	
26-11	4980-4987	imaging	_	
26-12	4988-4989	(	_	
26-13	4989-4993	fMRI	_	
26-14	4993-4994	)	_	
26-15	4995-4998	and	_	
26-16	4999-5007	positron	_	
26-17	5008-5016	emission	_	
26-18	5017-5027	tomography	_	
26-19	5028-5029	(	_	
26-20	5029-5032	PET	_	
26-21	5032-5033	)	_	
26-22	5033-5034	)	_	
26-23	5035-5037	is	_	
26-24	5038-5048	functional	_	
26-25	5049-5062	near-infrared	_	
26-26	5063-5075	spectroscopy	_	
26-27	5076-5077	(	_	
26-28	5077-5082	fNIRS	_	
26-29	5082-5083	)	_	
26-30	5083-5084	,	_	
26-31	5085-5090	which	_	
26-32	5091-5094	has	_	
26-33	5095-5099	been	_	
26-34	5100-5104	used	_	
26-35	5105-5107	to	_	
26-36	5108-5114	assess	_	
26-37	5115-5120	local	_	
26-38	5121-5132	hemodynamic	_	
26-39	5133-5140	changes	_	
26-40	5141-5143	in	_	
26-41	5144-5147	PFC	_	
26-42	5148-5156	activity	_	
26-43	5157-5160	and	_	
26-44	5161-5164	has	_	
26-45	5165-5168	the	_	
26-46	5169-5178	advantage	_	
26-47	5179-5181	of	_	
26-48	5182-5190	reducing	_	
26-49	5191-5208	movement-artifact	_	
26-50	5209-5215	errors	_	
26-51	5216-5219	and	_	
26-52	5220-5227	anxiety	_	
26-53	5227-5228	,	_	
26-54	5229-5241	particularly	_	
26-55	5242-5244	in	_	
26-56	5245-5252	younger	_	
26-57	5253-5261	children	_	
26-58	5261-5262	,	_	
26-59	5263-5270	related	_	
26-60	5271-5273	to	_	
26-61	5274-5277	the	_	
26-62	5278-5287	equipment	_	
26-63	5288-5292	used	_	
26-64	5293-5297	with	_	
26-65	5298-5309	traditional	_	
26-66	5310-5322	neuroimaging	_	
26-67	5323-5334	assessments	_	
26-68	5334-5335	.	_	

#Text=The fNIRS technology has advanced so that the equipment used is now portable, noninvasive, and commercially available at relatively low cost when compared to fMRI and PET scanning equipment.
27-1	5336-5339	The	_	
27-2	5340-5345	fNIRS	_	
27-3	5346-5356	technology	_	
27-4	5357-5360	has	_	
27-5	5361-5369	advanced	_	
27-6	5370-5372	so	_	
27-7	5373-5377	that	_	
27-8	5378-5381	the	_	
27-9	5382-5391	equipment	_	
27-10	5392-5396	used	_	
27-11	5397-5399	is	_	
27-12	5400-5403	now	_	
27-13	5404-5412	portable	_	
27-14	5412-5413	,	_	
27-15	5414-5425	noninvasive	_	
27-16	5425-5426	,	_	
27-17	5427-5430	and	_	
27-18	5431-5443	commercially	_	
27-19	5444-5453	available	_	
27-20	5454-5456	at	_	
27-21	5457-5467	relatively	_	
27-22	5468-5471	low	_	
27-23	5472-5476	cost	_	
27-24	5477-5481	when	_	
27-25	5482-5490	compared	_	
27-26	5491-5493	to	_	
27-27	5494-5498	fMRI	_	
27-28	5499-5502	and	_	
27-29	5503-5506	PET	_	
27-30	5507-5515	scanning	_	
27-31	5516-5525	equipment	_	
27-32	5525-5526	.	_	

#Text=FNIRS assesses levels of oxygenated (HBO) and deoxygenated (HBR) hemoglobin by emitting infrared light, ranging from 650 to 1000 uv, through human biologic tissue, which is nearly transparent to light in this range.
28-1	5527-5532	FNIRS	_	
28-2	5533-5541	assesses	_	
28-3	5542-5548	levels	_	
28-4	5549-5551	of	_	
28-5	5552-5562	oxygenated	_	
28-6	5563-5564	(	_	
28-7	5564-5567	HBO	_	
28-8	5567-5568	)	_	
28-9	5569-5572	and	_	
28-10	5573-5585	deoxygenated	_	
28-11	5586-5587	(	_	
28-12	5587-5590	HBR	_	
28-13	5590-5591	)	_	
28-14	5592-5602	hemoglobin	_	
28-15	5603-5605	by	_	
28-16	5606-5614	emitting	_	
28-17	5615-5623	infrared	_	
28-18	5624-5629	light	_	
28-19	5629-5630	,	_	
28-20	5631-5638	ranging	_	
28-21	5639-5643	from	_	
28-22	5644-5647	650	_	
28-23	5648-5650	to	_	
28-24	5651-5655	1000	_	
28-25	5656-5658	uv	_	
28-26	5658-5659	,	_	
28-27	5660-5667	through	_	
28-28	5668-5673	human	_	
28-29	5674-5682	biologic	_	
28-30	5683-5689	tissue	_	
28-31	5689-5690	,	_	
28-32	5691-5696	which	_	
28-33	5697-5699	is	_	
28-34	5700-5706	nearly	_	
28-35	5707-5718	transparent	_	
28-36	5719-5721	to	_	
28-37	5722-5727	light	_	
28-38	5728-5730	in	_	
28-39	5731-5735	this	_	
28-40	5736-5741	range	_	
28-41	5741-5742	.	_	

#Text=The infrared light is then differentially absorbed by chromophores, which are light-absorbing molecules (specifically, HBO or HBR), or diffusely scattered by other human tissue.
29-1	5743-5746	The	_	
29-2	5747-5755	infrared	_	
29-3	5756-5761	light	_	
29-4	5762-5764	is	_	
29-5	5765-5769	then	_	
29-6	5770-5784	differentially	_	
29-7	5785-5793	absorbed	_	
29-8	5794-5796	by	_	
29-9	5797-5809	chromophores	_	
29-10	5809-5810	,	_	
29-11	5811-5816	which	_	
29-12	5817-5820	are	_	
29-13	5821-5836	light-absorbing	_	
29-14	5837-5846	molecules	_	
29-15	5847-5848	(	_	
29-16	5848-5860	specifically	_	
29-17	5860-5861	,	_	
29-18	5862-5865	HBO	_	
29-19	5866-5868	or	_	
29-20	5869-5872	HBR	_	
29-21	5872-5873	)	_	
29-22	5873-5874	,	_	
29-23	5875-5877	or	_	
29-24	5878-5887	diffusely	_	
29-25	5888-5897	scattered	_	
29-26	5898-5900	by	_	
29-27	5901-5906	other	_	
29-28	5907-5912	human	_	
29-29	5913-5919	tissue	_	
29-30	5919-5920	.	_	

#Text=Estimates of relative changes in blood oxygenation in the PFC may be obtained by placing sensors on the scalp strategically located from the light emission and using the modified Beer-Lambert Law (MBLL) to make adjustments needed for diffusion of the light through human tissue.
30-1	5921-5930	Estimates	_	
30-2	5931-5933	of	_	
30-3	5934-5942	relative	_	
30-4	5943-5950	changes	_	
30-5	5951-5953	in	_	
30-6	5954-5959	blood	_	
30-7	5960-5971	oxygenation	_	
30-8	5972-5974	in	_	
30-9	5975-5978	the	_	
30-10	5979-5982	PFC	_	
30-11	5983-5986	may	_	
30-12	5987-5989	be	_	
30-13	5990-5998	obtained	_	
30-14	5999-6001	by	_	
30-15	6002-6009	placing	_	
30-16	6010-6017	sensors	_	
30-17	6018-6020	on	_	
30-18	6021-6024	the	_	
30-19	6025-6030	scalp	_	
30-20	6031-6044	strategically	_	
30-21	6045-6052	located	_	
30-22	6053-6057	from	_	
30-23	6058-6061	the	_	
30-24	6062-6067	light	_	
30-25	6068-6076	emission	_	
30-26	6077-6080	and	_	
30-27	6081-6086	using	_	
30-28	6087-6090	the	_	
30-29	6091-6099	modified	_	
30-30	6100-6112	Beer-Lambert	_	
30-31	6113-6116	Law	_	
30-32	6117-6118	(	_	
30-33	6118-6122	MBLL	_	
30-34	6122-6123	)	_	
30-35	6124-6126	to	_	
30-36	6127-6131	make	_	
30-37	6132-6143	adjustments	_	
30-38	6144-6150	needed	_	
30-39	6151-6154	for	_	
30-40	6155-6164	diffusion	_	
30-41	6165-6167	of	_	
30-42	6168-6171	the	_	
30-43	6172-6177	light	_	
30-44	6178-6185	through	_	
30-45	6186-6191	human	_	
30-46	6192-6198	tissue	_	
30-47	6198-6199	.	_	

#Text=The placement of the sensors directly on the scalp minimizes the impact of movement artifacts often found in other neuroimaging techniques.
31-1	6200-6203	The	_	
31-2	6204-6213	placement	_	
31-3	6214-6216	of	_	
31-4	6217-6220	the	_	
31-5	6221-6228	sensors	_	
31-6	6229-6237	directly	_	
31-7	6238-6240	on	_	
31-8	6241-6244	the	_	
31-9	6245-6250	scalp	_	
31-10	6251-6260	minimizes	_	
31-11	6261-6264	the	_	
31-12	6265-6271	impact	_	
31-13	6272-6274	of	_	
31-14	6275-6283	movement	_	
31-15	6284-6293	artifacts	_	
31-16	6294-6299	often	_	
31-17	6300-6305	found	_	
31-18	6306-6308	in	_	
31-19	6309-6314	other	_	
31-20	6315-6327	neuroimaging	_	
31-21	6328-6338	techniques	_	
31-22	6338-6339	.	_	

#Text=This method has been validated by documenting changes in blood oxygenation levels relative to blood oxygenation levels obtained in fMRI and PET studies.
32-1	6340-6344	This	_	
32-2	6345-6351	method	_	
32-3	6352-6355	has	_	
32-4	6356-6360	been	_	
32-5	6361-6370	validated	_	
32-6	6371-6373	by	_	
32-7	6374-6385	documenting	_	
32-8	6386-6393	changes	_	
32-9	6394-6396	in	_	
32-10	6397-6402	blood	_	
32-11	6403-6414	oxygenation	_	
32-12	6415-6421	levels	_	
32-13	6422-6430	relative	_	
32-14	6431-6433	to	_	
32-15	6434-6439	blood	_	
32-16	6440-6451	oxygenation	_	
32-17	6452-6458	levels	_	
32-18	6459-6467	obtained	_	
32-19	6468-6470	in	_	
32-20	6471-6475	fMRI	_	
32-21	6476-6479	and	_	
32-22	6480-6483	PET	_	
32-23	6484-6491	studies	_	
32-24	6491-6492	.	_	

#Text=Changes in brain activation levels using fNIRS have been found to differentiate known clinical groups from typically developing children and to be related to parent-reported measures of behavioral functioning.
33-1	6493-6500	Changes	_	
33-2	6501-6503	in	_	
33-3	6504-6509	brain	_	
33-4	6510-6520	activation	_	
33-5	6521-6527	levels	_	
33-6	6528-6533	using	_	
33-7	6534-6539	fNIRS	_	
33-8	6540-6544	have	_	
33-9	6545-6549	been	_	
33-10	6550-6555	found	_	
33-11	6556-6558	to	_	
33-12	6559-6572	differentiate	_	
33-13	6573-6578	known	_	
33-14	6579-6587	clinical	_	
33-15	6588-6594	groups	_	
33-16	6595-6599	from	_	
33-17	6600-6609	typically	_	
33-18	6610-6620	developing	_	
33-19	6621-6629	children	_	
33-20	6630-6633	and	_	
33-21	6634-6636	to	_	
33-22	6637-6639	be	_	
33-23	6640-6647	related	_	
33-24	6648-6650	to	_	
33-25	6651-6666	parent-reported	_	
33-26	6667-6675	measures	_	
33-27	6676-6678	of	_	
33-28	6679-6689	behavioral	_	
33-29	6690-6701	functioning	_	
33-30	6701-6702	.	_	

#Text=Changes in activation obtained from fNIRS have already been used to assess the impact of pharmacological interventions for children with Attention Deficit-Hyperactivity Disorder (ADHD) but have not yet been applied to understanding individual differences in children with FASDs.
34-1	6703-6710	Changes	_	
34-2	6711-6713	in	_	
34-3	6714-6724	activation	_	
34-4	6725-6733	obtained	_	
34-5	6734-6738	from	_	
34-6	6739-6744	fNIRS	_	
34-7	6745-6749	have	_	
34-8	6750-6757	already	_	
34-9	6758-6762	been	_	
34-10	6763-6767	used	_	
34-11	6768-6770	to	_	
34-12	6771-6777	assess	_	
34-13	6778-6781	the	_	
34-14	6782-6788	impact	_	
34-15	6789-6791	of	_	
34-16	6792-6807	pharmacological	_	
34-17	6808-6821	interventions	_	
34-18	6822-6825	for	_	
34-19	6826-6834	children	_	
34-20	6835-6839	with	_	
34-21	6840-6849	Attention	_	
34-22	6850-6871	Deficit-Hyperactivity	_	
34-23	6872-6880	Disorder	_	
34-24	6881-6882	(	_	
34-25	6882-6886	ADHD	_	
34-26	6886-6887	)	_	
34-27	6888-6891	but	_	
34-28	6892-6896	have	_	
34-29	6897-6900	not	_	
34-30	6901-6904	yet	_	
34-31	6905-6909	been	_	
34-32	6910-6917	applied	_	
34-33	6918-6920	to	_	
34-34	6921-6934	understanding	_	
34-35	6935-6945	individual	_	
34-36	6946-6957	differences	_	
34-37	6958-6960	in	_	
34-38	6961-6969	children	_	
34-39	6970-6974	with	_	
34-40	6975-6980	FASDs	_	
34-41	6980-6981	.	_	

#Text=To evaluate prenatal alcohol-related differences in PFC activity as measured by fNIRS, we used three groups of children: (1) children with a history of PAE (PAE), (2) typically developing children without a history of PAE (Controls), and (3) children with clinically significant developmental, learning, or behavioral problems (Clinical Contrast) who do not have a history of PAE.
35-1	6982-6984	To	_	
35-2	6985-6993	evaluate	_	
35-3	6994-7002	prenatal	_	
35-4	7003-7018	alcohol-related	_	
35-5	7019-7030	differences	_	
35-6	7031-7033	in	_	
35-7	7034-7037	PFC	_	
35-8	7038-7046	activity	_	
35-9	7047-7049	as	_	
35-10	7050-7058	measured	_	
35-11	7059-7061	by	_	
35-12	7062-7067	fNIRS	_	
35-13	7067-7068	,	_	
35-14	7069-7071	we	_	
35-15	7072-7076	used	_	
35-16	7077-7082	three	_	
35-17	7083-7089	groups	_	
35-18	7090-7092	of	_	
35-19	7093-7101	children	_	
35-20	7101-7102	:	_	
35-21	7103-7104	(	_	
35-22	7104-7105	1	_	
35-23	7105-7106	)	_	
35-24	7107-7115	children	_	
35-25	7116-7120	with	_	
35-26	7121-7122	a	_	
35-27	7123-7130	history	_	
35-28	7131-7133	of	_	
35-29	7134-7137	PAE	_	
35-30	7138-7139	(	_	
35-31	7139-7142	PAE	_	
35-32	7142-7143	)	_	
35-33	7143-7144	,	_	
35-34	7145-7146	(	_	
35-35	7146-7147	2	_	
35-36	7147-7148	)	_	
35-37	7149-7158	typically	_	
35-38	7159-7169	developing	_	
35-39	7170-7178	children	_	
35-40	7179-7186	without	_	
35-41	7187-7188	a	_	
35-42	7189-7196	history	_	
35-43	7197-7199	of	_	
35-44	7200-7203	PAE	_	
35-45	7204-7205	(	_	
35-46	7205-7213	Controls	_	
35-47	7213-7214	)	_	
35-48	7214-7215	,	_	
35-49	7216-7219	and	_	
35-50	7220-7221	(	_	
35-51	7221-7222	3	_	
35-52	7222-7223	)	_	
35-53	7224-7232	children	_	
35-54	7233-7237	with	_	
35-55	7238-7248	clinically	_	
35-56	7249-7260	significant	_	
35-57	7261-7274	developmental	_	
35-58	7274-7275	,	_	
35-59	7276-7284	learning	_	
35-60	7284-7285	,	_	
35-61	7286-7288	or	_	
35-62	7289-7299	behavioral	_	
35-63	7300-7308	problems	_	
35-64	7309-7310	(	_	
35-65	7310-7318	Clinical	_	
35-66	7319-7327	Contrast	_	
35-67	7327-7328	)	_	
35-68	7329-7332	who	_	
35-69	7333-7335	do	_	
35-70	7336-7339	not	_	
35-71	7340-7344	have	_	
35-72	7345-7346	a	_	
35-73	7347-7354	history	_	
35-74	7355-7357	of	_	
35-75	7358-7361	PAE	_	
35-76	7361-7362	.	_	

#Text=PFC activity was assessed during a task designed to elicit arousal and the associated PFC inhibitory responses needed to modulate the arousal during the course of the task.
36-1	7363-7366	PFC	_	
36-2	7367-7375	activity	_	
36-3	7376-7379	was	_	
36-4	7380-7388	assessed	_	
36-5	7389-7395	during	_	
36-6	7396-7397	a	_	
36-7	7398-7402	task	_	
36-8	7403-7411	designed	_	
36-9	7412-7414	to	_	
36-10	7415-7421	elicit	_	
36-11	7422-7429	arousal	_	
36-12	7430-7433	and	_	
36-13	7434-7437	the	_	
36-14	7438-7448	associated	_	
36-15	7449-7452	PFC	_	
36-16	7453-7463	inhibitory	_	
36-17	7464-7473	responses	_	
36-18	7474-7480	needed	_	
36-19	7481-7483	to	_	
36-20	7484-7492	modulate	_	
36-21	7493-7496	the	_	
36-22	7497-7504	arousal	_	
36-23	7505-7511	during	_	
36-24	7512-7515	the	_	
36-25	7516-7522	course	_	
36-26	7523-7525	of	_	
36-27	7526-7529	the	_	
36-28	7530-7534	task	_	
36-29	7534-7535	.	_	

#Text=Indices of PFC activity (levels of oxygenated (HBO) and deoxygenated hemoglobin (HBR)) were anticipated to vary as a function of group status.
#Text=2.
37-1	7536-7543	Indices	_	
37-2	7544-7546	of	_	
37-3	7547-7550	PFC	_	
37-4	7551-7559	activity	_	
37-5	7560-7561	(	_	
37-6	7561-7567	levels	_	
37-7	7568-7570	of	_	
37-8	7571-7581	oxygenated	_	
37-9	7582-7583	(	_	
37-10	7583-7586	HBO	_	
37-11	7586-7587	)	_	
37-12	7588-7591	and	_	
37-13	7592-7604	deoxygenated	_	
37-14	7605-7615	hemoglobin	_	
37-15	7616-7617	(	_	
37-16	7617-7620	HBR	_	
37-17	7620-7621	)	_	
37-18	7621-7622	)	_	
37-19	7623-7627	were	_	
37-20	7628-7639	anticipated	_	
37-21	7640-7642	to	_	
37-22	7643-7647	vary	_	
37-23	7648-7650	as	_	
37-24	7651-7652	a	_	
37-25	7653-7661	function	_	
37-26	7662-7664	of	_	
37-27	7665-7670	group	_	
37-28	7671-7677	status	_	
37-29	7677-7678	.	_	
37-30	7679-7680	2	_	
37-31	7680-7681	.	_	

#Text=Methods
#Text=2.1 Participants
#Text=Children who had enrolled in a larger multisite collaborative project designed to identify neurobehavioral characteristics that differentiate children with FASD from other groups of children were recruited for this study.
38-1	7682-7689	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
38-2	7690-7693	2.1	_	
38-3	7694-7706	Participants	_	
38-4	7707-7715	Children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-5	7716-7719	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-6	7720-7723	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-7	7724-7732	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-8	7733-7735	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-9	7736-7737	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-10	7738-7744	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-11	7745-7754	multisite	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-12	7755-7768	collaborative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-13	7769-7776	project	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-14	7777-7785	designed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-15	7786-7788	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-16	7789-7797	identify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-17	7798-7813	neurobehavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-18	7814-7829	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-19	7830-7834	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-20	7835-7848	differentiate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-21	7849-7857	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-22	7858-7862	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-23	7863-7867	FASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-24	7868-7872	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-25	7873-7878	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-26	7879-7885	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-27	7886-7888	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-28	7889-7897	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-29	7898-7902	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-30	7903-7912	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-31	7913-7916	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-32	7917-7921	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-33	7922-7927	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
38-34	7927-7928	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Participants were from the Atlanta metropolitan area who agreed to undergo neurobehavioral testing, a physical exam and allowed a 3-D photograph of their face to be obtained for the Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) study.
39-1	7929-7941	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-2	7942-7946	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-3	7947-7951	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-4	7952-7955	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-5	7956-7963	Atlanta	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-6	7964-7976	metropolitan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-7	7977-7981	area	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-8	7982-7985	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-9	7986-7992	agreed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-10	7993-7995	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-11	7996-8003	undergo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-12	8004-8019	neurobehavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[17]	
39-13	8020-8027	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[17]	
39-14	8027-8028	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-15	8029-8030	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-16	8031-8039	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-17	8040-8044	exam	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-18	8045-8048	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-19	8049-8056	allowed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-20	8057-8058	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-21	8059-8060	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-22	8060-8061	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-23	8061-8062	D	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-24	8063-8073	photograph	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-25	8074-8076	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-26	8077-8082	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-27	8083-8087	face	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-28	8088-8090	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-29	8091-8093	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-30	8094-8102	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-31	8103-8106	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-32	8107-8110	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-33	8111-8124	Collaborative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-34	8125-8135	Initiative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-35	8136-8138	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-36	8139-8144	Fetal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-37	8145-8152	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-38	8153-8161	Spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-39	8162-8171	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-40	8172-8173	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-41	8173-8179	CIFASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-42	8179-8180	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-43	8181-8186	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
39-44	8186-8187	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=After being pre-screened for enrollment criteria, guardians were asked to sign an informed consent form for the various components of the study, including a separate consenting procedure for the fNIRS assessment.
40-1	8188-8193	After	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-2	8194-8199	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-3	8200-8212	pre-screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-4	8213-8216	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-5	8217-8227	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-6	8228-8236	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-7	8236-8237	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-8	8238-8247	guardians	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-9	8248-8252	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-10	8253-8258	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-11	8259-8261	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-12	8262-8266	sign	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-13	8267-8269	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-14	8270-8278	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-15	8279-8286	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-16	8287-8291	form	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-17	8292-8295	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-18	8296-8299	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-19	8300-8307	various	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-20	8308-8318	components	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-21	8319-8321	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-22	8322-8325	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-23	8326-8331	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-24	8331-8332	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-25	8333-8342	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-26	8343-8344	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-27	8345-8353	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-28	8354-8364	consenting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-29	8365-8374	procedure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-30	8375-8378	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-31	8379-8382	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-32	8383-8388	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[19]	
40-33	8389-8399	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-34	8399-8400	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Consenting procedures and documents were approved by the Human Subjects Committee of the Emory University School of Medicine.
41-1	8401-8411	Consenting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-2	8412-8422	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-3	8423-8426	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-4	8427-8436	documents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-5	8437-8441	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-6	8442-8450	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-7	8451-8453	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-8	8454-8457	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-9	8458-8463	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-10	8464-8472	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-11	8473-8482	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-12	8483-8485	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-13	8486-8489	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-14	8490-8495	Emory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-15	8496-8506	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-16	8507-8513	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-17	8514-8516	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-18	8517-8525	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
41-19	8525-8526	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=Financial incentives were given to participants for each aspect of the multisite study assessment procedures, including a $20 reimbursement for participation in the fNIRS assessment.
42-1	8527-8536	Financial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-2	8537-8547	incentives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-3	8548-8552	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-4	8553-8558	given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-5	8559-8561	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-6	8562-8574	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-7	8575-8578	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-8	8579-8583	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-9	8584-8590	aspect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-10	8591-8593	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-11	8594-8597	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-12	8598-8607	multisite	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-13	8608-8613	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-14	8614-8624	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-15	8625-8635	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-16	8635-8636	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-17	8637-8646	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-18	8647-8648	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-19	8649-8652	$20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-20	8653-8666	reimbursement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-21	8667-8670	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-22	8671-8684	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-23	8685-8687	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-24	8688-8691	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-25	8692-8697	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[22]	
42-26	8698-8708	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
42-27	8708-8709	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=Exclusionary criteria for the CIFASD neurobehavioral study included being non-fluent in English, having a history of traumatic head injury or a loss of consciousness lasting over 30 minutes, being adopted from abroad after 5 years of age or within 2 years before enrollment, having other known causes of abnormal brain development (e.g., chromosomal abnormalities, neurofibromatosis), or having a mental health or physical limitations that prevented completion of the study’s procedures.
43-1	8710-8722	Exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-2	8723-8731	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-3	8732-8735	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-4	8736-8739	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-5	8740-8746	CIFASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-6	8747-8762	neurobehavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-7	8763-8768	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-8	8769-8777	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-9	8778-8783	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-10	8784-8794	non-fluent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-11	8795-8797	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-12	8798-8805	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-13	8805-8806	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-14	8807-8813	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-15	8814-8815	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-16	8816-8823	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-17	8824-8826	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-18	8827-8836	traumatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-19	8837-8841	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-20	8842-8848	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-21	8849-8851	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-22	8852-8853	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-23	8854-8858	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-24	8859-8861	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-25	8862-8875	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-26	8876-8883	lasting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-27	8884-8888	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-28	8889-8891	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-29	8892-8899	minutes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-30	8899-8900	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-31	8901-8906	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-32	8907-8914	adopted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-33	8915-8919	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-34	8920-8926	abroad	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-35	8927-8932	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-36	8933-8934	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-37	8935-8940	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-38	8941-8943	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-39	8944-8947	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-40	8948-8950	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-41	8951-8957	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-42	8958-8959	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-43	8960-8965	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-44	8966-8972	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-45	8973-8983	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-46	8983-8984	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-47	8985-8991	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-48	8992-8997	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-49	8998-9003	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-50	9004-9010	causes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-51	9011-9013	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-52	9014-9022	abnormal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-53	9023-9028	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-54	9029-9040	development	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-55	9041-9042	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-56	9042-9045	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-57	9045-9046	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-58	9046-9047	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-59	9048-9059	chromosomal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-60	9060-9073	abnormalities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-61	9073-9074	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-62	9075-9092	neurofibromatosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-63	9092-9093	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-64	9093-9094	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-65	9095-9097	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-66	9098-9104	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-67	9105-9106	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-68	9107-9113	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-69	9114-9120	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-70	9121-9123	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-71	9124-9132	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-72	9133-9144	limitations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-73	9145-9149	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-74	9150-9159	prevented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-75	9160-9170	completion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-76	9171-9173	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-77	9174-9177	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-78	9178-9183	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-79	9183-9184	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-80	9184-9185	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-81	9186-9196	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
43-82	9196-9197	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=Participant recruitment and the study’s procedures were carried out in accordance with the guidelines established by the Declaration of Helsinki.
44-1	9198-9209	Participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-2	9210-9221	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-3	9222-9225	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-4	9226-9229	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-5	9230-9235	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-6	9235-9236	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-7	9236-9237	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-8	9238-9248	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-9	9249-9253	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-10	9254-9261	carried	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-11	9262-9265	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-12	9266-9268	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-13	9269-9279	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-14	9280-9284	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-15	9285-9288	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-16	9289-9299	guidelines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-17	9300-9311	established	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-18	9312-9314	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-19	9315-9318	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-20	9319-9330	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-21	9331-9333	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-22	9334-9342	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
44-23	9342-9343	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=Forty-four children between the ages of 6 and 16 were evaluated.
45-1	9344-9354	Forty-four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-2	9355-9363	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-3	9364-9371	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-4	9372-9375	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-5	9376-9380	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-6	9381-9383	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-7	9384-9385	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-8	9386-9389	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-9	9390-9392	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-10	9393-9397	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-11	9398-9407	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
45-12	9407-9408	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=Participants were included in the prenatal alcohol-exposed (PAE) group if they had a history of heavy PAE, which was defined as greater than 13 drinks per week or greater than four drinks per drinking occasion during pregnancy, or when such exposure was suspected in a child with a clinical diagnosis of FAS.
46-1	9409-9421	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
46-2	9422-9426	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
46-3	9427-9435	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
46-4	9436-9438	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
46-5	9439-9442	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
46-6	9443-9451	prenatal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[27]	
46-7	9452-9467	alcohol-exposed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[27]	
46-8	9468-9469	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[27]	
46-9	9469-9472	PAE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[27]	
46-10	9472-9473	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[27]	
46-11	9474-9479	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[27]	
46-12	9480-9482	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-13	9483-9487	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-14	9488-9491	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-15	9492-9493	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-16	9494-9501	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-17	9502-9504	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-18	9505-9510	heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-19	9511-9514	PAE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-20	9514-9515	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-21	9516-9521	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-22	9522-9525	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-23	9526-9533	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-24	9534-9536	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-25	9537-9544	greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-26	9545-9549	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-27	9550-9552	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-28	9553-9559	drinks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-29	9560-9563	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-30	9564-9568	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-31	9569-9571	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-32	9572-9579	greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-33	9580-9584	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-34	9585-9589	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-35	9590-9596	drinks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-36	9597-9600	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-37	9601-9609	drinking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-38	9610-9618	occasion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-39	9619-9625	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-40	9626-9635	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-41	9635-9636	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-42	9637-9639	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-43	9640-9644	when	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-44	9645-9649	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-45	9650-9658	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-46	9659-9662	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-47	9663-9672	suspected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-48	9673-9675	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-49	9676-9677	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-50	9678-9683	child	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-51	9684-9688	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-52	9689-9690	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
46-53	9691-9699	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[28]	
46-54	9700-9709	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[28]	
46-55	9710-9712	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[28]	
46-56	9713-9716	FAS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[28]	
46-57	9716-9717	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=Participants were recruited from a multidisciplinary team clinic established to evaluate children with a history of alcohol and drug exposure or from the community when there was a confirmed positive history of PAE.
47-1	9718-9730	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-2	9731-9735	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-3	9736-9745	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-4	9746-9750	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-5	9751-9752	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-6	9753-9770	multidisciplinary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-7	9771-9775	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-8	9776-9782	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-9	9783-9794	established	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-10	9795-9797	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-11	9798-9806	evaluate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-12	9807-9815	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-13	9816-9820	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-14	9821-9822	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-15	9823-9830	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-16	9831-9833	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-17	9834-9841	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-18	9842-9845	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-19	9846-9850	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-20	9851-9859	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-21	9860-9862	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-22	9863-9867	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-23	9868-9871	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-24	9872-9881	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-25	9882-9886	when	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-26	9887-9892	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-27	9893-9896	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-28	9897-9898	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-29	9899-9908	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-30	9909-9917	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-31	9918-9925	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-32	9926-9928	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-33	9929-9932	PAE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
47-34	9932-9933	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	

#Text=Participants recruited from the clinic were identified from medical records under a HIPAA partial waiver.
48-1	9934-9946	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-2	9947-9956	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-3	9957-9961	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-4	9962-9965	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-5	9966-9972	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-6	9973-9977	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-7	9978-9988	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-8	9989-9993	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-9	9994-10001	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-10	10002-10009	records	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-11	10010-10015	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-12	10016-10017	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-13	10018-10023	HIPAA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-14	10024-10031	partial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-15	10032-10038	waiver	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
48-16	10038-10039	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=The clinic performs neurobehavioral testing and a physical examination where growth and dysmorphology are assessed using a standardized checklist.
49-1	10040-10043	The	_	
49-2	10044-10050	clinic	_	
49-3	10051-10059	performs	_	
49-4	10060-10075	neurobehavioral	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[31]	
49-5	10076-10083	testing	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale[31]	
49-6	10084-10087	and	_	
49-7	10088-10089	a	_	
49-8	10090-10098	physical	_	
49-9	10099-10110	examination	_	
49-10	10111-10116	where	_	
49-11	10117-10123	growth	_	
49-12	10124-10127	and	_	
49-13	10128-10141	dysmorphology	_	
49-14	10142-10145	are	_	
49-15	10146-10154	assessed	_	
49-16	10155-10160	using	_	
49-17	10161-10162	a	_	
49-18	10163-10175	standardized	_	
49-19	10176-10185	checklist	_	
49-20	10185-10186	.	_	

#Text=Dysmorphology was assessed by either a pediatric geneticist or developmental pediatrician with specialized training in assessing alcohol-related dysmorphology.
50-1	10187-10200	Dysmorphology	_	
50-2	10201-10204	was	_	
50-3	10205-10213	assessed	_	
50-4	10214-10216	by	_	
50-5	10217-10223	either	_	
50-6	10224-10225	a	_	
50-7	10226-10235	pediatric	_	
50-8	10236-10246	geneticist	_	
50-9	10247-10249	or	_	
50-10	10250-10263	developmental	_	
50-11	10264-10276	pediatrician	_	
50-12	10277-10281	with	_	
50-13	10282-10293	specialized	_	
50-14	10294-10302	training	_	
50-15	10303-10305	in	_	
50-16	10306-10315	assessing	_	
50-17	10316-10331	alcohol-related	_	
50-18	10332-10345	dysmorphology	_	
50-19	10345-10346	.	_	

#Text=A total score is computed from 30 items that are weighted relative to each features’ predictive validity for FAS symptomatology.
51-1	10347-10348	A	_	
51-2	10349-10354	total	_	
51-3	10355-10360	score	_	
51-4	10361-10363	is	_	
51-5	10364-10372	computed	_	
51-6	10373-10377	from	_	
51-7	10378-10380	30	_	
51-8	10381-10386	items	_	
51-9	10387-10391	that	_	
51-10	10392-10395	are	_	
51-11	10396-10404	weighted	_	
51-12	10405-10413	relative	_	
51-13	10414-10416	to	_	
51-14	10417-10421	each	_	
51-15	10422-10430	features	_	
51-16	10430-10431	’	_	
51-17	10432-10442	predictive	_	
51-18	10443-10451	validity	_	
51-19	10452-10455	for	_	
51-20	10456-10459	FAS	_	
51-21	10460-10474	symptomatology	_	
51-22	10474-10475	.	_	

#Text=As part of a series of prospective studies on prenatal alcohol exposure carried out from infancy to young adulthood, the checklist differentiated individuals with and without PAE.
52-1	10476-10478	As	_	
52-2	10479-10483	part	_	
52-3	10484-10486	of	_	
52-4	10487-10488	a	_	
52-5	10489-10495	series	_	
52-6	10496-10498	of	_	
52-7	10499-10510	prospective	_	
52-8	10511-10518	studies	_	
52-9	10519-10521	on	_	
52-10	10522-10530	prenatal	_	
52-11	10531-10538	alcohol	_	
52-12	10539-10547	exposure	_	
52-13	10548-10555	carried	_	
52-14	10556-10559	out	_	
52-15	10560-10564	from	_	
52-16	10565-10572	infancy	_	
52-17	10573-10575	to	_	
52-18	10576-10581	young	_	
52-19	10582-10591	adulthood	_	
52-20	10591-10592	,	_	
52-21	10593-10596	the	_	
52-22	10597-10606	checklist	_	
52-23	10607-10621	differentiated	_	
52-24	10622-10633	individuals	_	
52-25	10634-10638	with	_	
52-26	10639-10642	and	_	
52-27	10643-10650	without	_	
52-28	10651-10654	PAE	_	
52-29	10654-10655	.	_	

#Text=Additional details regarding the FASD diagnostic procedures of the clinic are published elsewhere.
53-1	10656-10666	Additional	_	
53-2	10667-10674	details	_	
53-3	10675-10684	regarding	_	
53-4	10685-10688	the	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[32]	
53-5	10689-10693	FASD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[32]	
53-6	10694-10704	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[32]	
53-7	10705-10715	procedures	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[32]	
53-8	10716-10718	of	_	
53-9	10719-10722	the	_	
53-10	10723-10729	clinic	_	
53-11	10730-10733	are	_	
53-12	10734-10743	published	_	
53-13	10744-10753	elsewhere	_	
53-14	10753-10754	.	_	

#Text=PAE histories were documented either directly from the biological mother’s report or from existing medical, social or legal records.
54-1	10755-10758	PAE	_	
54-2	10759-10768	histories	_	
54-3	10769-10773	were	_	
54-4	10774-10784	documented	_	
54-5	10785-10791	either	_	
54-6	10792-10800	directly	_	
54-7	10801-10805	from	_	
54-8	10806-10809	the	_	
54-9	10810-10820	biological	_	
54-10	10821-10827	mother	_	
54-11	10827-10828	’	_	
54-12	10828-10829	s	_	
54-13	10830-10836	report	_	
54-14	10837-10839	or	_	
54-15	10840-10844	from	_	
54-16	10845-10853	existing	_	
54-17	10854-10861	medical	_	
54-18	10861-10862	,	_	
54-19	10863-10869	social	_	
54-20	10870-10872	or	_	
54-21	10873-10878	legal	_	
54-22	10879-10886	records	_	
54-23	10886-10887	.	_	

#Text=In many cases seen through the clinic, accurate exposure history was not available.
55-1	10888-10890	In	_	
55-2	10891-10895	many	_	
55-3	10896-10901	cases	_	
55-4	10902-10906	seen	_	
55-5	10907-10914	through	_	
55-6	10915-10918	the	_	
55-7	10919-10925	clinic	_	
55-8	10925-10926	,	_	
55-9	10927-10935	accurate	_	
55-10	10936-10944	exposure	_	
55-11	10945-10952	history	_	
55-12	10953-10956	was	_	
55-13	10957-10960	not	_	
55-14	10961-10970	available	_	
55-15	10970-10971	.	_	

#Text=Offspring of mothers who were known to be “alcoholic” or alcohol abusing during pregnancy were considered to have heavy PAE.
56-1	10972-10981	Offspring	_	
56-2	10982-10984	of	_	
56-3	10985-10992	mothers	_	
56-4	10993-10996	who	_	
56-5	10997-11001	were	_	
56-6	11002-11007	known	_	
56-7	11008-11010	to	_	
56-8	11011-11013	be	_	
56-9	11014-11015	“	_	
56-10	11015-11024	alcoholic	_	
56-11	11024-11025	”	_	
56-12	11026-11028	or	_	
56-13	11029-11036	alcohol	_	
56-14	11037-11044	abusing	_	
56-15	11045-11051	during	_	
56-16	11052-11061	pregnancy	_	
56-17	11062-11066	were	_	
56-18	11067-11077	considered	_	
56-19	11078-11080	to	_	
56-20	11081-11085	have	_	
56-21	11086-11091	heavy	_	
56-22	11092-11095	PAE	_	
56-23	11095-11096	.	_	

#Text=Recruitment of participants from the community included those identified at public health fairs and other community programs (i.e.
57-1	11097-11108	Recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-2	11109-11111	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-3	11112-11124	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-4	11125-11129	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-5	11130-11133	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-6	11134-11143	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-7	11144-11152	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-8	11153-11158	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-9	11159-11169	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-10	11170-11172	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-11	11173-11179	public	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-12	11180-11186	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-13	11187-11192	fairs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-14	11193-11196	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-15	11197-11202	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-16	11203-11212	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-17	11213-11221	programs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-18	11222-11223	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-19	11223-11226	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
57-20	11226-11227	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	

#Text=PTA events at local schools).
58-1	11228-11231	PTA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
58-2	11232-11238	events	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
58-3	11239-11241	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
58-4	11242-11247	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
58-5	11248-11255	schools	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
58-6	11255-11256	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
58-7	11256-11257	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	

#Text=A total of 18 children were recruited for the PAE group.
59-1	11258-11259	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-2	11260-11265	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-3	11266-11268	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-4	11269-11271	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-5	11272-11280	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-6	11281-11285	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-7	11286-11295	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-8	11296-11299	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-9	11300-11303	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
59-10	11304-11307	PAE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[35]	
59-11	11308-11313	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[35]	
59-12	11313-11314	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[35]	

#Text=Nine had an FASD clinical diagnosis and nine were recruited from the community and identified as having heavy PAE.
60-1	11315-11319	Nine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-2	11320-11323	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-3	11324-11326	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-4	11327-11331	FASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[37]	
60-5	11332-11340	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[37]	
60-6	11341-11350	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[37]	
60-7	11351-11354	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-8	11355-11359	nine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-9	11360-11364	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-10	11365-11374	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-11	11375-11379	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-12	11380-11383	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-13	11384-11393	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-14	11394-11397	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-15	11398-11408	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-16	11409-11411	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-17	11412-11418	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-18	11419-11424	heavy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-19	11425-11428	PAE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]	
60-20	11428-11429	.	_	

#Text=Of the 18 enrolled, 12 were identified by their parents as having a significant behavioral problem and 7 were identified as having a significant learning or developmental problem.
61-1	11430-11432	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-2	11433-11436	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-3	11437-11439	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-4	11440-11448	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-5	11448-11449	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-6	11450-11452	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-7	11453-11457	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-8	11458-11468	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-9	11469-11471	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-10	11472-11477	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-11	11478-11485	parents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-12	11486-11488	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-13	11489-11495	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-14	11496-11497	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-15	11498-11509	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-16	11510-11520	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-17	11521-11528	problem	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-18	11529-11532	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-19	11533-11534	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-20	11535-11539	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-21	11540-11550	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-22	11551-11553	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-23	11554-11560	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-24	11561-11562	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-25	11563-11574	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-26	11575-11583	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-27	11584-11586	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-28	11587-11600	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-29	11601-11608	problem	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
61-30	11608-11609	.	_	

#Text=A comparison sample of 12 typically developing children (Control Group) was recruited from the Atlanta community.
62-1	11610-11611	A	_	
62-2	11612-11622	comparison	_	
62-3	11623-11629	sample	_	
62-4	11630-11632	of	_	
62-5	11633-11635	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-6	11636-11645	typically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-7	11646-11656	developing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-8	11657-11665	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-9	11666-11667	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-10	11667-11674	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-11	11675-11680	Group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-12	11680-11681	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[40]	
62-13	11682-11685	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-14	11686-11695	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-15	11696-11700	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-16	11701-11704	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-17	11705-11712	Atlanta	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-18	11713-11722	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	
62-19	11722-11723	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[39]	

#Text=Typically developing children were recruited from the non-alcohol exposed siblings of the children who were receiving services at the clinic and from community recruitments by targeting community programs and health fairs.
63-1	11724-11733	Typically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[42]	
63-2	11734-11744	developing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[42]	
63-3	11745-11753	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[42]	
63-4	11754-11758	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-5	11759-11768	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-6	11769-11773	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-7	11774-11777	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-8	11778-11789	non-alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-9	11790-11797	exposed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-10	11798-11806	siblings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-11	11807-11809	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-12	11810-11813	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-13	11814-11822	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-14	11823-11826	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-15	11827-11831	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-16	11832-11841	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-17	11842-11850	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-18	11851-11853	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-19	11854-11857	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-20	11858-11864	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-21	11865-11868	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-22	11869-11873	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-23	11874-11883	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-24	11884-11896	recruitments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-25	11897-11899	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-26	11900-11909	targeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-27	11910-11919	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-28	11920-11928	programs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-29	11929-11932	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-30	11933-11939	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-31	11940-11945	fairs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
63-32	11945-11946	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	

#Text=Subjects were included in the Control group if there was a reliable history of minimal or no exposure in pregnancy and the parent had no clinical significant emotional or behavioral concerns about the child.
64-1	11947-11955	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-2	11956-11960	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-3	11961-11969	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-4	11970-11972	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-5	11973-11976	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-6	11977-11984	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]	
64-7	11985-11990	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]	
64-8	11991-11993	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-9	11994-11999	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-10	12000-12003	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-11	12004-12005	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-12	12006-12014	reliable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-13	12015-12022	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-14	12023-12025	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-15	12026-12033	minimal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-16	12034-12036	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-17	12037-12039	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-18	12040-12048	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-19	12049-12051	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-20	12052-12061	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-21	12062-12065	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-22	12066-12069	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-23	12070-12076	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-24	12077-12080	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-25	12081-12083	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-26	12084-12092	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-27	12093-12104	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-28	12105-12114	emotional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-29	12115-12117	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-30	12118-12128	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-31	12129-12137	concerns	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-32	12138-12143	about	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-33	12144-12147	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-34	12148-12153	child	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	
64-35	12153-12154	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[43]	

#Text=Minimal PAE exposure was defined as less than one drink per week and never more than 2 drinks per occasion).
65-1	12155-12162	Minimal	_	
65-2	12163-12166	PAE	_	
65-3	12167-12175	exposure	_	
65-4	12176-12179	was	_	
65-5	12180-12187	defined	_	
65-6	12188-12190	as	_	
65-7	12191-12195	less	_	
65-8	12196-12200	than	_	
65-9	12201-12204	one	_	
65-10	12205-12210	drink	_	
65-11	12211-12214	per	_	
65-12	12215-12219	week	_	
65-13	12220-12223	and	_	
65-14	12224-12229	never	_	
65-15	12230-12234	more	_	
65-16	12235-12239	than	_	
65-17	12240-12241	2	_	
65-18	12242-12248	drinks	_	
65-19	12249-12252	per	_	
65-20	12253-12261	occasion	_	
65-21	12261-12262	)	_	
65-22	12262-12263	.	_	

#Text=None of the children assigned to the group was identified by their parents as having significant learning or developmental problems but one was identified as having a behavioral problem.
66-1	12264-12268	None	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-2	12269-12271	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-3	12272-12275	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-4	12276-12284	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-5	12285-12293	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-6	12294-12296	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-7	12297-12300	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-8	12301-12306	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-9	12307-12310	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-10	12311-12321	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-11	12322-12324	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-12	12325-12330	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-13	12331-12338	parents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-14	12339-12341	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-15	12342-12348	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-16	12349-12360	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-17	12361-12369	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-18	12370-12372	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-19	12373-12386	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-20	12387-12395	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-21	12396-12399	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-22	12400-12403	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-23	12404-12407	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-24	12408-12418	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-25	12419-12421	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-26	12422-12428	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-27	12429-12430	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-28	12431-12441	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-29	12442-12449	problem	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	
66-30	12449-12450	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]	

#Text=The parent was concerned about the child’s hyperactivity but the concern had not reached the level of seeking professional consultation regarding the behavior.
67-1	12451-12454	The	_	
67-2	12455-12461	parent	_	
67-3	12462-12465	was	_	
67-4	12466-12475	concerned	_	
67-5	12476-12481	about	_	
67-6	12482-12485	the	_	
67-7	12486-12491	child	_	
67-8	12491-12492	’	_	
67-9	12492-12493	s	_	
67-10	12494-12507	hyperactivity	_	
67-11	12508-12511	but	_	
67-12	12512-12515	the	_	
67-13	12516-12523	concern	_	
67-14	12524-12527	had	_	
67-15	12528-12531	not	_	
67-16	12532-12539	reached	_	
67-17	12540-12543	the	_	
67-18	12544-12549	level	_	
67-19	12550-12552	of	_	
67-20	12553-12560	seeking	_	
67-21	12561-12573	professional	_	
67-22	12574-12586	consultation	_	
67-23	12587-12596	regarding	_	
67-24	12597-12600	the	_	
67-25	12601-12609	behavior	_	
67-26	12609-12610	.	_	

#Text=Finally, an additional comparison sample of 14 children with identified developmental, learning or emotional/behavioral problems (Clinical Contrast Group) was recruited from siblings of those seen in the clinic, from community recruitments as described for the Control Group, and from the waiting room of a child psychiatry clinic.
68-1	12611-12618	Finally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-2	12618-12619	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-3	12620-12622	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-4	12623-12633	additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-5	12634-12644	comparison	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-6	12645-12651	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-7	12652-12654	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]	
68-8	12655-12657	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-9	12658-12666	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-10	12667-12671	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-11	12672-12682	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-12	12683-12696	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-13	12696-12697	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-14	12698-12706	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-15	12707-12709	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-16	12710-12719	emotional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-17	12719-12720	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-18	12720-12730	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-19	12731-12739	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[48]	
68-20	12740-12741	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-21	12741-12749	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-22	12750-12758	Contrast	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-23	12759-12764	Group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-24	12764-12765	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-25	12766-12769	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-26	12770-12779	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-27	12780-12784	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-28	12785-12793	siblings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-29	12794-12796	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-30	12797-12802	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-31	12803-12807	seen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-32	12808-12810	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-33	12811-12814	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-34	12815-12821	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-35	12821-12822	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-36	12823-12827	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-37	12828-12837	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-38	12838-12850	recruitments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-39	12851-12853	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-40	12854-12863	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-41	12864-12867	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-42	12868-12871	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-43	12872-12879	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[49]	
68-44	12880-12885	Group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[49]	
68-45	12885-12886	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-46	12887-12890	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-47	12891-12895	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-48	12896-12899	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-49	12900-12907	waiting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-50	12908-12912	room	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-51	12913-12915	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-52	12916-12917	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-53	12918-12923	child	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-54	12924-12934	psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-55	12935-12941	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	
68-56	12941-12942	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]	

#Text=Clinically significant levels of concern regarding behavioral and emotional functioning were defined as seeking assistance from a primary doctor or mental health professional regarding a developmental, learning, or emotional/behavioral problem or having a specific neurodevelopmental or mental health diagnosis.
69-1	12943-12953	Clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-2	12954-12965	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-3	12966-12972	levels	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-4	12973-12975	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-5	12976-12983	concern	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-6	12984-12993	regarding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-7	12994-13004	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-8	13005-13008	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-9	13009-13018	emotional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-10	13019-13030	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-11	13031-13035	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-12	13036-13043	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-13	13044-13046	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-14	13047-13054	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-15	13055-13065	assistance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-16	13066-13070	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-17	13071-13072	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-18	13073-13080	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-19	13081-13087	doctor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-20	13088-13090	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-21	13091-13097	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-22	13098-13104	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-23	13105-13117	professional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-24	13118-13127	regarding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-25	13128-13129	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-26	13130-13143	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-27	13143-13144	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-28	13145-13153	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-29	13153-13154	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-30	13155-13157	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-31	13158-13167	emotional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-32	13167-13168	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-33	13168-13178	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-34	13179-13186	problem	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-35	13187-13189	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-36	13190-13196	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-37	13197-13198	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-38	13199-13207	specific	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-39	13208-13226	neurodevelopmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-40	13227-13229	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-41	13230-13236	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-42	13237-13243	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-43	13244-13253	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
69-44	13253-13254	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	

#Text=Subjects were included if there was a reliable history of minimal or no PAE in pregnancy.
70-1	13255-13263	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-2	13264-13268	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-3	13269-13277	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-4	13278-13280	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-5	13281-13286	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-6	13287-13290	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-7	13291-13292	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-8	13293-13301	reliable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-9	13302-13309	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-10	13310-13312	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-11	13313-13320	minimal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-12	13321-13323	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-13	13324-13326	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-14	13327-13330	PAE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-15	13331-13333	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-16	13334-13343	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	
70-17	13343-13344	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[51]	

#Text=Of the 14 enrolled, 13 were identified by their parents as having a significant behavioral problem and 4 were identified as having a significant learning or developmental problem.
71-1	13345-13347	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-2	13348-13351	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-3	13352-13354	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-4	13355-13363	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-5	13363-13364	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-6	13365-13367	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-7	13368-13372	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-8	13373-13383	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-9	13384-13386	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-10	13387-13392	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-11	13393-13400	parents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-12	13401-13403	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-13	13404-13410	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-14	13411-13412	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-15	13413-13424	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-16	13425-13435	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-17	13436-13443	problem	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-18	13444-13447	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-19	13448-13449	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-20	13450-13454	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-21	13455-13465	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-22	13466-13468	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-23	13469-13475	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-24	13476-13477	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-25	13478-13489	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-26	13490-13498	learning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-27	13499-13501	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-28	13502-13515	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-29	13516-13523	problem	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	
71-30	13523-13524	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[52]	

#Text=The Clinical Contrast group provides an important contrast to the PAE group in that this group has similar neurobehavioral dysfunction but with heterogeneous etiologies.
#Text=2.1 FNIRS Procedures
#Text=To collect hemodynamic changes in the brain, FNIR Devices’ wearable neuroimaging device (distributed by Biopac as Model# FNIRS 100B) was placed on the forehead of the participant and Cognitive Optical Brain Imaging (COBI) Studio software was used to encode changes in light absorption during the computer game play.
72-1	13525-13528	The	_	
72-2	13529-13537	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[53]	
72-3	13538-13546	Contrast	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[53]	
72-4	13547-13552	group	http://maven.renci.org/NeuroBridge/neurobridge#NeurodevelopmentalDisorder[53]	
72-5	13553-13561	provides	_	
72-6	13562-13564	an	_	
72-7	13565-13574	important	_	
72-8	13575-13583	contrast	_	
72-9	13584-13586	to	_	
72-10	13587-13590	the	_	
72-11	13591-13594	PAE	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[54]	
72-12	13595-13600	group	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholRelatedNeurodevelopmentalDisorder[54]	
72-13	13601-13603	in	_	
72-14	13604-13608	that	_	
72-15	13609-13613	this	_	
72-16	13614-13619	group	_	
72-17	13620-13623	has	_	
72-18	13624-13631	similar	_	
72-19	13632-13647	neurobehavioral	_	
72-20	13648-13659	dysfunction	_	
72-21	13660-13663	but	_	
72-22	13664-13668	with	_	
72-23	13669-13682	heterogeneous	_	
72-24	13683-13693	etiologies	_	
72-25	13693-13694	.	_	
72-26	13695-13698	2.1	_	
72-27	13699-13704	FNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
72-28	13705-13715	Procedures	_	
72-29	13716-13718	To	_	
72-30	13719-13726	collect	_	
72-31	13727-13738	hemodynamic	_	
72-32	13739-13746	changes	_	
72-33	13747-13749	in	_	
72-34	13750-13753	the	_	
72-35	13754-13759	brain	_	
72-36	13759-13760	,	_	
72-37	13761-13765	FNIR	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[55]	
72-38	13766-13773	Devices	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[55]	
72-39	13773-13774	’	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[55]	
72-40	13775-13783	wearable	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[55]	
72-41	13784-13796	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[55]	
72-42	13797-13803	device	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[55]	
72-43	13804-13805	(	_	
72-44	13805-13816	distributed	_	
72-45	13817-13819	by	_	
72-46	13820-13826	Biopac	_	
72-47	13827-13829	as	_	
72-48	13830-13835	Model	_	
72-49	13835-13836	#	_	
72-50	13837-13842	FNIRS	_	
72-51	13843-13847	100B	_	
72-52	13847-13848	)	_	
72-53	13849-13852	was	_	
72-54	13853-13859	placed	_	
72-55	13860-13862	on	_	
72-56	13863-13866	the	_	
72-57	13867-13875	forehead	_	
72-58	13876-13878	of	_	
72-59	13879-13882	the	_	
72-60	13883-13894	participant	_	
72-61	13895-13898	and	_	
72-62	13899-13908	Cognitive	_	
72-63	13909-13916	Optical	_	
72-64	13917-13922	Brain	_	
72-65	13923-13930	Imaging	_	
72-66	13931-13932	(	_	
72-67	13932-13936	COBI	_	
72-68	13936-13937	)	_	
72-69	13938-13944	Studio	_	
72-70	13945-13953	software	_	
72-71	13954-13957	was	_	
72-72	13958-13962	used	_	
72-73	13963-13965	to	_	
72-74	13966-13972	encode	_	
72-75	13973-13980	changes	_	
72-76	13981-13983	in	_	
72-77	13984-13989	light	_	
72-78	13990-14000	absorption	_	
72-79	14001-14007	during	_	
72-80	14008-14011	the	_	
72-81	14012-14020	computer	_	
72-82	14021-14025	game	_	
72-83	14026-14030	play	_	
72-84	14030-14031	.	_	

#Text=The FNIRS device enables continuous and non-invasive monitoring of blood oxygenation and blood volume changes associated with human brain functioning.
73-1	14032-14035	The	_	
73-2	14036-14041	FNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
73-3	14042-14048	device	_	
73-4	14049-14056	enables	_	
73-5	14057-14067	continuous	_	
73-6	14068-14071	and	_	
73-7	14072-14084	non-invasive	_	
73-8	14085-14095	monitoring	_	
73-9	14096-14098	of	_	
73-10	14099-14104	blood	_	
73-11	14105-14116	oxygenation	_	
73-12	14117-14120	and	_	
73-13	14121-14126	blood	_	
73-14	14127-14133	volume	_	
73-15	14134-14141	changes	_	
73-16	14142-14152	associated	_	
73-17	14153-14157	with	_	
73-18	14158-14163	human	_	
73-19	14164-14169	brain	_	
73-20	14170-14181	functioning	_	
73-21	14181-14182	.	_	

#Text=The system consisted of a pad containing the LEDs and sensors that were placed on the participant’s forehead, a control box and power supply for acquisition of the infrared-light signal, and a laptop for the digital data acquisition and analysis software.
74-1	14183-14186	The	_	
74-2	14187-14193	system	_	
74-3	14194-14203	consisted	_	
74-4	14204-14206	of	_	
74-5	14207-14208	a	_	
74-6	14209-14212	pad	_	
74-7	14213-14223	containing	_	
74-8	14224-14227	the	_	
74-9	14228-14232	LEDs	_	
74-10	14233-14236	and	_	
74-11	14237-14244	sensors	_	
74-12	14245-14249	that	_	
74-13	14250-14254	were	_	
74-14	14255-14261	placed	_	
74-15	14262-14264	on	_	
74-16	14265-14268	the	_	
74-17	14269-14280	participant	_	
74-18	14280-14281	’	_	
74-19	14281-14282	s	_	
74-20	14283-14291	forehead	_	
74-21	14291-14292	,	_	
74-22	14293-14294	a	_	
74-23	14295-14302	control	_	
74-24	14303-14306	box	_	
74-25	14307-14310	and	_	
74-26	14311-14316	power	_	
74-27	14317-14323	supply	_	
74-28	14324-14327	for	_	
74-29	14328-14339	acquisition	_	
74-30	14340-14342	of	_	
74-31	14343-14346	the	_	
74-32	14347-14361	infrared-light	_	
74-33	14362-14368	signal	_	
74-34	14368-14369	,	_	
74-35	14370-14373	and	_	
74-36	14374-14375	a	_	
74-37	14376-14382	laptop	_	
74-38	14383-14386	for	_	
74-39	14387-14390	the	_	
74-40	14391-14398	digital	_	
74-41	14399-14403	data	_	
74-42	14404-14415	acquisition	_	
74-43	14416-14419	and	_	
74-44	14420-14428	analysis	_	
74-45	14429-14437	software	_	
74-46	14437-14438	.	_	

#Text=The hardware box was connected to a computer via a standard universal serial bus (USB) cable for data acquisition and controlled using COBI Studio.
75-1	14439-14442	The	_	
75-2	14443-14451	hardware	_	
75-3	14452-14455	box	_	
75-4	14456-14459	was	_	
75-5	14460-14469	connected	_	
75-6	14470-14472	to	_	
75-7	14473-14474	a	_	
75-8	14475-14483	computer	_	
75-9	14484-14487	via	_	
75-10	14488-14489	a	_	
75-11	14490-14498	standard	_	
75-12	14499-14508	universal	_	
75-13	14509-14515	serial	_	
75-14	14516-14519	bus	_	
75-15	14520-14521	(	_	
75-16	14521-14524	USB	_	
75-17	14524-14525	)	_	
75-18	14526-14531	cable	_	
75-19	14532-14535	for	_	
75-20	14536-14540	data	_	
75-21	14541-14552	acquisition	_	
75-22	14553-14556	and	_	
75-23	14557-14567	controlled	_	
75-24	14568-14573	using	_	
75-25	14574-14578	COBI	_	
75-26	14579-14585	Studio	_	
75-27	14585-14586	.	_	

#Text=The flexible sensor pad consisting of 4 light emitting diodes (LEDs) sources and 10 detectors, dividing the forehead into 16 optodes.
76-1	14587-14590	The	_	
76-2	14591-14599	flexible	_	
76-3	14600-14606	sensor	_	
76-4	14607-14610	pad	_	
76-5	14611-14621	consisting	_	
76-6	14622-14624	of	_	
76-7	14625-14626	4	_	
76-8	14627-14632	light	_	
76-9	14633-14641	emitting	_	
76-10	14642-14648	diodes	_	
76-11	14649-14650	(	_	
76-12	14650-14654	LEDs	_	
76-13	14654-14655	)	_	
76-14	14656-14663	sources	_	
76-15	14664-14667	and	_	
76-16	14668-14670	10	_	
76-17	14671-14680	detectors	_	
76-18	14680-14681	,	_	
76-19	14682-14690	dividing	_	
76-20	14691-14694	the	_	
76-21	14695-14703	forehead	_	
76-22	14704-14708	into	_	
76-23	14709-14711	16	_	
76-24	14712-14719	optodes	_	
76-25	14719-14720	.	_	

#Text=Light sources were controlled by the software and wavelengths of 730 nm and 850 nm were used to estimate simultaneously HBO and HBR levels and were presented with a time sequence of 50 msec.
77-1	14721-14726	Light	_	
77-2	14727-14734	sources	_	
77-3	14735-14739	were	_	
77-4	14740-14750	controlled	_	
77-5	14751-14753	by	_	
77-6	14754-14757	the	_	
77-7	14758-14766	software	_	
77-8	14767-14770	and	_	
77-9	14771-14782	wavelengths	_	
77-10	14783-14785	of	_	
77-11	14786-14789	730	_	
77-12	14790-14792	nm	_	
77-13	14793-14796	and	_	
77-14	14797-14800	850	_	
77-15	14801-14803	nm	_	
77-16	14804-14808	were	_	
77-17	14809-14813	used	_	
77-18	14814-14816	to	_	
77-19	14817-14825	estimate	_	
77-20	14826-14840	simultaneously	_	
77-21	14841-14844	HBO	_	
77-22	14845-14848	and	_	
77-23	14849-14852	HBR	_	
77-24	14853-14859	levels	_	
77-25	14860-14863	and	_	
77-26	14864-14868	were	_	
77-27	14869-14878	presented	_	
77-28	14879-14883	with	_	
77-29	14884-14885	a	_	
77-30	14886-14890	time	_	
77-31	14891-14899	sequence	_	
77-32	14900-14902	of	_	
77-33	14903-14905	50	_	
77-34	14906-14910	msec	_	
77-35	14910-14911	.	_	

#Text=The system recorded the two wavelengths and dark current for each of the optodes, totaling 48 measurements for each sampling period, and was collected at a rate of 2Hz.
78-1	14912-14915	The	_	
78-2	14916-14922	system	_	
78-3	14923-14931	recorded	_	
78-4	14932-14935	the	_	
78-5	14936-14939	two	_	
78-6	14940-14951	wavelengths	_	
78-7	14952-14955	and	_	
78-8	14956-14960	dark	_	
78-9	14961-14968	current	_	
78-10	14969-14972	for	_	
78-11	14973-14977	each	_	
78-12	14978-14980	of	_	
78-13	14981-14984	the	_	
78-14	14985-14992	optodes	_	
78-15	14992-14993	,	_	
78-16	14994-15002	totaling	_	
78-17	15003-15005	48	_	
78-18	15006-15018	measurements	_	
78-19	15019-15022	for	_	
78-20	15023-15027	each	_	
78-21	15028-15036	sampling	_	
78-22	15037-15043	period	_	
78-23	15043-15044	,	_	
78-24	15045-15048	and	_	
78-25	15049-15052	was	_	
78-26	15053-15062	collected	_	
78-27	15063-15065	at	_	
78-28	15066-15067	a	_	
78-29	15068-15072	rate	_	
78-30	15073-15075	of	_	
78-31	15076-15079	2Hz	_	
78-32	15079-15080	.	_	

#Text=The center of the pad was placed at the nasion point of the participant and secured to the head using Velcro wraps.
79-1	15081-15084	The	_	
79-2	15085-15091	center	_	
79-3	15092-15094	of	_	
79-4	15095-15098	the	_	
79-5	15099-15102	pad	_	
79-6	15103-15106	was	_	
79-7	15107-15113	placed	_	
79-8	15114-15116	at	_	
79-9	15117-15120	the	_	
79-10	15121-15127	nasion	_	
79-11	15128-15133	point	_	
79-12	15134-15136	of	_	
79-13	15137-15140	the	_	
79-14	15141-15152	participant	_	
79-15	15153-15156	and	_	
79-16	15157-15164	secured	_	
79-17	15165-15167	to	_	
79-18	15168-15171	the	_	
79-19	15172-15176	head	_	
79-20	15177-15182	using	_	
79-21	15183-15189	Velcro	_	
79-22	15190-15195	wraps	_	
79-23	15195-15196	.	_	

#Text=FNIRS does not allow for the absolute level of HBO and HBR at any one time point but instead relies on a comparison to baseline level of HBO and HBR to obtain an estimate of the changes in concentration.
80-1	15197-15202	FNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
80-2	15203-15207	does	_	
80-3	15208-15211	not	_	
80-4	15212-15217	allow	_	
80-5	15218-15221	for	_	
80-6	15222-15225	the	_	
80-7	15226-15234	absolute	_	
80-8	15235-15240	level	_	
80-9	15241-15243	of	_	
80-10	15244-15247	HBO	_	
80-11	15248-15251	and	_	
80-12	15252-15255	HBR	_	
80-13	15256-15258	at	_	
80-14	15259-15262	any	_	
80-15	15263-15266	one	_	
80-16	15267-15271	time	_	
80-17	15272-15277	point	_	
80-18	15278-15281	but	_	
80-19	15282-15289	instead	_	
80-20	15290-15296	relies	_	
80-21	15297-15299	on	_	
80-22	15300-15301	a	_	
80-23	15302-15312	comparison	_	
80-24	15313-15315	to	_	
80-25	15316-15324	baseline	_	
80-26	15325-15330	level	_	
80-27	15331-15333	of	_	
80-28	15334-15337	HBO	_	
80-29	15338-15341	and	_	
80-30	15342-15345	HBR	_	
80-31	15346-15348	to	_	
80-32	15349-15355	obtain	_	
80-33	15356-15358	an	_	
80-34	15359-15367	estimate	_	
80-35	15368-15370	of	_	
80-36	15371-15374	the	_	
80-37	15375-15382	changes	_	
80-38	15383-15385	in	_	
80-39	15386-15399	concentration	_	
80-40	15399-15400	.	_	

#Text=A 10 second baseline period collected prior to initiating the computer game was used as a comparison to obtain estimates of the relative levels of change in HBO and HBR as a function of task performance.
81-1	15401-15402	A	_	
81-2	15403-15405	10	_	
81-3	15406-15412	second	_	
81-4	15413-15421	baseline	_	
81-5	15422-15428	period	_	
81-6	15429-15438	collected	_	
81-7	15439-15444	prior	_	
81-8	15445-15447	to	_	
81-9	15448-15458	initiating	_	
81-10	15459-15462	the	_	
81-11	15463-15471	computer	_	
81-12	15472-15476	game	_	
81-13	15477-15480	was	_	
81-14	15481-15485	used	_	
81-15	15486-15488	as	_	
81-16	15489-15490	a	_	
81-17	15491-15501	comparison	_	
81-18	15502-15504	to	_	
81-19	15505-15511	obtain	_	
81-20	15512-15521	estimates	_	
81-21	15522-15524	of	_	
81-22	15525-15528	the	_	
81-23	15529-15537	relative	_	
81-24	15538-15544	levels	_	
81-25	15545-15547	of	_	
81-26	15548-15554	change	_	
81-27	15555-15557	in	_	
81-28	15558-15561	HBO	_	
81-29	15562-15565	and	_	
81-30	15566-15569	HBR	_	
81-31	15570-15572	as	_	
81-32	15573-15574	a	_	
81-33	15575-15583	function	_	
81-34	15584-15586	of	_	
81-35	15587-15591	task	_	
81-36	15592-15603	performance	_	
81-37	15603-15604	.	_	

#Text=The professional version of FNIRSoft@ from Drexel University was used to process, analyze, and visualize the fNIRS signals.
82-1	15605-15608	The	_	
82-2	15609-15621	professional	_	
82-3	15622-15629	version	_	
82-4	15630-15632	of	_	
82-5	15633-15641	FNIRSoft	_	
82-6	15641-15642	@	_	
82-7	15643-15647	from	_	
82-8	15648-15654	Drexel	_	
82-9	15655-15665	University	_	
82-10	15666-15669	was	_	
82-11	15670-15674	used	_	
82-12	15675-15677	to	_	
82-13	15678-15685	process	_	
82-14	15685-15686	,	_	
82-15	15687-15694	analyze	_	
82-16	15694-15695	,	_	
82-17	15696-15699	and	_	
82-18	15700-15709	visualize	_	
82-19	15710-15713	the	_	
82-20	15714-15719	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
82-21	15720-15727	signals	_	
82-22	15727-15728	.	_	

#Text=The software used MBLL to estimate the concentration of the chromophores (light absorbing molecules (HBO and HBR) from the intensity of the light detected by the sensors.
83-1	15729-15732	The	_	
83-2	15733-15741	software	_	
83-3	15742-15746	used	_	
83-4	15747-15751	MBLL	_	
83-5	15752-15754	to	_	
83-6	15755-15763	estimate	_	
83-7	15764-15767	the	_	
83-8	15768-15781	concentration	_	
83-9	15782-15784	of	_	
83-10	15785-15788	the	_	
83-11	15789-15801	chromophores	_	
83-12	15802-15803	(	_	
83-13	15803-15808	light	_	
83-14	15809-15818	absorbing	_	
83-15	15819-15828	molecules	_	
83-16	15829-15830	(	_	
83-17	15830-15833	HBO	_	
83-18	15834-15837	and	_	
83-19	15838-15841	HBR	_	
83-20	15841-15842	)	_	
83-21	15843-15847	from	_	
83-22	15848-15851	the	_	
83-23	15852-15861	intensity	_	
83-24	15862-15864	of	_	
83-25	15865-15868	the	_	
83-26	15869-15874	light	_	
83-27	15875-15883	detected	_	
83-28	15884-15886	by	_	
83-29	15887-15890	the	_	
83-30	15891-15898	sensors	_	
83-31	15898-15899	.	_	

#Text=Raw fNIRS and event marker data were uploaded into the software and then underwent preprocessing to remove artifacts in the data.
84-1	15900-15903	Raw	_	
84-2	15904-15909	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
84-3	15910-15913	and	_	
84-4	15914-15919	event	_	
84-5	15920-15926	marker	_	
84-6	15927-15931	data	_	
84-7	15932-15936	were	_	
84-8	15937-15945	uploaded	_	
84-9	15946-15950	into	_	
84-10	15951-15954	the	_	
84-11	15955-15963	software	_	
84-12	15964-15967	and	_	
84-13	15968-15972	then	_	
84-14	15973-15982	underwent	_	
84-15	15983-15996	preprocessing	_	
84-16	15997-15999	to	_	
84-17	16000-16006	remove	_	
84-18	16007-16016	artifacts	_	
84-19	16017-16019	in	_	
84-20	16020-16023	the	_	
84-21	16024-16028	data	_	
84-22	16028-16029	.	_	

#Text=A linear phase, low pass filter was applied to attenuate high frequency components of the signal followed by a median filtering procedure.
85-1	16030-16031	A	_	
85-2	16032-16038	linear	_	
85-3	16039-16044	phase	_	
85-4	16044-16045	,	_	
85-5	16046-16049	low	_	
85-6	16050-16054	pass	_	
85-7	16055-16061	filter	_	
85-8	16062-16065	was	_	
85-9	16066-16073	applied	_	
85-10	16074-16076	to	_	
85-11	16077-16086	attenuate	_	
85-12	16087-16091	high	_	
85-13	16092-16101	frequency	_	
85-14	16102-16112	components	_	
85-15	16113-16115	of	_	
85-16	16116-16119	the	_	
85-17	16120-16126	signal	_	
85-18	16127-16135	followed	_	
85-19	16136-16138	by	_	
85-20	16139-16140	a	_	
85-21	16141-16147	median	_	
85-22	16148-16157	filtering	_	
85-23	16158-16167	procedure	_	
85-24	16167-16168	.	_	

#Text=Next, to control for motion artifacts a Sliding-window Motion Artifact Rejection (SMAR) algorithm was applied.
86-1	16169-16173	Next	_	
86-2	16173-16174	,	_	
86-3	16175-16177	to	_	
86-4	16178-16185	control	_	
86-5	16186-16189	for	_	
86-6	16190-16196	motion	_	
86-7	16197-16206	artifacts	_	
86-8	16207-16208	a	_	
86-9	16209-16223	Sliding-window	_	
86-10	16224-16230	Motion	_	
86-11	16231-16239	Artifact	_	
86-12	16240-16249	Rejection	_	
86-13	16250-16251	(	_	
86-14	16251-16255	SMAR	_	
86-15	16255-16256	)	_	
86-16	16257-16266	algorithm	_	
86-17	16267-16270	was	_	
86-18	16271-16278	applied	_	
86-19	16278-16279	.	_	

#Text=Oxygenation levels were then computed from the cleaned data using MBLL, resulting in 16 optode estimates of HBO and HBR.
87-1	16280-16291	Oxygenation	_	
87-2	16292-16298	levels	_	
87-3	16299-16303	were	_	
87-4	16304-16308	then	_	
87-5	16309-16317	computed	_	
87-6	16318-16322	from	_	
87-7	16323-16326	the	_	
87-8	16327-16334	cleaned	_	
87-9	16335-16339	data	_	
87-10	16340-16345	using	_	
87-11	16346-16350	MBLL	_	
87-12	16350-16351	,	_	
87-13	16352-16361	resulting	_	
87-14	16362-16364	in	_	
87-15	16365-16367	16	_	
87-16	16368-16374	optode	_	
87-17	16375-16384	estimates	_	
87-18	16385-16387	of	_	
87-19	16388-16391	HBO	_	
87-20	16392-16395	and	_	
87-21	16396-16399	HBR	_	
87-22	16399-16400	.	_	

#Text=A detrending procedure was then applied to the data to eliminate measurement errors associated with prolonged sampling procedure used in the study.
#Text=2.2 FNIRS Task
#Text=The Frustration Emotion Task for Children (FETCH) is a computer-administered task that assesses individual differences in tolerance to frustrating events.
88-1	16401-16402	A	_	
88-2	16403-16413	detrending	_	
88-3	16414-16423	procedure	_	
88-4	16424-16427	was	_	
88-5	16428-16432	then	_	
88-6	16433-16440	applied	_	
88-7	16441-16443	to	_	
88-8	16444-16447	the	_	
88-9	16448-16452	data	_	
88-10	16453-16455	to	_	
88-11	16456-16465	eliminate	_	
88-12	16466-16477	measurement	_	
88-13	16478-16484	errors	_	
88-14	16485-16495	associated	_	
88-15	16496-16500	with	_	
88-16	16501-16510	prolonged	_	
88-17	16511-16519	sampling	_	
88-18	16520-16529	procedure	_	
88-19	16530-16534	used	_	
88-20	16535-16537	in	_	
88-21	16538-16541	the	_	
88-22	16542-16547	study	_	
88-23	16547-16548	.	_	
88-24	16549-16552	2.2	_	
88-25	16553-16558	FNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]	
88-26	16559-16563	Task	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-27	16564-16567	The	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-28	16568-16579	Frustration	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-29	16580-16587	Emotion	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-30	16588-16592	Task	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-31	16593-16596	for	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-32	16597-16605	Children	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-33	16606-16607	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-34	16607-16612	FETCH	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-35	16612-16613	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[56]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[57]	
88-36	16614-16616	is	_	
88-37	16617-16618	a	_	
88-38	16619-16640	computer-administered	_	
88-39	16641-16645	task	_	
88-40	16646-16650	that	_	
88-41	16651-16659	assesses	_	
88-42	16660-16670	individual	_	
88-43	16671-16682	differences	_	
88-44	16683-16685	in	_	
88-45	16686-16695	tolerance	_	
88-46	16696-16698	to	_	
88-47	16699-16710	frustrating	_	
88-48	16711-16717	events	_	
88-49	16717-16718	.	_	

#Text=Using fNIRS, children were found to have increased activity in the middle PFC in response to successful performance on the task and lateral PFC activity in response to frustration trials.
89-1	16719-16724	Using	_	
89-2	16725-16730	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
89-3	16730-16731	,	_	
89-4	16732-16740	children	_	
89-5	16741-16745	were	_	
89-6	16746-16751	found	_	
89-7	16752-16754	to	_	
89-8	16755-16759	have	_	
89-9	16760-16769	increased	_	
89-10	16770-16778	activity	_	
89-11	16779-16781	in	_	
89-12	16782-16785	the	_	
89-13	16786-16792	middle	_	
89-14	16793-16796	PFC	_	
89-15	16797-16799	in	_	
89-16	16800-16808	response	_	
89-17	16809-16811	to	_	
89-18	16812-16822	successful	_	
89-19	16823-16834	performance	_	
89-20	16835-16837	on	_	
89-21	16838-16841	the	_	
89-22	16842-16846	task	_	
89-23	16847-16850	and	_	
89-24	16851-16858	lateral	_	
89-25	16859-16862	PFC	_	
89-26	16863-16871	activity	_	
89-27	16872-16874	in	_	
89-28	16875-16883	response	_	
89-29	16884-16886	to	_	
89-30	16887-16898	frustration	_	
89-31	16899-16905	trials	_	
89-32	16905-16906	.	_	

#Text=The game requires the child to compete with a dog to retrieve a bone.
90-1	16907-16910	The	_	
90-2	16911-16915	game	_	
90-3	16916-16924	requires	_	
90-4	16925-16928	the	_	
90-5	16929-16934	child	_	
90-6	16935-16937	to	_	
90-7	16938-16945	compete	_	
90-8	16946-16950	with	_	
90-9	16951-16952	a	_	
90-10	16953-16956	dog	_	
90-11	16957-16959	to	_	
90-12	16960-16968	retrieve	_	
90-13	16969-16970	a	_	
90-14	16971-16975	bone	_	
90-15	16975-16976	.	_	

#Text=Three blocks are Win blocks (1, 3, & 5), defined by the child being able to be successful on 5 of the 6 trials, and three are Loss blocks (2, 4, & 6), defined as the child being unable to be successful on 5 of 6 trials.
91-1	16977-16982	Three	_	
91-2	16983-16989	blocks	_	
91-3	16990-16993	are	_	
91-4	16994-16997	Win	_	
91-5	16998-17004	blocks	_	
91-6	17005-17006	(	_	
91-7	17006-17007	1	_	
91-8	17007-17008	,	_	
91-9	17009-17010	3	_	
91-10	17010-17011	,	_	
91-11	17012-17013	&	_	
91-12	17014-17015	5	_	
91-13	17015-17016	)	_	
91-14	17016-17017	,	_	
91-15	17018-17025	defined	_	
91-16	17026-17028	by	_	
91-17	17029-17032	the	_	
91-18	17033-17038	child	_	
91-19	17039-17044	being	_	
91-20	17045-17049	able	_	
91-21	17050-17052	to	_	
91-22	17053-17055	be	_	
91-23	17056-17066	successful	_	
91-24	17067-17069	on	_	
91-25	17070-17071	5	_	
91-26	17072-17074	of	_	
91-27	17075-17078	the	_	
91-28	17079-17080	6	_	
91-29	17081-17087	trials	_	
91-30	17087-17088	,	_	
91-31	17089-17092	and	_	
91-32	17093-17098	three	_	
91-33	17099-17102	are	_	
91-34	17103-17107	Loss	_	
91-35	17108-17114	blocks	_	
91-36	17115-17116	(	_	
91-37	17116-17117	2	_	
91-38	17117-17118	,	_	
91-39	17119-17120	4	_	
91-40	17120-17121	,	_	
91-41	17122-17123	&	_	
91-42	17124-17125	6	_	
91-43	17125-17126	)	_	
91-44	17126-17127	,	_	
91-45	17128-17135	defined	_	
91-46	17136-17138	as	_	
91-47	17139-17142	the	_	
91-48	17143-17148	child	_	
91-49	17149-17154	being	_	
91-50	17155-17161	unable	_	
91-51	17162-17164	to	_	
91-52	17165-17167	be	_	
91-53	17168-17178	successful	_	
91-54	17179-17181	on	_	
91-55	17182-17183	5	_	
91-56	17184-17186	of	_	
91-57	17187-17188	6	_	
91-58	17189-17195	trials	_	
91-59	17195-17196	.	_	

#Text=Each of the first 6 trials lasts approximately 10,000 ms and has a delay, catch, feedback, and rest component.
92-1	17197-17201	Each	_	
92-2	17202-17204	of	_	
92-3	17205-17208	the	_	
92-4	17209-17214	first	_	
92-5	17215-17216	6	_	
92-6	17217-17223	trials	_	
92-7	17224-17229	lasts	_	
92-8	17230-17243	approximately	_	
92-9	17244-17250	10,000	_	
92-10	17251-17253	ms	_	
92-11	17254-17257	and	_	
92-12	17258-17261	has	_	
92-13	17262-17263	a	_	
92-14	17264-17269	delay	_	
92-15	17269-17270	,	_	
92-16	17271-17276	catch	_	
92-17	17276-17277	,	_	
92-18	17278-17286	feedback	_	
92-19	17286-17287	,	_	
92-20	17288-17291	and	_	
92-21	17292-17296	rest	_	
92-22	17297-17306	component	_	
92-23	17306-17307	.	_	

#Text=The delay and rest phases combined last approximately 6000 ms.
93-1	17308-17311	The	_	
93-2	17312-17317	delay	_	
93-3	17318-17321	and	_	
93-4	17322-17326	rest	_	
93-5	17327-17333	phases	_	
93-6	17334-17342	combined	_	
93-7	17343-17347	last	_	
93-8	17348-17361	approximately	_	
93-9	17362-17366	6000	_	
93-10	17367-17369	ms	_	
93-11	17369-17370	.	_	

#Text=The catch phase and individual trial feedback each last 2000 ms.
94-1	17371-17374	The	_	
94-2	17375-17380	catch	_	
94-3	17381-17386	phase	_	
94-4	17387-17390	and	_	
94-5	17391-17401	individual	_	
94-6	17402-17407	trial	_	
94-7	17408-17416	feedback	_	
94-8	17417-17421	each	_	
94-9	17422-17426	last	_	
94-10	17427-17431	2000	_	
94-11	17432-17434	ms	_	
94-12	17434-17435	.	_	

#Text=The total task performance time analyzed was 60,000 ms.
95-1	17436-17439	The	_	
95-2	17440-17445	total	_	
95-3	17446-17450	task	_	
95-4	17451-17462	performance	_	
95-5	17463-17467	time	_	
95-6	17468-17476	analyzed	_	
95-7	17477-17480	was	_	
95-8	17481-17487	60,000	_	
95-9	17488-17490	ms	_	
95-10	17490-17491	.	_	

#Text=Data were analyzed by aggregating across three blocks for each of the conditions (Win or Loss) and were then exported from the FNIRSoft software for further data analysis.
96-1	17492-17496	Data	_	
96-2	17497-17501	were	_	
96-3	17502-17510	analyzed	_	
96-4	17511-17513	by	_	
96-5	17514-17525	aggregating	_	
96-6	17526-17532	across	_	
96-7	17533-17538	three	_	
96-8	17539-17545	blocks	_	
96-9	17546-17549	for	_	
96-10	17550-17554	each	_	
96-11	17555-17557	of	_	
96-12	17558-17561	the	_	
96-13	17562-17572	conditions	_	
96-14	17573-17574	(	_	
96-15	17574-17577	Win	_	
96-16	17578-17580	or	_	
96-17	17581-17585	Loss	_	
96-18	17585-17586	)	_	
96-19	17587-17590	and	_	
96-20	17591-17595	were	_	
96-21	17596-17600	then	_	
96-22	17601-17609	exported	_	
96-23	17610-17614	from	_	
96-24	17615-17618	the	_	
96-25	17619-17627	FNIRSoft	_	
96-26	17628-17636	software	_	
96-27	17637-17640	for	_	
96-28	17641-17648	further	_	
96-29	17649-17653	data	_	
96-30	17654-17662	analysis	_	
96-31	17662-17663	.	_	

#Text=The HBO and HBR levels during the entire sampling period were analyzed to assess changes in neural activation as opposed to phasic changes associated with making a given response.
97-1	17664-17667	The	_	
97-2	17668-17671	HBO	_	
97-3	17672-17675	and	_	
97-4	17676-17679	HBR	_	
97-5	17680-17686	levels	_	
97-6	17687-17693	during	_	
97-7	17694-17697	the	_	
97-8	17698-17704	entire	_	
97-9	17705-17713	sampling	_	
97-10	17714-17720	period	_	
97-11	17721-17725	were	_	
97-12	17726-17734	analyzed	_	
97-13	17735-17737	to	_	
97-14	17738-17744	assess	_	
97-15	17745-17752	changes	_	
97-16	17753-17755	in	_	
97-17	17756-17762	neural	_	
97-18	17763-17773	activation	_	
97-19	17774-17776	as	_	
97-20	17777-17784	opposed	_	
97-21	17785-17787	to	_	
97-22	17788-17794	phasic	_	
97-23	17795-17802	changes	_	
97-24	17803-17813	associated	_	
97-25	17814-17818	with	_	
97-26	17819-17825	making	_	
97-27	17826-17827	a	_	
97-28	17828-17833	given	_	
97-29	17834-17842	response	_	
97-30	17842-17843	.	_	

#Text=After completing the respective trials for each block, participants were given feedback regarding their overall block performance and then asked to rate their emotional state by pointing to a series of faces with different expressions.
98-1	17844-17849	After	_	
98-2	17850-17860	completing	_	
98-3	17861-17864	the	_	
98-4	17865-17875	respective	_	
98-5	17876-17882	trials	_	
98-6	17883-17886	for	_	
98-7	17887-17891	each	_	
98-8	17892-17897	block	_	
98-9	17897-17898	,	_	
98-10	17899-17911	participants	_	
98-11	17912-17916	were	_	
98-12	17917-17922	given	_	
98-13	17923-17931	feedback	_	
98-14	17932-17941	regarding	_	
98-15	17942-17947	their	_	
98-16	17948-17955	overall	_	
98-17	17956-17961	block	_	
98-18	17962-17973	performance	_	
98-19	17974-17977	and	_	
98-20	17978-17982	then	_	
98-21	17983-17988	asked	_	
98-22	17989-17991	to	_	
98-23	17992-17996	rate	_	
98-24	17997-18002	their	_	
98-25	18003-18012	emotional	_	
98-26	18013-18018	state	_	
98-27	18019-18021	by	_	
98-28	18022-18030	pointing	_	
98-29	18031-18033	to	_	
98-30	18034-18035	a	_	
98-31	18036-18042	series	_	
98-32	18043-18045	of	_	
98-33	18046-18051	faces	_	
98-34	18052-18056	with	_	
98-35	18057-18066	different	_	
98-36	18067-18078	expressions	_	
98-37	18078-18079	.	_	

#Text=Their responses were coded using a likert scale ranging from −3 to +3 with 0 reflecting a neutral face, −3 reflecting a very unhappy face, and +3 a very happy face.
99-1	18080-18085	Their	_	
99-2	18086-18095	responses	_	
99-3	18096-18100	were	_	
99-4	18101-18106	coded	_	
99-5	18107-18112	using	_	
99-6	18113-18114	a	_	
99-7	18115-18121	likert	_	
99-8	18122-18127	scale	_	
99-9	18128-18135	ranging	_	
99-10	18136-18140	from	_	
99-11	18141-18142	−	_	
99-12	18142-18143	3	_	
99-13	18144-18146	to	_	
99-14	18147-18148	+	_	
99-15	18148-18149	3	_	
99-16	18150-18154	with	_	
99-17	18155-18156	0	_	
99-18	18157-18167	reflecting	_	
99-19	18168-18169	a	_	
99-20	18170-18177	neutral	_	
99-21	18178-18182	face	_	
99-22	18182-18183	,	_	
99-23	18184-18185	−	_	
99-24	18185-18186	3	_	
99-25	18187-18197	reflecting	_	
99-26	18198-18199	a	_	
99-27	18200-18204	very	_	
99-28	18205-18212	unhappy	_	
99-29	18213-18217	face	_	
99-30	18217-18218	,	_	
99-31	18219-18222	and	_	
99-32	18223-18224	+	_	
99-33	18224-18225	3	_	
99-34	18226-18227	a	_	
99-35	18228-18232	very	_	
99-36	18233-18238	happy	_	
99-37	18239-18243	face	_	
99-38	18243-18244	.	_	

#Text=The stimuli were those used previously but the scaling was altered from the previous 1–7 to more accurately reflect the valence of the emotion.
100-1	18245-18248	The	_	
100-2	18249-18256	stimuli	_	
100-3	18257-18261	were	_	
100-4	18262-18267	those	_	
100-5	18268-18272	used	_	
100-6	18273-18283	previously	_	
100-7	18284-18287	but	_	
100-8	18288-18291	the	_	
100-9	18292-18299	scaling	_	
100-10	18300-18303	was	_	
100-11	18304-18311	altered	_	
100-12	18312-18316	from	_	
100-13	18317-18320	the	_	
100-14	18321-18329	previous	_	
100-15	18330-18331	1	_	
100-16	18331-18332	–	_	
100-17	18332-18333	7	_	
100-18	18334-18336	to	_	
100-19	18337-18341	more	_	
100-20	18342-18352	accurately	_	
100-21	18353-18360	reflect	_	
100-22	18361-18364	the	_	
100-23	18365-18372	valence	_	
100-24	18373-18375	of	_	
100-25	18376-18379	the	_	
100-26	18380-18387	emotion	_	
100-27	18387-18388	.	_	

#Text=During game play, increased neural activation was anticipated for all of the children.
101-1	18389-18395	During	_	
101-2	18396-18400	game	_	
101-3	18401-18405	play	_	
101-4	18405-18406	,	_	
101-5	18407-18416	increased	_	
101-6	18417-18423	neural	_	
101-7	18424-18434	activation	_	
101-8	18435-18438	was	_	
101-9	18439-18450	anticipated	_	
101-10	18451-18454	for	_	
101-11	18455-18458	all	_	
101-12	18459-18461	of	_	
101-13	18462-18465	the	_	
101-14	18466-18474	children	_	
101-15	18474-18475	.	_	

#Text=Increased neural activation is indicated by increased levels of HBO as either increased concentrations of oxygenated blood relative to HBR are carried to the area activated and/or cerebral blood flow level increases.
102-1	18476-18485	Increased	_	
102-2	18486-18492	neural	_	
102-3	18493-18503	activation	_	
102-4	18504-18506	is	_	
102-5	18507-18516	indicated	_	
102-6	18517-18519	by	_	
102-7	18520-18529	increased	_	
102-8	18530-18536	levels	_	
102-9	18537-18539	of	_	
102-10	18540-18543	HBO	_	
102-11	18544-18546	as	_	
102-12	18547-18553	either	_	
102-13	18554-18563	increased	_	
102-14	18564-18578	concentrations	_	
102-15	18579-18581	of	_	
102-16	18582-18592	oxygenated	_	
102-17	18593-18598	blood	_	
102-18	18599-18607	relative	_	
102-19	18608-18610	to	_	
102-20	18611-18614	HBR	_	
102-21	18615-18618	are	_	
102-22	18619-18626	carried	_	
102-23	18627-18629	to	_	
102-24	18630-18633	the	_	
102-25	18634-18638	area	_	
102-26	18639-18648	activated	_	
102-27	18649-18652	and	_	
102-28	18652-18653	/	_	
102-29	18653-18655	or	_	
102-30	18656-18664	cerebral	_	
102-31	18665-18670	blood	_	
102-32	18671-18675	flow	_	
102-33	18676-18681	level	_	
102-34	18682-18691	increases	_	
102-35	18691-18692	.	_	

#Text=HBR levels were anticipated to decrease relative to baseline levels, resulting in negative values, as a functioning of relative increases in HBO as compared to HBR.
#Text=2.3 Analytic Plan
#Text=SPSS 24.0 was used for statistical analysis.
103-1	18693-18696	HBR	_	
103-2	18697-18703	levels	_	
103-3	18704-18708	were	_	
103-4	18709-18720	anticipated	_	
103-5	18721-18723	to	_	
103-6	18724-18732	decrease	_	
103-7	18733-18741	relative	_	
103-8	18742-18744	to	_	
103-9	18745-18753	baseline	_	
103-10	18754-18760	levels	_	
103-11	18760-18761	,	_	
103-12	18762-18771	resulting	_	
103-13	18772-18774	in	_	
103-14	18775-18783	negative	_	
103-15	18784-18790	values	_	
103-16	18790-18791	,	_	
103-17	18792-18794	as	_	
103-18	18795-18796	a	_	
103-19	18797-18808	functioning	_	
103-20	18809-18811	of	_	
103-21	18812-18820	relative	_	
103-22	18821-18830	increases	_	
103-23	18831-18833	in	_	
103-24	18834-18837	HBO	_	
103-25	18838-18840	as	_	
103-26	18841-18849	compared	_	
103-27	18850-18852	to	_	
103-28	18853-18856	HBR	_	
103-29	18856-18857	.	_	
103-30	18858-18861	2.3	_	
103-31	18862-18870	Analytic	_	
103-32	18871-18875	Plan	_	
103-33	18876-18880	SPSS	_	
103-34	18881-18885	24.0	_	
103-35	18886-18889	was	_	
103-36	18890-18894	used	_	
103-37	18895-18898	for	_	
103-38	18899-18910	statistical	_	
103-39	18911-18919	analysis	_	
103-40	18919-18920	.	_	

#Text=Descriptive statistics and frequency distributions to describe the characteristics of the individual and their families as well as the outcome measures were computed.
104-1	18921-18932	Descriptive	_	
104-2	18933-18943	statistics	_	
104-3	18944-18947	and	_	
104-4	18948-18957	frequency	_	
104-5	18958-18971	distributions	_	
104-6	18972-18974	to	_	
104-7	18975-18983	describe	_	
104-8	18984-18987	the	_	
104-9	18988-19003	characteristics	_	
104-10	19004-19006	of	_	
104-11	19007-19010	the	_	
104-12	19011-19021	individual	_	
104-13	19022-19025	and	_	
104-14	19026-19031	their	_	
104-15	19032-19040	families	_	
104-16	19041-19043	as	_	
104-17	19044-19048	well	_	
104-18	19049-19051	as	_	
104-19	19052-19055	the	_	
104-20	19056-19063	outcome	_	
104-21	19064-19072	measures	_	
104-22	19073-19077	were	_	
104-23	19078-19086	computed	_	
104-24	19086-19087	.	_	

#Text=To examine group differences in PFC activity, a mixed model analysis of variance was used to compare group differences in indices of PFC activity across the task conditions, Win vs.
105-1	19088-19090	To	_	
105-2	19091-19098	examine	_	
105-3	19099-19104	group	_	
105-4	19105-19116	differences	_	
105-5	19117-19119	in	_	
105-6	19120-19123	PFC	_	
105-7	19124-19132	activity	_	
105-8	19132-19133	,	_	
105-9	19134-19135	a	_	
105-10	19136-19141	mixed	_	
105-11	19142-19147	model	_	
105-12	19148-19156	analysis	_	
105-13	19157-19159	of	_	
105-14	19160-19168	variance	_	
105-15	19169-19172	was	_	
105-16	19173-19177	used	_	
105-17	19178-19180	to	_	
105-18	19181-19188	compare	_	
105-19	19189-19194	group	_	
105-20	19195-19206	differences	_	
105-21	19207-19209	in	_	
105-22	19210-19217	indices	_	
105-23	19218-19220	of	_	
105-24	19221-19224	PFC	_	
105-25	19225-19233	activity	_	
105-26	19234-19240	across	_	
105-27	19241-19244	the	_	
105-28	19245-19249	task	_	
105-29	19250-19260	conditions	_	
105-30	19260-19261	,	_	
105-31	19262-19265	Win	_	
105-32	19266-19268	vs	_	
105-33	19268-19269	.	_	

#Text=Loss.
106-1	19270-19274	Loss	_	
106-2	19274-19275	.	_	

#Text=Two separate analyses were conducted, which included separate analyses for HBO and HBR.
107-1	19276-19279	Two	_	
107-2	19280-19288	separate	_	
107-3	19289-19297	analyses	_	
107-4	19298-19302	were	_	
107-5	19303-19312	conducted	_	
107-6	19312-19313	,	_	
107-7	19314-19319	which	_	
107-8	19320-19328	included	_	
107-9	19329-19337	separate	_	
107-10	19338-19346	analyses	_	
107-11	19347-19350	for	_	
107-12	19351-19354	HBO	_	
107-13	19355-19358	and	_	
107-14	19359-19362	HBR	_	
107-15	19362-19363	.	_	

#Text=Condition (Win or Loss) was the between subjects factor and time was the repeated measure for each of the analyses with 120 samples.
108-1	19364-19373	Condition	_	
108-2	19374-19375	(	_	
108-3	19375-19378	Win	_	
108-4	19379-19381	or	_	
108-5	19382-19386	Loss	_	
108-6	19386-19387	)	_	
108-7	19388-19391	was	_	
108-8	19392-19395	the	_	
108-9	19396-19403	between	_	
108-10	19404-19412	subjects	_	
108-11	19413-19419	factor	_	
108-12	19420-19423	and	_	
108-13	19424-19428	time	_	
108-14	19429-19432	was	_	
108-15	19433-19436	the	_	
108-16	19437-19445	repeated	_	
108-17	19446-19453	measure	_	
108-18	19454-19457	for	_	
108-19	19458-19462	each	_	
108-20	19463-19465	of	_	
108-21	19466-19469	the	_	
108-22	19470-19478	analyses	_	
108-23	19479-19483	with	_	
108-24	19484-19487	120	_	
108-25	19488-19495	samples	_	
108-26	19495-19496	.	_	

#Text=To minimize the number of comparisons carried out in the study, data were aggregated across optodes.
109-1	19497-19499	To	_	
109-2	19500-19508	minimize	_	
109-3	19509-19512	the	_	
109-4	19513-19519	number	_	
109-5	19520-19522	of	_	
109-6	19523-19534	comparisons	_	
109-7	19535-19542	carried	_	
109-8	19543-19546	out	_	
109-9	19547-19549	in	_	
109-10	19550-19553	the	_	
109-11	19554-19559	study	_	
109-12	19559-19560	,	_	
109-13	19561-19565	data	_	
109-14	19566-19570	were	_	
109-15	19571-19581	aggregated	_	
109-16	19582-19588	across	_	
109-17	19589-19596	optodes	_	
109-18	19596-19597	.	_	

#Text=The 4 optodes placed on both the right and left side were aggregated to obtain an estimate of lateral PFC activity.
110-1	19598-19601	The	_	
110-2	19602-19603	4	_	
110-3	19604-19611	optodes	_	
110-4	19612-19618	placed	_	
110-5	19619-19621	on	_	
110-6	19622-19626	both	_	
110-7	19627-19630	the	_	
110-8	19631-19636	right	_	
110-9	19637-19640	and	_	
110-10	19641-19645	left	_	
110-11	19646-19650	side	_	
110-12	19651-19655	were	_	
110-13	19656-19666	aggregated	_	
110-14	19667-19669	to	_	
110-15	19670-19676	obtain	_	
110-16	19677-19679	an	_	
110-17	19680-19688	estimate	_	
110-18	19689-19691	of	_	
110-19	19692-19699	lateral	_	
110-20	19700-19703	PFC	_	
110-21	19704-19712	activity	_	
110-22	19712-19713	.	_	

#Text=Data obtained from the 8 optodes in the center were aggregated to estimate medial PFC activity.
111-1	19714-19718	Data	_	
111-2	19719-19727	obtained	_	
111-3	19728-19732	from	_	
111-4	19733-19736	the	_	
111-5	19737-19738	8	_	
111-6	19739-19746	optodes	_	
111-7	19747-19749	in	_	
111-8	19750-19753	the	_	
111-9	19754-19760	center	_	
111-10	19761-19765	were	_	
111-11	19766-19776	aggregated	_	
111-12	19777-19779	to	_	
111-13	19780-19788	estimate	_	
111-14	19789-19795	medial	_	
111-15	19796-19799	PFC	_	
111-16	19800-19808	activity	_	
111-17	19808-19809	.	_	

#Text=Missing fNIRS data can result from large head motions and sensor saturation or noise from the sensor pad pulling away from the skull.
112-1	19810-19817	Missing	_	
112-2	19818-19823	fNIRS	_	
112-3	19824-19828	data	_	
112-4	19829-19832	can	_	
112-5	19833-19839	result	_	
112-6	19840-19844	from	_	
112-7	19845-19850	large	_	
112-8	19851-19855	head	_	
112-9	19856-19863	motions	_	
112-10	19864-19867	and	_	
112-11	19868-19874	sensor	_	
112-12	19875-19885	saturation	_	
112-13	19886-19888	or	_	
112-14	19889-19894	noise	_	
112-15	19895-19899	from	_	
112-16	19900-19903	the	_	
112-17	19904-19910	sensor	_	
112-18	19911-19914	pad	_	
112-19	19915-19922	pulling	_	
112-20	19923-19927	away	_	
112-21	19928-19932	from	_	
112-22	19933-19936	the	_	
112-23	19937-19942	skull	_	
112-24	19942-19943	.	_	

#Text=To deal with the missing data, estimation was obtained using restricted maximum likelihood (REML), which imputes missing values and then generates parameter estimates and repeats this procedure using the estimates until there are minimal differences between iterations.
113-1	19944-19946	To	_	
113-2	19947-19951	deal	_	
113-3	19952-19956	with	_	
113-4	19957-19960	the	_	
113-5	19961-19968	missing	_	
113-6	19969-19973	data	_	
113-7	19973-19974	,	_	
113-8	19975-19985	estimation	_	
113-9	19986-19989	was	_	
113-10	19990-19998	obtained	_	
113-11	19999-20004	using	_	
113-12	20005-20015	restricted	_	
113-13	20016-20023	maximum	_	
113-14	20024-20034	likelihood	_	
113-15	20035-20036	(	_	
113-16	20036-20040	REML	_	
113-17	20040-20041	)	_	
113-18	20041-20042	,	_	
113-19	20043-20048	which	_	
113-20	20049-20056	imputes	_	
113-21	20057-20064	missing	_	
113-22	20065-20071	values	_	
113-23	20072-20075	and	_	
113-24	20076-20080	then	_	
113-25	20081-20090	generates	_	
113-26	20091-20100	parameter	_	
113-27	20101-20110	estimates	_	
113-28	20111-20114	and	_	
113-29	20115-20122	repeats	_	
113-30	20123-20127	this	_	
113-31	20128-20137	procedure	_	
113-32	20138-20143	using	_	
113-33	20144-20147	the	_	
113-34	20148-20157	estimates	_	
113-35	20158-20163	until	_	
113-36	20164-20169	there	_	
113-37	20170-20173	are	_	
113-38	20174-20181	minimal	_	
113-39	20182-20193	differences	_	
113-40	20194-20201	between	_	
113-41	20202-20212	iterations	_	
113-42	20212-20213	.	_	

#Text=REML has advantages over the maximum likelihood (ML) in that the REML method adjusts the degrees of freedom used for estimating fixed effects when estimating variance components and has been used previously in fNIRS studies.
114-1	20214-20218	REML	_	
114-2	20219-20222	has	_	
114-3	20223-20233	advantages	_	
114-4	20234-20238	over	_	
114-5	20239-20242	the	_	
114-6	20243-20250	maximum	_	
114-7	20251-20261	likelihood	_	
114-8	20262-20263	(	_	
114-9	20263-20265	ML	_	
114-10	20265-20266	)	_	
114-11	20267-20269	in	_	
114-12	20270-20274	that	_	
114-13	20275-20278	the	_	
114-14	20279-20283	REML	_	
114-15	20284-20290	method	_	
114-16	20291-20298	adjusts	_	
114-17	20299-20302	the	_	
114-18	20303-20310	degrees	_	
114-19	20311-20313	of	_	
114-20	20314-20321	freedom	_	
114-21	20322-20326	used	_	
114-22	20327-20330	for	_	
114-23	20331-20341	estimating	_	
114-24	20342-20347	fixed	_	
114-25	20348-20355	effects	_	
114-26	20356-20360	when	_	
114-27	20361-20371	estimating	_	
114-28	20372-20380	variance	_	
114-29	20381-20391	components	_	
114-30	20392-20395	and	_	
114-31	20396-20399	has	_	
114-32	20400-20404	been	_	
114-33	20405-20409	used	_	
114-34	20410-20420	previously	_	
114-35	20421-20423	in	_	
114-36	20424-20429	fNIRS	_	
114-37	20430-20437	studies	_	
114-38	20437-20438	.	_	

#Text=Post hoc comparisons were then carried out to contrast significant group effects using least square means and adjustments for multiple comparisons were made using a false discovery rate correction.
115-1	20439-20443	Post	_	
115-2	20444-20447	hoc	_	
115-3	20448-20459	comparisons	_	
115-4	20460-20464	were	_	
115-5	20465-20469	then	_	
115-6	20470-20477	carried	_	
115-7	20478-20481	out	_	
115-8	20482-20484	to	_	
115-9	20485-20493	contrast	_	
115-10	20494-20505	significant	_	
115-11	20506-20511	group	_	
115-12	20512-20519	effects	_	
115-13	20520-20525	using	_	
115-14	20526-20531	least	_	
115-15	20532-20538	square	_	
115-16	20539-20544	means	_	
115-17	20545-20548	and	_	
115-18	20549-20560	adjustments	_	
115-19	20561-20564	for	_	
115-20	20565-20573	multiple	_	
115-21	20574-20585	comparisons	_	
115-22	20586-20590	were	_	
115-23	20591-20595	made	_	
115-24	20596-20601	using	_	
115-25	20602-20603	a	_	
115-26	20604-20609	false	_	
115-27	20610-20619	discovery	_	
115-28	20620-20624	rate	_	
115-29	20625-20635	correction	_	
115-30	20635-20636	.	_	

#Text=Both the actual p-value and the adjusted p-value or q* are reported for the comparisons.
116-1	20637-20641	Both	_	
116-2	20642-20645	the	_	
116-3	20646-20652	actual	_	
116-4	20653-20660	p-value	_	
116-5	20661-20664	and	_	
116-6	20665-20668	the	_	
116-7	20669-20677	adjusted	_	
116-8	20678-20685	p-value	_	
116-9	20686-20688	or	_	
116-10	20689-20690	q	_	
116-11	20690-20691	*	_	
116-12	20692-20695	are	_	
116-13	20696-20704	reported	_	
116-14	20705-20708	for	_	
116-15	20709-20712	the	_	
116-16	20713-20724	comparisons	_	
116-17	20724-20725	.	_	

#Text=We hypothesized that children in the PAE group and in the Clinical Contrast group would differ from Controls as both groups have a pattern of behavioral or developmental dysfunction.
117-1	20726-20728	We	_	
117-2	20729-20741	hypothesized	_	
117-3	20742-20746	that	_	
117-4	20747-20755	children	_	
117-5	20756-20758	in	_	
117-6	20759-20762	the	_	
117-7	20763-20766	PAE	_	
117-8	20767-20772	group	_	
117-9	20773-20776	and	_	
117-10	20777-20779	in	_	
117-11	20780-20783	the	_	
117-12	20784-20792	Clinical	_	
117-13	20793-20801	Contrast	_	
117-14	20802-20807	group	_	
117-15	20808-20813	would	_	
117-16	20814-20820	differ	_	
117-17	20821-20825	from	_	
117-18	20826-20834	Controls	_	
117-19	20835-20837	as	_	
117-20	20838-20842	both	_	
117-21	20843-20849	groups	_	
117-22	20850-20854	have	_	
117-23	20855-20856	a	_	
117-24	20857-20864	pattern	_	
117-25	20865-20867	of	_	
117-26	20868-20878	behavioral	_	
117-27	20879-20881	or	_	
117-28	20882-20895	developmental	_	
117-29	20896-20907	dysfunction	_	
117-30	20907-20908	.	_	

#Text=Contrasts between the PAE and the Clinical Contrast group were also carried out to differentiate features of PFC activity that could be used to identify specific alcohol-related neurodevelopmental impairment of PFC activity relative to other disruptions to PFC activity that result in developmental and behavioral disruption.
#Text=3.
118-1	20909-20918	Contrasts	_	
118-2	20919-20926	between	_	
118-3	20927-20930	the	_	
118-4	20931-20934	PAE	_	
118-5	20935-20938	and	_	
118-6	20939-20942	the	_	
118-7	20943-20951	Clinical	_	
118-8	20952-20960	Contrast	_	
118-9	20961-20966	group	_	
118-10	20967-20971	were	_	
118-11	20972-20976	also	_	
118-12	20977-20984	carried	_	
118-13	20985-20988	out	_	
118-14	20989-20991	to	_	
118-15	20992-21005	differentiate	_	
118-16	21006-21014	features	_	
118-17	21015-21017	of	_	
118-18	21018-21021	PFC	_	
118-19	21022-21030	activity	_	
118-20	21031-21035	that	_	
118-21	21036-21041	could	_	
118-22	21042-21044	be	_	
118-23	21045-21049	used	_	
118-24	21050-21052	to	_	
118-25	21053-21061	identify	_	
118-26	21062-21070	specific	_	
118-27	21071-21086	alcohol-related	_	
118-28	21087-21105	neurodevelopmental	_	
118-29	21106-21116	impairment	_	
118-30	21117-21119	of	_	
118-31	21120-21123	PFC	_	
118-32	21124-21132	activity	_	
118-33	21133-21141	relative	_	
118-34	21142-21144	to	_	
118-35	21145-21150	other	_	
118-36	21151-21162	disruptions	_	
118-37	21163-21165	to	_	
118-38	21166-21169	PFC	_	
118-39	21170-21178	activity	_	
118-40	21179-21183	that	_	
118-41	21184-21190	result	_	
118-42	21191-21193	in	_	
118-43	21194-21207	developmental	_	
118-44	21208-21211	and	_	
118-45	21212-21222	behavioral	_	
118-46	21223-21233	disruption	_	
118-47	21233-21234	.	_	
118-48	21235-21236	3	_	
118-49	21236-21237	.	_	

#Text=Results
#Text=3.1 Group Characteristics
#Text=Demographic characteristics of the sample are outlined by group status in Table 1.
119-1	21238-21245	Results	_	
119-2	21246-21249	3.1	_	
119-3	21250-21255	Group	_	
119-4	21256-21271	Characteristics	_	
119-5	21272-21283	Demographic	_	
119-6	21284-21299	characteristics	_	
119-7	21300-21302	of	_	
119-8	21303-21306	the	_	
119-9	21307-21313	sample	_	
119-10	21314-21317	are	_	
119-11	21318-21326	outlined	_	
119-12	21327-21329	by	_	
119-13	21330-21335	group	_	
119-14	21336-21342	status	_	
119-15	21343-21345	in	_	
119-16	21346-21351	Table	_	
119-17	21352-21353	1	_	
119-18	21353-21354	.	_	

#Text=The groups did not differ in age, gender, racial identity, ethnicity, or child protective service involvement.
120-1	21355-21358	The	_	
120-2	21359-21365	groups	_	
120-3	21366-21369	did	_	
120-4	21370-21373	not	_	
120-5	21374-21380	differ	_	
120-6	21381-21383	in	_	
120-7	21384-21387	age	_	
120-8	21387-21388	,	_	
120-9	21389-21395	gender	_	
120-10	21395-21396	,	_	
120-11	21397-21403	racial	_	
120-12	21404-21412	identity	_	
120-13	21412-21413	,	_	
120-14	21414-21423	ethnicity	_	
120-15	21423-21424	,	_	
120-16	21425-21427	or	_	
120-17	21428-21433	child	_	
120-18	21434-21444	protective	_	
120-19	21445-21452	service	_	
120-20	21453-21464	involvement	_	
120-21	21464-21465	.	_	

#Text=Children’s current placement or caregiver varied as a function of group status (X (4) = 11.020, p < .026).
121-1	21466-21474	Children	_	
121-2	21474-21475	’	_	
121-3	21475-21476	s	_	
121-4	21477-21484	current	_	
121-5	21485-21494	placement	_	
121-6	21495-21497	or	_	
121-7	21498-21507	caregiver	_	
121-8	21508-21514	varied	_	
121-9	21515-21517	as	_	
121-10	21518-21519	a	_	
121-11	21520-21528	function	_	
121-12	21529-21531	of	_	
121-13	21532-21537	group	_	
121-14	21538-21544	status	_	
121-15	21545-21546	(	_	
121-16	21546-21547	X	_	
121-17	21548-21549	(	_	
121-18	21549-21550	4	_	
121-19	21550-21551	)	_	
121-20	21552-21553	=	_	
121-21	21554-21560	11.020	_	
121-22	21560-21561	,	_	
121-23	21562-21563	p	_	
121-24	21564-21565	<	_	
121-25	21566-21570	.026	_	
121-26	21570-21571	)	_	
121-27	21571-21572	.	_	

#Text=All of the children in the Control group were living with a biological parent while only 9 (50%) of the children with PAE were with a biological parent.
122-1	21573-21576	All	_	
122-2	21577-21579	of	_	
122-3	21580-21583	the	_	
122-4	21584-21592	children	_	
122-5	21593-21595	in	_	
122-6	21596-21599	the	_	
122-7	21600-21607	Control	_	
122-8	21608-21613	group	_	
122-9	21614-21618	were	_	
122-10	21619-21625	living	_	
122-11	21626-21630	with	_	
122-12	21631-21632	a	_	
122-13	21633-21643	biological	_	
122-14	21644-21650	parent	_	
122-15	21651-21656	while	_	
122-16	21657-21661	only	_	
122-17	21662-21663	9	_	
122-18	21664-21665	(	_	
122-19	21665-21668	50%	_	
122-20	21668-21669	)	_	
122-21	21670-21672	of	_	
122-22	21673-21676	the	_	
122-23	21677-21685	children	_	
122-24	21686-21690	with	_	
122-25	21691-21694	PAE	_	
122-26	21695-21699	were	_	
122-27	21700-21704	with	_	
122-28	21705-21706	a	_	
122-29	21707-21717	biological	_	
122-30	21718-21724	parent	_	
122-31	21724-21725	.	_	

#Text=The other children with a history of PAE were living with a relative (n=6, 33.3%) or either a legal guardian or adoptive parent (n=3, 16.7%).
123-1	21726-21729	The	_	
123-2	21730-21735	other	_	
123-3	21736-21744	children	_	
123-4	21745-21749	with	_	
123-5	21750-21751	a	_	
123-6	21752-21759	history	_	
123-7	21760-21762	of	_	
123-8	21763-21766	PAE	_	
123-9	21767-21771	were	_	
123-10	21772-21778	living	_	
123-11	21779-21783	with	_	
123-12	21784-21785	a	_	
123-13	21786-21794	relative	_	
123-14	21795-21796	(	_	
123-15	21796-21797	n	_	
123-16	21797-21798	=	_	
123-17	21798-21799	6	_	
123-18	21799-21800	,	_	
123-19	21801-21806	33.3%	_	
123-20	21806-21807	)	_	
123-21	21808-21810	or	_	
123-22	21811-21817	either	_	
123-23	21818-21819	a	_	
123-24	21820-21825	legal	_	
123-25	21826-21834	guardian	_	
123-26	21835-21837	or	_	
123-27	21838-21846	adoptive	_	
123-28	21847-21853	parent	_	
123-29	21854-21855	(	_	
123-30	21855-21856	n	_	
123-31	21856-21857	=	_	
123-32	21857-21858	3	_	
123-33	21858-21859	,	_	
123-34	21860-21865	16.7%	_	
123-35	21865-21866	)	_	
123-36	21866-21867	.	_	

#Text=For the Clinical Contrast Group, 12 (85.7%) of the children were living with a biological parent, 1 (7.1%) was in kinship care, and 1 (7.1%) was living with a legal guardian or adoptive parent.
124-1	21868-21871	For	_	
124-2	21872-21875	the	_	
124-3	21876-21884	Clinical	_	
124-4	21885-21893	Contrast	_	
124-5	21894-21899	Group	_	
124-6	21899-21900	,	_	
124-7	21901-21903	12	_	
124-8	21904-21905	(	_	
124-9	21905-21910	85.7%	_	
124-10	21910-21911	)	_	
124-11	21912-21914	of	_	
124-12	21915-21918	the	_	
124-13	21919-21927	children	_	
124-14	21928-21932	were	_	
124-15	21933-21939	living	_	
124-16	21940-21944	with	_	
124-17	21945-21946	a	_	
124-18	21947-21957	biological	_	
124-19	21958-21964	parent	_	
124-20	21964-21965	,	_	
124-21	21966-21967	1	_	
124-22	21968-21969	(	_	
124-23	21969-21973	7.1%	_	
124-24	21973-21974	)	_	
124-25	21975-21978	was	_	
124-26	21979-21981	in	_	
124-27	21982-21989	kinship	_	
124-28	21990-21994	care	_	
124-29	21994-21995	,	_	
124-30	21996-21999	and	_	
124-31	22000-22001	1	_	
124-32	22002-22003	(	_	
124-33	22003-22007	7.1%	_	
124-34	22007-22008	)	_	
124-35	22009-22012	was	_	
124-36	22013-22019	living	_	
124-37	22020-22024	with	_	
124-38	22025-22026	a	_	
124-39	22027-22032	legal	_	
124-40	22033-22041	guardian	_	
124-41	22042-22044	or	_	
124-42	22045-22053	adoptive	_	
124-43	22054-22060	parent	_	
124-44	22060-22061	.	_	

#Text=Overall level of intellectual functioning as estimated using the Differential Ability Scales, 2nd edition’s General Conceptual Ability score also varied as a function of group status (F (2, 41) = 4.94, p < .012) with the Clinical Contrast group (x=78.3 (std = 12.7)) performing significantly lower than did the Controls (x = 92.8 (std = 9.1)) and those in the PAE group (x=87.8 (std = 13.2)).
#Text=3.2 Missing PFC Activity Data
#Text=Incomplete data for HBO occurred across the entire sampling period was 9.1% for the Medial area, 6.3% for the Lateral Left side, and 3.9% for the Lateral Right side.
125-1	22062-22069	Overall	_	
125-2	22070-22075	level	_	
125-3	22076-22078	of	_	
125-4	22079-22091	intellectual	_	
125-5	22092-22103	functioning	_	
125-6	22104-22106	as	_	
125-7	22107-22116	estimated	_	
125-8	22117-22122	using	_	
125-9	22123-22126	the	_	
125-10	22127-22139	Differential	_	
125-11	22140-22147	Ability	_	
125-12	22148-22154	Scales	_	
125-13	22154-22155	,	_	
125-14	22156-22159	2nd	_	
125-15	22160-22167	edition	_	
125-16	22167-22168	’	_	
125-17	22168-22169	s	_	
125-18	22170-22177	General	_	
125-19	22178-22188	Conceptual	_	
125-20	22189-22196	Ability	_	
125-21	22197-22202	score	_	
125-22	22203-22207	also	_	
125-23	22208-22214	varied	_	
125-24	22215-22217	as	_	
125-25	22218-22219	a	_	
125-26	22220-22228	function	_	
125-27	22229-22231	of	_	
125-28	22232-22237	group	_	
125-29	22238-22244	status	_	
125-30	22245-22246	(	_	
125-31	22246-22247	F	_	
125-32	22248-22249	(	_	
125-33	22249-22250	2	_	
125-34	22250-22251	,	_	
125-35	22252-22254	41	_	
125-36	22254-22255	)	_	
125-37	22256-22257	=	_	
125-38	22258-22262	4.94	_	
125-39	22262-22263	,	_	
125-40	22264-22265	p	_	
125-41	22266-22267	<	_	
125-42	22268-22272	.012	_	
125-43	22272-22273	)	_	
125-44	22274-22278	with	_	
125-45	22279-22282	the	_	
125-46	22283-22291	Clinical	_	
125-47	22292-22300	Contrast	_	
125-48	22301-22306	group	_	
125-49	22307-22308	(	_	
125-50	22308-22309	x	_	
125-51	22309-22310	=	_	
125-52	22310-22314	78.3	_	
125-53	22315-22316	(	_	
125-54	22316-22319	std	_	
125-55	22320-22321	=	_	
125-56	22322-22326	12.7	_	
125-57	22326-22327	)	_	
125-58	22327-22328	)	_	
125-59	22329-22339	performing	_	
125-60	22340-22353	significantly	_	
125-61	22354-22359	lower	_	
125-62	22360-22364	than	_	
125-63	22365-22368	did	_	
125-64	22369-22372	the	_	
125-65	22373-22381	Controls	_	
125-66	22382-22383	(	_	
125-67	22383-22384	x	_	
125-68	22385-22386	=	_	
125-69	22387-22391	92.8	_	
125-70	22392-22393	(	_	
125-71	22393-22396	std	_	
125-72	22397-22398	=	_	
125-73	22399-22402	9.1	_	
125-74	22402-22403	)	_	
125-75	22403-22404	)	_	
125-76	22405-22408	and	_	
125-77	22409-22414	those	_	
125-78	22415-22417	in	_	
125-79	22418-22421	the	_	
125-80	22422-22425	PAE	_	
125-81	22426-22431	group	_	
125-82	22432-22433	(	_	
125-83	22433-22434	x	_	
125-84	22434-22435	=	_	
125-85	22435-22439	87.8	_	
125-86	22440-22441	(	_	
125-87	22441-22444	std	_	
125-88	22445-22446	=	_	
125-89	22447-22451	13.2	_	
125-90	22451-22452	)	_	
125-91	22452-22453	)	_	
125-92	22453-22454	.	_	
125-93	22455-22458	3.2	_	
125-94	22459-22466	Missing	_	
125-95	22467-22470	PFC	_	
125-96	22471-22479	Activity	_	
125-97	22480-22484	Data	_	
125-98	22485-22495	Incomplete	_	
125-99	22496-22500	data	_	
125-100	22501-22504	for	_	
125-101	22505-22508	HBO	_	
125-102	22509-22517	occurred	_	
125-103	22518-22524	across	_	
125-104	22525-22528	the	_	
125-105	22529-22535	entire	_	
125-106	22536-22544	sampling	_	
125-107	22545-22551	period	_	
125-108	22552-22555	was	_	
125-109	22556-22560	9.1%	_	
125-110	22561-22564	for	_	
125-111	22565-22568	the	_	
125-112	22569-22575	Medial	_	
125-113	22576-22580	area	_	
125-114	22580-22581	,	_	
125-115	22582-22586	6.3%	_	
125-116	22587-22590	for	_	
125-117	22591-22594	the	_	
125-118	22595-22602	Lateral	_	
125-119	22603-22607	Left	_	
125-120	22608-22612	side	_	
125-121	22612-22613	,	_	
125-122	22614-22617	and	_	
125-123	22618-22622	3.9%	_	
125-124	22623-22626	for	_	
125-125	22627-22630	the	_	
125-126	22631-22638	Lateral	_	
125-127	22639-22644	Right	_	
125-128	22645-22649	side	_	
125-129	22649-22650	.	_	

#Text=For HBR, incomplete data occurred in 3.6% for the Medial area, 8.7% for the Lateral Left side, and 5.9 % for the Lateral Right side.
#Text=3.3 FETCH Task Validity
#Text=Ratings of emotional reactions differed by condition with Win blocks associated with significantly higher (t (1,43) = 9.35, p < .000) positive emotional ratings (x = 2.11 (1.17)) as compared to the Loss Blocks (x = −0.65 (1.77).
126-1	22651-22654	For	_	
126-2	22655-22658	HBR	_	
126-3	22658-22659	,	_	
126-4	22660-22670	incomplete	_	
126-5	22671-22675	data	_	
126-6	22676-22684	occurred	_	
126-7	22685-22687	in	_	
126-8	22688-22692	3.6%	_	
126-9	22693-22696	for	_	
126-10	22697-22700	the	_	
126-11	22701-22707	Medial	_	
126-12	22708-22712	area	_	
126-13	22712-22713	,	_	
126-14	22714-22718	8.7%	_	
126-15	22719-22722	for	_	
126-16	22723-22726	the	_	
126-17	22727-22734	Lateral	_	
126-18	22735-22739	Left	_	
126-19	22740-22744	side	_	
126-20	22744-22745	,	_	
126-21	22746-22749	and	_	
126-22	22750-22753	5.9	_	
126-23	22754-22755	%	_	
126-24	22756-22759	for	_	
126-25	22760-22763	the	_	
126-26	22764-22771	Lateral	_	
126-27	22772-22777	Right	_	
126-28	22778-22782	side	_	
126-29	22782-22783	.	_	
126-30	22784-22787	3.3	_	
126-31	22788-22793	FETCH	_	
126-32	22794-22798	Task	_	
126-33	22799-22807	Validity	_	
126-34	22808-22815	Ratings	_	
126-35	22816-22818	of	_	
126-36	22819-22828	emotional	_	
126-37	22829-22838	reactions	_	
126-38	22839-22847	differed	_	
126-39	22848-22850	by	_	
126-40	22851-22860	condition	_	
126-41	22861-22865	with	_	
126-42	22866-22869	Win	_	
126-43	22870-22876	blocks	_	
126-44	22877-22887	associated	_	
126-45	22888-22892	with	_	
126-46	22893-22906	significantly	_	
126-47	22907-22913	higher	_	
126-48	22914-22915	(	_	
126-49	22915-22916	t	_	
126-50	22917-22918	(	_	
126-51	22918-22922	1,43	_	
126-52	22922-22923	)	_	
126-53	22924-22925	=	_	
126-54	22926-22930	9.35	_	
126-55	22930-22931	,	_	
126-56	22932-22933	p	_	
126-57	22934-22935	<	_	
126-58	22936-22940	.000	_	
126-59	22940-22941	)	_	
126-60	22942-22950	positive	_	
126-61	22951-22960	emotional	_	
126-62	22961-22968	ratings	_	
126-63	22969-22970	(	_	
126-64	22970-22971	x	_	
126-65	22972-22973	=	_	
126-66	22974-22978	2.11	_	
126-67	22979-22980	(	_	
126-68	22980-22984	1.17	_	
126-69	22984-22985	)	_	
126-70	22985-22986	)	_	
126-71	22987-22989	as	_	
126-72	22990-22998	compared	_	
126-73	22999-23001	to	_	
126-74	23002-23005	the	_	
126-75	23006-23010	Loss	_	
126-76	23011-23017	Blocks	_	
126-77	23018-23019	(	_	
126-78	23019-23020	x	_	
126-79	23021-23022	=	_	
126-80	23023-23024	−	_	
126-81	23024-23028	0.65	_	
126-82	23029-23030	(	_	
126-83	23030-23034	1.77	_	
126-84	23034-23035	)	_	
126-85	23035-23036	.	_	

#Text=For each of the comparison groups this was true as well (Controls: t (1, 11) = 4.407, p < .001; PAE : t (1, 17) = 6.75, p < .000; Clinical Contrast: t (1,13) = 4.641, p < .000) and the magnitude of the difference between the conditions did not differ by group status.
127-1	23037-23040	For	_	
127-2	23041-23045	each	_	
127-3	23046-23048	of	_	
127-4	23049-23052	the	_	
127-5	23053-23063	comparison	_	
127-6	23064-23070	groups	_	
127-7	23071-23075	this	_	
127-8	23076-23079	was	_	
127-9	23080-23084	true	_	
127-10	23085-23087	as	_	
127-11	23088-23092	well	_	
127-12	23093-23094	(	_	
127-13	23094-23102	Controls	_	
127-14	23102-23103	:	_	
127-15	23104-23105	t	_	
127-16	23106-23107	(	_	
127-17	23107-23108	1	_	
127-18	23108-23109	,	_	
127-19	23110-23112	11	_	
127-20	23112-23113	)	_	
127-21	23114-23115	=	_	
127-22	23116-23121	4.407	_	
127-23	23121-23122	,	_	
127-24	23123-23124	p	_	
127-25	23125-23126	<	_	
127-26	23127-23131	.001	_	
127-27	23131-23132	;	_	
127-28	23133-23136	PAE	_	
127-29	23137-23138	:	_	
127-30	23139-23140	t	_	
127-31	23141-23142	(	_	
127-32	23142-23143	1	_	
127-33	23143-23144	,	_	
127-34	23145-23147	17	_	
127-35	23147-23148	)	_	
127-36	23149-23150	=	_	
127-37	23151-23155	6.75	_	
127-38	23155-23156	,	_	
127-39	23157-23158	p	_	
127-40	23159-23160	<	_	
127-41	23161-23165	.000	_	
127-42	23165-23166	;	_	
127-43	23167-23175	Clinical	_	
127-44	23176-23184	Contrast	_	
127-45	23184-23185	:	_	
127-46	23186-23187	t	_	
127-47	23188-23189	(	_	
127-48	23189-23193	1,13	_	
127-49	23193-23194	)	_	
127-50	23195-23196	=	_	
127-51	23197-23202	4.641	_	
127-52	23202-23203	,	_	
127-53	23204-23205	p	_	
127-54	23206-23207	<	_	
127-55	23208-23212	.000	_	
127-56	23212-23213	)	_	
127-57	23214-23217	and	_	
127-58	23218-23221	the	_	
127-59	23222-23231	magnitude	_	
127-60	23232-23234	of	_	
127-61	23235-23238	the	_	
127-62	23239-23249	difference	_	
127-63	23250-23257	between	_	
127-64	23258-23261	the	_	
127-65	23262-23272	conditions	_	
127-66	23273-23276	did	_	
127-67	23277-23280	not	_	
127-68	23281-23287	differ	_	
127-69	23288-23290	by	_	
127-70	23291-23296	group	_	
127-71	23297-23303	status	_	
127-72	23303-23304	.	_	

#Text=There was, however, a significant relationship between the child’s age and their ratings in the Win condition (r = −0.38, p < .011) and the Loss condition (r = 0.43, p < .004) as well as the discrepancy in ratings between the two conditions (r = −0.61, p < .000).
#Text=3.4 Child’s Age and PFC Activation
#Text=The relationship between participant age and levels of HBO and HBR during performance on the Loss and Win conditions were examined but only one significant relationship was obtained.
128-1	23305-23310	There	_	
128-2	23311-23314	was	_	
128-3	23314-23315	,	_	
128-4	23316-23323	however	_	
128-5	23323-23324	,	_	
128-6	23325-23326	a	_	
128-7	23327-23338	significant	_	
128-8	23339-23351	relationship	_	
128-9	23352-23359	between	_	
128-10	23360-23363	the	_	
128-11	23364-23369	child	_	
128-12	23369-23370	’	_	
128-13	23370-23371	s	_	
128-14	23372-23375	age	_	
128-15	23376-23379	and	_	
128-16	23380-23385	their	_	
128-17	23386-23393	ratings	_	
128-18	23394-23396	in	_	
128-19	23397-23400	the	_	
128-20	23401-23404	Win	_	
128-21	23405-23414	condition	_	
128-22	23415-23416	(	_	
128-23	23416-23417	r	_	
128-24	23418-23419	=	_	
128-25	23420-23421	−	_	
128-26	23421-23425	0.38	_	
128-27	23425-23426	,	_	
128-28	23427-23428	p	_	
128-29	23429-23430	<	_	
128-30	23431-23435	.011	_	
128-31	23435-23436	)	_	
128-32	23437-23440	and	_	
128-33	23441-23444	the	_	
128-34	23445-23449	Loss	_	
128-35	23450-23459	condition	_	
128-36	23460-23461	(	_	
128-37	23461-23462	r	_	
128-38	23463-23464	=	_	
128-39	23465-23469	0.43	_	
128-40	23469-23470	,	_	
128-41	23471-23472	p	_	
128-42	23473-23474	<	_	
128-43	23475-23479	.004	_	
128-44	23479-23480	)	_	
128-45	23481-23483	as	_	
128-46	23484-23488	well	_	
128-47	23489-23491	as	_	
128-48	23492-23495	the	_	
128-49	23496-23507	discrepancy	_	
128-50	23508-23510	in	_	
128-51	23511-23518	ratings	_	
128-52	23519-23526	between	_	
128-53	23527-23530	the	_	
128-54	23531-23534	two	_	
128-55	23535-23545	conditions	_	
128-56	23546-23547	(	_	
128-57	23547-23548	r	_	
128-58	23549-23550	=	_	
128-59	23551-23552	−	_	
128-60	23552-23556	0.61	_	
128-61	23556-23557	,	_	
128-62	23558-23559	p	_	
128-63	23560-23561	<	_	
128-64	23562-23566	.000	_	
128-65	23566-23567	)	_	
128-66	23567-23568	.	_	
128-67	23569-23572	3.4	_	
128-68	23573-23578	Child	_	
128-69	23578-23579	’	_	
128-70	23579-23580	s	_	
128-71	23581-23584	Age	_	
128-72	23585-23588	and	_	
128-73	23589-23592	PFC	_	
128-74	23593-23603	Activation	_	
128-75	23604-23607	The	_	
128-76	23608-23620	relationship	_	
128-77	23621-23628	between	_	
128-78	23629-23640	participant	_	
128-79	23641-23644	age	_	
128-80	23645-23648	and	_	
128-81	23649-23655	levels	_	
128-82	23656-23658	of	_	
128-83	23659-23662	HBO	_	
128-84	23663-23666	and	_	
128-85	23667-23670	HBR	_	
128-86	23671-23677	during	_	
128-87	23678-23689	performance	_	
128-88	23690-23692	on	_	
128-89	23693-23696	the	_	
128-90	23697-23701	Loss	_	
128-91	23702-23705	and	_	
128-92	23706-23709	Win	_	
128-93	23710-23720	conditions	_	
128-94	23721-23725	were	_	
128-95	23726-23734	examined	_	
128-96	23735-23738	but	_	
128-97	23739-23743	only	_	
128-98	23744-23747	one	_	
128-99	23748-23759	significant	_	
128-100	23760-23772	relationship	_	
128-101	23773-23776	was	_	
128-102	23777-23785	obtained	_	
128-103	23785-23786	.	_	

#Text=The child’s age was negatively related to activation, or levels of HBO, in the Right Lateral PFC during the Loss blocks (r = −0.421, p < .004).
#Text=3.5 Group Differences in Changes in Oxygenation Levels During Game Play
#Text=In comparing baseline relative to game play, all groups across both Win and Loss conditions demonstrated an increase in HBO, reflecting an increase in neural activation.
129-1	23787-23790	The	_	
129-2	23791-23796	child	_	
129-3	23796-23797	’	_	
129-4	23797-23798	s	_	
129-5	23799-23802	age	_	
129-6	23803-23806	was	_	
129-7	23807-23817	negatively	_	
129-8	23818-23825	related	_	
129-9	23826-23828	to	_	
129-10	23829-23839	activation	_	
129-11	23839-23840	,	_	
129-12	23841-23843	or	_	
129-13	23844-23850	levels	_	
129-14	23851-23853	of	_	
129-15	23854-23857	HBO	_	
129-16	23857-23858	,	_	
129-17	23859-23861	in	_	
129-18	23862-23865	the	_	
129-19	23866-23871	Right	_	
129-20	23872-23879	Lateral	_	
129-21	23880-23883	PFC	_	
129-22	23884-23890	during	_	
129-23	23891-23894	the	_	
129-24	23895-23899	Loss	_	
129-25	23900-23906	blocks	_	
129-26	23907-23908	(	_	
129-27	23908-23909	r	_	
129-28	23910-23911	=	_	
129-29	23912-23913	−	_	
129-30	23913-23918	0.421	_	
129-31	23918-23919	,	_	
129-32	23920-23921	p	_	
129-33	23922-23923	<	_	
129-34	23924-23928	.004	_	
129-35	23928-23929	)	_	
129-36	23929-23930	.	_	
129-37	23931-23934	3.5	_	
129-38	23935-23940	Group	_	
129-39	23941-23952	Differences	_	
129-40	23953-23955	in	_	
129-41	23956-23963	Changes	_	
129-42	23964-23966	in	_	
129-43	23967-23978	Oxygenation	_	
129-44	23979-23985	Levels	_	
129-45	23986-23992	During	_	
129-46	23993-23997	Game	_	
129-47	23998-24002	Play	_	
129-48	24003-24005	In	_	
129-49	24006-24015	comparing	_	
129-50	24016-24024	baseline	_	
129-51	24025-24033	relative	_	
129-52	24034-24036	to	_	
129-53	24037-24041	game	_	
129-54	24042-24046	play	_	
129-55	24046-24047	,	_	
129-56	24048-24051	all	_	
129-57	24052-24058	groups	_	
129-58	24059-24065	across	_	
129-59	24066-24070	both	_	
129-60	24071-24074	Win	_	
129-61	24075-24078	and	_	
129-62	24079-24083	Loss	_	
129-63	24084-24094	conditions	_	
129-64	24095-24107	demonstrated	_	
129-65	24108-24110	an	_	
129-66	24111-24119	increase	_	
129-67	24120-24122	in	_	
129-68	24123-24126	HBO	_	
129-69	24126-24127	,	_	
129-70	24128-24138	reflecting	_	
129-71	24139-24141	an	_	
129-72	24142-24150	increase	_	
129-73	24151-24153	in	_	
129-74	24154-24160	neural	_	
129-75	24161-24171	activation	_	
129-76	24171-24172	.	_	

#Text=The exception was the performance of controls in the area of the Lateral Right PFC.
130-1	24173-24176	The	_	
130-2	24177-24186	exception	_	
130-3	24187-24190	was	_	
130-4	24191-24194	the	_	
130-5	24195-24206	performance	_	
130-6	24207-24209	of	_	
130-7	24210-24218	controls	_	
130-8	24219-24221	in	_	
130-9	24222-24225	the	_	
130-10	24226-24230	area	_	
130-11	24231-24233	of	_	
130-12	24234-24237	the	_	
130-13	24238-24245	Lateral	_	
130-14	24246-24251	Right	_	
130-15	24252-24255	PFC	_	
130-16	24255-24256	.	_	

#Text=Although there was a minimal increase in HBO in this area during the Win condition for this group, during the Loss condition the level of HBO was reduced, reflecting an inhibition of this area relative to the baseline period.
131-1	24257-24265	Although	_	
131-2	24266-24271	there	_	
131-3	24272-24275	was	_	
131-4	24276-24277	a	_	
131-5	24278-24285	minimal	_	
131-6	24286-24294	increase	_	
131-7	24295-24297	in	_	
131-8	24298-24301	HBO	_	
131-9	24302-24304	in	_	
131-10	24305-24309	this	_	
131-11	24310-24314	area	_	
131-12	24315-24321	during	_	
131-13	24322-24325	the	_	
131-14	24326-24329	Win	_	
131-15	24330-24339	condition	_	
131-16	24340-24343	for	_	
131-17	24344-24348	this	_	
131-18	24349-24354	group	_	
131-19	24354-24355	,	_	
131-20	24356-24362	during	_	
131-21	24363-24366	the	_	
131-22	24367-24371	Loss	_	
131-23	24372-24381	condition	_	
131-24	24382-24385	the	_	
131-25	24386-24391	level	_	
131-26	24392-24394	of	_	
131-27	24395-24398	HBO	_	
131-28	24399-24402	was	_	
131-29	24403-24410	reduced	_	
131-30	24410-24411	,	_	
131-31	24412-24422	reflecting	_	
131-32	24423-24425	an	_	
131-33	24426-24436	inhibition	_	
131-34	24437-24439	of	_	
131-35	24440-24444	this	_	
131-36	24445-24449	area	_	
131-37	24450-24458	relative	_	
131-38	24459-24461	to	_	
131-39	24462-24465	the	_	
131-40	24466-24474	baseline	_	
131-41	24475-24481	period	_	
131-42	24481-24482	.	_	

#Text=All groups demonstrated a reduction in HBR levels as a function of task perfomance relative to baseline levels, indicating an increased utilization of oxygen and increased levels of neural activation during task performance relative to baseline levels.
132-1	24483-24486	All	_	
132-2	24487-24493	groups	_	
132-3	24494-24506	demonstrated	_	
132-4	24507-24508	a	_	
132-5	24509-24518	reduction	_	
132-6	24519-24521	in	_	
132-7	24522-24525	HBR	_	
132-8	24526-24532	levels	_	
132-9	24533-24535	as	_	
132-10	24536-24537	a	_	
132-11	24538-24546	function	_	
132-12	24547-24549	of	_	
132-13	24550-24554	task	_	
132-14	24555-24565	perfomance	_	
132-15	24566-24574	relative	_	
132-16	24575-24577	to	_	
132-17	24578-24586	baseline	_	
132-18	24587-24593	levels	_	
132-19	24593-24594	,	_	
132-20	24595-24605	indicating	_	
132-21	24606-24608	an	_	
132-22	24609-24618	increased	_	
132-23	24619-24630	utilization	_	
132-24	24631-24633	of	_	
132-25	24634-24640	oxygen	_	
132-26	24641-24644	and	_	
132-27	24645-24654	increased	_	
132-28	24655-24661	levels	_	
132-29	24662-24664	of	_	
132-30	24665-24671	neural	_	
132-31	24672-24682	activation	_	
132-32	24683-24689	during	_	
132-33	24690-24694	task	_	
132-34	24695-24706	performance	_	
132-35	24707-24715	relative	_	
132-36	24716-24718	to	_	
132-37	24719-24727	baseline	_	
132-38	24728-24734	levels	_	
132-39	24734-24735	.	_	

#Text=Figures 1 (HBO) and 2 (HBR) display the overall means across the Win and Loss conditions by group status and scatter plots of the dispersion of HBO and HBR levels are presented by group, condition, and PFC area in Supplemental Figures 1 and 2.
133-1	24736-24743	Figures	_	
133-2	24744-24745	1	_	
133-3	24746-24747	(	_	
133-4	24747-24750	HBO	_	
133-5	24750-24751	)	_	
133-6	24752-24755	and	_	
133-7	24756-24757	2	_	
133-8	24758-24759	(	_	
133-9	24759-24762	HBR	_	
133-10	24762-24763	)	_	
133-11	24764-24771	display	_	
133-12	24772-24775	the	_	
133-13	24776-24783	overall	_	
133-14	24784-24789	means	_	
133-15	24790-24796	across	_	
133-16	24797-24800	the	_	
133-17	24801-24804	Win	_	
133-18	24805-24808	and	_	
133-19	24809-24813	Loss	_	
133-20	24814-24824	conditions	_	
133-21	24825-24827	by	_	
133-22	24828-24833	group	_	
133-23	24834-24840	status	_	
133-24	24841-24844	and	_	
133-25	24845-24852	scatter	_	
133-26	24853-24858	plots	_	
133-27	24859-24861	of	_	
133-28	24862-24865	the	_	
133-29	24866-24876	dispersion	_	
133-30	24877-24879	of	_	
133-31	24880-24883	HBO	_	
133-32	24884-24887	and	_	
133-33	24888-24891	HBR	_	
133-34	24892-24898	levels	_	
133-35	24899-24902	are	_	
133-36	24903-24912	presented	_	
133-37	24913-24915	by	_	
133-38	24916-24921	group	_	
133-39	24921-24922	,	_	
133-40	24923-24932	condition	_	
133-41	24932-24933	,	_	
133-42	24934-24937	and	_	
133-43	24938-24941	PFC	_	
133-44	24942-24946	area	_	
133-45	24947-24949	in	_	
133-46	24950-24962	Supplemental	_	
133-47	24963-24970	Figures	_	
133-48	24971-24972	1	_	
133-49	24973-24976	and	_	
133-50	24977-24978	2	_	
133-51	24978-24979	.	_	

#Text=The following describes the relative group and condition differences obtained in the study.
#Text=3.5.1 HBO During Game Play
#Text=During game play, a significant Condition effect was obtained for each of the aggregated measures (Lateral Left: F (1, 8433.739) = 106.635, p < .000; Lateral Right: F (1, 9140.677) = 49.336, p < .000; and Medial: F (1, 9056.906) = 217.143, p < .000) with each area associated with a reduction in HBO levels in the Loss relative to the Win condition.
134-1	24980-24983	The	_	
134-2	24984-24993	following	_	
134-3	24994-25003	describes	_	
134-4	25004-25007	the	_	
134-5	25008-25016	relative	_	
134-6	25017-25022	group	_	
134-7	25023-25026	and	_	
134-8	25027-25036	condition	_	
134-9	25037-25048	differences	_	
134-10	25049-25057	obtained	_	
134-11	25058-25060	in	_	
134-12	25061-25064	the	_	
134-13	25065-25070	study	_	
134-14	25070-25071	.	_	
134-15	25072-25077	3.5.1	_	
134-16	25078-25081	HBO	_	
134-17	25082-25088	During	_	
134-18	25089-25093	Game	_	
134-19	25094-25098	Play	_	
134-20	25099-25105	During	_	
134-21	25106-25110	game	_	
134-22	25111-25115	play	_	
134-23	25115-25116	,	_	
134-24	25117-25118	a	_	
134-25	25119-25130	significant	_	
134-26	25131-25140	Condition	_	
134-27	25141-25147	effect	_	
134-28	25148-25151	was	_	
134-29	25152-25160	obtained	_	
134-30	25161-25164	for	_	
134-31	25165-25169	each	_	
134-32	25170-25172	of	_	
134-33	25173-25176	the	_	
134-34	25177-25187	aggregated	_	
134-35	25188-25196	measures	_	
134-36	25197-25198	(	_	
134-37	25198-25205	Lateral	_	
134-38	25206-25210	Left	_	
134-39	25210-25211	:	_	
134-40	25212-25213	F	_	
134-41	25214-25215	(	_	
134-42	25215-25216	1	_	
134-43	25216-25217	,	_	
134-44	25218-25226	8433.739	_	
134-45	25226-25227	)	_	
134-46	25228-25229	=	_	
134-47	25230-25237	106.635	_	
134-48	25237-25238	,	_	
134-49	25239-25240	p	_	
134-50	25241-25242	<	_	
134-51	25243-25247	.000	_	
134-52	25247-25248	;	_	
134-53	25249-25256	Lateral	_	
134-54	25257-25262	Right	_	
134-55	25262-25263	:	_	
134-56	25264-25265	F	_	
134-57	25266-25267	(	_	
134-58	25267-25268	1	_	
134-59	25268-25269	,	_	
134-60	25270-25278	9140.677	_	
134-61	25278-25279	)	_	
134-62	25280-25281	=	_	
134-63	25282-25288	49.336	_	
134-64	25288-25289	,	_	
134-65	25290-25291	p	_	
134-66	25292-25293	<	_	
134-67	25294-25298	.000	_	
134-68	25298-25299	;	_	
134-69	25300-25303	and	_	
134-70	25304-25310	Medial	_	
134-71	25310-25311	:	_	
134-72	25312-25313	F	_	
134-73	25314-25315	(	_	
134-74	25315-25316	1	_	
134-75	25316-25317	,	_	
134-76	25318-25326	9056.906	_	
134-77	25326-25327	)	_	
134-78	25328-25329	=	_	
134-79	25330-25337	217.143	_	
134-80	25337-25338	,	_	
134-81	25339-25340	p	_	
134-82	25341-25342	<	_	
134-83	25343-25347	.000	_	
134-84	25347-25348	)	_	
134-85	25349-25353	with	_	
134-86	25354-25358	each	_	
134-87	25359-25363	area	_	
134-88	25364-25374	associated	_	
134-89	25375-25379	with	_	
134-90	25380-25381	a	_	
134-91	25382-25391	reduction	_	
134-92	25392-25394	in	_	
134-93	25395-25398	HBO	_	
134-94	25399-25405	levels	_	
134-95	25406-25408	in	_	
134-96	25409-25412	the	_	
134-97	25413-25417	Loss	_	
134-98	25418-25426	relative	_	
134-99	25427-25429	to	_	
134-100	25430-25433	the	_	
134-101	25434-25437	Win	_	
134-102	25438-25447	condition	_	
134-103	25447-25448	.	_	

#Text=Relative to group differences, a significant group effect was found in the Lateral Left (F (2, 8352.206) = 5.086, p < .006), Lateral Right (F (2, 9114.632) = 75.292, p < .000) and Medial (F (2, 9107.268) = 8.699, p < .000) areas but the group differences were not uniform.
135-1	25449-25457	Relative	_	
135-2	25458-25460	to	_	
135-3	25461-25466	group	_	
135-4	25467-25478	differences	_	
135-5	25478-25479	,	_	
135-6	25480-25481	a	_	
135-7	25482-25493	significant	_	
135-8	25494-25499	group	_	
135-9	25500-25506	effect	_	
135-10	25507-25510	was	_	
135-11	25511-25516	found	_	
135-12	25517-25519	in	_	
135-13	25520-25523	the	_	
135-14	25524-25531	Lateral	_	
135-15	25532-25536	Left	_	
135-16	25537-25538	(	_	
135-17	25538-25539	F	_	
135-18	25540-25541	(	_	
135-19	25541-25542	2	_	
135-20	25542-25543	,	_	
135-21	25544-25552	8352.206	_	
135-22	25552-25553	)	_	
135-23	25554-25555	=	_	
135-24	25556-25561	5.086	_	
135-25	25561-25562	,	_	
135-26	25563-25564	p	_	
135-27	25565-25566	<	_	
135-28	25567-25571	.006	_	
135-29	25571-25572	)	_	
135-30	25572-25573	,	_	
135-31	25574-25581	Lateral	_	
135-32	25582-25587	Right	_	
135-33	25588-25589	(	_	
135-34	25589-25590	F	_	
135-35	25591-25592	(	_	
135-36	25592-25593	2	_	
135-37	25593-25594	,	_	
135-38	25595-25603	9114.632	_	
135-39	25603-25604	)	_	
135-40	25605-25606	=	_	
135-41	25607-25613	75.292	_	
135-42	25613-25614	,	_	
135-43	25615-25616	p	_	
135-44	25617-25618	<	_	
135-45	25619-25623	.000	_	
135-46	25623-25624	)	_	
135-47	25625-25628	and	_	
135-48	25629-25635	Medial	_	
135-49	25636-25637	(	_	
135-50	25637-25638	F	_	
135-51	25639-25640	(	_	
135-52	25640-25641	2	_	
135-53	25641-25642	,	_	
135-54	25643-25651	9107.268	_	
135-55	25651-25652	)	_	
135-56	25653-25654	=	_	
135-57	25655-25660	8.699	_	
135-58	25660-25661	,	_	
135-59	25662-25663	p	_	
135-60	25664-25665	<	_	
135-61	25666-25670	.000	_	
135-62	25670-25671	)	_	
135-63	25672-25677	areas	_	
135-64	25678-25681	but	_	
135-65	25682-25685	the	_	
135-66	25686-25691	group	_	
135-67	25692-25703	differences	_	
135-68	25704-25708	were	_	
135-69	25709-25712	not	_	
135-70	25713-25720	uniform	_	
135-71	25720-25721	.	_	

#Text=Table 2 displays the means by group status.
136-1	25722-25727	Table	_	
136-2	25728-25729	2	_	
136-3	25730-25738	displays	_	
136-4	25739-25742	the	_	
136-5	25743-25748	means	_	
136-6	25749-25751	by	_	
136-7	25752-25757	group	_	
136-8	25758-25764	status	_	
136-9	25764-25765	.	_	

#Text=For the Lateral Left, the Control group demonstrated greater levels of HBO than did the PAE group (t = 3.089, p < .0020, q* < .006) but was not significantly different from the Clinical Contrast group who also did not differ from the PAE group.
137-1	25766-25769	For	_	
137-2	25770-25773	the	_	
137-3	25774-25781	Lateral	_	
137-4	25782-25786	Left	_	
137-5	25786-25787	,	_	
137-6	25788-25791	the	_	
137-7	25792-25799	Control	_	
137-8	25800-25805	group	_	
137-9	25806-25818	demonstrated	_	
137-10	25819-25826	greater	_	
137-11	25827-25833	levels	_	
137-12	25834-25836	of	_	
137-13	25837-25840	HBO	_	
137-14	25841-25845	than	_	
137-15	25846-25849	did	_	
137-16	25850-25853	the	_	
137-17	25854-25857	PAE	_	
137-18	25858-25863	group	_	
137-19	25864-25865	(	_	
137-20	25865-25866	t	_	
137-21	25867-25868	=	_	
137-22	25869-25874	3.089	_	
137-23	25874-25875	,	_	
137-24	25876-25877	p	_	
137-25	25878-25879	<	_	
137-26	25880-25885	.0020	_	
137-27	25885-25886	,	_	
137-28	25887-25888	q	_	
137-29	25888-25889	*	_	
137-30	25890-25891	<	_	
137-31	25892-25896	.006	_	
137-32	25896-25897	)	_	
137-33	25898-25901	but	_	
137-34	25902-25905	was	_	
137-35	25906-25909	not	_	
137-36	25910-25923	significantly	_	
137-37	25924-25933	different	_	
137-38	25934-25938	from	_	
137-39	25939-25942	the	_	
137-40	25943-25951	Clinical	_	
137-41	25952-25960	Contrast	_	
137-42	25961-25966	group	_	
137-43	25967-25970	who	_	
137-44	25971-25975	also	_	
137-45	25976-25979	did	_	
137-46	25980-25983	not	_	
137-47	25984-25990	differ	_	
137-48	25991-25995	from	_	
137-49	25996-25999	the	_	
137-50	26000-26003	PAE	_	
137-51	26004-26009	group	_	
137-52	26009-26010	.	_	

#Text=For the Lateral Right mean, the Controls had the least amount of HBO throughout the measurement period, followed by the PAE group, and then the Clinical Contrast group with each group significantly differing from each other (Controls vs.
138-1	26011-26014	For	_	
138-2	26015-26018	the	_	
138-3	26019-26026	Lateral	_	
138-4	26027-26032	Right	_	
138-5	26033-26037	mean	_	
138-6	26037-26038	,	_	
138-7	26039-26042	the	_	
138-8	26043-26051	Controls	_	
138-9	26052-26055	had	_	
138-10	26056-26059	the	_	
138-11	26060-26065	least	_	
138-12	26066-26072	amount	_	
138-13	26073-26075	of	_	
138-14	26076-26079	HBO	_	
138-15	26080-26090	throughout	_	
138-16	26091-26094	the	_	
138-17	26095-26106	measurement	_	
138-18	26107-26113	period	_	
138-19	26113-26114	,	_	
138-20	26115-26123	followed	_	
138-21	26124-26126	by	_	
138-22	26127-26130	the	_	
138-23	26131-26134	PAE	_	
138-24	26135-26140	group	_	
138-25	26140-26141	,	_	
138-26	26142-26145	and	_	
138-27	26146-26150	then	_	
138-28	26151-26154	the	_	
138-29	26155-26163	Clinical	_	
138-30	26164-26172	Contrast	_	
138-31	26173-26178	group	_	
138-32	26179-26183	with	_	
138-33	26184-26188	each	_	
138-34	26189-26194	group	_	
138-35	26195-26208	significantly	_	
138-36	26209-26218	differing	_	
138-37	26219-26223	from	_	
138-38	26224-26228	each	_	
138-39	26229-26234	other	_	
138-40	26235-26236	(	_	
138-41	26236-26244	Controls	_	
138-42	26245-26247	vs	_	
138-43	26247-26248	.	_	

#Text=PAE: t = 8.477, p < .0000, q* < .0000; Controls vs.
139-1	26249-26252	PAE	_	
139-2	26252-26253	:	_	
139-3	26254-26255	t	_	
139-4	26256-26257	=	_	
139-5	26258-26263	8.477	_	
139-6	26263-26264	,	_	
139-7	26265-26266	p	_	
139-8	26267-26268	<	_	
139-9	26269-26274	.0000	_	
139-10	26274-26275	,	_	
139-11	26276-26277	q	_	
139-12	26277-26278	*	_	
139-13	26279-26280	<	_	
139-14	26281-26286	.0000	_	
139-15	26286-26287	;	_	
139-16	26288-26296	Controls	_	
139-17	26297-26299	vs	_	
139-18	26299-26300	.	_	

#Text=Clinical Contrast: t = 11.729, p < .0000, q* < .0000; PAE vs.
140-1	26301-26309	Clinical	_	
140-2	26310-26318	Contrast	_	
140-3	26318-26319	:	_	
140-4	26320-26321	t	_	
140-5	26322-26323	=	_	
140-6	26324-26330	11.729	_	
140-7	26330-26331	,	_	
140-8	26332-26333	p	_	
140-9	26334-26335	<	_	
140-10	26336-26341	.0000	_	
140-11	26341-26342	,	_	
140-12	26343-26344	q	_	
140-13	26344-26345	*	_	
140-14	26346-26347	<	_	
140-15	26348-26353	.0000	_	
140-16	26353-26354	;	_	
140-17	26355-26358	PAE	_	
140-18	26359-26361	vs	_	
140-19	26361-26362	.	_	

#Text=Clinical Contrast: t = 4.148, p < .0000, q* < .0000).
141-1	26363-26371	Clinical	_	
141-2	26372-26380	Contrast	_	
141-3	26380-26381	:	_	
141-4	26382-26383	t	_	
141-5	26384-26385	=	_	
141-6	26386-26391	4.148	_	
141-7	26391-26392	,	_	
141-8	26393-26394	p	_	
141-9	26395-26396	<	_	
141-10	26397-26402	.0000	_	
141-11	26402-26403	,	_	
141-12	26404-26405	q	_	
141-13	26405-26406	*	_	
141-14	26407-26408	<	_	
141-15	26409-26414	.0000	_	
141-16	26414-26415	)	_	
141-17	26415-26416	.	_	

#Text=For the Medial mean, the PAE group displayed less HBO relative to both other groups who did not differ from one another (PAE vs.
142-1	26417-26420	For	_	
142-2	26421-26424	the	_	
142-3	26425-26431	Medial	_	
142-4	26432-26436	mean	_	
142-5	26436-26437	,	_	
142-6	26438-26441	the	_	
142-7	26442-26445	PAE	_	
142-8	26446-26451	group	_	
142-9	26452-26461	displayed	_	
142-10	26462-26466	less	_	
142-11	26467-26470	HBO	_	
142-12	26471-26479	relative	_	
142-13	26480-26482	to	_	
142-14	26483-26487	both	_	
142-15	26488-26493	other	_	
142-16	26494-26500	groups	_	
142-17	26501-26504	who	_	
142-18	26505-26508	did	_	
142-19	26509-26512	not	_	
142-20	26513-26519	differ	_	
142-21	26520-26524	from	_	
142-22	26525-26528	one	_	
142-23	26529-26536	another	_	
142-24	26537-26538	(	_	
142-25	26538-26541	PAE	_	
142-26	26542-26544	vs	_	
142-27	26544-26545	.	_	

#Text=Controls: t = 2.601, p < .0093, q* < .01395; PAE vs.
143-1	26546-26554	Controls	_	
143-2	26554-26555	:	_	
143-3	26556-26557	t	_	
143-4	26558-26559	=	_	
143-5	26560-26565	2.601	_	
143-6	26565-26566	,	_	
143-7	26567-26568	p	_	
143-8	26569-26570	<	_	
143-9	26571-26576	.0093	_	
143-10	26576-26577	,	_	
143-11	26578-26579	q	_	
143-12	26579-26580	*	_	
143-13	26581-26582	<	_	
143-14	26583-26589	.01395	_	
143-15	26589-26590	;	_	
143-16	26591-26594	PAE	_	
143-17	26595-26597	vs	_	
143-18	26597-26598	.	_	

#Text=Clinical Contrast: t = 4.013, p < .0001, q* < .0003).
144-1	26599-26607	Clinical	_	
144-2	26608-26616	Contrast	_	
144-3	26616-26617	:	_	
144-4	26618-26619	t	_	
144-5	26620-26621	=	_	
144-6	26622-26627	4.013	_	
144-7	26627-26628	,	_	
144-8	26629-26630	p	_	
144-9	26631-26632	<	_	
144-10	26633-26638	.0001	_	
144-11	26638-26639	,	_	
144-12	26640-26641	q	_	
144-13	26641-26642	*	_	
144-14	26643-26644	<	_	
144-15	26645-26650	.0003	_	
144-16	26650-26651	)	_	
144-17	26651-26652	.	_	

#Text=In addition to the main effects for group, significant interaction effects were obtained on the Lateral Left (F (2, 8352.307) = 65.799, p < .000) and the Medial (F (2, 9107.666) = 20.604, p < .000) areas.
145-1	26653-26655	In	_	
145-2	26656-26664	addition	_	
145-3	26665-26667	to	_	
145-4	26668-26671	the	_	
145-5	26672-26676	main	_	
145-6	26677-26684	effects	_	
145-7	26685-26688	for	_	
145-8	26689-26694	group	_	
145-9	26694-26695	,	_	
145-10	26696-26707	significant	_	
145-11	26708-26719	interaction	_	
145-12	26720-26727	effects	_	
145-13	26728-26732	were	_	
145-14	26733-26741	obtained	_	
145-15	26742-26744	on	_	
145-16	26745-26748	the	_	
145-17	26749-26756	Lateral	_	
145-18	26757-26761	Left	_	
145-19	26762-26763	(	_	
145-20	26763-26764	F	_	
145-21	26765-26766	(	_	
145-22	26766-26767	2	_	
145-23	26767-26768	,	_	
145-24	26769-26777	8352.307	_	
145-25	26777-26778	)	_	
145-26	26779-26780	=	_	
145-27	26781-26787	65.799	_	
145-28	26787-26788	,	_	
145-29	26789-26790	p	_	
145-30	26791-26792	<	_	
145-31	26793-26797	.000	_	
145-32	26797-26798	)	_	
145-33	26799-26802	and	_	
145-34	26803-26806	the	_	
145-35	26807-26813	Medial	_	
145-36	26814-26815	(	_	
145-37	26815-26816	F	_	
145-38	26817-26818	(	_	
145-39	26818-26819	2	_	
145-40	26819-26820	,	_	
145-41	26821-26829	9107.666	_	
145-42	26829-26830	)	_	
145-43	26831-26832	=	_	
145-44	26833-26839	20.604	_	
145-45	26839-26840	,	_	
145-46	26841-26842	p	_	
145-47	26843-26844	<	_	
145-48	26845-26849	.000	_	
145-49	26849-26850	)	_	
145-50	26851-26856	areas	_	
145-51	26856-26857	.	_	

#Text=Figure 3 displays the mean levels of HBO as a function of group status and condition for each of the aggregated measures.
146-1	26858-26864	Figure	_	
146-2	26865-26866	3	_	
146-3	26867-26875	displays	_	
146-4	26876-26879	the	_	
146-5	26880-26884	mean	_	
146-6	26885-26891	levels	_	
146-7	26892-26894	of	_	
146-8	26895-26898	HBO	_	
146-9	26899-26901	as	_	
146-10	26902-26903	a	_	
146-11	26904-26912	function	_	
146-12	26913-26915	of	_	
146-13	26916-26921	group	_	
146-14	26922-26928	status	_	
146-15	26929-26932	and	_	
146-16	26933-26942	condition	_	
146-17	26943-26946	for	_	
146-18	26947-26951	each	_	
146-19	26952-26954	of	_	
146-20	26955-26958	the	_	
146-21	26959-26969	aggregated	_	
146-22	26970-26978	measures	_	
146-23	26978-26979	.	_	

#Text=In the Win condition, HBO levels in the Lateral Left of the Clinical Contrast group were higher than both other groups (Clincal Contrat vs.
147-1	26980-26982	In	_	
147-2	26983-26986	the	_	
147-3	26987-26990	Win	_	
147-4	26991-27000	condition	_	
147-5	27000-27001	,	_	
147-6	27002-27005	HBO	_	
147-7	27006-27012	levels	_	
147-8	27013-27015	in	_	
147-9	27016-27019	the	_	
147-10	27020-27027	Lateral	_	
147-11	27028-27032	Left	_	
147-12	27033-27035	of	_	
147-13	27036-27039	the	_	
147-14	27040-27048	Clinical	_	
147-15	27049-27057	Contrast	_	
147-16	27058-27063	group	_	
147-17	27064-27068	were	_	
147-18	27069-27075	higher	_	
147-19	27076-27080	than	_	
147-20	27081-27085	both	_	
147-21	27086-27091	other	_	
147-22	27092-27098	groups	_	
147-23	27099-27100	(	_	
147-24	27100-27107	Clincal	_	
147-25	27108-27115	Contrat	_	
147-26	27116-27118	vs	_	
147-27	27118-27119	.	_	

#Text=PAE: t = 6.643, p < .0001, q* < .00015; Clinical Contrast vs.
148-1	27120-27123	PAE	_	
148-2	27123-27124	:	_	
148-3	27125-27126	t	_	
148-4	27127-27128	=	_	
148-5	27129-27134	6.643	_	
148-6	27134-27135	,	_	
148-7	27136-27137	p	_	
148-8	27138-27139	<	_	
148-9	27140-27145	.0001	_	
148-10	27145-27146	,	_	
148-11	27147-27148	q	_	
148-12	27148-27149	*	_	
148-13	27150-27151	<	_	
148-14	27152-27158	.00015	_	
148-15	27158-27159	;	_	
148-16	27160-27168	Clinical	_	
148-17	27169-27177	Contrast	_	
148-18	27178-27180	vs	_	
148-19	27180-27181	.	_	

#Text=Controls: t = 7.394, p < .0001, q* = .00015) who did not differ from each other.
149-1	27182-27190	Controls	_	
149-2	27190-27191	:	_	
149-3	27192-27193	t	_	
149-4	27194-27195	=	_	
149-5	27196-27201	7.394	_	
149-6	27201-27202	,	_	
149-7	27203-27204	p	_	
149-8	27205-27206	<	_	
149-9	27207-27212	.0001	_	
149-10	27212-27213	,	_	
149-11	27214-27215	q	_	
149-12	27215-27216	*	_	
149-13	27217-27218	=	_	
149-14	27219-27225	.00015	_	
149-15	27225-27226	)	_	
149-16	27227-27230	who	_	
149-17	27231-27234	did	_	
149-18	27235-27238	not	_	
149-19	27239-27245	differ	_	
149-20	27246-27250	from	_	
149-21	27251-27255	each	_	
149-22	27256-27261	other	_	
149-23	27261-27262	.	_	

#Text=In the Medial PFC during the Win condition, the PAE group had significantly lower HBO than than did both other groups (Controls vs PAE: t = 3.641, p < .0003, q* < .00054; PAE vs Clinical Contrast: t = 7.500, p < .0001, q* = .00023) who also differed from each other (Controls < Clinical Contrast: t = 3.287, p < .001, q* = .0015).
150-1	27263-27265	In	_	
150-2	27266-27269	the	_	
150-3	27270-27276	Medial	_	
150-4	27277-27280	PFC	_	
150-5	27281-27287	during	_	
150-6	27288-27291	the	_	
150-7	27292-27295	Win	_	
150-8	27296-27305	condition	_	
150-9	27305-27306	,	_	
150-10	27307-27310	the	_	
150-11	27311-27314	PAE	_	
150-12	27315-27320	group	_	
150-13	27321-27324	had	_	
150-14	27325-27338	significantly	_	
150-15	27339-27344	lower	_	
150-16	27345-27348	HBO	_	
150-17	27349-27353	than	_	
150-18	27354-27358	than	_	
150-19	27359-27362	did	_	
150-20	27363-27367	both	_	
150-21	27368-27373	other	_	
150-22	27374-27380	groups	_	
150-23	27381-27382	(	_	
150-24	27382-27390	Controls	_	
150-25	27391-27393	vs	_	
150-26	27394-27397	PAE	_	
150-27	27397-27398	:	_	
150-28	27399-27400	t	_	
150-29	27401-27402	=	_	
150-30	27403-27408	3.641	_	
150-31	27408-27409	,	_	
150-32	27410-27411	p	_	
150-33	27412-27413	<	_	
150-34	27414-27419	.0003	_	
150-35	27419-27420	,	_	
150-36	27421-27422	q	_	
150-37	27422-27423	*	_	
150-38	27424-27425	<	_	
150-39	27426-27432	.00054	_	
150-40	27432-27433	;	_	
150-41	27434-27437	PAE	_	
150-42	27438-27440	vs	_	
150-43	27441-27449	Clinical	_	
150-44	27450-27458	Contrast	_	
150-45	27458-27459	:	_	
150-46	27460-27461	t	_	
150-47	27462-27463	=	_	
150-48	27464-27469	7.500	_	
150-49	27469-27470	,	_	
150-50	27471-27472	p	_	
150-51	27473-27474	<	_	
150-52	27475-27480	.0001	_	
150-53	27480-27481	,	_	
150-54	27482-27483	q	_	
150-55	27483-27484	*	_	
150-56	27485-27486	=	_	
150-57	27487-27493	.00023	_	
150-58	27493-27494	)	_	
150-59	27495-27498	who	_	
150-60	27499-27503	also	_	
150-61	27504-27512	differed	_	
150-62	27513-27517	from	_	
150-63	27518-27522	each	_	
150-64	27523-27528	other	_	
150-65	27529-27530	(	_	
150-66	27530-27538	Controls	_	
150-67	27539-27540	<	_	
150-68	27541-27549	Clinical	_	
150-69	27550-27558	Contrast	_	
150-70	27558-27559	:	_	
150-71	27560-27561	t	_	
150-72	27562-27563	=	_	
150-73	27564-27569	3.287	_	
150-74	27569-27570	,	_	
150-75	27571-27572	p	_	
150-76	27573-27574	<	_	
150-77	27575-27579	.001	_	
150-78	27579-27580	,	_	
150-79	27581-27582	q	_	
150-80	27582-27583	*	_	
150-81	27584-27585	=	_	
150-82	27586-27591	.0015	_	
150-83	27591-27592	)	_	
150-84	27592-27593	.	_	

#Text=In the Loss condition, the Medial PFC levels did not differ by group status but the PAE demonstrated lower levels of HBO in the Lateral Left relative to the Controls (t = 5.646, p < .0001, q* < .00015) but greater levels relative to the Clinical Contrast group (t = 3.700, p < .0002, q* = .00026) who also differed from Controls (t=8.6609, p < .0001, q* < .00015).
151-1	27594-27596	In	_	
151-2	27597-27600	the	_	
151-3	27601-27605	Loss	_	
151-4	27606-27615	condition	_	
151-5	27615-27616	,	_	
151-6	27617-27620	the	_	
151-7	27621-27627	Medial	_	
151-8	27628-27631	PFC	_	
151-9	27632-27638	levels	_	
151-10	27639-27642	did	_	
151-11	27643-27646	not	_	
151-12	27647-27653	differ	_	
151-13	27654-27656	by	_	
151-14	27657-27662	group	_	
151-15	27663-27669	status	_	
151-16	27670-27673	but	_	
151-17	27674-27677	the	_	
151-18	27678-27681	PAE	_	
151-19	27682-27694	demonstrated	_	
151-20	27695-27700	lower	_	
151-21	27701-27707	levels	_	
151-22	27708-27710	of	_	
151-23	27711-27714	HBO	_	
151-24	27715-27717	in	_	
151-25	27718-27721	the	_	
151-26	27722-27729	Lateral	_	
151-27	27730-27734	Left	_	
151-28	27735-27743	relative	_	
151-29	27744-27746	to	_	
151-30	27747-27750	the	_	
151-31	27751-27759	Controls	_	
151-32	27760-27761	(	_	
151-33	27761-27762	t	_	
151-34	27763-27764	=	_	
151-35	27765-27770	5.646	_	
151-36	27770-27771	,	_	
151-37	27772-27773	p	_	
151-38	27774-27775	<	_	
151-39	27776-27781	.0001	_	
151-40	27781-27782	,	_	
151-41	27783-27784	q	_	
151-42	27784-27785	*	_	
151-43	27786-27787	<	_	
151-44	27788-27794	.00015	_	
151-45	27794-27795	)	_	
151-46	27796-27799	but	_	
151-47	27800-27807	greater	_	
151-48	27808-27814	levels	_	
151-49	27815-27823	relative	_	
151-50	27824-27826	to	_	
151-51	27827-27830	the	_	
151-52	27831-27839	Clinical	_	
151-53	27840-27848	Contrast	_	
151-54	27849-27854	group	_	
151-55	27855-27856	(	_	
151-56	27856-27857	t	_	
151-57	27858-27859	=	_	
151-58	27860-27865	3.700	_	
151-59	27865-27866	,	_	
151-60	27867-27868	p	_	
151-61	27869-27870	<	_	
151-62	27871-27876	.0002	_	
151-63	27876-27877	,	_	
151-64	27878-27879	q	_	
151-65	27879-27880	*	_	
151-66	27881-27882	=	_	
151-67	27883-27889	.00026	_	
151-68	27889-27890	)	_	
151-69	27891-27894	who	_	
151-70	27895-27899	also	_	
151-71	27900-27908	differed	_	
151-72	27909-27913	from	_	
151-73	27914-27922	Controls	_	
151-74	27923-27924	(	_	
151-75	27924-27925	t	_	
151-76	27925-27926	=	_	
151-77	27926-27932	8.6609	_	
151-78	27932-27933	,	_	
151-79	27934-27935	p	_	
151-80	27936-27937	<	_	
151-81	27938-27943	.0001	_	
151-82	27943-27944	,	_	
151-83	27945-27946	q	_	
151-84	27946-27947	*	_	
151-85	27948-27949	<	_	
151-86	27950-27956	.00015	_	
151-87	27956-27957	)	_	
151-88	27957-27958	.	_	

#Text=Contrasts of within group differences relative to their levels of HBO between the two conditions were also done.
152-1	27959-27968	Contrasts	_	
152-2	27969-27971	of	_	
152-3	27972-27978	within	_	
152-4	27979-27984	group	_	
152-5	27985-27996	differences	_	
152-6	27997-28005	relative	_	
152-7	28006-28008	to	_	
152-8	28009-28014	their	_	
152-9	28015-28021	levels	_	
152-10	28022-28024	of	_	
152-11	28025-28028	HBO	_	
152-12	28029-28036	between	_	
152-13	28037-28040	the	_	
152-14	28041-28044	two	_	
152-15	28045-28055	conditions	_	
152-16	28056-28060	were	_	
152-17	28061-28065	also	_	
152-18	28066-28070	done	_	
152-19	28070-28071	.	_	

#Text=For the Lateral Left, the Controls demonstrated increased HBO in the Loss condition (t = 1.970, p < .0489, q* < .0550) but both the PAE (t = 6.022, p < .0001, q* < .00015) and Clinical Contrast group (t = 14.864, p < .0001, q* < .00015) demonstrated a reduction in HBO in this condition with the Clinical Contrast group having a greater reduction in HBO than did the PAE group.
153-1	28072-28075	For	_	
153-2	28076-28079	the	_	
153-3	28080-28087	Lateral	_	
153-4	28088-28092	Left	_	
153-5	28092-28093	,	_	
153-6	28094-28097	the	_	
153-7	28098-28106	Controls	_	
153-8	28107-28119	demonstrated	_	
153-9	28120-28129	increased	_	
153-10	28130-28133	HBO	_	
153-11	28134-28136	in	_	
153-12	28137-28140	the	_	
153-13	28141-28145	Loss	_	
153-14	28146-28155	condition	_	
153-15	28156-28157	(	_	
153-16	28157-28158	t	_	
153-17	28159-28160	=	_	
153-18	28161-28166	1.970	_	
153-19	28166-28167	,	_	
153-20	28168-28169	p	_	
153-21	28170-28171	<	_	
153-22	28172-28177	.0489	_	
153-23	28177-28178	,	_	
153-24	28179-28180	q	_	
153-25	28180-28181	*	_	
153-26	28182-28183	<	_	
153-27	28184-28189	.0550	_	
153-28	28189-28190	)	_	
153-29	28191-28194	but	_	
153-30	28195-28199	both	_	
153-31	28200-28203	the	_	
153-32	28204-28207	PAE	_	
153-33	28208-28209	(	_	
153-34	28209-28210	t	_	
153-35	28211-28212	=	_	
153-36	28213-28218	6.022	_	
153-37	28218-28219	,	_	
153-38	28220-28221	p	_	
153-39	28222-28223	<	_	
153-40	28224-28229	.0001	_	
153-41	28229-28230	,	_	
153-42	28231-28232	q	_	
153-43	28232-28233	*	_	
153-44	28234-28235	<	_	
153-45	28236-28242	.00015	_	
153-46	28242-28243	)	_	
153-47	28244-28247	and	_	
153-48	28248-28256	Clinical	_	
153-49	28257-28265	Contrast	_	
153-50	28266-28271	group	_	
153-51	28272-28273	(	_	
153-52	28273-28274	t	_	
153-53	28275-28276	=	_	
153-54	28277-28283	14.864	_	
153-55	28283-28284	,	_	
153-56	28285-28286	p	_	
153-57	28287-28288	<	_	
153-58	28289-28294	.0001	_	
153-59	28294-28295	,	_	
153-60	28296-28297	q	_	
153-61	28297-28298	*	_	
153-62	28299-28300	<	_	
153-63	28301-28307	.00015	_	
153-64	28307-28308	)	_	
153-65	28309-28321	demonstrated	_	
153-66	28322-28323	a	_	
153-67	28324-28333	reduction	_	
153-68	28334-28336	in	_	
153-69	28337-28340	HBO	_	
153-70	28341-28343	in	_	
153-71	28344-28348	this	_	
153-72	28349-28358	condition	_	
153-73	28359-28363	with	_	
153-74	28364-28367	the	_	
153-75	28368-28376	Clinical	_	
153-76	28377-28385	Contrast	_	
153-77	28386-28391	group	_	
153-78	28392-28398	having	_	
153-79	28399-28400	a	_	
153-80	28401-28408	greater	_	
153-81	28409-28418	reduction	_	
153-82	28419-28421	in	_	
153-83	28422-28425	HBO	_	
153-84	28426-28430	than	_	
153-85	28431-28434	did	_	
153-86	28435-28438	the	_	
153-87	28439-28442	PAE	_	
153-88	28443-28448	group	_	
153-89	28448-28449	.	_	

#Text=Finally, in the Medial area, each of the groups demonstrated a reduction in HBO in the Loss relative to the Win condition but the magnitude of the change was greatest among the Clinical Contrast group (t = 13.181, p < .0001, q* < .00023), followed by the Controls (t = 7.081, p < .0001, q* < .00023), and then the PAE group (t = 5.248, p < .0001, q* < .00023).
#Text=3.5.2 HBR During Game Play
#Text=Condition effects were found for each of the indices of PFC activation (Lateral Left: (F (1, 8495.145) = 90.775, p < .000; Lateral Right: (F (1, 8905.423) = 125.019, p < .000; and Medial (F (1, 8741.428) = 105.563, p < .000) with greater levels of HBR present in Loss relative to the Win condition for each measure.
154-1	28450-28457	Finally	_	
154-2	28457-28458	,	_	
154-3	28459-28461	in	_	
154-4	28462-28465	the	_	
154-5	28466-28472	Medial	_	
154-6	28473-28477	area	_	
154-7	28477-28478	,	_	
154-8	28479-28483	each	_	
154-9	28484-28486	of	_	
154-10	28487-28490	the	_	
154-11	28491-28497	groups	_	
154-12	28498-28510	demonstrated	_	
154-13	28511-28512	a	_	
154-14	28513-28522	reduction	_	
154-15	28523-28525	in	_	
154-16	28526-28529	HBO	_	
154-17	28530-28532	in	_	
154-18	28533-28536	the	_	
154-19	28537-28541	Loss	_	
154-20	28542-28550	relative	_	
154-21	28551-28553	to	_	
154-22	28554-28557	the	_	
154-23	28558-28561	Win	_	
154-24	28562-28571	condition	_	
154-25	28572-28575	but	_	
154-26	28576-28579	the	_	
154-27	28580-28589	magnitude	_	
154-28	28590-28592	of	_	
154-29	28593-28596	the	_	
154-30	28597-28603	change	_	
154-31	28604-28607	was	_	
154-32	28608-28616	greatest	_	
154-33	28617-28622	among	_	
154-34	28623-28626	the	_	
154-35	28627-28635	Clinical	_	
154-36	28636-28644	Contrast	_	
154-37	28645-28650	group	_	
154-38	28651-28652	(	_	
154-39	28652-28653	t	_	
154-40	28654-28655	=	_	
154-41	28656-28662	13.181	_	
154-42	28662-28663	,	_	
154-43	28664-28665	p	_	
154-44	28666-28667	<	_	
154-45	28668-28673	.0001	_	
154-46	28673-28674	,	_	
154-47	28675-28676	q	_	
154-48	28676-28677	*	_	
154-49	28678-28679	<	_	
154-50	28680-28686	.00023	_	
154-51	28686-28687	)	_	
154-52	28687-28688	,	_	
154-53	28689-28697	followed	_	
154-54	28698-28700	by	_	
154-55	28701-28704	the	_	
154-56	28705-28713	Controls	_	
154-57	28714-28715	(	_	
154-58	28715-28716	t	_	
154-59	28717-28718	=	_	
154-60	28719-28724	7.081	_	
154-61	28724-28725	,	_	
154-62	28726-28727	p	_	
154-63	28728-28729	<	_	
154-64	28730-28735	.0001	_	
154-65	28735-28736	,	_	
154-66	28737-28738	q	_	
154-67	28738-28739	*	_	
154-68	28740-28741	<	_	
154-69	28742-28748	.00023	_	
154-70	28748-28749	)	_	
154-71	28749-28750	,	_	
154-72	28751-28754	and	_	
154-73	28755-28759	then	_	
154-74	28760-28763	the	_	
154-75	28764-28767	PAE	_	
154-76	28768-28773	group	_	
154-77	28774-28775	(	_	
154-78	28775-28776	t	_	
154-79	28777-28778	=	_	
154-80	28779-28784	5.248	_	
154-81	28784-28785	,	_	
154-82	28786-28787	p	_	
154-83	28788-28789	<	_	
154-84	28790-28795	.0001	_	
154-85	28795-28796	,	_	
154-86	28797-28798	q	_	
154-87	28798-28799	*	_	
154-88	28800-28801	<	_	
154-89	28802-28808	.00023	_	
154-90	28808-28809	)	_	
154-91	28809-28810	.	_	
154-92	28811-28816	3.5.2	_	
154-93	28817-28820	HBR	_	
154-94	28821-28827	During	_	
154-95	28828-28832	Game	_	
154-96	28833-28837	Play	_	
154-97	28838-28847	Condition	_	
154-98	28848-28855	effects	_	
154-99	28856-28860	were	_	
154-100	28861-28866	found	_	
154-101	28867-28870	for	_	
154-102	28871-28875	each	_	
154-103	28876-28878	of	_	
154-104	28879-28882	the	_	
154-105	28883-28890	indices	_	
154-106	28891-28893	of	_	
154-107	28894-28897	PFC	_	
154-108	28898-28908	activation	_	
154-109	28909-28910	(	_	
154-110	28910-28917	Lateral	_	
154-111	28918-28922	Left	_	
154-112	28922-28923	:	_	
154-113	28924-28925	(	_	
154-114	28925-28926	F	_	
154-115	28927-28928	(	_	
154-116	28928-28929	1	_	
154-117	28929-28930	,	_	
154-118	28931-28939	8495.145	_	
154-119	28939-28940	)	_	
154-120	28941-28942	=	_	
154-121	28943-28949	90.775	_	
154-122	28949-28950	,	_	
154-123	28951-28952	p	_	
154-124	28953-28954	<	_	
154-125	28955-28959	.000	_	
154-126	28959-28960	;	_	
154-127	28961-28968	Lateral	_	
154-128	28969-28974	Right	_	
154-129	28974-28975	:	_	
154-130	28976-28977	(	_	
154-131	28977-28978	F	_	
154-132	28979-28980	(	_	
154-133	28980-28981	1	_	
154-134	28981-28982	,	_	
154-135	28983-28991	8905.423	_	
154-136	28991-28992	)	_	
154-137	28993-28994	=	_	
154-138	28995-29002	125.019	_	
154-139	29002-29003	,	_	
154-140	29004-29005	p	_	
154-141	29006-29007	<	_	
154-142	29008-29012	.000	_	
154-143	29012-29013	;	_	
154-144	29014-29017	and	_	
154-145	29018-29024	Medial	_	
154-146	29025-29026	(	_	
154-147	29026-29027	F	_	
154-148	29028-29029	(	_	
154-149	29029-29030	1	_	
154-150	29030-29031	,	_	
154-151	29032-29040	8741.428	_	
154-152	29040-29041	)	_	
154-153	29042-29043	=	_	
154-154	29044-29051	105.563	_	
154-155	29051-29052	,	_	
154-156	29053-29054	p	_	
154-157	29055-29056	<	_	
154-158	29057-29061	.000	_	
154-159	29061-29062	)	_	
154-160	29063-29067	with	_	
154-161	29068-29075	greater	_	
154-162	29076-29082	levels	_	
154-163	29083-29085	of	_	
154-164	29086-29089	HBR	_	
154-165	29090-29097	present	_	
154-166	29098-29100	in	_	
154-167	29101-29105	Loss	_	
154-168	29106-29114	relative	_	
154-169	29115-29117	to	_	
154-170	29118-29121	the	_	
154-171	29122-29125	Win	_	
154-172	29126-29135	condition	_	
154-173	29136-29139	for	_	
154-174	29140-29144	each	_	
154-175	29145-29152	measure	_	
154-176	29152-29153	.	_	

#Text=Significant group and group by condition effects were also found for each sampled area of the PFC (Lateral Left: Group-F (2, 8009.136) = 17.465, p < .000; Interaction-F (2, 8009.217) = 44.215, p < .000; Lateral Right: Group-F (2, 8865.029) = 13.736, p < .000; Interaction-F (2, 8864.881) = 35.864, p < .000; and Medial: Group- F (2, 8516.959) = 8.003, p < .000; Interaction-F (2, 8517.283) = 49.737, p < .000).
155-1	29154-29165	Significant	_	
155-2	29166-29171	group	_	
155-3	29172-29175	and	_	
155-4	29176-29181	group	_	
155-5	29182-29184	by	_	
155-6	29185-29194	condition	_	
155-7	29195-29202	effects	_	
155-8	29203-29207	were	_	
155-9	29208-29212	also	_	
155-10	29213-29218	found	_	
155-11	29219-29222	for	_	
155-12	29223-29227	each	_	
155-13	29228-29235	sampled	_	
155-14	29236-29240	area	_	
155-15	29241-29243	of	_	
155-16	29244-29247	the	_	
155-17	29248-29251	PFC	_	
155-18	29252-29253	(	_	
155-19	29253-29260	Lateral	_	
155-20	29261-29265	Left	_	
155-21	29265-29266	:	_	
155-22	29267-29274	Group-F	_	
155-23	29275-29276	(	_	
155-24	29276-29277	2	_	
155-25	29277-29278	,	_	
155-26	29279-29287	8009.136	_	
155-27	29287-29288	)	_	
155-28	29289-29290	=	_	
155-29	29291-29297	17.465	_	
155-30	29297-29298	,	_	
155-31	29299-29300	p	_	
155-32	29301-29302	<	_	
155-33	29303-29307	.000	_	
155-34	29307-29308	;	_	
155-35	29309-29322	Interaction-F	_	
155-36	29323-29324	(	_	
155-37	29324-29325	2	_	
155-38	29325-29326	,	_	
155-39	29327-29335	8009.217	_	
155-40	29335-29336	)	_	
155-41	29337-29338	=	_	
155-42	29339-29345	44.215	_	
155-43	29345-29346	,	_	
155-44	29347-29348	p	_	
155-45	29349-29350	<	_	
155-46	29351-29355	.000	_	
155-47	29355-29356	;	_	
155-48	29357-29364	Lateral	_	
155-49	29365-29370	Right	_	
155-50	29370-29371	:	_	
155-51	29372-29379	Group-F	_	
155-52	29380-29381	(	_	
155-53	29381-29382	2	_	
155-54	29382-29383	,	_	
155-55	29384-29392	8865.029	_	
155-56	29392-29393	)	_	
155-57	29394-29395	=	_	
155-58	29396-29402	13.736	_	
155-59	29402-29403	,	_	
155-60	29404-29405	p	_	
155-61	29406-29407	<	_	
155-62	29408-29412	.000	_	
155-63	29412-29413	;	_	
155-64	29414-29427	Interaction-F	_	
155-65	29428-29429	(	_	
155-66	29429-29430	2	_	
155-67	29430-29431	,	_	
155-68	29432-29440	8864.881	_	
155-69	29440-29441	)	_	
155-70	29442-29443	=	_	
155-71	29444-29450	35.864	_	
155-72	29450-29451	,	_	
155-73	29452-29453	p	_	
155-74	29454-29455	<	_	
155-75	29456-29460	.000	_	
155-76	29460-29461	;	_	
155-77	29462-29465	and	_	
155-78	29466-29472	Medial	_	
155-79	29472-29473	:	_	
155-80	29474-29479	Group	_	
155-81	29479-29480	-	_	
155-82	29481-29482	F	_	
155-83	29483-29484	(	_	
155-84	29484-29485	2	_	
155-85	29485-29486	,	_	
155-86	29487-29495	8516.959	_	
155-87	29495-29496	)	_	
155-88	29497-29498	=	_	
155-89	29499-29504	8.003	_	
155-90	29504-29505	,	_	
155-91	29506-29507	p	_	
155-92	29508-29509	<	_	
155-93	29510-29514	.000	_	
155-94	29514-29515	;	_	
155-95	29516-29529	Interaction-F	_	
155-96	29530-29531	(	_	
155-97	29531-29532	2	_	
155-98	29532-29533	,	_	
155-99	29534-29542	8517.283	_	
155-100	29542-29543	)	_	
155-101	29544-29545	=	_	
155-102	29546-29552	49.737	_	
155-103	29552-29553	,	_	
155-104	29554-29555	p	_	
155-105	29556-29557	<	_	
155-106	29558-29562	.000	_	
155-107	29562-29563	)	_	
155-108	29563-29564	.	_	

#Text=Relative to the main effects of group, for all of the areas of PFC, the PAE group demonstrated greater levels of HBR than did the Controls (Lateral Left t = 3.690, p < .0002, q* < .0003; Lateral Right t = 4.434, p < .0001, q* < .00015; Medial t = 3.796, p < .0001, q* < .0003) and the Clinical Contrast group (Lateral Left t= 5.629, p < .0001, q* < .0003; Lateral Right t = 4.3352, p < .0001, q* < .00015; Medial t = 2.704, p < .0069, q* < .01035).
156-1	29565-29573	Relative	_	
156-2	29574-29576	to	_	
156-3	29577-29580	the	_	
156-4	29581-29585	main	_	
156-5	29586-29593	effects	_	
156-6	29594-29596	of	_	
156-7	29597-29602	group	_	
156-8	29602-29603	,	_	
156-9	29604-29607	for	_	
156-10	29608-29611	all	_	
156-11	29612-29614	of	_	
156-12	29615-29618	the	_	
156-13	29619-29624	areas	_	
156-14	29625-29627	of	_	
156-15	29628-29631	PFC	_	
156-16	29631-29632	,	_	
156-17	29633-29636	the	_	
156-18	29637-29640	PAE	_	
156-19	29641-29646	group	_	
156-20	29647-29659	demonstrated	_	
156-21	29660-29667	greater	_	
156-22	29668-29674	levels	_	
156-23	29675-29677	of	_	
156-24	29678-29681	HBR	_	
156-25	29682-29686	than	_	
156-26	29687-29690	did	_	
156-27	29691-29694	the	_	
156-28	29695-29703	Controls	_	
156-29	29704-29705	(	_	
156-30	29705-29712	Lateral	_	
156-31	29713-29717	Left	_	
156-32	29718-29719	t	_	
156-33	29720-29721	=	_	
156-34	29722-29727	3.690	_	
156-35	29727-29728	,	_	
156-36	29729-29730	p	_	
156-37	29731-29732	<	_	
156-38	29733-29738	.0002	_	
156-39	29738-29739	,	_	
156-40	29740-29741	q	_	
156-41	29741-29742	*	_	
156-42	29743-29744	<	_	
156-43	29745-29750	.0003	_	
156-44	29750-29751	;	_	
156-45	29752-29759	Lateral	_	
156-46	29760-29765	Right	_	
156-47	29766-29767	t	_	
156-48	29768-29769	=	_	
156-49	29770-29775	4.434	_	
156-50	29775-29776	,	_	
156-51	29777-29778	p	_	
156-52	29779-29780	<	_	
156-53	29781-29786	.0001	_	
156-54	29786-29787	,	_	
156-55	29788-29789	q	_	
156-56	29789-29790	*	_	
156-57	29791-29792	<	_	
156-58	29793-29799	.00015	_	
156-59	29799-29800	;	_	
156-60	29801-29807	Medial	_	
156-61	29808-29809	t	_	
156-62	29810-29811	=	_	
156-63	29812-29817	3.796	_	
156-64	29817-29818	,	_	
156-65	29819-29820	p	_	
156-66	29821-29822	<	_	
156-67	29823-29828	.0001	_	
156-68	29828-29829	,	_	
156-69	29830-29831	q	_	
156-70	29831-29832	*	_	
156-71	29833-29834	<	_	
156-72	29835-29840	.0003	_	
156-73	29840-29841	)	_	
156-74	29842-29845	and	_	
156-75	29846-29849	the	_	
156-76	29850-29858	Clinical	_	
156-77	29859-29867	Contrast	_	
156-78	29868-29873	group	_	
156-79	29874-29875	(	_	
156-80	29875-29882	Lateral	_	
156-81	29883-29887	Left	_	
156-82	29888-29889	t	_	
156-83	29889-29890	=	_	
156-84	29891-29896	5.629	_	
156-85	29896-29897	,	_	
156-86	29898-29899	p	_	
156-87	29900-29901	<	_	
156-88	29902-29907	.0001	_	
156-89	29907-29908	,	_	
156-90	29909-29910	q	_	
156-91	29910-29911	*	_	
156-92	29912-29913	<	_	
156-93	29914-29919	.0003	_	
156-94	29919-29920	;	_	
156-95	29921-29928	Lateral	_	
156-96	29929-29934	Right	_	
156-97	29935-29936	t	_	
156-98	29937-29938	=	_	
156-99	29939-29945	4.3352	_	
156-100	29945-29946	,	_	
156-101	29947-29948	p	_	
156-102	29949-29950	<	_	
156-103	29951-29956	.0001	_	
156-104	29956-29957	,	_	
156-105	29958-29959	q	_	
156-106	29959-29960	*	_	
156-107	29961-29962	<	_	
156-108	29963-29969	.00015	_	
156-109	29969-29970	;	_	
156-110	29971-29977	Medial	_	
156-111	29978-29979	t	_	
156-112	29980-29981	=	_	
156-113	29982-29987	2.704	_	
156-114	29987-29988	,	_	
156-115	29989-29990	p	_	
156-116	29991-29992	<	_	
156-117	29993-29998	.0069	_	
156-118	29998-29999	,	_	
156-119	30000-30001	q	_	
156-120	30001-30002	*	_	
156-121	30003-30004	<	_	
156-122	30005-30011	.01035	_	
156-123	30011-30012	)	_	
156-124	30012-30013	.	_	

#Text=Table 3 displays the mean level of HBR for each of the three groups.
157-1	30014-30019	Table	_	
157-2	30020-30021	3	_	
157-3	30022-30030	displays	_	
157-4	30031-30034	the	_	
157-5	30035-30039	mean	_	
157-6	30040-30045	level	_	
157-7	30046-30048	of	_	
157-8	30049-30052	HBR	_	
157-9	30053-30056	for	_	
157-10	30057-30061	each	_	
157-11	30062-30064	of	_	
157-12	30065-30068	the	_	
157-13	30069-30074	three	_	
157-14	30075-30081	groups	_	
157-15	30081-30082	.	_	

#Text=When examining group means within a condition, the main effect of greater levels of HBR in the PAE group was true in all of the PFC areas for the Win condition (Lateral Left: PAE vs.
158-1	30083-30087	When	_	
158-2	30088-30097	examining	_	
158-3	30098-30103	group	_	
158-4	30104-30109	means	_	
158-5	30110-30116	within	_	
158-6	30117-30118	a	_	
158-7	30119-30128	condition	_	
158-8	30128-30129	,	_	
158-9	30130-30133	the	_	
158-10	30134-30138	main	_	
158-11	30139-30145	effect	_	
158-12	30146-30148	of	_	
158-13	30149-30156	greater	_	
158-14	30157-30163	levels	_	
158-15	30164-30166	of	_	
158-16	30167-30170	HBR	_	
158-17	30171-30173	in	_	
158-18	30174-30177	the	_	
158-19	30178-30181	PAE	_	
158-20	30182-30187	group	_	
158-21	30188-30191	was	_	
158-22	30192-30196	true	_	
158-23	30197-30199	in	_	
158-24	30200-30203	all	_	
158-25	30204-30206	of	_	
158-26	30207-30210	the	_	
158-27	30211-30214	PFC	_	
158-28	30215-30220	areas	_	
158-29	30221-30224	for	_	
158-30	30225-30228	the	_	
158-31	30229-30232	Win	_	
158-32	30233-30242	condition	_	
158-33	30243-30244	(	_	
158-34	30244-30251	Lateral	_	
158-35	30252-30256	Left	_	
158-36	30256-30257	:	_	
158-37	30258-30261	PAE	_	
158-38	30262-30264	vs	_	
158-39	30264-30265	.	_	

#Text=Controls t = 6.130, p < .0001, q* < .00016; PAE vs.
159-1	30266-30274	Controls	_	
159-2	30275-30276	t	_	
159-3	30277-30278	=	_	
159-4	30279-30284	6.130	_	
159-5	30284-30285	,	_	
159-6	30286-30287	p	_	
159-7	30288-30289	<	_	
159-8	30290-30295	.0001	_	
159-9	30295-30296	,	_	
159-10	30297-30298	q	_	
159-11	30298-30299	*	_	
159-12	30300-30301	<	_	
159-13	30302-30308	.00016	_	
159-14	30308-30309	;	_	
159-15	30310-30313	PAE	_	
159-16	30314-30316	vs	_	
159-17	30316-30317	.	_	

#Text=Clinical Contrast t = 11.335, p < .0001, q* < .00016; Lateral Right: PAE vs.
160-1	30318-30326	Clinical	_	
160-2	30327-30335	Contrast	_	
160-3	30336-30337	t	_	
160-4	30338-30339	=	_	
160-5	30340-30346	11.335	_	
160-6	30346-30347	,	_	
160-7	30348-30349	p	_	
160-8	30350-30351	<	_	
160-9	30352-30357	.0001	_	
160-10	30357-30358	,	_	
160-11	30359-30360	q	_	
160-12	30360-30361	*	_	
160-13	30362-30363	<	_	
160-14	30364-30370	.00016	_	
160-15	30370-30371	;	_	
160-16	30372-30379	Lateral	_	
160-17	30380-30385	Right	_	
160-18	30385-30386	:	_	
160-19	30387-30390	PAE	_	
160-20	30391-30393	vs	_	
160-21	30393-30394	.	_	

#Text=Controls t = 2.065, p < .0390, q* < .0501; PAE vs.
161-1	30395-30403	Controls	_	
161-2	30404-30405	t	_	
161-3	30406-30407	=	_	
161-4	30408-30413	2.065	_	
161-5	30413-30414	,	_	
161-6	30415-30416	p	_	
161-7	30417-30418	<	_	
161-8	30419-30424	.0390	_	
161-9	30424-30425	,	_	
161-10	30426-30427	q	_	
161-11	30427-30428	*	_	
161-12	30429-30430	<	_	
161-13	30431-30436	.0501	_	
161-14	30436-30437	;	_	
161-15	30438-30441	PAE	_	
161-16	30442-30444	vs	_	
161-17	30444-30445	.	_	

#Text=Clinical Contrast t = 8.316, p < .0001, q* < .00015; Medial: PAE vs.
162-1	30446-30454	Clinical	_	
162-2	30455-30463	Contrast	_	
162-3	30464-30465	t	_	
162-4	30466-30467	=	_	
162-5	30468-30473	8.316	_	
162-6	30473-30474	,	_	
162-7	30475-30476	p	_	
162-8	30477-30478	<	_	
162-9	30479-30484	.0001	_	
162-10	30484-30485	,	_	
162-11	30486-30487	q	_	
162-12	30487-30488	*	_	
162-13	30489-30490	<	_	
162-14	30491-30497	.00015	_	
162-15	30497-30498	;	_	
162-16	30499-30505	Medial	_	
162-17	30505-30506	:	_	
162-18	30507-30510	PAE	_	
162-19	30511-30513	vs	_	
162-20	30513-30514	.	_	

#Text=Controls t = 6.225, p < .0001, q* < .00013; PAE vs.
163-1	30515-30523	Controls	_	
163-2	30524-30525	t	_	
163-3	30526-30527	=	_	
163-4	30528-30533	6.225	_	
163-5	30533-30534	,	_	
163-6	30535-30536	p	_	
163-7	30537-30538	<	_	
163-8	30539-30544	.0001	_	
163-9	30544-30545	,	_	
163-10	30546-30547	q	_	
163-11	30547-30548	*	_	
163-12	30549-30550	<	_	
163-13	30551-30557	.00013	_	
163-14	30557-30558	;	_	
163-15	30559-30562	PAE	_	
163-16	30563-30565	vs	_	
163-17	30565-30566	.	_	

#Text=Clinical Contrast t = 9.936, p < .0001, q* < .00013) and the HBR levels of Controls were higher than the Clinical Contrast group in all of the PFC areas in the Win condition (Lateral Left t = 4.281, p < .0001, q* < .00016; Lateral Right t = 5.462, p < .0001, q* < .00015; Medial t = 3.039, p < .0024, q* < .0027).
164-1	30567-30575	Clinical	_	
164-2	30576-30584	Contrast	_	
164-3	30585-30586	t	_	
164-4	30587-30588	=	_	
164-5	30589-30594	9.936	_	
164-6	30594-30595	,	_	
164-7	30596-30597	p	_	
164-8	30598-30599	<	_	
164-9	30600-30605	.0001	_	
164-10	30605-30606	,	_	
164-11	30607-30608	q	_	
164-12	30608-30609	*	_	
164-13	30610-30611	<	_	
164-14	30612-30618	.00013	_	
164-15	30618-30619	)	_	
164-16	30620-30623	and	_	
164-17	30624-30627	the	_	
164-18	30628-30631	HBR	_	
164-19	30632-30638	levels	_	
164-20	30639-30641	of	_	
164-21	30642-30650	Controls	_	
164-22	30651-30655	were	_	
164-23	30656-30662	higher	_	
164-24	30663-30667	than	_	
164-25	30668-30671	the	_	
164-26	30672-30680	Clinical	_	
164-27	30681-30689	Contrast	_	
164-28	30690-30695	group	_	
164-29	30696-30698	in	_	
164-30	30699-30702	all	_	
164-31	30703-30705	of	_	
164-32	30706-30709	the	_	
164-33	30710-30713	PFC	_	
164-34	30714-30719	areas	_	
164-35	30720-30722	in	_	
164-36	30723-30726	the	_	
164-37	30727-30730	Win	_	
164-38	30731-30740	condition	_	
164-39	30741-30742	(	_	
164-40	30742-30749	Lateral	_	
164-41	30750-30754	Left	_	
164-42	30755-30756	t	_	
164-43	30757-30758	=	_	
164-44	30759-30764	4.281	_	
164-45	30764-30765	,	_	
164-46	30766-30767	p	_	
164-47	30768-30769	<	_	
164-48	30770-30775	.0001	_	
164-49	30775-30776	,	_	
164-50	30777-30778	q	_	
164-51	30778-30779	*	_	
164-52	30780-30781	<	_	
164-53	30782-30788	.00016	_	
164-54	30788-30789	;	_	
164-55	30790-30797	Lateral	_	
164-56	30798-30803	Right	_	
164-57	30804-30805	t	_	
164-58	30806-30807	=	_	
164-59	30808-30813	5.462	_	
164-60	30813-30814	,	_	
164-61	30815-30816	p	_	
164-62	30817-30818	<	_	
164-63	30819-30824	.0001	_	
164-64	30824-30825	,	_	
164-65	30826-30827	q	_	
164-66	30827-30828	*	_	
164-67	30829-30830	<	_	
164-68	30831-30837	.00015	_	
164-69	30837-30838	;	_	
164-70	30839-30845	Medial	_	
164-71	30846-30847	t	_	
164-72	30848-30849	=	_	
164-73	30850-30855	3.039	_	
164-74	30855-30856	,	_	
164-75	30857-30858	p	_	
164-76	30859-30860	<	_	
164-77	30861-30866	.0024	_	
164-78	30866-30867	,	_	
164-79	30868-30869	q	_	
164-80	30869-30870	*	_	
164-81	30871-30872	<	_	
164-82	30873-30878	.0027	_	
164-83	30878-30879	)	_	
164-84	30879-30880	.	_	

#Text=In the Loss condition, the PAE group continued to have higher levels of HBR than did Controls in the Lateral Right area of the PFC (t = 4.045, p < .0001, q* .00015) but did not differ in the other areas in comparison to this group.
165-1	30881-30883	In	_	
165-2	30884-30887	the	_	
165-3	30888-30892	Loss	_	
165-4	30893-30902	condition	_	
165-5	30902-30903	,	_	
165-6	30904-30907	the	_	
165-7	30908-30911	PAE	_	
165-8	30912-30917	group	_	
165-9	30918-30927	continued	_	
165-10	30928-30930	to	_	
165-11	30931-30935	have	_	
165-12	30936-30942	higher	_	
165-13	30943-30949	levels	_	
165-14	30950-30952	of	_	
165-15	30953-30956	HBR	_	
165-16	30957-30961	than	_	
165-17	30962-30965	did	_	
165-18	30966-30974	Controls	_	
165-19	30975-30977	in	_	
165-20	30978-30981	the	_	
165-21	30982-30989	Lateral	_	
165-22	30990-30995	Right	_	
165-23	30996-31000	area	_	
165-24	31001-31003	of	_	
165-25	31004-31007	the	_	
165-26	31008-31011	PFC	_	
165-27	31012-31013	(	_	
165-28	31013-31014	t	_	
165-29	31015-31016	=	_	
165-30	31017-31022	4.045	_	
165-31	31022-31023	,	_	
165-32	31024-31025	p	_	
165-33	31026-31027	<	_	
165-34	31028-31033	.0001	_	
165-35	31033-31034	,	_	
165-36	31035-31036	q	_	
165-37	31036-31037	*	_	
165-38	31038-31044	.00015	_	
165-39	31044-31045	)	_	
165-40	31046-31049	but	_	
165-41	31050-31053	did	_	
165-42	31054-31057	not	_	
165-43	31058-31064	differ	_	
165-44	31065-31067	in	_	
165-45	31068-31071	the	_	
165-46	31072-31077	other	_	
165-47	31078-31083	areas	_	
165-48	31084-31086	in	_	
165-49	31087-31097	comparison	_	
165-50	31098-31100	to	_	
165-51	31101-31105	this	_	
165-52	31106-31111	group	_	
165-53	31111-31112	.	_	

#Text=Relative to the Clinical Contrast group, the PAE group had lower levels of HBR in the Lateral Left and Medial areas of the PFC (Lateral Left t = 2.426, p < .0153, q* < .0204; Medial t = 4.673, p < .0001, q* < .00013) as did the Controls in the Lateral Right (t = 5.342, p < .0001, q* < .00015) and Medial (t = 3.988, p < .0001, q* < .00013) areas of the PFC.
166-1	31113-31121	Relative	_	
166-2	31122-31124	to	_	
166-3	31125-31128	the	_	
166-4	31129-31137	Clinical	_	
166-5	31138-31146	Contrast	_	
166-6	31147-31152	group	_	
166-7	31152-31153	,	_	
166-8	31154-31157	the	_	
166-9	31158-31161	PAE	_	
166-10	31162-31167	group	_	
166-11	31168-31171	had	_	
166-12	31172-31177	lower	_	
166-13	31178-31184	levels	_	
166-14	31185-31187	of	_	
166-15	31188-31191	HBR	_	
166-16	31192-31194	in	_	
166-17	31195-31198	the	_	
166-18	31199-31206	Lateral	_	
166-19	31207-31211	Left	_	
166-20	31212-31215	and	_	
166-21	31216-31222	Medial	_	
166-22	31223-31228	areas	_	
166-23	31229-31231	of	_	
166-24	31232-31235	the	_	
166-25	31236-31239	PFC	_	
166-26	31240-31241	(	_	
166-27	31241-31248	Lateral	_	
166-28	31249-31253	Left	_	
166-29	31254-31255	t	_	
166-30	31256-31257	=	_	
166-31	31258-31263	2.426	_	
166-32	31263-31264	,	_	
166-33	31265-31266	p	_	
166-34	31267-31268	<	_	
166-35	31269-31274	.0153	_	
166-36	31274-31275	,	_	
166-37	31276-31277	q	_	
166-38	31277-31278	*	_	
166-39	31279-31280	<	_	
166-40	31281-31286	.0204	_	
166-41	31286-31287	;	_	
166-42	31288-31294	Medial	_	
166-43	31295-31296	t	_	
166-44	31297-31298	=	_	
166-45	31299-31304	4.673	_	
166-46	31304-31305	,	_	
166-47	31306-31307	p	_	
166-48	31308-31309	<	_	
166-49	31310-31315	.0001	_	
166-50	31315-31316	,	_	
166-51	31317-31318	q	_	
166-52	31318-31319	*	_	
166-53	31320-31321	<	_	
166-54	31322-31328	.00013	_	
166-55	31328-31329	)	_	
166-56	31330-31332	as	_	
166-57	31333-31336	did	_	
166-58	31337-31340	the	_	
166-59	31341-31349	Controls	_	
166-60	31350-31352	in	_	
166-61	31353-31356	the	_	
166-62	31357-31364	Lateral	_	
166-63	31365-31370	Right	_	
166-64	31371-31372	(	_	
166-65	31372-31373	t	_	
166-66	31374-31375	=	_	
166-67	31376-31381	5.342	_	
166-68	31381-31382	,	_	
166-69	31383-31384	p	_	
166-70	31385-31386	<	_	
166-71	31387-31392	.0001	_	
166-72	31392-31393	,	_	
166-73	31394-31395	q	_	
166-74	31395-31396	*	_	
166-75	31397-31398	<	_	
166-76	31399-31405	.00015	_	
166-77	31405-31406	)	_	
166-78	31407-31410	and	_	
166-79	31411-31417	Medial	_	
166-80	31418-31419	(	_	
166-81	31419-31420	t	_	
166-82	31421-31422	=	_	
166-83	31423-31428	3.988	_	
166-84	31428-31429	,	_	
166-85	31430-31431	p	_	
166-86	31432-31433	<	_	
166-87	31434-31439	.0001	_	
166-88	31439-31440	,	_	
166-89	31441-31442	q	_	
166-90	31442-31443	*	_	
166-91	31444-31445	<	_	
166-92	31446-31452	.00013	_	
166-93	31452-31453	)	_	
166-94	31454-31459	areas	_	
166-95	31460-31462	of	_	
166-96	31463-31466	the	_	
166-97	31467-31470	PFC	_	
166-98	31470-31471	.	_	

#Text=Contrast in HBR levels between conditions for each group were also examined.
167-1	31472-31480	Contrast	_	
167-2	31481-31483	in	_	
167-3	31484-31487	HBR	_	
167-4	31488-31494	levels	_	
167-5	31495-31502	between	_	
167-6	31503-31513	conditions	_	
167-7	31514-31517	for	_	
167-8	31518-31522	each	_	
167-9	31523-31528	group	_	
167-10	31529-31533	were	_	
167-11	31534-31538	also	_	
167-12	31539-31547	examined	_	
167-13	31547-31548	.	_	

#Text=In the Lateral Left and Medial areas, both the Controls (Lateral Left t =5.136, p < .0001, q* < .00016; Medial t = 4.922, p < .0001, q* < .00016) and the Clinical Contrast (Lateral Left t =11.617, p < .00018, q* < .00016; Medial t = 12.995, p < .0001, q* < .00013) group showed greater levels of HBR in the Loss condition relative to the Win condition but the PAE group did not show a significant difference in HBR relative to condition.
168-1	31549-31551	In	_	
168-2	31552-31555	the	_	
168-3	31556-31563	Lateral	_	
168-4	31564-31568	Left	_	
168-5	31569-31572	and	_	
168-6	31573-31579	Medial	_	
168-7	31580-31585	areas	_	
168-8	31585-31586	,	_	
168-9	31587-31591	both	_	
168-10	31592-31595	the	_	
168-11	31596-31604	Controls	_	
168-12	31605-31606	(	_	
168-13	31606-31613	Lateral	_	
168-14	31614-31618	Left	_	
168-15	31619-31620	t	_	
168-16	31621-31622	=	_	
168-17	31622-31627	5.136	_	
168-18	31627-31628	,	_	
168-19	31629-31630	p	_	
168-20	31631-31632	<	_	
168-21	31633-31638	.0001	_	
168-22	31638-31639	,	_	
168-23	31640-31641	q	_	
168-24	31641-31642	*	_	
168-25	31643-31644	<	_	
168-26	31645-31651	.00016	_	
168-27	31651-31652	;	_	
168-28	31653-31659	Medial	_	
168-29	31660-31661	t	_	
168-30	31662-31663	=	_	
168-31	31664-31669	4.922	_	
168-32	31669-31670	,	_	
168-33	31671-31672	p	_	
168-34	31673-31674	<	_	
168-35	31675-31680	.0001	_	
168-36	31680-31681	,	_	
168-37	31682-31683	q	_	
168-38	31683-31684	*	_	
168-39	31685-31686	<	_	
168-40	31687-31693	.00016	_	
168-41	31693-31694	)	_	
168-42	31695-31698	and	_	
168-43	31699-31702	the	_	
168-44	31703-31711	Clinical	_	
168-45	31712-31720	Contrast	_	
168-46	31721-31722	(	_	
168-47	31722-31729	Lateral	_	
168-48	31730-31734	Left	_	
168-49	31735-31736	t	_	
168-50	31737-31738	=	_	
168-51	31738-31744	11.617	_	
168-52	31744-31745	,	_	
168-53	31746-31747	p	_	
168-54	31748-31749	<	_	
168-55	31750-31756	.00018	_	
168-56	31756-31757	,	_	
168-57	31758-31759	q	_	
168-58	31759-31760	*	_	
168-59	31761-31762	<	_	
168-60	31763-31769	.00016	_	
168-61	31769-31770	;	_	
168-62	31771-31777	Medial	_	
168-63	31778-31779	t	_	
168-64	31780-31781	=	_	
168-65	31782-31788	12.995	_	
168-66	31788-31789	,	_	
168-67	31790-31791	p	_	
168-68	31792-31793	<	_	
168-69	31794-31799	.0001	_	
168-70	31799-31800	,	_	
168-71	31801-31802	q	_	
168-72	31802-31803	*	_	
168-73	31804-31805	<	_	
168-74	31806-31812	.00013	_	
168-75	31812-31813	)	_	
168-76	31814-31819	group	_	
168-77	31820-31826	showed	_	
168-78	31827-31834	greater	_	
168-79	31835-31841	levels	_	
168-80	31842-31844	of	_	
168-81	31845-31848	HBR	_	
168-82	31849-31851	in	_	
168-83	31852-31855	the	_	
168-84	31856-31860	Loss	_	
168-85	31861-31870	condition	_	
168-86	31871-31879	relative	_	
168-87	31880-31882	to	_	
168-88	31883-31886	the	_	
168-89	31887-31890	Win	_	
168-90	31891-31900	condition	_	
168-91	31901-31904	but	_	
168-92	31905-31908	the	_	
168-93	31909-31912	PAE	_	
168-94	31913-31918	group	_	
168-95	31919-31922	did	_	
168-96	31923-31926	not	_	
168-97	31927-31931	show	_	
168-98	31932-31933	a	_	
168-99	31934-31945	significant	_	
168-100	31946-31956	difference	_	
168-101	31957-31959	in	_	
168-102	31960-31963	HBR	_	
168-103	31964-31972	relative	_	
168-104	31973-31975	to	_	
168-105	31976-31985	condition	_	
168-106	31985-31986	.	_	

#Text=Interaction effects in the Lateral Right indicated that all of the groups had greater levels of HBR in the Loss relative to the Win condition but the magnitude of the difference was greatest in the Clinical Contrast group (t = 13.336, p < .0001; q* < .00015) followed by the PAE group (t = 4.833, p < .0001; q* < .00015) and then the Controls who only demonstrated a marginal effect of condition (t= 1.715, p < .0816, q* < .0908).
169-1	31987-31998	Interaction	_	
169-2	31999-32006	effects	_	
169-3	32007-32009	in	_	
169-4	32010-32013	the	_	
169-5	32014-32021	Lateral	_	
169-6	32022-32027	Right	_	
169-7	32028-32037	indicated	_	
169-8	32038-32042	that	_	
169-9	32043-32046	all	_	
169-10	32047-32049	of	_	
169-11	32050-32053	the	_	
169-12	32054-32060	groups	_	
169-13	32061-32064	had	_	
169-14	32065-32072	greater	_	
169-15	32073-32079	levels	_	
169-16	32080-32082	of	_	
169-17	32083-32086	HBR	_	
169-18	32087-32089	in	_	
169-19	32090-32093	the	_	
169-20	32094-32098	Loss	_	
169-21	32099-32107	relative	_	
169-22	32108-32110	to	_	
169-23	32111-32114	the	_	
169-24	32115-32118	Win	_	
169-25	32119-32128	condition	_	
169-26	32129-32132	but	_	
169-27	32133-32136	the	_	
169-28	32137-32146	magnitude	_	
169-29	32147-32149	of	_	
169-30	32150-32153	the	_	
169-31	32154-32164	difference	_	
169-32	32165-32168	was	_	
169-33	32169-32177	greatest	_	
169-34	32178-32180	in	_	
169-35	32181-32184	the	_	
169-36	32185-32193	Clinical	_	
169-37	32194-32202	Contrast	_	
169-38	32203-32208	group	_	
169-39	32209-32210	(	_	
169-40	32210-32211	t	_	
169-41	32212-32213	=	_	
169-42	32214-32220	13.336	_	
169-43	32220-32221	,	_	
169-44	32222-32223	p	_	
169-45	32224-32225	<	_	
169-46	32226-32231	.0001	_	
169-47	32231-32232	;	_	
169-48	32233-32234	q	_	
169-49	32234-32235	*	_	
169-50	32236-32237	<	_	
169-51	32238-32244	.00015	_	
169-52	32244-32245	)	_	
169-53	32246-32254	followed	_	
169-54	32255-32257	by	_	
169-55	32258-32261	the	_	
169-56	32262-32265	PAE	_	
169-57	32266-32271	group	_	
169-58	32272-32273	(	_	
169-59	32273-32274	t	_	
169-60	32275-32276	=	_	
169-61	32277-32282	4.833	_	
169-62	32282-32283	,	_	
169-63	32284-32285	p	_	
169-64	32286-32287	<	_	
169-65	32288-32293	.0001	_	
169-66	32293-32294	;	_	
169-67	32295-32296	q	_	
169-68	32296-32297	*	_	
169-69	32298-32299	<	_	
169-70	32300-32306	.00015	_	
169-71	32306-32307	)	_	
169-72	32308-32311	and	_	
169-73	32312-32316	then	_	
169-74	32317-32320	the	_	
169-75	32321-32329	Controls	_	
169-76	32330-32333	who	_	
169-77	32334-32338	only	_	
169-78	32339-32351	demonstrated	_	
169-79	32352-32353	a	_	
169-80	32354-32362	marginal	_	
169-81	32363-32369	effect	_	
169-82	32370-32372	of	_	
169-83	32373-32382	condition	_	
169-84	32383-32384	(	_	
169-85	32384-32385	t	_	
169-86	32385-32386	=	_	
169-87	32387-32392	1.715	_	
169-88	32392-32393	,	_	
169-89	32394-32395	p	_	
169-90	32396-32397	<	_	
169-91	32398-32403	.0816	_	
169-92	32403-32404	,	_	
169-93	32405-32406	q	_	
169-94	32406-32407	*	_	
169-95	32408-32409	<	_	
169-96	32410-32415	.0908	_	
169-97	32415-32416	)	_	
169-98	32416-32417	.	_	

#Text=Figure 4 displays the means as a function of group status and condition for each of the areas.
#Text=4.
170-1	32418-32424	Figure	_	
170-2	32425-32426	4	_	
170-3	32427-32435	displays	_	
170-4	32436-32439	the	_	
170-5	32440-32445	means	_	
170-6	32446-32448	as	_	
170-7	32449-32450	a	_	
170-8	32451-32459	function	_	
170-9	32460-32462	of	_	
170-10	32463-32468	group	_	
170-11	32469-32475	status	_	
170-12	32476-32479	and	_	
170-13	32480-32489	condition	_	
170-14	32490-32493	for	_	
170-15	32494-32498	each	_	
170-16	32499-32501	of	_	
170-17	32502-32505	the	_	
170-18	32506-32511	areas	_	
170-19	32511-32512	.	_	
170-20	32513-32514	4	_	
170-21	32514-32515	.	_	

#Text=Discussion
#Text=PFC activity as assessed by fNIRS was used to compare participants with a history of PAE to typically developing children and those in a clinical contrast group with other neurobehavioral problems.
171-1	32516-32526	Discussion	_	
171-2	32527-32530	PFC	_	
171-3	32531-32539	activity	_	
171-4	32540-32542	as	_	
171-5	32543-32551	assessed	_	
171-6	32552-32554	by	_	
171-7	32555-32560	fNIRS	_	
171-8	32561-32564	was	_	
171-9	32565-32569	used	_	
171-10	32570-32572	to	_	
171-11	32573-32580	compare	_	
171-12	32581-32593	participants	_	
171-13	32594-32598	with	_	
171-14	32599-32600	a	_	
171-15	32601-32608	history	_	
171-16	32609-32611	of	_	
171-17	32612-32615	PAE	_	
171-18	32616-32618	to	_	
171-19	32619-32628	typically	_	
171-20	32629-32639	developing	_	
171-21	32640-32648	children	_	
171-22	32649-32652	and	_	
171-23	32653-32658	those	_	
171-24	32659-32661	in	_	
171-25	32662-32663	a	_	
171-26	32664-32672	clinical	_	
171-27	32673-32681	contrast	_	
171-28	32682-32687	group	_	
171-29	32688-32692	with	_	
171-30	32693-32698	other	_	
171-31	32699-32714	neurobehavioral	_	
171-32	32715-32723	problems	_	
171-33	32723-32724	.	_	

#Text=A computerized game designed to elicit activity in the PFC assessed the differential effects of winning and losing in a competitive situation.
172-1	32725-32726	A	_	
172-2	32727-32739	computerized	_	
172-3	32740-32744	game	_	
172-4	32745-32753	designed	_	
172-5	32754-32756	to	_	
172-6	32757-32763	elicit	_	
172-7	32764-32772	activity	_	
172-8	32773-32775	in	_	
172-9	32776-32779	the	_	
172-10	32780-32783	PFC	_	
172-11	32784-32792	assessed	_	
172-12	32793-32796	the	_	
172-13	32797-32809	differential	_	
172-14	32810-32817	effects	_	
172-15	32818-32820	of	_	
172-16	32821-32828	winning	_	
172-17	32829-32832	and	_	
172-18	32833-32839	losing	_	
172-19	32840-32842	in	_	
172-20	32843-32844	a	_	
172-21	32845-32856	competitive	_	
172-22	32857-32866	situation	_	
172-23	32866-32867	.	_	

#Text=Ratings of emotional responses to the game play suggested that winning was associated with positive emotions and losing was associated with negative emotions with participant age attenuating the magnitude of the ratings.
173-1	32868-32875	Ratings	_	
173-2	32876-32878	of	_	
173-3	32879-32888	emotional	_	
173-4	32889-32898	responses	_	
173-5	32899-32901	to	_	
173-6	32902-32905	the	_	
173-7	32906-32910	game	_	
173-8	32911-32915	play	_	
173-9	32916-32925	suggested	_	
173-10	32926-32930	that	_	
173-11	32931-32938	winning	_	
173-12	32939-32942	was	_	
173-13	32943-32953	associated	_	
173-14	32954-32958	with	_	
173-15	32959-32967	positive	_	
173-16	32968-32976	emotions	_	
173-17	32977-32980	and	_	
173-18	32981-32987	losing	_	
173-19	32988-32991	was	_	
173-20	32992-33002	associated	_	
173-21	33003-33007	with	_	
173-22	33008-33016	negative	_	
173-23	33017-33025	emotions	_	
173-24	33026-33030	with	_	
173-25	33031-33042	participant	_	
173-26	33043-33046	age	_	
173-27	33047-33058	attenuating	_	
173-28	33059-33062	the	_	
173-29	33063-33072	magnitude	_	
173-30	33073-33075	of	_	
173-31	33076-33079	the	_	
173-32	33080-33087	ratings	_	
173-33	33087-33088	.	_	

#Text=When examining the game effects across all of the participants enrolled in the study, losing blocks were, on average, associated with lower levels of HBO and higher levels of HBR relative to the winning blocks in both the task performance.
174-1	33089-33093	When	_	
174-2	33094-33103	examining	_	
174-3	33104-33107	the	_	
174-4	33108-33112	game	_	
174-5	33113-33120	effects	_	
174-6	33121-33127	across	_	
174-7	33128-33131	all	_	
174-8	33132-33134	of	_	
174-9	33135-33138	the	_	
174-10	33139-33151	participants	_	
174-11	33152-33160	enrolled	_	
174-12	33161-33163	in	_	
174-13	33164-33167	the	_	
174-14	33168-33173	study	_	
174-15	33173-33174	,	_	
174-16	33175-33181	losing	_	
174-17	33182-33188	blocks	_	
174-18	33189-33193	were	_	
174-19	33193-33194	,	_	
174-20	33195-33197	on	_	
174-21	33198-33205	average	_	
174-22	33205-33206	,	_	
174-23	33207-33217	associated	_	
174-24	33218-33222	with	_	
174-25	33223-33228	lower	_	
174-26	33229-33235	levels	_	
174-27	33236-33238	of	_	
174-28	33239-33242	HBO	_	
174-29	33243-33246	and	_	
174-30	33247-33253	higher	_	
174-31	33254-33260	levels	_	
174-32	33261-33263	of	_	
174-33	33264-33267	HBR	_	
174-34	33268-33276	relative	_	
174-35	33277-33279	to	_	
174-36	33280-33283	the	_	
174-37	33284-33291	winning	_	
174-38	33292-33298	blocks	_	
174-39	33299-33301	in	_	
174-40	33302-33306	both	_	
174-41	33307-33310	the	_	
174-42	33311-33315	task	_	
174-43	33316-33327	performance	_	
174-44	33327-33328	.	_	

#Text=These findings suggest that on average, when dealing with negative emotions, there was less PFC neural activation in contrast to conditions associated with positive emotions.
175-1	33329-33334	These	_	
175-2	33335-33343	findings	_	
175-3	33344-33351	suggest	_	
175-4	33352-33356	that	_	
175-5	33357-33359	on	_	
175-6	33360-33367	average	_	
175-7	33367-33368	,	_	
175-8	33369-33373	when	_	
175-9	33374-33381	dealing	_	
175-10	33382-33386	with	_	
175-11	33387-33395	negative	_	
175-12	33396-33404	emotions	_	
175-13	33404-33405	,	_	
175-14	33406-33411	there	_	
175-15	33412-33415	was	_	
175-16	33416-33420	less	_	
175-17	33421-33424	PFC	_	
175-18	33425-33431	neural	_	
175-19	33432-33442	activation	_	
175-20	33443-33445	in	_	
175-21	33446-33454	contrast	_	
175-22	33455-33457	to	_	
175-23	33458-33468	conditions	_	
175-24	33469-33479	associated	_	
175-25	33480-33484	with	_	
175-26	33485-33493	positive	_	
175-27	33494-33502	emotions	_	
175-28	33502-33503	.	_	

#Text=Although there were significant age effects on the emotional ratings associated with the task conditions, maturational effects on levels of HBO and HBR were only present on the Loss condition in the Right Lateral area, which indexes activity of the right dorsal lateral PFC (R-DLPFC).
176-1	33504-33512	Although	_	
176-2	33513-33518	there	_	
176-3	33519-33523	were	_	
176-4	33524-33535	significant	_	
176-5	33536-33539	age	_	
176-6	33540-33547	effects	_	
176-7	33548-33550	on	_	
176-8	33551-33554	the	_	
176-9	33555-33564	emotional	_	
176-10	33565-33572	ratings	_	
176-11	33573-33583	associated	_	
176-12	33584-33588	with	_	
176-13	33589-33592	the	_	
176-14	33593-33597	task	_	
176-15	33598-33608	conditions	_	
176-16	33608-33609	,	_	
176-17	33610-33622	maturational	_	
176-18	33623-33630	effects	_	
176-19	33631-33633	on	_	
176-20	33634-33640	levels	_	
176-21	33641-33643	of	_	
176-22	33644-33647	HBO	_	
176-23	33648-33651	and	_	
176-24	33652-33655	HBR	_	
176-25	33656-33660	were	_	
176-26	33661-33665	only	_	
176-27	33666-33673	present	_	
176-28	33674-33676	on	_	
176-29	33677-33680	the	_	
176-30	33681-33685	Loss	_	
176-31	33686-33695	condition	_	
176-32	33696-33698	in	_	
176-33	33699-33702	the	_	
176-34	33703-33708	Right	_	
176-35	33709-33716	Lateral	_	
176-36	33717-33721	area	_	
176-37	33721-33722	,	_	
176-38	33723-33728	which	_	
176-39	33729-33736	indexes	_	
176-40	33737-33745	activity	_	
176-41	33746-33748	of	_	
176-42	33749-33752	the	_	
176-43	33753-33758	right	_	
176-44	33759-33765	dorsal	_	
176-45	33766-33773	lateral	_	
176-46	33774-33777	PFC	_	
176-47	33778-33779	(	_	
176-48	33779-33786	R-DLPFC	_	
176-49	33786-33787	)	_	
176-50	33787-33788	.	_	

#Text=A decrease in HBO level in the Loss condition was associated with older participants, suggesting that less neural activity in the R-DLPFC was needed to cope with negative emotions as individuals matured.
177-1	33789-33790	A	_	
177-2	33791-33799	decrease	_	
177-3	33800-33802	in	_	
177-4	33803-33806	HBO	_	
177-5	33807-33812	level	_	
177-6	33813-33815	in	_	
177-7	33816-33819	the	_	
177-8	33820-33824	Loss	_	
177-9	33825-33834	condition	_	
177-10	33835-33838	was	_	
177-11	33839-33849	associated	_	
177-12	33850-33854	with	_	
177-13	33855-33860	older	_	
177-14	33861-33873	participants	_	
177-15	33873-33874	,	_	
177-16	33875-33885	suggesting	_	
177-17	33886-33890	that	_	
177-18	33891-33895	less	_	
177-19	33896-33902	neural	_	
177-20	33903-33911	activity	_	
177-21	33912-33914	in	_	
177-22	33915-33918	the	_	
177-23	33919-33926	R-DLPFC	_	
177-24	33927-33930	was	_	
177-25	33931-33937	needed	_	
177-26	33938-33940	to	_	
177-27	33941-33945	cope	_	
177-28	33946-33950	with	_	
177-29	33951-33959	negative	_	
177-30	33960-33968	emotions	_	
177-31	33969-33971	as	_	
177-32	33972-33983	individuals	_	
177-33	33984-33991	matured	_	
177-34	33991-33992	.	_	

#Text=For the R-DLPFC, only a main effect of group status was found with typically developing children showing the least amount of HBO followed by the PAE group and then the Clinical Contrast group, suggesting the emotional valence of the condition was irrelevant to group differences in activation of the R-DLPFC during game play.
178-1	33993-33996	For	_	
178-2	33997-34000	the	_	
178-3	34001-34008	R-DLPFC	_	
178-4	34008-34009	,	_	
178-5	34010-34014	only	_	
178-6	34015-34016	a	_	
178-7	34017-34021	main	_	
178-8	34022-34028	effect	_	
178-9	34029-34031	of	_	
178-10	34032-34037	group	_	
178-11	34038-34044	status	_	
178-12	34045-34048	was	_	
178-13	34049-34054	found	_	
178-14	34055-34059	with	_	
178-15	34060-34069	typically	_	
178-16	34070-34080	developing	_	
178-17	34081-34089	children	_	
178-18	34090-34097	showing	_	
178-19	34098-34101	the	_	
178-20	34102-34107	least	_	
178-21	34108-34114	amount	_	
178-22	34115-34117	of	_	
178-23	34118-34121	HBO	_	
178-24	34122-34130	followed	_	
178-25	34131-34133	by	_	
178-26	34134-34137	the	_	
178-27	34138-34141	PAE	_	
178-28	34142-34147	group	_	
178-29	34148-34151	and	_	
178-30	34152-34156	then	_	
178-31	34157-34160	the	_	
178-32	34161-34169	Clinical	_	
178-33	34170-34178	Contrast	_	
178-34	34179-34184	group	_	
178-35	34184-34185	,	_	
178-36	34186-34196	suggesting	_	
178-37	34197-34200	the	_	
178-38	34201-34210	emotional	_	
178-39	34211-34218	valence	_	
178-40	34219-34221	of	_	
178-41	34222-34225	the	_	
178-42	34226-34235	condition	_	
178-43	34236-34239	was	_	
178-44	34240-34250	irrelevant	_	
178-45	34251-34253	to	_	
178-46	34254-34259	group	_	
178-47	34260-34271	differences	_	
178-48	34272-34274	in	_	
178-49	34275-34285	activation	_	
178-50	34286-34288	of	_	
178-51	34289-34292	the	_	
178-52	34293-34300	R-DLPFC	_	
178-53	34301-34307	during	_	
178-54	34308-34312	game	_	
178-55	34313-34317	play	_	
178-56	34317-34318	.	_	

#Text=This was the only PFC area where condition of the task did not impact group differences.
179-1	34319-34323	This	_	
179-2	34324-34327	was	_	
179-3	34328-34331	the	_	
179-4	34332-34336	only	_	
179-5	34337-34340	PFC	_	
179-6	34341-34345	area	_	
179-7	34346-34351	where	_	
179-8	34352-34361	condition	_	
179-9	34362-34364	of	_	
179-10	34365-34368	the	_	
179-11	34369-34373	task	_	
179-12	34374-34377	did	_	
179-13	34378-34381	not	_	
179-14	34382-34388	impact	_	
179-15	34389-34394	group	_	
179-16	34395-34406	differences	_	
179-17	34406-34407	.	_	

#Text=Relative to group differences in the Win condition, children with PAE had less activation, as indicated by lower levels of HBO in the medial areas of the PFC and higher levels of HBR in all areas of the PFC relative to both contrast groups.
180-1	34408-34416	Relative	_	
180-2	34417-34419	to	_	
180-3	34420-34425	group	_	
180-4	34426-34437	differences	_	
180-5	34438-34440	in	_	
180-6	34441-34444	the	_	
180-7	34445-34448	Win	_	
180-8	34449-34458	condition	_	
180-9	34458-34459	,	_	
180-10	34460-34468	children	_	
180-11	34469-34473	with	_	
180-12	34474-34477	PAE	_	
180-13	34478-34481	had	_	
180-14	34482-34486	less	_	
180-15	34487-34497	activation	_	
180-16	34497-34498	,	_	
180-17	34499-34501	as	_	
180-18	34502-34511	indicated	_	
180-19	34512-34514	by	_	
180-20	34515-34520	lower	_	
180-21	34521-34527	levels	_	
180-22	34528-34530	of	_	
180-23	34531-34534	HBO	_	
180-24	34535-34537	in	_	
180-25	34538-34541	the	_	
180-26	34542-34548	medial	_	
180-27	34549-34554	areas	_	
180-28	34555-34557	of	_	
180-29	34558-34561	the	_	
180-30	34562-34565	PFC	_	
180-31	34566-34569	and	_	
180-32	34570-34576	higher	_	
180-33	34577-34583	levels	_	
180-34	34584-34586	of	_	
180-35	34587-34590	HBR	_	
180-36	34591-34593	in	_	
180-37	34594-34597	all	_	
180-38	34598-34603	areas	_	
180-39	34604-34606	of	_	
180-40	34607-34610	the	_	
180-41	34611-34614	PFC	_	
180-42	34615-34623	relative	_	
180-43	34624-34626	to	_	
180-44	34627-34631	both	_	
180-45	34632-34640	contrast	_	
180-46	34641-34647	groups	_	
180-47	34647-34648	.	_	

#Text=Medial areas of the PFC have been linked to important functional skills, including reward processing and self-monitoring, and are known to be disrupted by PAE.
181-1	34649-34655	Medial	_	
181-2	34656-34661	areas	_	
181-3	34662-34664	of	_	
181-4	34665-34668	the	_	
181-5	34669-34672	PFC	_	
181-6	34673-34677	have	_	
181-7	34678-34682	been	_	
181-8	34683-34689	linked	_	
181-9	34690-34692	to	_	
181-10	34693-34702	important	_	
181-11	34703-34713	functional	_	
181-12	34714-34720	skills	_	
181-13	34720-34721	,	_	
181-14	34722-34731	including	_	
181-15	34732-34738	reward	_	
181-16	34739-34749	processing	_	
181-17	34750-34753	and	_	
181-18	34754-34769	self-monitoring	_	
181-19	34769-34770	,	_	
181-20	34771-34774	and	_	
181-21	34775-34778	are	_	
181-22	34779-34784	known	_	
181-23	34785-34787	to	_	
181-24	34788-34790	be	_	
181-25	34791-34800	disrupted	_	
181-26	34801-34803	by	_	
181-27	34804-34807	PAE	_	
181-28	34807-34808	.	_	

#Text=In the Loss condition, the clinical contrast group demonstrated lower levels of medial PFC HBO as compared to the PAE group and typically developing controls who did not differ from each other, suggesting that neural activation in the context of negative emotions was better at discriminating the clinical contrast group.
182-1	34809-34811	In	_	
182-2	34812-34815	the	_	
182-3	34816-34820	Loss	_	
182-4	34821-34830	condition	_	
182-5	34830-34831	,	_	
182-6	34832-34835	the	_	
182-7	34836-34844	clinical	_	
182-8	34845-34853	contrast	_	
182-9	34854-34859	group	_	
182-10	34860-34872	demonstrated	_	
182-11	34873-34878	lower	_	
182-12	34879-34885	levels	_	
182-13	34886-34888	of	_	
182-14	34889-34895	medial	_	
182-15	34896-34899	PFC	_	
182-16	34900-34903	HBO	_	
182-17	34904-34906	as	_	
182-18	34907-34915	compared	_	
182-19	34916-34918	to	_	
182-20	34919-34922	the	_	
182-21	34923-34926	PAE	_	
182-22	34927-34932	group	_	
182-23	34933-34936	and	_	
182-24	34937-34946	typically	_	
182-25	34947-34957	developing	_	
182-26	34958-34966	controls	_	
182-27	34967-34970	who	_	
182-28	34971-34974	did	_	
182-29	34975-34978	not	_	
182-30	34979-34985	differ	_	
182-31	34986-34990	from	_	
182-32	34991-34995	each	_	
182-33	34996-35001	other	_	
182-34	35001-35002	,	_	
182-35	35003-35013	suggesting	_	
182-36	35014-35018	that	_	
182-37	35019-35025	neural	_	
182-38	35026-35036	activation	_	
182-39	35037-35039	in	_	
182-40	35040-35043	the	_	
182-41	35044-35051	context	_	
182-42	35052-35054	of	_	
182-43	35055-35063	negative	_	
182-44	35064-35072	emotions	_	
182-45	35073-35076	was	_	
182-46	35077-35083	better	_	
182-47	35084-35086	at	_	
182-48	35087-35101	discriminating	_	
182-49	35102-35105	the	_	
182-50	35106-35114	clinical	_	
182-51	35115-35123	contrast	_	
182-52	35124-35129	group	_	
182-53	35129-35130	.	_	

#Text=In the L-DLPFC, the PAE group had lower levels of HBO during the winning condition when compared to the clinical contrast group but did not differ from controls.
183-1	35131-35133	In	_	
183-2	35134-35137	the	_	
183-3	35138-35145	L-DLPFC	_	
183-4	35145-35146	,	_	
183-5	35147-35150	the	_	
183-6	35151-35154	PAE	_	
183-7	35155-35160	group	_	
183-8	35161-35164	had	_	
183-9	35165-35170	lower	_	
183-10	35171-35177	levels	_	
183-11	35178-35180	of	_	
183-12	35181-35184	HBO	_	
183-13	35185-35191	during	_	
183-14	35192-35195	the	_	
183-15	35196-35203	winning	_	
183-16	35204-35213	condition	_	
183-17	35214-35218	when	_	
183-18	35219-35227	compared	_	
183-19	35228-35230	to	_	
183-20	35231-35234	the	_	
183-21	35235-35243	clinical	_	
183-22	35244-35252	contrast	_	
183-23	35253-35258	group	_	
183-24	35259-35262	but	_	
183-25	35263-35266	did	_	
183-26	35267-35270	not	_	
183-27	35271-35277	differ	_	
183-28	35278-35282	from	_	
183-29	35283-35291	controls	_	
183-30	35291-35292	.	_	

#Text=While losing, activation of the L-DLPFC was intermediate for the PAE group who had lower levels of HBO than the typically developing children but higher levels than that of the clinical contrast group.
184-1	35293-35298	While	_	
184-2	35299-35305	losing	_	
184-3	35305-35306	,	_	
184-4	35307-35317	activation	_	
184-5	35318-35320	of	_	
184-6	35321-35324	the	_	
184-7	35325-35332	L-DLPFC	_	
184-8	35333-35336	was	_	
184-9	35337-35349	intermediate	_	
184-10	35350-35353	for	_	
184-11	35354-35357	the	_	
184-12	35358-35361	PAE	_	
184-13	35362-35367	group	_	
184-14	35368-35371	who	_	
184-15	35372-35375	had	_	
184-16	35376-35381	lower	_	
184-17	35382-35388	levels	_	
184-18	35389-35391	of	_	
184-19	35392-35395	HBO	_	
184-20	35396-35400	than	_	
184-21	35401-35404	the	_	
184-22	35405-35414	typically	_	
184-23	35415-35425	developing	_	
184-24	35426-35434	children	_	
184-25	35435-35438	but	_	
184-26	35439-35445	higher	_	
184-27	35446-35452	levels	_	
184-28	35453-35457	than	_	
184-29	35458-35462	that	_	
184-30	35463-35465	of	_	
184-31	35466-35469	the	_	
184-32	35470-35478	clinical	_	
184-33	35479-35487	contrast	_	
184-34	35488-35493	group	_	
184-35	35493-35494	.	_	

#Text=These findings suggest that oxygenation levels of children with PAE may be better differentiated from both typically developing children and other children with clinical problems using tasks that elicit positive emotions.
185-1	35495-35500	These	_	
185-2	35501-35509	findings	_	
185-3	35510-35517	suggest	_	
185-4	35518-35522	that	_	
185-5	35523-35534	oxygenation	_	
185-6	35535-35541	levels	_	
185-7	35542-35544	of	_	
185-8	35545-35553	children	_	
185-9	35554-35558	with	_	
185-10	35559-35562	PAE	_	
185-11	35563-35566	may	_	
185-12	35567-35569	be	_	
185-13	35570-35576	better	_	
185-14	35577-35591	differentiated	_	
185-15	35592-35596	from	_	
185-16	35597-35601	both	_	
185-17	35602-35611	typically	_	
185-18	35612-35622	developing	_	
185-19	35623-35631	children	_	
185-20	35632-35635	and	_	
185-21	35636-35641	other	_	
185-22	35642-35650	children	_	
185-23	35651-35655	with	_	
185-24	35656-35664	clinical	_	
185-25	35665-35673	problems	_	
185-26	35674-35679	using	_	
185-27	35680-35685	tasks	_	
185-28	35686-35690	that	_	
185-29	35691-35697	elicit	_	
185-30	35698-35706	positive	_	
185-31	35707-35715	emotions	_	
185-32	35715-35716	.	_	

#Text=Relative to changes in level of response in the Win and Loss conditions within each group, the PAE group had no significant differences in HBR levels as a function of the condition (Win vs.
186-1	35717-35725	Relative	_	
186-2	35726-35728	to	_	
186-3	35729-35736	changes	_	
186-4	35737-35739	in	_	
186-5	35740-35745	level	_	
186-6	35746-35748	of	_	
186-7	35749-35757	response	_	
186-8	35758-35760	in	_	
186-9	35761-35764	the	_	
186-10	35765-35768	Win	_	
186-11	35769-35772	and	_	
186-12	35773-35777	Loss	_	
186-13	35778-35788	conditions	_	
186-14	35789-35795	within	_	
186-15	35796-35800	each	_	
186-16	35801-35806	group	_	
186-17	35806-35807	,	_	
186-18	35808-35811	the	_	
186-19	35812-35815	PAE	_	
186-20	35816-35821	group	_	
186-21	35822-35825	had	_	
186-22	35826-35828	no	_	
186-23	35829-35840	significant	_	
186-24	35841-35852	differences	_	
186-25	35853-35855	in	_	
186-26	35856-35859	HBR	_	
186-27	35860-35866	levels	_	
186-28	35867-35869	as	_	
186-29	35870-35871	a	_	
186-30	35872-35880	function	_	
186-31	35881-35883	of	_	
186-32	35884-35887	the	_	
186-33	35888-35897	condition	_	
186-34	35898-35899	(	_	
186-35	35899-35902	Win	_	
186-36	35903-35905	vs	_	
186-37	35905-35906	.	_	

#Text=Loss) in either the L-DLPFC or the medial area during game play but both other groups demonstrated increased HBR levels in response to the Loss condition.
187-1	35907-35911	Loss	_	
187-2	35911-35912	)	_	
187-3	35913-35915	in	_	
187-4	35916-35922	either	_	
187-5	35923-35926	the	_	
187-6	35927-35934	L-DLPFC	_	
187-7	35935-35937	or	_	
187-8	35938-35941	the	_	
187-9	35942-35948	medial	_	
187-10	35949-35953	area	_	
187-11	35954-35960	during	_	
187-12	35961-35965	game	_	
187-13	35966-35970	play	_	
187-14	35971-35974	but	_	
187-15	35975-35979	both	_	
187-16	35980-35985	other	_	
187-17	35986-35992	groups	_	
187-18	35993-36005	demonstrated	_	
187-19	36006-36015	increased	_	
187-20	36016-36019	HBR	_	
187-21	36020-36026	levels	_	
187-22	36027-36029	in	_	
187-23	36030-36038	response	_	
187-24	36039-36041	to	_	
187-25	36042-36045	the	_	
187-26	36046-36050	Loss	_	
187-27	36051-36060	condition	_	
187-28	36060-36061	.	_	

#Text=These findings suggest that the valence of the emotional experience during game play did not trigger different levels of PFC activity in these areas in children with PAE in contrast to the reaction of the other groups of children.
188-1	36062-36067	These	_	
188-2	36068-36076	findings	_	
188-3	36077-36084	suggest	_	
188-4	36085-36089	that	_	
188-5	36090-36093	the	_	
188-6	36094-36101	valence	_	
188-7	36102-36104	of	_	
188-8	36105-36108	the	_	
188-9	36109-36118	emotional	_	
188-10	36119-36129	experience	_	
188-11	36130-36136	during	_	
188-12	36137-36141	game	_	
188-13	36142-36146	play	_	
188-14	36147-36150	did	_	
188-15	36151-36154	not	_	
188-16	36155-36162	trigger	_	
188-17	36163-36172	different	_	
188-18	36173-36179	levels	_	
188-19	36180-36182	of	_	
188-20	36183-36186	PFC	_	
188-21	36187-36195	activity	_	
188-22	36196-36198	in	_	
188-23	36199-36204	these	_	
188-24	36205-36210	areas	_	
188-25	36211-36213	in	_	
188-26	36214-36222	children	_	
188-27	36223-36227	with	_	
188-28	36228-36231	PAE	_	
188-29	36232-36234	in	_	
188-30	36235-36243	contrast	_	
188-31	36244-36246	to	_	
188-32	36247-36250	the	_	
188-33	36251-36259	reaction	_	
188-34	36260-36262	of	_	
188-35	36263-36266	the	_	
188-36	36267-36272	other	_	
188-37	36273-36279	groups	_	
188-38	36280-36282	of	_	
188-39	36283-36291	children	_	
188-40	36291-36292	.	_	

#Text=The only area that demonstrated a condition effect on HBR levels in children with PAE was the R-DLPFC with the magnitude of the difference falling between those of the other two groups.
189-1	36293-36296	The	_	
189-2	36297-36301	only	_	
189-3	36302-36306	area	_	
189-4	36307-36311	that	_	
189-5	36312-36324	demonstrated	_	
189-6	36325-36326	a	_	
189-7	36327-36336	condition	_	
189-8	36337-36343	effect	_	
189-9	36344-36346	on	_	
189-10	36347-36350	HBR	_	
189-11	36351-36357	levels	_	
189-12	36358-36360	in	_	
189-13	36361-36369	children	_	
189-14	36370-36374	with	_	
189-15	36375-36378	PAE	_	
189-16	36379-36382	was	_	
189-17	36383-36386	the	_	
189-18	36387-36394	R-DLPFC	_	
189-19	36395-36399	with	_	
189-20	36400-36403	the	_	
189-21	36404-36413	magnitude	_	
189-22	36414-36416	of	_	
189-23	36417-36420	the	_	
189-24	36421-36431	difference	_	
189-25	36432-36439	falling	_	
189-26	36440-36447	between	_	
189-27	36448-36453	those	_	
189-28	36454-36456	of	_	
189-29	36457-36460	the	_	
189-30	36461-36466	other	_	
189-31	36467-36470	two	_	
189-32	36471-36477	groups	_	
189-33	36477-36478	.	_	

#Text=The diminished differences in PFC activity associated with losing relative to winning in the PAE children may be related to perceived effectiveness in playing the game.
190-1	36479-36482	The	_	
190-2	36483-36493	diminished	_	
190-3	36494-36505	differences	_	
190-4	36506-36508	in	_	
190-5	36509-36512	PFC	_	
190-6	36513-36521	activity	_	
190-7	36522-36532	associated	_	
190-8	36533-36537	with	_	
190-9	36538-36544	losing	_	
190-10	36545-36553	relative	_	
190-11	36554-36556	to	_	
190-12	36557-36564	winning	_	
190-13	36565-36567	in	_	
190-14	36568-36571	the	_	
190-15	36572-36575	PAE	_	
190-16	36576-36584	children	_	
190-17	36585-36588	may	_	
190-18	36589-36591	be	_	
190-19	36592-36599	related	_	
190-20	36600-36602	to	_	
190-21	36603-36612	perceived	_	
190-22	36613-36626	effectiveness	_	
190-23	36627-36629	in	_	
190-24	36630-36637	playing	_	
190-25	36638-36641	the	_	
190-26	36642-36646	game	_	
190-27	36646-36647	.	_	

#Text=Although there were no group differences in emotional ratings, these were not made until after the children received feedback regarding their performance for an entire block of six trials.
191-1	36648-36656	Although	_	
191-2	36657-36662	there	_	
191-3	36663-36667	were	_	
191-4	36668-36670	no	_	
191-5	36671-36676	group	_	
191-6	36677-36688	differences	_	
191-7	36689-36691	in	_	
191-8	36692-36701	emotional	_	
191-9	36702-36709	ratings	_	
191-10	36709-36710	,	_	
191-11	36711-36716	these	_	
191-12	36717-36721	were	_	
191-13	36722-36725	not	_	
191-14	36726-36730	made	_	
191-15	36731-36736	until	_	
191-16	36737-36742	after	_	
191-17	36743-36746	the	_	
191-18	36747-36755	children	_	
191-19	36756-36764	received	_	
191-20	36765-36773	feedback	_	
191-21	36774-36783	regarding	_	
191-22	36784-36789	their	_	
191-23	36790-36801	performance	_	
191-24	36802-36805	for	_	
191-25	36806-36808	an	_	
191-26	36809-36815	entire	_	
191-27	36816-36821	block	_	
191-28	36822-36824	of	_	
191-29	36825-36828	six	_	
191-30	36829-36835	trials	_	
191-31	36835-36836	.	_	

#Text=As problems with both number perception and self-monitoring are associated with PAE, it is possible that children with PAE were not monitoring their Win and Loss experiences or overall success rate within the context of the game as closely as were the other children.
192-1	36837-36839	As	_	
192-2	36840-36848	problems	_	
192-3	36849-36853	with	_	
192-4	36854-36858	both	_	
192-5	36859-36865	number	_	
192-6	36866-36876	perception	_	
192-7	36877-36880	and	_	
192-8	36881-36896	self-monitoring	_	
192-9	36897-36900	are	_	
192-10	36901-36911	associated	_	
192-11	36912-36916	with	_	
192-12	36917-36920	PAE	_	
192-13	36920-36921	,	_	
192-14	36922-36924	it	_	
192-15	36925-36927	is	_	
192-16	36928-36936	possible	_	
192-17	36937-36941	that	_	
192-18	36942-36950	children	_	
192-19	36951-36955	with	_	
192-20	36956-36959	PAE	_	
192-21	36960-36964	were	_	
192-22	36965-36968	not	_	
192-23	36969-36979	monitoring	_	
192-24	36980-36985	their	_	
192-25	36986-36989	Win	_	
192-26	36990-36993	and	_	
192-27	36994-36998	Loss	_	
192-28	36999-37010	experiences	_	
192-29	37011-37013	or	_	
192-30	37014-37021	overall	_	
192-31	37022-37029	success	_	
192-32	37030-37034	rate	_	
192-33	37035-37041	within	_	
192-34	37042-37045	the	_	
192-35	37046-37053	context	_	
192-36	37054-37056	of	_	
192-37	37057-37060	the	_	
192-38	37061-37065	game	_	
192-39	37066-37068	as	_	
192-40	37069-37076	closely	_	
192-41	37077-37079	as	_	
192-42	37080-37084	were	_	
192-43	37085-37088	the	_	
192-44	37089-37094	other	_	
192-45	37095-37103	children	_	
192-46	37103-37104	.	_	

#Text=This lack of monitoring may have diminished differential oxygen utilization associated with conditions.
193-1	37105-37109	This	_	
193-2	37110-37114	lack	_	
193-3	37115-37117	of	_	
193-4	37118-37128	monitoring	_	
193-5	37129-37132	may	_	
193-6	37133-37137	have	_	
193-7	37138-37148	diminished	_	
193-8	37149-37161	differential	_	
193-9	37162-37168	oxygen	_	
193-10	37169-37180	utilization	_	
193-11	37181-37191	associated	_	
193-12	37192-37196	with	_	
193-13	37197-37207	conditions	_	
193-14	37207-37208	.	_	

#Text=Magnitude estimation, which is a skill needed for estimating on-going performance levels during game play, was associated with a reduction in medial PFC activation in children with PAE relative to typically developing children during a proximity judgement task.
194-1	37209-37218	Magnitude	_	
194-2	37219-37229	estimation	_	
194-3	37229-37230	,	_	
194-4	37231-37236	which	_	
194-5	37237-37239	is	_	
194-6	37240-37241	a	_	
194-7	37242-37247	skill	_	
194-8	37248-37254	needed	_	
194-9	37255-37258	for	_	
194-10	37259-37269	estimating	_	
194-11	37270-37278	on-going	_	
194-12	37279-37290	performance	_	
194-13	37291-37297	levels	_	
194-14	37298-37304	during	_	
194-15	37305-37309	game	_	
194-16	37310-37314	play	_	
194-17	37314-37315	,	_	
194-18	37316-37319	was	_	
194-19	37320-37330	associated	_	
194-20	37331-37335	with	_	
194-21	37336-37337	a	_	
194-22	37338-37347	reduction	_	
194-23	37348-37350	in	_	
194-24	37351-37357	medial	_	
194-25	37358-37361	PFC	_	
194-26	37362-37372	activation	_	
194-27	37373-37375	in	_	
194-28	37376-37384	children	_	
194-29	37385-37389	with	_	
194-30	37390-37393	PAE	_	
194-31	37394-37402	relative	_	
194-32	37403-37405	to	_	
194-33	37406-37415	typically	_	
194-34	37416-37426	developing	_	
194-35	37427-37435	children	_	
194-36	37436-37442	during	_	
194-37	37443-37444	a	_	
194-38	37445-37454	proximity	_	
194-39	37455-37464	judgement	_	
194-40	37465-37469	task	_	
194-41	37469-37470	.	_	

#Text=The most distinguishing feature of the responses of the typically developing children was their pattern of differential responsiveness relative to specific areas of the PFC.
195-1	37471-37474	The	_	
195-2	37475-37479	most	_	
195-3	37480-37494	distinguishing	_	
195-4	37495-37502	feature	_	
195-5	37503-37505	of	_	
195-6	37506-37509	the	_	
195-7	37510-37519	responses	_	
195-8	37520-37522	of	_	
195-9	37523-37526	the	_	
195-10	37527-37536	typically	_	
195-11	37537-37547	developing	_	
195-12	37548-37556	children	_	
195-13	37557-37560	was	_	
195-14	37561-37566	their	_	
195-15	37567-37574	pattern	_	
195-16	37575-37577	of	_	
195-17	37578-37590	differential	_	
195-18	37591-37605	responsiveness	_	
195-19	37606-37614	relative	_	
195-20	37615-37617	to	_	
195-21	37618-37626	specific	_	
195-22	37627-37632	areas	_	
195-23	37633-37635	of	_	
195-24	37636-37639	the	_	
195-25	37640-37643	PFC	_	
195-26	37643-37644	.	_	

#Text=When contrasting the change in level of response in the Win and Loss conditions, increased activation as indicated by increased levels of HBO in the L-DLPFC in response to losing during game performance was found in typically developing children relative to both other groups who demonstrated reductions in HBO levels when contrasting the Win and Loss conditions.
196-1	37645-37649	When	_	
196-2	37650-37661	contrasting	_	
196-3	37662-37665	the	_	
196-4	37666-37672	change	_	
196-5	37673-37675	in	_	
196-6	37676-37681	level	_	
196-7	37682-37684	of	_	
196-8	37685-37693	response	_	
196-9	37694-37696	in	_	
196-10	37697-37700	the	_	
196-11	37701-37704	Win	_	
196-12	37705-37708	and	_	
196-13	37709-37713	Loss	_	
196-14	37714-37724	conditions	_	
196-15	37724-37725	,	_	
196-16	37726-37735	increased	_	
196-17	37736-37746	activation	_	
196-18	37747-37749	as	_	
196-19	37750-37759	indicated	_	
196-20	37760-37762	by	_	
196-21	37763-37772	increased	_	
196-22	37773-37779	levels	_	
196-23	37780-37782	of	_	
196-24	37783-37786	HBO	_	
196-25	37787-37789	in	_	
196-26	37790-37793	the	_	
196-27	37794-37801	L-DLPFC	_	
196-28	37802-37804	in	_	
196-29	37805-37813	response	_	
196-30	37814-37816	to	_	
196-31	37817-37823	losing	_	
196-32	37824-37830	during	_	
196-33	37831-37835	game	_	
196-34	37836-37847	performance	_	
196-35	37848-37851	was	_	
196-36	37852-37857	found	_	
196-37	37858-37860	in	_	
196-38	37861-37870	typically	_	
196-39	37871-37881	developing	_	
196-40	37882-37890	children	_	
196-41	37891-37899	relative	_	
196-42	37900-37902	to	_	
196-43	37903-37907	both	_	
196-44	37908-37913	other	_	
196-45	37914-37920	groups	_	
196-46	37921-37924	who	_	
196-47	37925-37937	demonstrated	_	
196-48	37938-37948	reductions	_	
196-49	37949-37951	in	_	
196-50	37952-37955	HBO	_	
196-51	37956-37962	levels	_	
196-52	37963-37967	when	_	
196-53	37968-37979	contrasting	_	
196-54	37980-37983	the	_	
196-55	37984-37987	Win	_	
196-56	37988-37991	and	_	
196-57	37992-37996	Loss	_	
196-58	37997-38007	conditions	_	
196-59	38007-38008	.	_	

#Text=L-DLPFC is an area of the brain linked to dealing with negative emotions, planning and inhibitory control.
197-1	38009-38016	L-DLPFC	_	
197-2	38017-38019	is	_	
197-3	38020-38022	an	_	
197-4	38023-38027	area	_	
197-5	38028-38030	of	_	
197-6	38031-38034	the	_	
197-7	38035-38040	brain	_	
197-8	38041-38047	linked	_	
197-9	38048-38050	to	_	
197-10	38051-38058	dealing	_	
197-11	38059-38063	with	_	
197-12	38064-38072	negative	_	
197-13	38073-38081	emotions	_	
197-14	38081-38082	,	_	
197-15	38083-38091	planning	_	
197-16	38092-38095	and	_	
197-17	38096-38106	inhibitory	_	
197-18	38107-38114	control	_	
197-19	38114-38115	.	_	

#Text=Typically developing controls also seemed to rely less on activation of the R-DLPFC to cope with the emotional arousal associated with the task regardless of the valence of arousal.
198-1	38116-38125	Typically	_	
198-2	38126-38136	developing	_	
198-3	38137-38145	controls	_	
198-4	38146-38150	also	_	
198-5	38151-38157	seemed	_	
198-6	38158-38160	to	_	
198-7	38161-38165	rely	_	
198-8	38166-38170	less	_	
198-9	38171-38173	on	_	
198-10	38174-38184	activation	_	
198-11	38185-38187	of	_	
198-12	38188-38191	the	_	
198-13	38192-38199	R-DLPFC	_	
198-14	38200-38202	to	_	
198-15	38203-38207	cope	_	
198-16	38208-38212	with	_	
198-17	38213-38216	the	_	
198-18	38217-38226	emotional	_	
198-19	38227-38234	arousal	_	
198-20	38235-38245	associated	_	
198-21	38246-38250	with	_	
198-22	38251-38254	the	_	
198-23	38255-38259	task	_	
198-24	38260-38270	regardless	_	
198-25	38271-38273	of	_	
198-26	38274-38277	the	_	
198-27	38278-38285	valence	_	
198-28	38286-38288	of	_	
198-29	38289-38296	arousal	_	
198-30	38296-38297	.	_	

#Text=The age effect found in the R-DLPFC, which was a decrease in HBO level in the Loss condition being associated with increased age, is suggestive that the hemispheric specialization found in the typically developing children may be a positive developmental maturational process but it will be important to explore this by relating this pattern of response to neurobehavioral outcomes and replicating the finding in another sample.
199-1	38298-38301	The	_	
199-2	38302-38305	age	_	
199-3	38306-38312	effect	_	
199-4	38313-38318	found	_	
199-5	38319-38321	in	_	
199-6	38322-38325	the	_	
199-7	38326-38333	R-DLPFC	_	
199-8	38333-38334	,	_	
199-9	38335-38340	which	_	
199-10	38341-38344	was	_	
199-11	38345-38346	a	_	
199-12	38347-38355	decrease	_	
199-13	38356-38358	in	_	
199-14	38359-38362	HBO	_	
199-15	38363-38368	level	_	
199-16	38369-38371	in	_	
199-17	38372-38375	the	_	
199-18	38376-38380	Loss	_	
199-19	38381-38390	condition	_	
199-20	38391-38396	being	_	
199-21	38397-38407	associated	_	
199-22	38408-38412	with	_	
199-23	38413-38422	increased	_	
199-24	38423-38426	age	_	
199-25	38426-38427	,	_	
199-26	38428-38430	is	_	
199-27	38431-38441	suggestive	_	
199-28	38442-38446	that	_	
199-29	38447-38450	the	_	
199-30	38451-38462	hemispheric	_	
199-31	38463-38477	specialization	_	
199-32	38478-38483	found	_	
199-33	38484-38486	in	_	
199-34	38487-38490	the	_	
199-35	38491-38500	typically	_	
199-36	38501-38511	developing	_	
199-37	38512-38520	children	_	
199-38	38521-38524	may	_	
199-39	38525-38527	be	_	
199-40	38528-38529	a	_	
199-41	38530-38538	positive	_	
199-42	38539-38552	developmental	_	
199-43	38553-38565	maturational	_	
199-44	38566-38573	process	_	
199-45	38574-38577	but	_	
199-46	38578-38580	it	_	
199-47	38581-38585	will	_	
199-48	38586-38588	be	_	
199-49	38589-38598	important	_	
199-50	38599-38601	to	_	
199-51	38602-38609	explore	_	
199-52	38610-38614	this	_	
199-53	38615-38617	by	_	
199-54	38618-38626	relating	_	
199-55	38627-38631	this	_	
199-56	38632-38639	pattern	_	
199-57	38640-38642	of	_	
199-58	38643-38651	response	_	
199-59	38652-38654	to	_	
199-60	38655-38670	neurobehavioral	_	
199-61	38671-38679	outcomes	_	
199-62	38680-38683	and	_	
199-63	38684-38695	replicating	_	
199-64	38696-38699	the	_	
199-65	38700-38707	finding	_	
199-66	38708-38710	in	_	
199-67	38711-38718	another	_	
199-68	38719-38725	sample	_	
199-69	38725-38726	.	_	

#Text=Although differentiating children with PAE from typically developing children often is not a difficult task, it is also important to differentiate patterns of responses of these children from other children with clinical problems not caused by PAE.
200-1	38727-38735	Although	_	
200-2	38736-38751	differentiating	_	
200-3	38752-38760	children	_	
200-4	38761-38765	with	_	
200-5	38766-38769	PAE	_	
200-6	38770-38774	from	_	
200-7	38775-38784	typically	_	
200-8	38785-38795	developing	_	
200-9	38796-38804	children	_	
200-10	38805-38810	often	_	
200-11	38811-38813	is	_	
200-12	38814-38817	not	_	
200-13	38818-38819	a	_	
200-14	38820-38829	difficult	_	
200-15	38830-38834	task	_	
200-16	38834-38835	,	_	
200-17	38836-38838	it	_	
200-18	38839-38841	is	_	
200-19	38842-38846	also	_	
200-20	38847-38856	important	_	
200-21	38857-38859	to	_	
200-22	38860-38873	differentiate	_	
200-23	38874-38882	patterns	_	
200-24	38883-38885	of	_	
200-25	38886-38895	responses	_	
200-26	38896-38898	of	_	
200-27	38899-38904	these	_	
200-28	38905-38913	children	_	
200-29	38914-38918	from	_	
200-30	38919-38924	other	_	
200-31	38925-38933	children	_	
200-32	38934-38938	with	_	
200-33	38939-38947	clinical	_	
200-34	38948-38956	problems	_	
200-35	38957-38960	not	_	
200-36	38961-38967	caused	_	
200-37	38968-38970	by	_	
200-38	38971-38974	PAE	_	
200-39	38974-38975	.	_	

#Text=Children in the Clinical Contrast group demonstrated the greatest activation, as indexed by increased HBO levels, of the R-DLPFC during both conditions of game play and had the greatest contrast in PFC activation between the Win and Loss conditions.
201-1	38976-38984	Children	_	
201-2	38985-38987	in	_	
201-3	38988-38991	the	_	
201-4	38992-39000	Clinical	_	
201-5	39001-39009	Contrast	_	
201-6	39010-39015	group	_	
201-7	39016-39028	demonstrated	_	
201-8	39029-39032	the	_	
201-9	39033-39041	greatest	_	
201-10	39042-39052	activation	_	
201-11	39052-39053	,	_	
201-12	39054-39056	as	_	
201-13	39057-39064	indexed	_	
201-14	39065-39067	by	_	
201-15	39068-39077	increased	_	
201-16	39078-39081	HBO	_	
201-17	39082-39088	levels	_	
201-18	39088-39089	,	_	
201-19	39090-39092	of	_	
201-20	39093-39096	the	_	
201-21	39097-39104	R-DLPFC	_	
201-22	39105-39111	during	_	
201-23	39112-39116	both	_	
201-24	39117-39127	conditions	_	
201-25	39128-39130	of	_	
201-26	39131-39135	game	_	
201-27	39136-39140	play	_	
201-28	39141-39144	and	_	
201-29	39145-39148	had	_	
201-30	39149-39152	the	_	
201-31	39153-39161	greatest	_	
201-32	39162-39170	contrast	_	
201-33	39171-39173	in	_	
201-34	39174-39177	PFC	_	
201-35	39178-39188	activation	_	
201-36	39189-39196	between	_	
201-37	39197-39200	the	_	
201-38	39201-39204	Win	_	
201-39	39205-39208	and	_	
201-40	39209-39213	Loss	_	
201-41	39214-39224	conditions	_	
201-42	39224-39225	.	_	

#Text=Although children with PAE demonstrated a similar pattern to the children in the clinical contrast group, the magnitude of the decline in HBO in the Loss relative to the Win condition in game play was greater for the Clinical Contrast group, suggesting that children in the Clinical Contrast group were more responsive to the valence of the emotional arousal.
202-1	39226-39234	Although	_	
202-2	39235-39243	children	_	
202-3	39244-39248	with	_	
202-4	39249-39252	PAE	_	
202-5	39253-39265	demonstrated	_	
202-6	39266-39267	a	_	
202-7	39268-39275	similar	_	
202-8	39276-39283	pattern	_	
202-9	39284-39286	to	_	
202-10	39287-39290	the	_	
202-11	39291-39299	children	_	
202-12	39300-39302	in	_	
202-13	39303-39306	the	_	
202-14	39307-39315	clinical	_	
202-15	39316-39324	contrast	_	
202-16	39325-39330	group	_	
202-17	39330-39331	,	_	
202-18	39332-39335	the	_	
202-19	39336-39345	magnitude	_	
202-20	39346-39348	of	_	
202-21	39349-39352	the	_	
202-22	39353-39360	decline	_	
202-23	39361-39363	in	_	
202-24	39364-39367	HBO	_	
202-25	39368-39370	in	_	
202-26	39371-39374	the	_	
202-27	39375-39379	Loss	_	
202-28	39380-39388	relative	_	
202-29	39389-39391	to	_	
202-30	39392-39395	the	_	
202-31	39396-39399	Win	_	
202-32	39400-39409	condition	_	
202-33	39410-39412	in	_	
202-34	39413-39417	game	_	
202-35	39418-39422	play	_	
202-36	39423-39426	was	_	
202-37	39427-39434	greater	_	
202-38	39435-39438	for	_	
202-39	39439-39442	the	_	
202-40	39443-39451	Clinical	_	
202-41	39452-39460	Contrast	_	
202-42	39461-39466	group	_	
202-43	39466-39467	,	_	
202-44	39468-39478	suggesting	_	
202-45	39479-39483	that	_	
202-46	39484-39492	children	_	
202-47	39493-39495	in	_	
202-48	39496-39499	the	_	
202-49	39500-39508	Clinical	_	
202-50	39509-39517	Contrast	_	
202-51	39518-39523	group	_	
202-52	39524-39528	were	_	
202-53	39529-39533	more	_	
202-54	39534-39544	responsive	_	
202-55	39545-39547	to	_	
202-56	39548-39551	the	_	
202-57	39552-39559	valence	_	
202-58	39560-39562	of	_	
202-59	39563-39566	the	_	
202-60	39567-39576	emotional	_	
202-61	39577-39584	arousal	_	
202-62	39584-39585	.	_	

#Text=This pattern of differential responsiveness to the valence of the emotional arousal was also seen in all areas of the PFC that showed increased levels of HBR in response to losing, which is the key distinguishing difference between those in the PAE and Clinical Contrast groups.
203-1	39586-39590	This	_	
203-2	39591-39598	pattern	_	
203-3	39599-39601	of	_	
203-4	39602-39614	differential	_	
203-5	39615-39629	responsiveness	_	
203-6	39630-39632	to	_	
203-7	39633-39636	the	_	
203-8	39637-39644	valence	_	
203-9	39645-39647	of	_	
203-10	39648-39651	the	_	
203-11	39652-39661	emotional	_	
203-12	39662-39669	arousal	_	
203-13	39670-39673	was	_	
203-14	39674-39678	also	_	
203-15	39679-39683	seen	_	
203-16	39684-39686	in	_	
203-17	39687-39690	all	_	
203-18	39691-39696	areas	_	
203-19	39697-39699	of	_	
203-20	39700-39703	the	_	
203-21	39704-39707	PFC	_	
203-22	39708-39712	that	_	
203-23	39713-39719	showed	_	
203-24	39720-39729	increased	_	
203-25	39730-39736	levels	_	
203-26	39737-39739	of	_	
203-27	39740-39743	HBR	_	
203-28	39744-39746	in	_	
203-29	39747-39755	response	_	
203-30	39756-39758	to	_	
203-31	39759-39765	losing	_	
203-32	39765-39766	,	_	
203-33	39767-39772	which	_	
203-34	39773-39775	is	_	
203-35	39776-39779	the	_	
203-36	39780-39783	key	_	
203-37	39784-39798	distinguishing	_	
203-38	39799-39809	difference	_	
203-39	39810-39817	between	_	
203-40	39818-39823	those	_	
203-41	39824-39826	in	_	
203-42	39827-39830	the	_	
203-43	39831-39834	PAE	_	
203-44	39835-39838	and	_	
203-45	39839-39847	Clinical	_	
203-46	39848-39856	Contrast	_	
203-47	39857-39863	groups	_	
203-48	39863-39864	.	_	

#Text=This suggests that the Clinical Contrast group had a specific alteration in coping with negative emotions as compared to children with PAE who were better differentiated by the positive emotional condition.
204-1	39865-39869	This	_	
204-2	39870-39878	suggests	_	
204-3	39879-39883	that	_	
204-4	39884-39887	the	_	
204-5	39888-39896	Clinical	_	
204-6	39897-39905	Contrast	_	
204-7	39906-39911	group	_	
204-8	39912-39915	had	_	
204-9	39916-39917	a	_	
204-10	39918-39926	specific	_	
204-11	39927-39937	alteration	_	
204-12	39938-39940	in	_	
204-13	39941-39947	coping	_	
204-14	39948-39952	with	_	
204-15	39953-39961	negative	_	
204-16	39962-39970	emotions	_	
204-17	39971-39973	as	_	
204-18	39974-39982	compared	_	
204-19	39983-39985	to	_	
204-20	39986-39994	children	_	
204-21	39995-39999	with	_	
204-22	40000-40003	PAE	_	
204-23	40004-40007	who	_	
204-24	40008-40012	were	_	
204-25	40013-40019	better	_	
204-26	40020-40034	differentiated	_	
204-27	40035-40037	by	_	
204-28	40038-40041	the	_	
204-29	40042-40050	positive	_	
204-30	40051-40060	emotional	_	
204-31	40061-40070	condition	_	
204-32	40070-40071	.	_	

#Text=Although the use of FNIRS provides an opportunity to explore functional brain activation in populations that could not be appropriately sampled using traditional neuroimaging techniques, the methodology has limitations in that it can only sample a limited window of brain activation.
205-1	40072-40080	Although	_	
205-2	40081-40084	the	_	
205-3	40085-40088	use	_	
205-4	40089-40091	of	_	
205-5	40092-40097	FNIRS	_	
205-6	40098-40106	provides	_	
205-7	40107-40109	an	_	
205-8	40110-40121	opportunity	_	
205-9	40122-40124	to	_	
205-10	40125-40132	explore	_	
205-11	40133-40143	functional	_	
205-12	40144-40149	brain	_	
205-13	40150-40160	activation	_	
205-14	40161-40163	in	_	
205-15	40164-40175	populations	_	
205-16	40176-40180	that	_	
205-17	40181-40186	could	_	
205-18	40187-40190	not	_	
205-19	40191-40193	be	_	
205-20	40194-40207	appropriately	_	
205-21	40208-40215	sampled	_	
205-22	40216-40221	using	_	
205-23	40222-40233	traditional	_	
205-24	40234-40246	neuroimaging	_	
205-25	40247-40257	techniques	_	
205-26	40257-40258	,	_	
205-27	40259-40262	the	_	
205-28	40263-40274	methodology	_	
205-29	40275-40278	has	_	
205-30	40279-40290	limitations	_	
205-31	40291-40293	in	_	
205-32	40294-40298	that	_	
205-33	40299-40301	it	_	
205-34	40302-40305	can	_	
205-35	40306-40310	only	_	
205-36	40311-40317	sample	_	
205-37	40318-40319	a	_	
205-38	40320-40327	limited	_	
205-39	40328-40334	window	_	
205-40	40335-40337	of	_	
205-41	40338-40343	brain	_	
205-42	40344-40354	activation	_	
205-43	40354-40355	.	_	

#Text=The infrared light is only capable of being absorbed and appropriately reflecting back within a range of about 2–3 mm into the cortex and therefore can only provide estimates of changes in blood oxygenation observed at the cortical surface level.
206-1	40356-40359	The	_	
206-2	40360-40368	infrared	_	
206-3	40369-40374	light	_	
206-4	40375-40377	is	_	
206-5	40378-40382	only	_	
206-6	40383-40390	capable	_	
206-7	40391-40393	of	_	
206-8	40394-40399	being	_	
206-9	40400-40408	absorbed	_	
206-10	40409-40412	and	_	
206-11	40413-40426	appropriately	_	
206-12	40427-40437	reflecting	_	
206-13	40438-40442	back	_	
206-14	40443-40449	within	_	
206-15	40450-40451	a	_	
206-16	40452-40457	range	_	
206-17	40458-40460	of	_	
206-18	40461-40466	about	_	
206-19	40467-40468	2	_	
206-20	40468-40469	–	_	
206-21	40469-40470	3	_	
206-22	40471-40473	mm	_	
206-23	40474-40478	into	_	
206-24	40479-40482	the	_	
206-25	40483-40489	cortex	_	
206-26	40490-40493	and	_	
206-27	40494-40503	therefore	_	
206-28	40504-40507	can	_	
206-29	40508-40512	only	_	
206-30	40513-40520	provide	_	
206-31	40521-40530	estimates	_	
206-32	40531-40533	of	_	
206-33	40534-40541	changes	_	
206-34	40542-40544	in	_	
206-35	40545-40550	blood	_	
206-36	40551-40562	oxygenation	_	
206-37	40563-40571	observed	_	
206-38	40572-40574	at	_	
206-39	40575-40578	the	_	
206-40	40579-40587	cortical	_	
206-41	40588-40595	surface	_	
206-42	40596-40601	level	_	
206-43	40601-40602	.	_	

#Text=Subcortical regions that are involved in inhibitory control, problem-solving, reward processing and emotional regulation cannot be sampled using this methodology.
207-1	40603-40614	Subcortical	_	
207-2	40615-40622	regions	_	
207-3	40623-40627	that	_	
207-4	40628-40631	are	_	
207-5	40632-40640	involved	_	
207-6	40641-40643	in	_	
207-7	40644-40654	inhibitory	_	
207-8	40655-40662	control	_	
207-9	40662-40663	,	_	
207-10	40664-40679	problem-solving	_	
207-11	40679-40680	,	_	
207-12	40681-40687	reward	_	
207-13	40688-40698	processing	_	
207-14	40699-40702	and	_	
207-15	40703-40712	emotional	_	
207-16	40713-40723	regulation	_	
207-17	40724-40730	cannot	_	
207-18	40731-40733	be	_	
207-19	40734-40741	sampled	_	
207-20	40742-40747	using	_	
207-21	40748-40752	this	_	
207-22	40753-40764	methodology	_	
207-23	40764-40765	.	_	

#Text=Another methodological limitation of fNIRS is that the MBLL formula that is used to estimate the changes in HBO and HBR from baseline to task performance assumes the extracranial blood flow remains constant.
208-1	40766-40773	Another	_	
208-2	40774-40788	methodological	_	
208-3	40789-40799	limitation	_	
208-4	40800-40802	of	_	
208-5	40803-40808	fNIRS	_	
208-6	40809-40811	is	_	
208-7	40812-40816	that	_	
208-8	40817-40820	the	_	
208-9	40821-40825	MBLL	_	
208-10	40826-40833	formula	_	
208-11	40834-40838	that	_	
208-12	40839-40841	is	_	
208-13	40842-40846	used	_	
208-14	40847-40849	to	_	
208-15	40850-40858	estimate	_	
208-16	40859-40862	the	_	
208-17	40863-40870	changes	_	
208-18	40871-40873	in	_	
208-19	40874-40877	HBO	_	
208-20	40878-40881	and	_	
208-21	40882-40885	HBR	_	
208-22	40886-40890	from	_	
208-23	40891-40899	baseline	_	
208-24	40900-40902	to	_	
208-25	40903-40907	task	_	
208-26	40908-40919	performance	_	
208-27	40920-40927	assumes	_	
208-28	40928-40931	the	_	
208-29	40932-40944	extracranial	_	
208-30	40945-40950	blood	_	
208-31	40951-40955	flow	_	
208-32	40956-40963	remains	_	
208-33	40964-40972	constant	_	
208-34	40972-40973	.	_	

#Text=It is possible that differential changes in skin blood flow during game play may have contributed to the obtained group differences but these differences would have had to vary as a function of group status and be uncorrelated with the cerebral changes in HBO and HBR in order to threaten the internal validity of the study.
209-1	40974-40976	It	_	
209-2	40977-40979	is	_	
209-3	40980-40988	possible	_	
209-4	40989-40993	that	_	
209-5	40994-41006	differential	_	
209-6	41007-41014	changes	_	
209-7	41015-41017	in	_	
209-8	41018-41022	skin	_	
209-9	41023-41028	blood	_	
209-10	41029-41033	flow	_	
209-11	41034-41040	during	_	
209-12	41041-41045	game	_	
209-13	41046-41050	play	_	
209-14	41051-41054	may	_	
209-15	41055-41059	have	_	
209-16	41060-41071	contributed	_	
209-17	41072-41074	to	_	
209-18	41075-41078	the	_	
209-19	41079-41087	obtained	_	
209-20	41088-41093	group	_	
209-21	41094-41105	differences	_	
209-22	41106-41109	but	_	
209-23	41110-41115	these	_	
209-24	41116-41127	differences	_	
209-25	41128-41133	would	_	
209-26	41134-41138	have	_	
209-27	41139-41142	had	_	
209-28	41143-41145	to	_	
209-29	41146-41150	vary	_	
209-30	41151-41153	as	_	
209-31	41154-41155	a	_	
209-32	41156-41164	function	_	
209-33	41165-41167	of	_	
209-34	41168-41173	group	_	
209-35	41174-41180	status	_	
209-36	41181-41184	and	_	
209-37	41185-41187	be	_	
209-38	41188-41200	uncorrelated	_	
209-39	41201-41205	with	_	
209-40	41206-41209	the	_	
209-41	41210-41218	cerebral	_	
209-42	41219-41226	changes	_	
209-43	41227-41229	in	_	
209-44	41230-41233	HBO	_	
209-45	41234-41237	and	_	
209-46	41238-41241	HBR	_	
209-47	41242-41244	in	_	
209-48	41245-41250	order	_	
209-49	41251-41253	to	_	
209-50	41254-41262	threaten	_	
209-51	41263-41266	the	_	
209-52	41267-41275	internal	_	
209-53	41276-41284	validity	_	
209-54	41285-41287	of	_	
209-55	41288-41291	the	_	
209-56	41292-41297	study	_	
209-57	41297-41298	.	_	

#Text=Recent research has indicated that changes in skin blood flow were highly positively related to changes in HBO and HBR levels (r = 0.737).
210-1	41299-41305	Recent	_	
210-2	41306-41314	research	_	
210-3	41315-41318	has	_	
210-4	41319-41328	indicated	_	
210-5	41329-41333	that	_	
210-6	41334-41341	changes	_	
210-7	41342-41344	in	_	
210-8	41345-41349	skin	_	
210-9	41350-41355	blood	_	
210-10	41356-41360	flow	_	
210-11	41361-41365	were	_	
210-12	41366-41372	highly	_	
210-13	41373-41383	positively	_	
210-14	41384-41391	related	_	
210-15	41392-41394	to	_	
210-16	41395-41402	changes	_	
210-17	41403-41405	in	_	
210-18	41406-41409	HBO	_	
210-19	41410-41413	and	_	
210-20	41414-41417	HBR	_	
210-21	41418-41424	levels	_	
210-22	41425-41426	(	_	
210-23	41426-41427	r	_	
210-24	41428-41429	=	_	
210-25	41430-41435	0.737	_	
210-26	41435-41436	)	_	
210-27	41436-41437	.	_	

#Text=To obtain an estimate of changes in skin blood flow, one study formulated a correction factor used in the MBLL formula that was derived for each individual by monitoring simultaneously changes in cerebral oxygenation levels and changes in skin blood flow and then applied the individual correction factor to the analysis of task performance changes.
211-1	41438-41440	To	_	
211-2	41441-41447	obtain	_	
211-3	41448-41450	an	_	
211-4	41451-41459	estimate	_	
211-5	41460-41462	of	_	
211-6	41463-41470	changes	_	
211-7	41471-41473	in	_	
211-8	41474-41478	skin	_	
211-9	41479-41484	blood	_	
211-10	41485-41489	flow	_	
211-11	41489-41490	,	_	
211-12	41491-41494	one	_	
211-13	41495-41500	study	_	
211-14	41501-41511	formulated	_	
211-15	41512-41513	a	_	
211-16	41514-41524	correction	_	
211-17	41525-41531	factor	_	
211-18	41532-41536	used	_	
211-19	41537-41539	in	_	
211-20	41540-41543	the	_	
211-21	41544-41548	MBLL	_	
211-22	41549-41556	formula	_	
211-23	41557-41561	that	_	
211-24	41562-41565	was	_	
211-25	41566-41573	derived	_	
211-26	41574-41577	for	_	
211-27	41578-41582	each	_	
211-28	41583-41593	individual	_	
211-29	41594-41596	by	_	
211-30	41597-41607	monitoring	_	
211-31	41608-41622	simultaneously	_	
211-32	41623-41630	changes	_	
211-33	41631-41633	in	_	
211-34	41634-41642	cerebral	_	
211-35	41643-41654	oxygenation	_	
211-36	41655-41661	levels	_	
211-37	41662-41665	and	_	
211-38	41666-41673	changes	_	
211-39	41674-41676	in	_	
211-40	41677-41681	skin	_	
211-41	41682-41687	blood	_	
211-42	41688-41692	flow	_	
211-43	41693-41696	and	_	
211-44	41697-41701	then	_	
211-45	41702-41709	applied	_	
211-46	41710-41713	the	_	
211-47	41714-41724	individual	_	
211-48	41725-41735	correction	_	
211-49	41736-41742	factor	_	
211-50	41743-41745	to	_	
211-51	41746-41749	the	_	
211-52	41750-41758	analysis	_	
211-53	41759-41761	of	_	
211-54	41762-41766	task	_	
211-55	41767-41778	performance	_	
211-56	41779-41786	changes	_	
211-57	41786-41787	.	_	

#Text=Future fNIRS studies with children with FASDs may benefit from using such a protocol to rule out any such biases that differential levels of skin blood flow may have in group comparison studies.
212-1	41788-41794	Future	_	
212-2	41795-41800	fNIRS	_	
212-3	41801-41808	studies	_	
212-4	41809-41813	with	_	
212-5	41814-41822	children	_	
212-6	41823-41827	with	_	
212-7	41828-41833	FASDs	_	
212-8	41834-41837	may	_	
212-9	41838-41845	benefit	_	
212-10	41846-41850	from	_	
212-11	41851-41856	using	_	
212-12	41857-41861	such	_	
212-13	41862-41863	a	_	
212-14	41864-41872	protocol	_	
212-15	41873-41875	to	_	
212-16	41876-41880	rule	_	
212-17	41881-41884	out	_	
212-18	41885-41888	any	_	
212-19	41889-41893	such	_	
212-20	41894-41900	biases	_	
212-21	41901-41905	that	_	
212-22	41906-41918	differential	_	
212-23	41919-41925	levels	_	
212-24	41926-41928	of	_	
212-25	41929-41933	skin	_	
212-26	41934-41939	blood	_	
212-27	41940-41944	flow	_	
212-28	41945-41948	may	_	
212-29	41949-41953	have	_	
212-30	41954-41956	in	_	
212-31	41957-41962	group	_	
212-32	41963-41973	comparison	_	
212-33	41974-41981	studies	_	
212-34	41981-41982	.	_	

#Text=The fNIRS assessment provided a method of quantifying individual differences in PFC activation in both children with a history of PAE and those with other clinical problems not related to PAE that resulted in group differences relative to typically developing children and from each other.
213-1	41983-41986	The	_	
213-2	41987-41992	fNIRS	_	
213-3	41993-42003	assessment	_	
213-4	42004-42012	provided	_	
213-5	42013-42014	a	_	
213-6	42015-42021	method	_	
213-7	42022-42024	of	_	
213-8	42025-42036	quantifying	_	
213-9	42037-42047	individual	_	
213-10	42048-42059	differences	_	
213-11	42060-42062	in	_	
213-12	42063-42066	PFC	_	
213-13	42067-42077	activation	_	
213-14	42078-42080	in	_	
213-15	42081-42085	both	_	
213-16	42086-42094	children	_	
213-17	42095-42099	with	_	
213-18	42100-42101	a	_	
213-19	42102-42109	history	_	
213-20	42110-42112	of	_	
213-21	42113-42116	PAE	_	
213-22	42117-42120	and	_	
213-23	42121-42126	those	_	
213-24	42127-42131	with	_	
213-25	42132-42137	other	_	
213-26	42138-42146	clinical	_	
213-27	42147-42155	problems	_	
213-28	42156-42159	not	_	
213-29	42160-42167	related	_	
213-30	42168-42170	to	_	
213-31	42171-42174	PAE	_	
213-32	42175-42179	that	_	
213-33	42180-42188	resulted	_	
213-34	42189-42191	in	_	
213-35	42192-42197	group	_	
213-36	42198-42209	differences	_	
213-37	42210-42218	relative	_	
213-38	42219-42221	to	_	
213-39	42222-42231	typically	_	
213-40	42232-42242	developing	_	
213-41	42243-42251	children	_	
213-42	42252-42255	and	_	
213-43	42256-42260	from	_	
213-44	42261-42265	each	_	
213-45	42266-42271	other	_	
213-46	42271-42272	.	_	

#Text=With both of these populations replications and extensions of these findings are needed but the initial results suggests that changes in oxygenation levels as a function of coping with emotional arousal may serve as potential biomarker of alcohol-related neurodevelopmental damage.
214-1	42273-42277	With	_	
214-2	42278-42282	both	_	
214-3	42283-42285	of	_	
214-4	42286-42291	these	_	
214-5	42292-42303	populations	_	
214-6	42304-42316	replications	_	
214-7	42317-42320	and	_	
214-8	42321-42331	extensions	_	
214-9	42332-42334	of	_	
214-10	42335-42340	these	_	
214-11	42341-42349	findings	_	
214-12	42350-42353	are	_	
214-13	42354-42360	needed	_	
214-14	42361-42364	but	_	
214-15	42365-42368	the	_	
214-16	42369-42376	initial	_	
214-17	42377-42384	results	_	
214-18	42385-42393	suggests	_	
214-19	42394-42398	that	_	
214-20	42399-42406	changes	_	
214-21	42407-42409	in	_	
214-22	42410-42421	oxygenation	_	
214-23	42422-42428	levels	_	
214-24	42429-42431	as	_	
214-25	42432-42433	a	_	
214-26	42434-42442	function	_	
214-27	42443-42445	of	_	
214-28	42446-42452	coping	_	
214-29	42453-42457	with	_	
214-30	42458-42467	emotional	_	
214-31	42468-42475	arousal	_	
214-32	42476-42479	may	_	
214-33	42480-42485	serve	_	
214-34	42486-42488	as	_	
214-35	42489-42498	potential	_	
214-36	42499-42508	biomarker	_	
214-37	42509-42511	of	_	
214-38	42512-42527	alcohol-related	_	
214-39	42528-42546	neurodevelopmental	_	
214-40	42547-42553	damage	_	
214-41	42553-42554	.	_	

#Text=Of course, additional studies are needed where estimates of the sensitivity and specificity of the fNIR outcomes would need to be assessed relative to their ability to differentiate children with PAE from both typically developing children and other children with neurobehavioral disorders.
215-1	42555-42557	Of	_	
215-2	42558-42564	course	_	
215-3	42564-42565	,	_	
215-4	42566-42576	additional	_	
215-5	42577-42584	studies	_	
215-6	42585-42588	are	_	
215-7	42589-42595	needed	_	
215-8	42596-42601	where	_	
215-9	42602-42611	estimates	_	
215-10	42612-42614	of	_	
215-11	42615-42618	the	_	
215-12	42619-42630	sensitivity	_	
215-13	42631-42634	and	_	
215-14	42635-42646	specificity	_	
215-15	42647-42649	of	_	
215-16	42650-42653	the	_	
215-17	42654-42658	fNIR	_	
215-18	42659-42667	outcomes	_	
215-19	42668-42673	would	_	
215-20	42674-42678	need	_	
215-21	42679-42681	to	_	
215-22	42682-42684	be	_	
215-23	42685-42693	assessed	_	
215-24	42694-42702	relative	_	
215-25	42703-42705	to	_	
215-26	42706-42711	their	_	
215-27	42712-42719	ability	_	
215-28	42720-42722	to	_	
215-29	42723-42736	differentiate	_	
215-30	42737-42745	children	_	
215-31	42746-42750	with	_	
215-32	42751-42754	PAE	_	
215-33	42755-42759	from	_	
215-34	42760-42764	both	_	
215-35	42765-42774	typically	_	
215-36	42775-42785	developing	_	
215-37	42786-42794	children	_	
215-38	42795-42798	and	_	
215-39	42799-42804	other	_	
215-40	42805-42813	children	_	
215-41	42814-42818	with	_	
215-42	42819-42834	neurobehavioral	_	
215-43	42835-42844	disorders	_	
215-44	42844-42845	.	_	

#Text=For individuals with a history of PAE, considerable effort has been devoted to understanding the neural bases of the learning and behavioral deficits seen in these children with considerable evidence supporting the adverse impact on the size, cytoarchitecture, function, and connectivity of the brain.
216-1	42846-42849	For	_	
216-2	42850-42861	individuals	_	
216-3	42862-42866	with	_	
216-4	42867-42868	a	_	
216-5	42869-42876	history	_	
216-6	42877-42879	of	_	
216-7	42880-42883	PAE	_	
216-8	42883-42884	,	_	
216-9	42885-42897	considerable	_	
216-10	42898-42904	effort	_	
216-11	42905-42908	has	_	
216-12	42909-42913	been	_	
216-13	42914-42921	devoted	_	
216-14	42922-42924	to	_	
216-15	42925-42938	understanding	_	
216-16	42939-42942	the	_	
216-17	42943-42949	neural	_	
216-18	42950-42955	bases	_	
216-19	42956-42958	of	_	
216-20	42959-42962	the	_	
216-21	42963-42971	learning	_	
216-22	42972-42975	and	_	
216-23	42976-42986	behavioral	_	
216-24	42987-42995	deficits	_	
216-25	42996-43000	seen	_	
216-26	43001-43003	in	_	
216-27	43004-43009	these	_	
216-28	43010-43018	children	_	
216-29	43019-43023	with	_	
216-30	43024-43036	considerable	_	
216-31	43037-43045	evidence	_	
216-32	43046-43056	supporting	_	
216-33	43057-43060	the	_	
216-34	43061-43068	adverse	_	
216-35	43069-43075	impact	_	
216-36	43076-43078	on	_	
216-37	43079-43082	the	_	
216-38	43083-43087	size	_	
216-39	43087-43088	,	_	
216-40	43089-43105	cytoarchitecture	_	
216-41	43105-43106	,	_	
216-42	43107-43115	function	_	
216-43	43115-43116	,	_	
216-44	43117-43120	and	_	
216-45	43121-43133	connectivity	_	
216-46	43134-43136	of	_	
216-47	43137-43140	the	_	
216-48	43141-43146	brain	_	
216-49	43146-43147	.	_	

#Text=The results of this study indicated that utilization of oxygen in the PFC to modulate arousal was altered as a function of PAE, which may indicate damage to neural tissue of the PFC or disruption to the connectivty of the neural tissue in this area resulting in disruption to oxygen utilization.
217-1	43148-43151	The	_	
217-2	43152-43159	results	_	
217-3	43160-43162	of	_	
217-4	43163-43167	this	_	
217-5	43168-43173	study	_	
217-6	43174-43183	indicated	_	
217-7	43184-43188	that	_	
217-8	43189-43200	utilization	_	
217-9	43201-43203	of	_	
217-10	43204-43210	oxygen	_	
217-11	43211-43213	in	_	
217-12	43214-43217	the	_	
217-13	43218-43221	PFC	_	
217-14	43222-43224	to	_	
217-15	43225-43233	modulate	_	
217-16	43234-43241	arousal	_	
217-17	43242-43245	was	_	
217-18	43246-43253	altered	_	
217-19	43254-43256	as	_	
217-20	43257-43258	a	_	
217-21	43259-43267	function	_	
217-22	43268-43270	of	_	
217-23	43271-43274	PAE	_	
217-24	43274-43275	,	_	
217-25	43276-43281	which	_	
217-26	43282-43285	may	_	
217-27	43286-43294	indicate	_	
217-28	43295-43301	damage	_	
217-29	43302-43304	to	_	
217-30	43305-43311	neural	_	
217-31	43312-43318	tissue	_	
217-32	43319-43321	of	_	
217-33	43322-43325	the	_	
217-34	43326-43329	PFC	_	
217-35	43330-43332	or	_	
217-36	43333-43343	disruption	_	
217-37	43344-43346	to	_	
217-38	43347-43350	the	_	
217-39	43351-43362	connectivty	_	
217-40	43363-43365	of	_	
217-41	43366-43369	the	_	
217-42	43370-43376	neural	_	
217-43	43377-43383	tissue	_	
217-44	43384-43386	in	_	
217-45	43387-43391	this	_	
217-46	43392-43396	area	_	
217-47	43397-43406	resulting	_	
217-48	43407-43409	in	_	
217-49	43410-43420	disruption	_	
217-50	43421-43423	to	_	
217-51	43424-43430	oxygen	_	
217-52	43431-43442	utilization	_	
217-53	43442-43443	.	_	

#Text=The results, however, may also indicate another source of disruption to neural activation that is not as well understood, the neurovascular system that provides the oxygen supply to the brain tissue.
218-1	43444-43447	The	_	
218-2	43448-43455	results	_	
218-3	43455-43456	,	_	
218-4	43457-43464	however	_	
218-5	43464-43465	,	_	
218-6	43466-43469	may	_	
218-7	43470-43474	also	_	
218-8	43475-43483	indicate	_	
218-9	43484-43491	another	_	
218-10	43492-43498	source	_	
218-11	43499-43501	of	_	
218-12	43502-43512	disruption	_	
218-13	43513-43515	to	_	
218-14	43516-43522	neural	_	
218-15	43523-43533	activation	_	
218-16	43534-43538	that	_	
218-17	43539-43541	is	_	
218-18	43542-43545	not	_	
218-19	43546-43548	as	_	
218-20	43549-43553	well	_	
218-21	43554-43564	understood	_	
218-22	43564-43565	,	_	
218-23	43566-43569	the	_	
218-24	43570-43583	neurovascular	_	
218-25	43584-43590	system	_	
218-26	43591-43595	that	_	
218-27	43596-43604	provides	_	
218-28	43605-43608	the	_	
218-29	43609-43615	oxygen	_	
218-30	43616-43622	supply	_	
218-31	43623-43625	to	_	
218-32	43626-43629	the	_	
218-33	43630-43635	brain	_	
218-34	43636-43642	tissue	_	
218-35	43642-43643	.	_	

#Text=The results of this study suggest that there is a disruption to cerebral blood flow during the task in children with a history of PAE that is most salient when dealing with positive emotional arousal.
219-1	43644-43647	The	_	
219-2	43648-43655	results	_	
219-3	43656-43658	of	_	
219-4	43659-43663	this	_	
219-5	43664-43669	study	_	
219-6	43670-43677	suggest	_	
219-7	43678-43682	that	_	
219-8	43683-43688	there	_	
219-9	43689-43691	is	_	
219-10	43692-43693	a	_	
219-11	43694-43704	disruption	_	
219-12	43705-43707	to	_	
219-13	43708-43716	cerebral	_	
219-14	43717-43722	blood	_	
219-15	43723-43727	flow	_	
219-16	43728-43734	during	_	
219-17	43735-43738	the	_	
219-18	43739-43743	task	_	
219-19	43744-43746	in	_	
219-20	43747-43755	children	_	
219-21	43756-43760	with	_	
219-22	43761-43762	a	_	
219-23	43763-43770	history	_	
219-24	43771-43773	of	_	
219-25	43774-43777	PAE	_	
219-26	43778-43782	that	_	
219-27	43783-43785	is	_	
219-28	43786-43790	most	_	
219-29	43791-43798	salient	_	
219-30	43799-43803	when	_	
219-31	43804-43811	dealing	_	
219-32	43812-43816	with	_	
219-33	43817-43825	positive	_	
219-34	43826-43835	emotional	_	
219-35	43836-43843	arousal	_	
219-36	43843-43844	.	_	

#Text=Across all areas of the PFC in the Win condition, these children showed less neural activation as indicated by increased levels of HBR relative to children in the other two groups but the results are not consistent with the estimates of neural activation obtained from changes in levels of HBO.
220-1	43845-43851	Across	_	
220-2	43852-43855	all	_	
220-3	43856-43861	areas	_	
220-4	43862-43864	of	_	
220-5	43865-43868	the	_	
220-6	43869-43872	PFC	_	
220-7	43873-43875	in	_	
220-8	43876-43879	the	_	
220-9	43880-43883	Win	_	
220-10	43884-43893	condition	_	
220-11	43893-43894	,	_	
220-12	43895-43900	these	_	
220-13	43901-43909	children	_	
220-14	43910-43916	showed	_	
220-15	43917-43921	less	_	
220-16	43922-43928	neural	_	
220-17	43929-43939	activation	_	
220-18	43940-43942	as	_	
220-19	43943-43952	indicated	_	
220-20	43953-43955	by	_	
220-21	43956-43965	increased	_	
220-22	43966-43972	levels	_	
220-23	43973-43975	of	_	
220-24	43976-43979	HBR	_	
220-25	43980-43988	relative	_	
220-26	43989-43991	to	_	
220-27	43992-44000	children	_	
220-28	44001-44003	in	_	
220-29	44004-44007	the	_	
220-30	44008-44013	other	_	
220-31	44014-44017	two	_	
220-32	44018-44024	groups	_	
220-33	44025-44028	but	_	
220-34	44029-44032	the	_	
220-35	44033-44040	results	_	
220-36	44041-44044	are	_	
220-37	44045-44048	not	_	
220-38	44049-44059	consistent	_	
220-39	44060-44064	with	_	
220-40	44065-44068	the	_	
220-41	44069-44078	estimates	_	
220-42	44079-44081	of	_	
220-43	44082-44088	neural	_	
220-44	44089-44099	activation	_	
220-45	44100-44108	obtained	_	
220-46	44109-44113	from	_	
220-47	44114-44121	changes	_	
220-48	44122-44124	in	_	
220-49	44125-44131	levels	_	
220-50	44132-44134	of	_	
220-51	44135-44138	HBO	_	
220-52	44138-44139	.	_	

#Text=In the Win condition, the PAE group had lower levels of L-DLPFC HBO relative to the clinical contrast group, which is consistent with the higher levels of HBR but did not differ in HBO levels from the typically developing group of children despite showing differences in HBR levels.
221-1	44140-44142	In	_	
221-2	44143-44146	the	_	
221-3	44147-44150	Win	_	
221-4	44151-44160	condition	_	
221-5	44160-44161	,	_	
221-6	44162-44165	the	_	
221-7	44166-44169	PAE	_	
221-8	44170-44175	group	_	
221-9	44176-44179	had	_	
221-10	44180-44185	lower	_	
221-11	44186-44192	levels	_	
221-12	44193-44195	of	_	
221-13	44196-44203	L-DLPFC	_	
221-14	44204-44207	HBO	_	
221-15	44208-44216	relative	_	
221-16	44217-44219	to	_	
221-17	44220-44223	the	_	
221-18	44224-44232	clinical	_	
221-19	44233-44241	contrast	_	
221-20	44242-44247	group	_	
221-21	44247-44248	,	_	
221-22	44249-44254	which	_	
221-23	44255-44257	is	_	
221-24	44258-44268	consistent	_	
221-25	44269-44273	with	_	
221-26	44274-44277	the	_	
221-27	44278-44284	higher	_	
221-28	44285-44291	levels	_	
221-29	44292-44294	of	_	
221-30	44295-44298	HBR	_	
221-31	44299-44302	but	_	
221-32	44303-44306	did	_	
221-33	44307-44310	not	_	
221-34	44311-44317	differ	_	
221-35	44318-44320	in	_	
221-36	44321-44324	HBO	_	
221-37	44325-44331	levels	_	
221-38	44332-44336	from	_	
221-39	44337-44340	the	_	
221-40	44341-44350	typically	_	
221-41	44351-44361	developing	_	
221-42	44362-44367	group	_	
221-43	44368-44370	of	_	
221-44	44371-44379	children	_	
221-45	44380-44387	despite	_	
221-46	44388-44395	showing	_	
221-47	44396-44407	differences	_	
221-48	44408-44410	in	_	
221-49	44411-44414	HBR	_	
221-50	44415-44421	levels	_	
221-51	44421-44422	.	_	

#Text=Although the childern in the PAE group demonstrated higher levels of HBR in the R-DLPFC and lower levels of HBO in this area relative to the clinical contrast group, the PAE group demonstrated an increased level of HBO relative to the typically developing group despite showing an increased level of HBR.
222-1	44423-44431	Although	_	
222-2	44432-44435	the	_	
222-3	44436-44444	childern	_	
222-4	44445-44447	in	_	
222-5	44448-44451	the	_	
222-6	44452-44455	PAE	_	
222-7	44456-44461	group	_	
222-8	44462-44474	demonstrated	_	
222-9	44475-44481	higher	_	
222-10	44482-44488	levels	_	
222-11	44489-44491	of	_	
222-12	44492-44495	HBR	_	
222-13	44496-44498	in	_	
222-14	44499-44502	the	_	
222-15	44503-44510	R-DLPFC	_	
222-16	44511-44514	and	_	
222-17	44515-44520	lower	_	
222-18	44521-44527	levels	_	
222-19	44528-44530	of	_	
222-20	44531-44534	HBO	_	
222-21	44535-44537	in	_	
222-22	44538-44542	this	_	
222-23	44543-44547	area	_	
222-24	44548-44556	relative	_	
222-25	44557-44559	to	_	
222-26	44560-44563	the	_	
222-27	44564-44572	clinical	_	
222-28	44573-44581	contrast	_	
222-29	44582-44587	group	_	
222-30	44587-44588	,	_	
222-31	44589-44592	the	_	
222-32	44593-44596	PAE	_	
222-33	44597-44602	group	_	
222-34	44603-44615	demonstrated	_	
222-35	44616-44618	an	_	
222-36	44619-44628	increased	_	
222-37	44629-44634	level	_	
222-38	44635-44637	of	_	
222-39	44638-44641	HBO	_	
222-40	44642-44650	relative	_	
222-41	44651-44653	to	_	
222-42	44654-44657	the	_	
222-43	44658-44667	typically	_	
222-44	44668-44678	developing	_	
222-45	44679-44684	group	_	
222-46	44685-44692	despite	_	
222-47	44693-44700	showing	_	
222-48	44701-44703	an	_	
222-49	44704-44713	increased	_	
222-50	44714-44719	level	_	
222-51	44720-44722	of	_	
222-52	44723-44726	HBR	_	
222-53	44726-44727	.	_	

#Text=These findings suggest that there was an increase of cerebral blood flow as indicated by an increase in HBO but not an associated decrease in HBR.
223-1	44728-44733	These	_	
223-2	44734-44742	findings	_	
223-3	44743-44750	suggest	_	
223-4	44751-44755	that	_	
223-5	44756-44761	there	_	
223-6	44762-44765	was	_	
223-7	44766-44768	an	_	
223-8	44769-44777	increase	_	
223-9	44778-44780	of	_	
223-10	44781-44789	cerebral	_	
223-11	44790-44795	blood	_	
223-12	44796-44800	flow	_	
223-13	44801-44803	as	_	
223-14	44804-44813	indicated	_	
223-15	44814-44816	by	_	
223-16	44817-44819	an	_	
223-17	44820-44828	increase	_	
223-18	44829-44831	in	_	
223-19	44832-44835	HBO	_	
223-20	44836-44839	but	_	
223-21	44840-44843	not	_	
223-22	44844-44846	an	_	
223-23	44847-44857	associated	_	
223-24	44858-44866	decrease	_	
223-25	44867-44869	in	_	
223-26	44870-44873	HBR	_	
223-27	44873-44874	.	_	

#Text=This pattern of change in relative levels of HBO and HBR is suggestive of disruption to the perfusion of oxygen to the activated neural tissue between the groups, resulting in changes in the ratio of HBO and HBR.
224-1	44875-44879	This	_	
224-2	44880-44887	pattern	_	
224-3	44888-44890	of	_	
224-4	44891-44897	change	_	
224-5	44898-44900	in	_	
224-6	44901-44909	relative	_	
224-7	44910-44916	levels	_	
224-8	44917-44919	of	_	
224-9	44920-44923	HBO	_	
224-10	44924-44927	and	_	
224-11	44928-44931	HBR	_	
224-12	44932-44934	is	_	
224-13	44935-44945	suggestive	_	
224-14	44946-44948	of	_	
224-15	44949-44959	disruption	_	
224-16	44960-44962	to	_	
224-17	44963-44966	the	_	
224-18	44967-44976	perfusion	_	
224-19	44977-44979	of	_	
224-20	44980-44986	oxygen	_	
224-21	44987-44989	to	_	
224-22	44990-44993	the	_	
224-23	44994-45003	activated	_	
224-24	45004-45010	neural	_	
224-25	45011-45017	tissue	_	
224-26	45018-45025	between	_	
224-27	45026-45029	the	_	
224-28	45030-45036	groups	_	
224-29	45036-45037	,	_	
224-30	45038-45047	resulting	_	
224-31	45048-45050	in	_	
224-32	45051-45058	changes	_	
224-33	45059-45061	in	_	
224-34	45062-45065	the	_	
224-35	45066-45071	ratio	_	
224-36	45072-45074	of	_	
224-37	45075-45078	HBO	_	
224-38	45079-45082	and	_	
224-39	45083-45086	HBR	_	
224-40	45086-45087	.	_	

#Text=Increased prevalence of cardiac malformations and disruptions to cardiac function in the form of heart murmurs, which are mostly considered benign, are commonly found in children with FASDs.
225-1	45088-45097	Increased	_	
225-2	45098-45108	prevalence	_	
225-3	45109-45111	of	_	
225-4	45112-45119	cardiac	_	
225-5	45120-45133	malformations	_	
225-6	45134-45137	and	_	
225-7	45138-45149	disruptions	_	
225-8	45150-45152	to	_	
225-9	45153-45160	cardiac	_	
225-10	45161-45169	function	_	
225-11	45170-45172	in	_	
225-12	45173-45176	the	_	
225-13	45177-45181	form	_	
225-14	45182-45184	of	_	
225-15	45185-45190	heart	_	
225-16	45191-45198	murmurs	_	
225-17	45198-45199	,	_	
225-18	45200-45205	which	_	
225-19	45206-45209	are	_	
225-20	45210-45216	mostly	_	
225-21	45217-45227	considered	_	
225-22	45228-45234	benign	_	
225-23	45234-45235	,	_	
225-24	45236-45239	are	_	
225-25	45240-45248	commonly	_	
225-26	45249-45254	found	_	
225-27	45255-45257	in	_	
225-28	45258-45266	children	_	
225-29	45267-45271	with	_	
225-30	45272-45277	FASDs	_	
225-31	45277-45278	.	_	

#Text=Yet, little is known about the neurovascular system that connects the heart and the brain and to what extent problems with this system may alter the perfusion of oxygen to the brain needed for neural activation in children with FASDs.
226-1	45279-45282	Yet	_	
226-2	45282-45283	,	_	
226-3	45284-45290	little	_	
226-4	45291-45293	is	_	
226-5	45294-45299	known	_	
226-6	45300-45305	about	_	
226-7	45306-45309	the	_	
226-8	45310-45323	neurovascular	_	
226-9	45324-45330	system	_	
226-10	45331-45335	that	_	
226-11	45336-45344	connects	_	
226-12	45345-45348	the	_	
226-13	45349-45354	heart	_	
226-14	45355-45358	and	_	
226-15	45359-45362	the	_	
226-16	45363-45368	brain	_	
226-17	45369-45372	and	_	
226-18	45373-45375	to	_	
226-19	45376-45380	what	_	
226-20	45381-45387	extent	_	
226-21	45388-45396	problems	_	
226-22	45397-45401	with	_	
226-23	45402-45406	this	_	
226-24	45407-45413	system	_	
226-25	45414-45417	may	_	
226-26	45418-45423	alter	_	
226-27	45424-45427	the	_	
226-28	45428-45437	perfusion	_	
226-29	45438-45440	of	_	
226-30	45441-45447	oxygen	_	
226-31	45448-45450	to	_	
226-32	45451-45454	the	_	
226-33	45455-45460	brain	_	
226-34	45461-45467	needed	_	
226-35	45468-45471	for	_	
226-36	45472-45478	neural	_	
226-37	45479-45489	activation	_	
226-38	45490-45492	in	_	
226-39	45493-45501	children	_	
226-40	45502-45506	with	_	
226-41	45507-45512	FASDs	_	
226-42	45512-45513	.	_	

#Text=In animal models, PAE has been found to alter reproductive vasculature of the mother’s placenta, including alterations to blood flow, the structural resistance of vessels, and angiogenesis and in offspring, to alter the cortical vascular density, disrupt spatial orientation of microvessels, and alter the receptor expression of vascular endothelial growth factors.
227-1	45514-45516	In	_	
227-2	45517-45523	animal	_	
227-3	45524-45530	models	_	
227-4	45530-45531	,	_	
227-5	45532-45535	PAE	_	
227-6	45536-45539	has	_	
227-7	45540-45544	been	_	
227-8	45545-45550	found	_	
227-9	45551-45553	to	_	
227-10	45554-45559	alter	_	
227-11	45560-45572	reproductive	_	
227-12	45573-45584	vasculature	_	
227-13	45585-45587	of	_	
227-14	45588-45591	the	_	
227-15	45592-45598	mother	_	
227-16	45598-45599	’	_	
227-17	45599-45600	s	_	
227-18	45601-45609	placenta	_	
227-19	45609-45610	,	_	
227-20	45611-45620	including	_	
227-21	45621-45632	alterations	_	
227-22	45633-45635	to	_	
227-23	45636-45641	blood	_	
227-24	45642-45646	flow	_	
227-25	45646-45647	,	_	
227-26	45648-45651	the	_	
227-27	45652-45662	structural	_	
227-28	45663-45673	resistance	_	
227-29	45674-45676	of	_	
227-30	45677-45684	vessels	_	
227-31	45684-45685	,	_	
227-32	45686-45689	and	_	
227-33	45690-45702	angiogenesis	_	
227-34	45703-45706	and	_	
227-35	45707-45709	in	_	
227-36	45710-45719	offspring	_	
227-37	45719-45720	,	_	
227-38	45721-45723	to	_	
227-39	45724-45729	alter	_	
227-40	45730-45733	the	_	
227-41	45734-45742	cortical	_	
227-42	45743-45751	vascular	_	
227-43	45752-45759	density	_	
227-44	45759-45760	,	_	
227-45	45761-45768	disrupt	_	
227-46	45769-45776	spatial	_	
227-47	45777-45788	orientation	_	
227-48	45789-45791	of	_	
227-49	45792-45804	microvessels	_	
227-50	45804-45805	,	_	
227-51	45806-45809	and	_	
227-52	45810-45815	alter	_	
227-53	45816-45819	the	_	
227-54	45820-45828	receptor	_	
227-55	45829-45839	expression	_	
227-56	45840-45842	of	_	
227-57	45843-45851	vascular	_	
227-58	45852-45863	endothelial	_	
227-59	45864-45870	growth	_	
227-60	45871-45878	factors	_	
227-61	45878-45879	.	_	

#Text=Using brains of deceased human fetuses, those with FASD had alterations to the radial organizaton of the vasculature and disorganization of microvessels, particularly among older fetuses and alterations in the overall amount of vessel area.
228-1	45880-45885	Using	_	
228-2	45886-45892	brains	_	
228-3	45893-45895	of	_	
228-4	45896-45904	deceased	_	
228-5	45905-45910	human	_	
228-6	45911-45918	fetuses	_	
228-7	45918-45919	,	_	
228-8	45920-45925	those	_	
228-9	45926-45930	with	_	
228-10	45931-45935	FASD	_	
228-11	45936-45939	had	_	
228-12	45940-45951	alterations	_	
228-13	45952-45954	to	_	
228-14	45955-45958	the	_	
228-15	45959-45965	radial	_	
228-16	45966-45977	organizaton	_	
228-17	45978-45980	of	_	
228-18	45981-45984	the	_	
228-19	45985-45996	vasculature	_	
228-20	45997-46000	and	_	
228-21	46001-46016	disorganization	_	
228-22	46017-46019	of	_	
228-23	46020-46032	microvessels	_	
228-24	46032-46033	,	_	
228-25	46034-46046	particularly	_	
228-26	46047-46052	among	_	
228-27	46053-46058	older	_	
228-28	46059-46066	fetuses	_	
228-29	46067-46070	and	_	
228-30	46071-46082	alterations	_	
228-31	46083-46085	in	_	
228-32	46086-46089	the	_	
228-33	46090-46097	overall	_	
228-34	46098-46104	amount	_	
228-35	46105-46107	of	_	
228-36	46108-46114	vessel	_	
228-37	46115-46119	area	_	
228-38	46119-46120	.	_	

#Text=The results of this study suggest that the delivery of oxygen to neural tissue during activation may be altered as a function of a history of PAE.
229-1	46121-46124	The	_	
229-2	46125-46132	results	_	
229-3	46133-46135	of	_	
229-4	46136-46140	this	_	
229-5	46141-46146	study	_	
229-6	46147-46154	suggest	_	
229-7	46155-46159	that	_	
229-8	46160-46163	the	_	
229-9	46164-46172	delivery	_	
229-10	46173-46175	of	_	
229-11	46176-46182	oxygen	_	
229-12	46183-46185	to	_	
229-13	46186-46192	neural	_	
229-14	46193-46199	tissue	_	
229-15	46200-46206	during	_	
229-16	46207-46217	activation	_	
229-17	46218-46221	may	_	
229-18	46222-46224	be	_	
229-19	46225-46232	altered	_	
229-20	46233-46235	as	_	
229-21	46236-46237	a	_	
229-22	46238-46246	function	_	
229-23	46247-46249	of	_	
229-24	46250-46251	a	_	
229-25	46252-46259	history	_	
229-26	46260-46262	of	_	
229-27	46263-46266	PAE	_	
229-28	46266-46267	.	_	

#Text=The association between the fNIRS indices of PFC activation during the FETCH task and the negative behavioral outcomes often found in children with PAE has not yet been explored but will be important to assist with our understanding of the implications of the obtained group differences found in this study.
230-1	46268-46271	The	_	
230-2	46272-46283	association	_	
230-3	46284-46291	between	_	
230-4	46292-46295	the	_	
230-5	46296-46301	fNIRS	_	
230-6	46302-46309	indices	_	
230-7	46310-46312	of	_	
230-8	46313-46316	PFC	_	
230-9	46317-46327	activation	_	
230-10	46328-46334	during	_	
230-11	46335-46338	the	_	
230-12	46339-46344	FETCH	_	
230-13	46345-46349	task	_	
230-14	46350-46353	and	_	
230-15	46354-46357	the	_	
230-16	46358-46366	negative	_	
230-17	46367-46377	behavioral	_	
230-18	46378-46386	outcomes	_	
230-19	46387-46392	often	_	
230-20	46393-46398	found	_	
230-21	46399-46401	in	_	
230-22	46402-46410	children	_	
230-23	46411-46415	with	_	
230-24	46416-46419	PAE	_	
230-25	46420-46423	has	_	
230-26	46424-46427	not	_	
230-27	46428-46431	yet	_	
230-28	46432-46436	been	_	
230-29	46437-46445	explored	_	
230-30	46446-46449	but	_	
230-31	46450-46454	will	_	
230-32	46455-46457	be	_	
230-33	46458-46467	important	_	
230-34	46468-46470	to	_	
230-35	46471-46477	assist	_	
230-36	46478-46482	with	_	
230-37	46483-46486	our	_	
230-38	46487-46500	understanding	_	
230-39	46501-46503	of	_	
230-40	46504-46507	the	_	
230-41	46508-46520	implications	_	
230-42	46521-46523	of	_	
230-43	46524-46527	the	_	
230-44	46528-46536	obtained	_	
230-45	46537-46542	group	_	
230-46	46543-46554	differences	_	
230-47	46555-46560	found	_	
230-48	46561-46563	in	_	
230-49	46564-46568	this	_	
230-50	46569-46574	study	_	
230-51	46574-46575	.	_	

#Text=Future work should evaluate the relationships between the various indices of HBO and HBR and parental ratings of behavioral functioning and the child’s performance on standardized measures of neurocognitive functioning.
231-1	46576-46582	Future	_	
231-2	46583-46587	work	_	
231-3	46588-46594	should	_	
231-4	46595-46603	evaluate	_	
231-5	46604-46607	the	_	
231-6	46608-46621	relationships	_	
231-7	46622-46629	between	_	
231-8	46630-46633	the	_	
231-9	46634-46641	various	_	
231-10	46642-46649	indices	_	
231-11	46650-46652	of	_	
231-12	46653-46656	HBO	_	
231-13	46657-46660	and	_	
231-14	46661-46664	HBR	_	
231-15	46665-46668	and	_	
231-16	46669-46677	parental	_	
231-17	46678-46685	ratings	_	
231-18	46686-46688	of	_	
231-19	46689-46699	behavioral	_	
231-20	46700-46711	functioning	_	
231-21	46712-46715	and	_	
231-22	46716-46719	the	_	
231-23	46720-46725	child	_	
231-24	46725-46726	’	_	
231-25	46726-46727	s	_	
231-26	46728-46739	performance	_	
231-27	46740-46742	on	_	
231-28	46743-46755	standardized	_	
231-29	46756-46764	measures	_	
231-30	46765-46767	of	_	
231-31	46768-46782	neurocognitive	_	
231-32	46783-46794	functioning	_	
231-33	46794-46795	.	_	

#Text=Previous research has indicated that fNIRS outcomes during the FETCH task were related to parental measures of frustration tolerance.
232-1	46796-46804	Previous	_	
232-2	46805-46813	research	_	
232-3	46814-46817	has	_	
232-4	46818-46827	indicated	_	
232-5	46828-46832	that	_	
232-6	46833-46838	fNIRS	_	
232-7	46839-46847	outcomes	_	
232-8	46848-46854	during	_	
232-9	46855-46858	the	_	
232-10	46859-46864	FETCH	_	
232-11	46865-46869	task	_	
232-12	46870-46874	were	_	
232-13	46875-46882	related	_	
232-14	46883-46885	to	_	
232-15	46886-46894	parental	_	
232-16	46895-46903	measures	_	
232-17	46904-46906	of	_	
232-18	46907-46918	frustration	_	
232-19	46919-46928	tolerance	_	
232-20	46928-46929	.	_	

#Text=Evaluating the differential predictive validity of these outcomes in children with PAE relative to children with other neurobehavioral problems will be aid in our understanding of the specificity of the teratogenic effects of PAE.
#Text=5.
233-1	46930-46940	Evaluating	_	
233-2	46941-46944	the	_	
233-3	46945-46957	differential	_	
233-4	46958-46968	predictive	_	
233-5	46969-46977	validity	_	
233-6	46978-46980	of	_	
233-7	46981-46986	these	_	
233-8	46987-46995	outcomes	_	
233-9	46996-46998	in	_	
233-10	46999-47007	children	_	
233-11	47008-47012	with	_	
233-12	47013-47016	PAE	_	
233-13	47017-47025	relative	_	
233-14	47026-47028	to	_	
233-15	47029-47037	children	_	
233-16	47038-47042	with	_	
233-17	47043-47048	other	_	
233-18	47049-47064	neurobehavioral	_	
233-19	47065-47073	problems	_	
233-20	47074-47078	will	_	
233-21	47079-47081	be	_	
233-22	47082-47085	aid	_	
233-23	47086-47088	in	_	
233-24	47089-47092	our	_	
233-25	47093-47106	understanding	_	
233-26	47107-47109	of	_	
233-27	47110-47113	the	_	
233-28	47114-47125	specificity	_	
233-29	47126-47128	of	_	
233-30	47129-47132	the	_	
233-31	47133-47144	teratogenic	_	
233-32	47145-47152	effects	_	
233-33	47153-47155	of	_	
233-34	47156-47159	PAE	_	
233-35	47159-47160	.	_	
233-36	47161-47162	5	_	
233-37	47162-47163	.	_	

#Text=Conclusion
#Text=Children with Fetal Alcohol Spectrum Disorders have multiple neurobehavioral symptoms of which deficits in executive functioning skills seem to underlie.
234-1	47164-47174	Conclusion	_	
234-2	47175-47183	Children	_	
234-3	47184-47188	with	_	
234-4	47189-47194	Fetal	_	
234-5	47195-47202	Alcohol	_	
234-6	47203-47211	Spectrum	_	
234-7	47212-47221	Disorders	_	
234-8	47222-47226	have	_	
234-9	47227-47235	multiple	_	
234-10	47236-47251	neurobehavioral	_	
234-11	47252-47260	symptoms	_	
234-12	47261-47263	of	_	
234-13	47264-47269	which	_	
234-14	47270-47278	deficits	_	
234-15	47279-47281	in	_	
234-16	47282-47291	executive	_	
234-17	47292-47303	functioning	_	
234-18	47304-47310	skills	_	
234-19	47311-47315	seem	_	
234-20	47316-47318	to	_	
234-21	47319-47327	underlie	_	
234-22	47327-47328	.	_	

#Text=Assessment of PFC activity using fNIRS resulted in group differences between children with PAE and typically developing children and a clinical contrast group, suggesting such assessments may be a potential useful biomarker for improving identification of alcohol-affected children.
235-1	47329-47339	Assessment	_	
235-2	47340-47342	of	_	
235-3	47343-47346	PFC	_	
235-4	47347-47355	activity	_	
235-5	47356-47361	using	_	
235-6	47362-47367	fNIRS	_	
235-7	47368-47376	resulted	_	
235-8	47377-47379	in	_	
235-9	47380-47385	group	_	
235-10	47386-47397	differences	_	
235-11	47398-47405	between	_	
235-12	47406-47414	children	_	
235-13	47415-47419	with	_	
235-14	47420-47423	PAE	_	
235-15	47424-47427	and	_	
235-16	47428-47437	typically	_	
235-17	47438-47448	developing	_	
235-18	47449-47457	children	_	
235-19	47458-47461	and	_	
235-20	47462-47463	a	_	
235-21	47464-47472	clinical	_	
235-22	47473-47481	contrast	_	
235-23	47482-47487	group	_	
235-24	47487-47488	,	_	
235-25	47489-47499	suggesting	_	
235-26	47500-47504	such	_	
235-27	47505-47516	assessments	_	
235-28	47517-47520	may	_	
235-29	47521-47523	be	_	
235-30	47524-47525	a	_	
235-31	47526-47535	potential	_	
235-32	47536-47542	useful	_	
235-33	47543-47552	biomarker	_	
235-34	47553-47556	for	_	
235-35	47557-47566	improving	_	
235-36	47567-47581	identification	_	
235-37	47582-47584	of	_	
235-38	47585-47601	alcohol-affected	_	
235-39	47602-47610	children	_	
235-40	47610-47611	.	_	

#Text=In dealing with positive emotional arousal, children with PAE had less activation in the medial PFC areas, higher levels of HBR in all areas of the PFC, and less specialization of areas of PFC activity in response to a task known to elicit emotional arousal.
236-1	47612-47614	In	_	
236-2	47615-47622	dealing	_	
236-3	47623-47627	with	_	
236-4	47628-47636	positive	_	
236-5	47637-47646	emotional	_	
236-6	47647-47654	arousal	_	
236-7	47654-47655	,	_	
236-8	47656-47664	children	_	
236-9	47665-47669	with	_	
236-10	47670-47673	PAE	_	
236-11	47674-47677	had	_	
236-12	47678-47682	less	_	
236-13	47683-47693	activation	_	
236-14	47694-47696	in	_	
236-15	47697-47700	the	_	
236-16	47701-47707	medial	_	
236-17	47708-47711	PFC	_	
236-18	47712-47717	areas	_	
236-19	47717-47718	,	_	
236-20	47719-47725	higher	_	
236-21	47726-47732	levels	_	
236-22	47733-47735	of	_	
236-23	47736-47739	HBR	_	
236-24	47740-47742	in	_	
236-25	47743-47746	all	_	
236-26	47747-47752	areas	_	
236-27	47753-47755	of	_	
236-28	47756-47759	the	_	
236-29	47760-47763	PFC	_	
236-30	47763-47764	,	_	
236-31	47765-47768	and	_	
236-32	47769-47773	less	_	
236-33	47774-47788	specialization	_	
236-34	47789-47791	of	_	
236-35	47792-47797	areas	_	
236-36	47798-47800	of	_	
236-37	47801-47804	PFC	_	
236-38	47805-47813	activity	_	
236-39	47814-47816	in	_	
236-40	47817-47825	response	_	
236-41	47826-47828	to	_	
236-42	47829-47830	a	_	
236-43	47831-47835	task	_	
236-44	47836-47841	known	_	
236-45	47842-47844	to	_	
236-46	47845-47851	elicit	_	
236-47	47852-47861	emotional	_	
236-48	47862-47869	arousal	_	
236-49	47869-47870	.	_	

#Text=The relationship between changes in PFC activation associated with emotional arousal should be further explored in children with a history of PAE to provide insight into the mechanisms by which learning, problem-solving, and arousal regulation are disrupted in these children.
237-1	47871-47874	The	_	
237-2	47875-47887	relationship	_	
237-3	47888-47895	between	_	
237-4	47896-47903	changes	_	
237-5	47904-47906	in	_	
237-6	47907-47910	PFC	_	
237-7	47911-47921	activation	_	
237-8	47922-47932	associated	_	
237-9	47933-47937	with	_	
237-10	47938-47947	emotional	_	
237-11	47948-47955	arousal	_	
237-12	47956-47962	should	_	
237-13	47963-47965	be	_	
237-14	47966-47973	further	_	
237-15	47974-47982	explored	_	
237-16	47983-47985	in	_	
237-17	47986-47994	children	_	
237-18	47995-47999	with	_	
237-19	48000-48001	a	_	
237-20	48002-48009	history	_	
237-21	48010-48012	of	_	
237-22	48013-48016	PAE	_	
237-23	48017-48019	to	_	
237-24	48020-48027	provide	_	
237-25	48028-48035	insight	_	
237-26	48036-48040	into	_	
237-27	48041-48044	the	_	
237-28	48045-48055	mechanisms	_	
237-29	48056-48058	by	_	
237-30	48059-48064	which	_	
237-31	48065-48073	learning	_	
237-32	48073-48074	,	_	
237-33	48075-48090	problem-solving	_	
237-34	48090-48091	,	_	
237-35	48092-48095	and	_	
237-36	48096-48103	arousal	_	
237-37	48104-48114	regulation	_	
237-38	48115-48118	are	_	
237-39	48119-48128	disrupted	_	
237-40	48129-48131	in	_	
237-41	48132-48137	these	_	
237-42	48138-48146	children	_	
237-43	48146-48147	.	_	

#Text=Specifically, the relationship between PFC activation should be related to behavioral measures of EF and behavioral adjustment to determine if differential responsiveness in brain activation and oxygen depletion predicts the real-world behavioral deficits that are often reported in these children.
238-1	48148-48160	Specifically	_	
238-2	48160-48161	,	_	
238-3	48162-48165	the	_	
238-4	48166-48178	relationship	_	
238-5	48179-48186	between	_	
238-6	48187-48190	PFC	_	
238-7	48191-48201	activation	_	
238-8	48202-48208	should	_	
238-9	48209-48211	be	_	
238-10	48212-48219	related	_	
238-11	48220-48222	to	_	
238-12	48223-48233	behavioral	_	
238-13	48234-48242	measures	_	
238-14	48243-48245	of	_	
238-15	48246-48248	EF	_	
238-16	48249-48252	and	_	
238-17	48253-48263	behavioral	_	
238-18	48264-48274	adjustment	_	
238-19	48275-48277	to	_	
238-20	48278-48287	determine	_	
238-21	48288-48290	if	_	
238-22	48291-48303	differential	_	
238-23	48304-48318	responsiveness	_	
238-24	48319-48321	in	_	
238-25	48322-48327	brain	_	
238-26	48328-48338	activation	_	
238-27	48339-48342	and	_	
238-28	48343-48349	oxygen	_	
238-29	48350-48359	depletion	_	
238-30	48360-48368	predicts	_	
238-31	48369-48372	the	_	
238-32	48373-48383	real-world	_	
238-33	48384-48394	behavioral	_	
238-34	48395-48403	deficits	_	
238-35	48404-48408	that	_	
238-36	48409-48412	are	_	
238-37	48413-48418	often	_	
238-38	48419-48427	reported	_	
238-39	48428-48430	in	_	
238-40	48431-48436	these	_	
238-41	48437-48445	children	_	
238-42	48445-48446	.	_	

#Text=In addition, changes in PFC activation may provide an important tool in evaluating intervention programs for these children that frequently target behavioral and cognitive inhibition.
239-1	48447-48449	In	_	
239-2	48450-48458	addition	_	
239-3	48458-48459	,	_	
239-4	48460-48467	changes	_	
239-5	48468-48470	in	_	
239-6	48471-48474	PFC	_	
239-7	48475-48485	activation	_	
239-8	48486-48489	may	_	
239-9	48490-48497	provide	_	
239-10	48498-48500	an	_	
239-11	48501-48510	important	_	
239-12	48511-48515	tool	_	
239-13	48516-48518	in	_	
239-14	48519-48529	evaluating	_	
239-15	48530-48542	intervention	_	
239-16	48543-48551	programs	_	
239-17	48552-48555	for	_	
239-18	48556-48561	these	_	
239-19	48562-48570	children	_	
239-20	48571-48575	that	_	
239-21	48576-48586	frequently	_	
239-22	48587-48593	target	_	
239-23	48594-48604	behavioral	_	
239-24	48605-48608	and	_	
239-25	48609-48618	cognitive	_	
239-26	48619-48629	inhibition	_	
239-27	48629-48630	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
240-1	48631-48644	Supplementary	_	
240-2	48645-48653	Material	_	
240-3	48654-48658	This	_	
240-4	48659-48661	is	_	
240-5	48662-48663	a	_	
240-6	48664-48667	PDF	_	
240-7	48668-48672	file	_	
240-8	48673-48675	of	_	
240-9	48676-48678	an	_	
240-10	48679-48687	unedited	_	
240-11	48688-48698	manuscript	_	
240-12	48699-48703	that	_	
240-13	48704-48707	has	_	
240-14	48708-48712	been	_	
240-15	48713-48721	accepted	_	
240-16	48722-48725	for	_	
240-17	48726-48737	publication	_	
240-18	48737-48738	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
241-1	48739-48741	As	_	
241-2	48742-48743	a	_	
241-3	48744-48751	service	_	
241-4	48752-48754	to	_	
241-5	48755-48758	our	_	
241-6	48759-48768	customers	_	
241-7	48769-48771	we	_	
241-8	48772-48775	are	_	
241-9	48776-48785	providing	_	
241-10	48786-48790	this	_	
241-11	48791-48796	early	_	
241-12	48797-48804	version	_	
241-13	48805-48807	of	_	
241-14	48808-48811	the	_	
241-15	48812-48822	manuscript	_	
241-16	48822-48823	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
242-1	48824-48827	The	_	
242-2	48828-48838	manuscript	_	
242-3	48839-48843	will	_	
242-4	48844-48851	undergo	_	
242-5	48852-48863	copyediting	_	
242-6	48863-48864	,	_	
242-7	48865-48876	typesetting	_	
242-8	48876-48877	,	_	
242-9	48878-48881	and	_	
242-10	48882-48888	review	_	
242-11	48889-48891	of	_	
242-12	48892-48895	the	_	
242-13	48896-48905	resulting	_	
242-14	48906-48911	proof	_	
242-15	48912-48918	before	_	
242-16	48919-48921	it	_	
242-17	48922-48924	is	_	
242-18	48925-48934	published	_	
242-19	48935-48937	in	_	
242-20	48938-48941	its	_	
242-21	48942-48947	final	_	
242-22	48948-48955	citable	_	
242-23	48956-48960	form	_	
242-24	48960-48961	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
243-1	48962-48968	Please	_	
243-2	48969-48973	note	_	
243-3	48974-48978	that	_	
243-4	48979-48985	during	_	
243-5	48986-48989	the	_	
243-6	48990-49000	production	_	
243-7	49001-49008	process	_	
243-8	49009-49015	errors	_	
243-9	49016-49019	may	_	
243-10	49020-49022	be	_	
243-11	49023-49033	discovered	_	
243-12	49034-49039	which	_	
243-13	49040-49045	could	_	
243-14	49046-49052	affect	_	
243-15	49053-49056	the	_	
243-16	49057-49064	content	_	
243-17	49064-49065	,	_	
243-18	49066-49069	and	_	
243-19	49070-49073	all	_	
243-20	49074-49079	legal	_	
243-21	49080-49091	disclaimers	_	
243-22	49092-49096	that	_	
243-23	49097-49102	apply	_	
243-24	49103-49105	to	_	
243-25	49106-49109	the	_	
243-26	49110-49117	journal	_	
243-27	49118-49125	pertain	_	
243-28	49125-49126	.	_	

#Text=Conflict of interest statement         
#Text=The authors declare that there are no conflicts of interest.
244-1	49138-49146	Conflict	_	
244-2	49147-49149	of	_	
244-3	49150-49158	interest	_	
244-4	49159-49168	statement	_	
244-5	49178-49181	The	_	
244-6	49182-49189	authors	_	
244-7	49190-49197	declare	_	
244-8	49198-49202	that	_	
244-9	49203-49208	there	_	
244-10	49209-49212	are	_	
244-11	49213-49215	no	_	
244-12	49216-49225	conflicts	_	
244-13	49226-49228	of	_	
244-14	49229-49237	interest	_	
244-15	49237-49238	.	_	

#Text=Normative database of judgment of complexity task with functional near infrared spectroscopy–application for TBI
#Text=Neuropsychological characteristics of Italian children with fetal alcohol spectrum disorders
#Text=Improved prefrontal activity in AD/HD children treated with atomoxetine: a NIRS study
#Text=Forebrain hypoplasia following acute prenatal ethanol exposure: quantitative analysis of effects on specific forebrain nuclei
#Text=Sliding-window motion artifact rejection for functional nearinfrared spectroscopy
#Text=Using MazeSuite and functional near infrared spectroscopy to study learning in spatial navigation
#Text=Controlling the false discovery rate – a practical and powerful approach to multiple testing
#Text=Twenty years of functional near-infrared spectroscopy: introduction for the special issue
#Text=Effects of prenatal alcohol exposure at school age: II Attention and behavior
#Text=Neuronal reduction in frontal cortex of primates after prenatal alcohol exposure
#Text=Misdiagnosis and missed diagnoses in foster and adopted children with prenatal alcohol exposure
#Text=Neurodevelopmental functioning in children with FAS, pFAS, and ARND
#Text=Effects of prenatal alcohol exposure at school age.
245-1	49239-49248	Normative	_	
245-2	49249-49257	database	_	
245-3	49258-49260	of	_	
245-4	49261-49269	judgment	_	
245-5	49270-49272	of	_	
245-6	49273-49283	complexity	_	
245-7	49284-49288	task	_	
245-8	49289-49293	with	_	
245-9	49294-49304	functional	_	
245-10	49305-49309	near	_	
245-11	49310-49318	infrared	_	
245-12	49319-49343	spectroscopy–application	_	
245-13	49344-49347	for	_	
245-14	49348-49351	TBI	_	
245-15	49352-49370	Neuropsychological	_	
245-16	49371-49386	characteristics	_	
245-17	49387-49389	of	_	
245-18	49390-49397	Italian	_	
245-19	49398-49406	children	_	
245-20	49407-49411	with	_	
245-21	49412-49417	fetal	_	
245-22	49418-49425	alcohol	_	
245-23	49426-49434	spectrum	_	
245-24	49435-49444	disorders	_	
245-25	49445-49453	Improved	_	
245-26	49454-49464	prefrontal	_	
245-27	49465-49473	activity	_	
245-28	49474-49476	in	_	
245-29	49477-49479	AD	_	
245-30	49479-49480	/	_	
245-31	49480-49482	HD	_	
245-32	49483-49491	children	_	
245-33	49492-49499	treated	_	
245-34	49500-49504	with	_	
245-35	49505-49516	atomoxetine	_	
245-36	49516-49517	:	_	
245-37	49518-49519	a	_	
245-38	49520-49524	NIRS	_	
245-39	49525-49530	study	_	
245-40	49531-49540	Forebrain	_	
245-41	49541-49551	hypoplasia	_	
245-42	49552-49561	following	_	
245-43	49562-49567	acute	_	
245-44	49568-49576	prenatal	_	
245-45	49577-49584	ethanol	_	
245-46	49585-49593	exposure	_	
245-47	49593-49594	:	_	
245-48	49595-49607	quantitative	_	
245-49	49608-49616	analysis	_	
245-50	49617-49619	of	_	
245-51	49620-49627	effects	_	
245-52	49628-49630	on	_	
245-53	49631-49639	specific	_	
245-54	49640-49649	forebrain	_	
245-55	49650-49656	nuclei	_	
245-56	49657-49671	Sliding-window	_	
245-57	49672-49678	motion	_	
245-58	49679-49687	artifact	_	
245-59	49688-49697	rejection	_	
245-60	49698-49701	for	_	
245-61	49702-49712	functional	_	
245-62	49713-49725	nearinfrared	_	
245-63	49726-49738	spectroscopy	_	
245-64	49739-49744	Using	_	
245-65	49745-49754	MazeSuite	_	
245-66	49755-49758	and	_	
245-67	49759-49769	functional	_	
245-68	49770-49774	near	_	
245-69	49775-49783	infrared	_	
245-70	49784-49796	spectroscopy	_	
245-71	49797-49799	to	_	
245-72	49800-49805	study	_	
245-73	49806-49814	learning	_	
245-74	49815-49817	in	_	
245-75	49818-49825	spatial	_	
245-76	49826-49836	navigation	_	
245-77	49837-49848	Controlling	_	
245-78	49849-49852	the	_	
245-79	49853-49858	false	_	
245-80	49859-49868	discovery	_	
245-81	49869-49873	rate	_	
245-82	49874-49875	–	_	
245-83	49876-49877	a	_	
245-84	49878-49887	practical	_	
245-85	49888-49891	and	_	
245-86	49892-49900	powerful	_	
245-87	49901-49909	approach	_	
245-88	49910-49912	to	_	
245-89	49913-49921	multiple	_	
245-90	49922-49929	testing	_	
245-91	49930-49936	Twenty	_	
245-92	49937-49942	years	_	
245-93	49943-49945	of	_	
245-94	49946-49956	functional	_	
245-95	49957-49970	near-infrared	_	
245-96	49971-49983	spectroscopy	_	
245-97	49983-49984	:	_	
245-98	49985-49997	introduction	_	
245-99	49998-50001	for	_	
245-100	50002-50005	the	_	
245-101	50006-50013	special	_	
245-102	50014-50019	issue	_	
245-103	50020-50027	Effects	_	
245-104	50028-50030	of	_	
245-105	50031-50039	prenatal	_	
245-106	50040-50047	alcohol	_	
245-107	50048-50056	exposure	_	
245-108	50057-50059	at	_	
245-109	50060-50066	school	_	
245-110	50067-50070	age	_	
245-111	50070-50071	:	_	
245-112	50072-50074	II	_	
245-113	50075-50084	Attention	_	
245-114	50085-50088	and	_	
245-115	50089-50097	behavior	_	
245-116	50098-50106	Neuronal	_	
245-117	50107-50116	reduction	_	
245-118	50117-50119	in	_	
245-119	50120-50127	frontal	_	
245-120	50128-50134	cortex	_	
245-121	50135-50137	of	_	
245-122	50138-50146	primates	_	
245-123	50147-50152	after	_	
245-124	50153-50161	prenatal	_	
245-125	50162-50169	alcohol	_	
245-126	50170-50178	exposure	_	
245-127	50179-50191	Misdiagnosis	_	
245-128	50192-50195	and	_	
245-129	50196-50202	missed	_	
245-130	50203-50212	diagnoses	_	
245-131	50213-50215	in	_	
245-132	50216-50222	foster	_	
245-133	50223-50226	and	_	
245-134	50227-50234	adopted	_	
245-135	50235-50243	children	_	
245-136	50244-50248	with	_	
245-137	50249-50257	prenatal	_	
245-138	50258-50265	alcohol	_	
245-139	50266-50274	exposure	_	
245-140	50275-50293	Neurodevelopmental	_	
245-141	50294-50305	functioning	_	
245-142	50306-50308	in	_	
245-143	50309-50317	children	_	
245-144	50318-50322	with	_	
245-145	50323-50326	FAS	_	
245-146	50326-50327	,	_	
245-147	50328-50332	pFAS	_	
245-148	50332-50333	,	_	
245-149	50334-50337	and	_	
245-150	50338-50342	ARND	_	
245-151	50343-50350	Effects	_	
245-152	50351-50353	of	_	
245-153	50354-50362	prenatal	_	
245-154	50363-50370	alcohol	_	
245-155	50371-50379	exposure	_	
245-156	50380-50382	at	_	
245-157	50383-50389	school	_	
245-158	50390-50393	age	_	
245-159	50393-50394	.	_	

#Text=I.
246-1	50395-50396	I	_	
246-2	50396-50397	.	_	

#Text=Physical and cognitive development
#Text=A comparison among 5 methods for the clinical diagnosis of Fetal Alcohol Spectrum Disorders
#Text=Functional neuroimaging in the examination of effects of prenatal alcohol exposure
#Text=A comparison of children affected by prenatal alcohol exposure and attention deficit, hyperactivity disorder
#Text=
#Text=Contributions of anterior cingulate cortex to behaviour
#Text=
#Text=A comparison of generalized linear mixed model procedures with estimating equations for variance and covariance parameter estimation in longitudinal studies and group randomized trials
#Text=Dysmorphia Checklist
#Text=A brief review on the history of human functional near-infrared spectroscopy (fNIRS) development and fields of application
#Text=Prenatal alcohol exposure affects frontalstriatal BOLD response during inhibitory control
#Text=The Influence of Extrinsic Reinforcement on Children with Heavy Prenatal Alcohol Exposure
#Text=Executive function deficits in children with fetal alcohol spectrum disorders (FASD) measured using the Cambridge Neuropsychological Tests Automated Battery (CANTAB)
#Text=Infant stress reactivity and prenatal alcohol exposure
#Text=Variability of (functional) hemodynamics as measured with simultaneous fNIRS and fMRI during intertemporal ch oice
#Text=Vigilance paradigm for preschool children used to relate vigilance behavior to IQ and prenatal exposure to alcohol
#Text=Near-infrared spectroscopy determined cerebral oxygenation with eliminated skin blood flow in young males
#Text=Influence of skin blood flow and source-detector distance on near-infrared spectroscopy-determined cerebral oxygenation in humans
#Text=Prefrontal activation during inhibitory control measured by near-infrared spectroscopy for differentiating between autism spectrum disorders and attention deficit hyperactivity disorder in adults
#Text=Number processing in adolescents with prenatal alcohol exposure and ADHD: differences in the neurobehavioral phenotype
#Text=Prenatal alcohol exposure affects vasculature development in the neonatal brain
#Text=
#Text=The impact of prenatal alcohol exposure on neurophysiological encoding of environmental events at six months
#Text=Socio-cognitive habilitation using the math interactive learning experience program for alcohol-affected children
#Text=Parent training to improve self regulation and adaptive living skills of children with FASD
#Text=Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): Proposed DSM-5 diagnosis
#Text=Investigating the efficacy of an attention training programme in children with foetal alcohol spectrum disorder
#Text=The modified Beer-Lambert law revisited
#Text=Letter and category fluency in children with fetal alcohol syndrome from a community in South Africa
#Text=Specific impairments in selfregulation in children exposed to alcohol prenatally
#Text=The effects of prenatal alcohol exposure on executive functioning
#Text=Teratogenic effects of alcohol on attention
#Text=Imaging the impact of prenatal alcohol exposure on the structure of the developing human brain
#Text=Prenatal alcohol exposure, adaptive function, and entry into adult roles in a prospective study of young adults
#Text=Evaluation of spatial working memory function in children and adults with fetal alcohol spectrum disorders: a functional magnetic resonance imaging study
#Text=Effects of methylphenidate in children with attention deficit hyperactivity disorder: a near-infrared spectroscopy study with CANTAB(R)
#Text=Executive functioning in children with heavy prenatal alcohol exposure
#Text=A review of the neurobehavioral deficits in children with fetal alcohol syndrome or prenatal exposure to alcohol
#Text=Heavy prenatal alcohol exposure with or without physical features of fetal alcohol syndrome leads to IQ deficits
#Text=Toward a neurobehavioral profile of fetal alcohol spectrum disorders
#Text=Further development of a neurobehavioral profile of fetal alcohol spectrum disorders
#Text=Event-related functional magnetic resonance imaging of reward-related brain circuitry in children and adolescents
#Text=Prevalence and characteristics of fetal alcohol spectrum disorders
#Text=Brain imaging and fetal alcohol spectrum disorders
#Text=Children with heavy prenatal alcohol exposure demonstrate deficits on multiple measures of concept formation
#Text=
#Text=An FMRI study of number processing in children with fetal alcohol syndrome
#Text=Clinically-oriented monitoring of acute effects of methylphenidate on cerebral hemodynamics in ADHD children using fNIRS
#Text=Fetal Alcohol Spectrum Disorders: Recent Neuroimaging Findings
#Text=Improving executive functioning in children with fetal alcohol spectrum disorders
#Text=
#Text=The clinical utility and specificity of parent report of executive function among children with prenatal alcohol exposure
#Text=Fetal alcohol syndrome and the developing socio-emotional brain
#Text=Prenatal alcohol exposure and infant negative affect as precursors of depressive features in children
#Text=Psychiatric conditions associated with prenatal alcohol exposure
#Text=Altered frontal-parietal functioning during verbal working memory in children and adolescents with heavy prenatal alcohol exposure
#Text=Near-infrared spectroscopy in functional activation studies: Can NIRS demonstrate cortical activation?
247-1	50398-50406	Physical	_	
247-2	50407-50410	and	_	
247-3	50411-50420	cognitive	_	
247-4	50421-50432	development	_	
247-5	50433-50434	A	_	
247-6	50435-50445	comparison	_	
247-7	50446-50451	among	_	
247-8	50452-50453	5	_	
247-9	50454-50461	methods	_	
247-10	50462-50465	for	_	
247-11	50466-50469	the	_	
247-12	50470-50478	clinical	_	
247-13	50479-50488	diagnosis	_	
247-14	50489-50491	of	_	
247-15	50492-50497	Fetal	_	
247-16	50498-50505	Alcohol	_	
247-17	50506-50514	Spectrum	_	
247-18	50515-50524	Disorders	_	
247-19	50525-50535	Functional	_	
247-20	50536-50548	neuroimaging	_	
247-21	50549-50551	in	_	
247-22	50552-50555	the	_	
247-23	50556-50567	examination	_	
247-24	50568-50570	of	_	
247-25	50571-50578	effects	_	
247-26	50579-50581	of	_	
247-27	50582-50590	prenatal	_	
247-28	50591-50598	alcohol	_	
247-29	50599-50607	exposure	_	
247-30	50608-50609	A	_	
247-31	50610-50620	comparison	_	
247-32	50621-50623	of	_	
247-33	50624-50632	children	_	
247-34	50633-50641	affected	_	
247-35	50642-50644	by	_	
247-36	50645-50653	prenatal	_	
247-37	50654-50661	alcohol	_	
247-38	50662-50670	exposure	_	
247-39	50671-50674	and	_	
247-40	50675-50684	attention	_	
247-41	50685-50692	deficit	_	
247-42	50692-50693	,	_	
247-43	50694-50707	hyperactivity	_	
247-44	50708-50716	disorder	_	
247-45	50718-50731	Contributions	_	
247-46	50732-50734	of	_	
247-47	50735-50743	anterior	_	
247-48	50744-50753	cingulate	_	
247-49	50754-50760	cortex	_	
247-50	50761-50763	to	_	
247-51	50764-50773	behaviour	_	
247-52	50775-50776	A	_	
247-53	50777-50787	comparison	_	
247-54	50788-50790	of	_	
247-55	50791-50802	generalized	_	
247-56	50803-50809	linear	_	
247-57	50810-50815	mixed	_	
247-58	50816-50821	model	_	
247-59	50822-50832	procedures	_	
247-60	50833-50837	with	_	
247-61	50838-50848	estimating	_	
247-62	50849-50858	equations	_	
247-63	50859-50862	for	_	
247-64	50863-50871	variance	_	
247-65	50872-50875	and	_	
247-66	50876-50886	covariance	_	
247-67	50887-50896	parameter	_	
247-68	50897-50907	estimation	_	
247-69	50908-50910	in	_	
247-70	50911-50923	longitudinal	_	
247-71	50924-50931	studies	_	
247-72	50932-50935	and	_	
247-73	50936-50941	group	_	
247-74	50942-50952	randomized	_	
247-75	50953-50959	trials	_	
247-76	50960-50970	Dysmorphia	_	
247-77	50971-50980	Checklist	_	
247-78	50981-50982	A	_	
247-79	50983-50988	brief	_	
247-80	50989-50995	review	_	
247-81	50996-50998	on	_	
247-82	50999-51002	the	_	
247-83	51003-51010	history	_	
247-84	51011-51013	of	_	
247-85	51014-51019	human	_	
247-86	51020-51030	functional	_	
247-87	51031-51044	near-infrared	_	
247-88	51045-51057	spectroscopy	_	
247-89	51058-51059	(	_	
247-90	51059-51064	fNIRS	_	
247-91	51064-51065	)	_	
247-92	51066-51077	development	_	
247-93	51078-51081	and	_	
247-94	51082-51088	fields	_	
247-95	51089-51091	of	_	
247-96	51092-51103	application	_	
247-97	51104-51112	Prenatal	_	
247-98	51113-51120	alcohol	_	
247-99	51121-51129	exposure	_	
247-100	51130-51137	affects	_	
247-101	51138-51153	frontalstriatal	_	
247-102	51154-51158	BOLD	_	
247-103	51159-51167	response	_	
247-104	51168-51174	during	_	
247-105	51175-51185	inhibitory	_	
247-106	51186-51193	control	_	
247-107	51194-51197	The	_	
247-108	51198-51207	Influence	_	
247-109	51208-51210	of	_	
247-110	51211-51220	Extrinsic	_	
247-111	51221-51234	Reinforcement	_	
247-112	51235-51237	on	_	
247-113	51238-51246	Children	_	
247-114	51247-51251	with	_	
247-115	51252-51257	Heavy	_	
247-116	51258-51266	Prenatal	_	
247-117	51267-51274	Alcohol	_	
247-118	51275-51283	Exposure	_	
247-119	51284-51293	Executive	_	
247-120	51294-51302	function	_	
247-121	51303-51311	deficits	_	
247-122	51312-51314	in	_	
247-123	51315-51323	children	_	
247-124	51324-51328	with	_	
247-125	51329-51334	fetal	_	
247-126	51335-51342	alcohol	_	
247-127	51343-51351	spectrum	_	
247-128	51352-51361	disorders	_	
247-129	51362-51363	(	_	
247-130	51363-51367	FASD	_	
247-131	51367-51368	)	_	
247-132	51369-51377	measured	_	
247-133	51378-51383	using	_	
247-134	51384-51387	the	_	
247-135	51388-51397	Cambridge	_	
247-136	51398-51416	Neuropsychological	_	
247-137	51417-51422	Tests	_	
247-138	51423-51432	Automated	_	
247-139	51433-51440	Battery	_	
247-140	51441-51442	(	_	
247-141	51442-51448	CANTAB	_	
247-142	51448-51449	)	_	
247-143	51450-51456	Infant	_	
247-144	51457-51463	stress	_	
247-145	51464-51474	reactivity	_	
247-146	51475-51478	and	_	
247-147	51479-51487	prenatal	_	
247-148	51488-51495	alcohol	_	
247-149	51496-51504	exposure	_	
247-150	51505-51516	Variability	_	
247-151	51517-51519	of	_	
247-152	51520-51521	(	_	
247-153	51521-51531	functional	_	
247-154	51531-51532	)	_	
247-155	51533-51545	hemodynamics	_	
247-156	51546-51548	as	_	
247-157	51549-51557	measured	_	
247-158	51558-51562	with	_	
247-159	51563-51575	simultaneous	_	
247-160	51576-51581	fNIRS	_	
247-161	51582-51585	and	_	
247-162	51586-51590	fMRI	_	
247-163	51591-51597	during	_	
247-164	51598-51611	intertemporal	_	
247-165	51612-51614	ch	_	
247-166	51615-51619	oice	_	
247-167	51620-51629	Vigilance	_	
247-168	51630-51638	paradigm	_	
247-169	51639-51642	for	_	
247-170	51643-51652	preschool	_	
247-171	51653-51661	children	_	
247-172	51662-51666	used	_	
247-173	51667-51669	to	_	
247-174	51670-51676	relate	_	
247-175	51677-51686	vigilance	_	
247-176	51687-51695	behavior	_	
247-177	51696-51698	to	_	
247-178	51699-51701	IQ	_	
247-179	51702-51705	and	_	
247-180	51706-51714	prenatal	_	
247-181	51715-51723	exposure	_	
247-182	51724-51726	to	_	
247-183	51727-51734	alcohol	_	
247-184	51735-51748	Near-infrared	_	
247-185	51749-51761	spectroscopy	_	
247-186	51762-51772	determined	_	
247-187	51773-51781	cerebral	_	
247-188	51782-51793	oxygenation	_	
247-189	51794-51798	with	_	
247-190	51799-51809	eliminated	_	
247-191	51810-51814	skin	_	
247-192	51815-51820	blood	_	
247-193	51821-51825	flow	_	
247-194	51826-51828	in	_	
247-195	51829-51834	young	_	
247-196	51835-51840	males	_	
247-197	51841-51850	Influence	_	
247-198	51851-51853	of	_	
247-199	51854-51858	skin	_	
247-200	51859-51864	blood	_	
247-201	51865-51869	flow	_	
247-202	51870-51873	and	_	
247-203	51874-51889	source-detector	_	
247-204	51890-51898	distance	_	
247-205	51899-51901	on	_	
247-206	51902-51915	near-infrared	_	
247-207	51916-51939	spectroscopy-determined	_	
247-208	51940-51948	cerebral	_	
247-209	51949-51960	oxygenation	_	
247-210	51961-51963	in	_	
247-211	51964-51970	humans	_	
247-212	51971-51981	Prefrontal	_	
247-213	51982-51992	activation	_	
247-214	51993-51999	during	_	
247-215	52000-52010	inhibitory	_	
247-216	52011-52018	control	_	
247-217	52019-52027	measured	_	
247-218	52028-52030	by	_	
247-219	52031-52044	near-infrared	_	
247-220	52045-52057	spectroscopy	_	
247-221	52058-52061	for	_	
247-222	52062-52077	differentiating	_	
247-223	52078-52085	between	_	
247-224	52086-52092	autism	_	
247-225	52093-52101	spectrum	_	
247-226	52102-52111	disorders	_	
247-227	52112-52115	and	_	
247-228	52116-52125	attention	_	
247-229	52126-52133	deficit	_	
247-230	52134-52147	hyperactivity	_	
247-231	52148-52156	disorder	_	
247-232	52157-52159	in	_	
247-233	52160-52166	adults	_	
247-234	52167-52173	Number	_	
247-235	52174-52184	processing	_	
247-236	52185-52187	in	_	
247-237	52188-52199	adolescents	_	
247-238	52200-52204	with	_	
247-239	52205-52213	prenatal	_	
247-240	52214-52221	alcohol	_	
247-241	52222-52230	exposure	_	
247-242	52231-52234	and	_	
247-243	52235-52239	ADHD	_	
247-244	52239-52240	:	_	
247-245	52241-52252	differences	_	
247-246	52253-52255	in	_	
247-247	52256-52259	the	_	
247-248	52260-52275	neurobehavioral	_	
247-249	52276-52285	phenotype	_	
247-250	52286-52294	Prenatal	_	
247-251	52295-52302	alcohol	_	
247-252	52303-52311	exposure	_	
247-253	52312-52319	affects	_	
247-254	52320-52331	vasculature	_	
247-255	52332-52343	development	_	
247-256	52344-52346	in	_	
247-257	52347-52350	the	_	
247-258	52351-52359	neonatal	_	
247-259	52360-52365	brain	_	
247-260	52367-52370	The	_	
247-261	52371-52377	impact	_	
247-262	52378-52380	of	_	
247-263	52381-52389	prenatal	_	
247-264	52390-52397	alcohol	_	
247-265	52398-52406	exposure	_	
247-266	52407-52409	on	_	
247-267	52410-52428	neurophysiological	_	
247-268	52429-52437	encoding	_	
247-269	52438-52440	of	_	
247-270	52441-52454	environmental	_	
247-271	52455-52461	events	_	
247-272	52462-52464	at	_	
247-273	52465-52468	six	_	
247-274	52469-52475	months	_	
247-275	52476-52491	Socio-cognitive	_	
247-276	52492-52504	habilitation	_	
247-277	52505-52510	using	_	
247-278	52511-52514	the	_	
247-279	52515-52519	math	_	
247-280	52520-52531	interactive	_	
247-281	52532-52540	learning	_	
247-282	52541-52551	experience	_	
247-283	52552-52559	program	_	
247-284	52560-52563	for	_	
247-285	52564-52580	alcohol-affected	_	
247-286	52581-52589	children	_	
247-287	52590-52596	Parent	_	
247-288	52597-52605	training	_	
247-289	52606-52608	to	_	
247-290	52609-52616	improve	_	
247-291	52617-52621	self	_	
247-292	52622-52632	regulation	_	
247-293	52633-52636	and	_	
247-294	52637-52645	adaptive	_	
247-295	52646-52652	living	_	
247-296	52653-52659	skills	_	
247-297	52660-52662	of	_	
247-298	52663-52671	children	_	
247-299	52672-52676	with	_	
247-300	52677-52681	FASD	_	
247-301	52682-52697	Neurobehavioral	_	
247-302	52698-52706	Disorder	_	
247-303	52707-52717	Associated	_	
247-304	52718-52722	with	_	
247-305	52723-52731	Prenatal	_	
247-306	52732-52739	Alcohol	_	
247-307	52740-52748	Exposure	_	
247-308	52749-52750	(	_	
247-309	52750-52756	ND-PAE	_	
247-310	52756-52757	)	_	
247-311	52757-52758	:	_	
247-312	52759-52767	Proposed	_	
247-313	52768-52771	DSM	_	
247-314	52771-52772	-	_	
247-315	52772-52773	5	_	
247-316	52774-52783	diagnosis	_	
247-317	52784-52797	Investigating	_	
247-318	52798-52801	the	_	
247-319	52802-52810	efficacy	_	
247-320	52811-52813	of	_	
247-321	52814-52816	an	_	
247-322	52817-52826	attention	_	
247-323	52827-52835	training	_	
247-324	52836-52845	programme	_	
247-325	52846-52848	in	_	
247-326	52849-52857	children	_	
247-327	52858-52862	with	_	
247-328	52863-52869	foetal	_	
247-329	52870-52877	alcohol	_	
247-330	52878-52886	spectrum	_	
247-331	52887-52895	disorder	_	
247-332	52896-52899	The	_	
247-333	52900-52908	modified	_	
247-334	52909-52921	Beer-Lambert	_	
247-335	52922-52925	law	_	
247-336	52926-52935	revisited	_	
247-337	52936-52942	Letter	_	
247-338	52943-52946	and	_	
247-339	52947-52955	category	_	
247-340	52956-52963	fluency	_	
247-341	52964-52966	in	_	
247-342	52967-52975	children	_	
247-343	52976-52980	with	_	
247-344	52981-52986	fetal	_	
247-345	52987-52994	alcohol	_	
247-346	52995-53003	syndrome	_	
247-347	53004-53008	from	_	
247-348	53009-53010	a	_	
247-349	53011-53020	community	_	
247-350	53021-53023	in	_	
247-351	53024-53029	South	_	
247-352	53030-53036	Africa	_	
247-353	53037-53045	Specific	_	
247-354	53046-53057	impairments	_	
247-355	53058-53060	in	_	
247-356	53061-53075	selfregulation	_	
247-357	53076-53078	in	_	
247-358	53079-53087	children	_	
247-359	53088-53095	exposed	_	
247-360	53096-53098	to	_	
247-361	53099-53106	alcohol	_	
247-362	53107-53117	prenatally	_	
247-363	53118-53121	The	_	
247-364	53122-53129	effects	_	
247-365	53130-53132	of	_	
247-366	53133-53141	prenatal	_	
247-367	53142-53149	alcohol	_	
247-368	53150-53158	exposure	_	
247-369	53159-53161	on	_	
247-370	53162-53171	executive	_	
247-371	53172-53183	functioning	_	
247-372	53184-53195	Teratogenic	_	
247-373	53196-53203	effects	_	
247-374	53204-53206	of	_	
247-375	53207-53214	alcohol	_	
247-376	53215-53217	on	_	
247-377	53218-53227	attention	_	
247-378	53228-53235	Imaging	_	
247-379	53236-53239	the	_	
247-380	53240-53246	impact	_	
247-381	53247-53249	of	_	
247-382	53250-53258	prenatal	_	
247-383	53259-53266	alcohol	_	
247-384	53267-53275	exposure	_	
247-385	53276-53278	on	_	
247-386	53279-53282	the	_	
247-387	53283-53292	structure	_	
247-388	53293-53295	of	_	
247-389	53296-53299	the	_	
247-390	53300-53310	developing	_	
247-391	53311-53316	human	_	
247-392	53317-53322	brain	_	
247-393	53323-53331	Prenatal	_	
247-394	53332-53339	alcohol	_	
247-395	53340-53348	exposure	_	
247-396	53348-53349	,	_	
247-397	53350-53358	adaptive	_	
247-398	53359-53367	function	_	
247-399	53367-53368	,	_	
247-400	53369-53372	and	_	
247-401	53373-53378	entry	_	
247-402	53379-53383	into	_	
247-403	53384-53389	adult	_	
247-404	53390-53395	roles	_	
247-405	53396-53398	in	_	
247-406	53399-53400	a	_	
247-407	53401-53412	prospective	_	
247-408	53413-53418	study	_	
247-409	53419-53421	of	_	
247-410	53422-53427	young	_	
247-411	53428-53434	adults	_	
247-412	53435-53445	Evaluation	_	
247-413	53446-53448	of	_	
247-414	53449-53456	spatial	_	
247-415	53457-53464	working	_	
247-416	53465-53471	memory	_	
247-417	53472-53480	function	_	
247-418	53481-53483	in	_	
247-419	53484-53492	children	_	
247-420	53493-53496	and	_	
247-421	53497-53503	adults	_	
247-422	53504-53508	with	_	
247-423	53509-53514	fetal	_	
247-424	53515-53522	alcohol	_	
247-425	53523-53531	spectrum	_	
247-426	53532-53541	disorders	_	
247-427	53541-53542	:	_	
247-428	53543-53544	a	_	
247-429	53545-53555	functional	_	
247-430	53556-53564	magnetic	_	
247-431	53565-53574	resonance	_	
247-432	53575-53582	imaging	_	
247-433	53583-53588	study	_	
247-434	53589-53596	Effects	_	
247-435	53597-53599	of	_	
247-436	53600-53615	methylphenidate	_	
247-437	53616-53618	in	_	
247-438	53619-53627	children	_	
247-439	53628-53632	with	_	
247-440	53633-53642	attention	_	
247-441	53643-53650	deficit	_	
247-442	53651-53664	hyperactivity	_	
247-443	53665-53673	disorder	_	
247-444	53673-53674	:	_	
247-445	53675-53676	a	_	
247-446	53677-53690	near-infrared	_	
247-447	53691-53703	spectroscopy	_	
247-448	53704-53709	study	_	
247-449	53710-53714	with	_	
247-450	53715-53721	CANTAB	_	
247-451	53721-53722	(	_	
247-452	53722-53723	R	_	
247-453	53723-53724	)	_	
247-454	53725-53734	Executive	_	
247-455	53735-53746	functioning	_	
247-456	53747-53749	in	_	
247-457	53750-53758	children	_	
247-458	53759-53763	with	_	
247-459	53764-53769	heavy	_	
247-460	53770-53778	prenatal	_	
247-461	53779-53786	alcohol	_	
247-462	53787-53795	exposure	_	
247-463	53796-53797	A	_	
247-464	53798-53804	review	_	
247-465	53805-53807	of	_	
247-466	53808-53811	the	_	
247-467	53812-53827	neurobehavioral	_	
247-468	53828-53836	deficits	_	
247-469	53837-53839	in	_	
247-470	53840-53848	children	_	
247-471	53849-53853	with	_	
247-472	53854-53859	fetal	_	
247-473	53860-53867	alcohol	_	
247-474	53868-53876	syndrome	_	
247-475	53877-53879	or	_	
247-476	53880-53888	prenatal	_	
247-477	53889-53897	exposure	_	
247-478	53898-53900	to	_	
247-479	53901-53908	alcohol	_	
247-480	53909-53914	Heavy	_	
247-481	53915-53923	prenatal	_	
247-482	53924-53931	alcohol	_	
247-483	53932-53940	exposure	_	
247-484	53941-53945	with	_	
247-485	53946-53948	or	_	
247-486	53949-53956	without	_	
247-487	53957-53965	physical	_	
247-488	53966-53974	features	_	
247-489	53975-53977	of	_	
247-490	53978-53983	fetal	_	
247-491	53984-53991	alcohol	_	
247-492	53992-54000	syndrome	_	
247-493	54001-54006	leads	_	
247-494	54007-54009	to	_	
247-495	54010-54012	IQ	_	
247-496	54013-54021	deficits	_	
247-497	54022-54028	Toward	_	
247-498	54029-54030	a	_	
247-499	54031-54046	neurobehavioral	_	
247-500	54047-54054	profile	_	
247-501	54055-54057	of	_	
247-502	54058-54063	fetal	_	
247-503	54064-54071	alcohol	_	
247-504	54072-54080	spectrum	_	
247-505	54081-54090	disorders	_	
247-506	54091-54098	Further	_	
247-507	54099-54110	development	_	
247-508	54111-54113	of	_	
247-509	54114-54115	a	_	
247-510	54116-54131	neurobehavioral	_	
247-511	54132-54139	profile	_	
247-512	54140-54142	of	_	
247-513	54143-54148	fetal	_	
247-514	54149-54156	alcohol	_	
247-515	54157-54165	spectrum	_	
247-516	54166-54175	disorders	_	
247-517	54176-54189	Event-related	_	
247-518	54190-54200	functional	_	
247-519	54201-54209	magnetic	_	
247-520	54210-54219	resonance	_	
247-521	54220-54227	imaging	_	
247-522	54228-54230	of	_	
247-523	54231-54245	reward-related	_	
247-524	54246-54251	brain	_	
247-525	54252-54261	circuitry	_	
247-526	54262-54264	in	_	
247-527	54265-54273	children	_	
247-528	54274-54277	and	_	
247-529	54278-54289	adolescents	_	
247-530	54290-54300	Prevalence	_	
247-531	54301-54304	and	_	
247-532	54305-54320	characteristics	_	
247-533	54321-54323	of	_	
247-534	54324-54329	fetal	_	
247-535	54330-54337	alcohol	_	
247-536	54338-54346	spectrum	_	
247-537	54347-54356	disorders	_	
247-538	54357-54362	Brain	_	
247-539	54363-54370	imaging	_	
247-540	54371-54374	and	_	
247-541	54375-54380	fetal	_	
247-542	54381-54388	alcohol	_	
247-543	54389-54397	spectrum	_	
247-544	54398-54407	disorders	_	
247-545	54408-54416	Children	_	
247-546	54417-54421	with	_	
247-547	54422-54427	heavy	_	
247-548	54428-54436	prenatal	_	
247-549	54437-54444	alcohol	_	
247-550	54445-54453	exposure	_	
247-551	54454-54465	demonstrate	_	
247-552	54466-54474	deficits	_	
247-553	54475-54477	on	_	
247-554	54478-54486	multiple	_	
247-555	54487-54495	measures	_	
247-556	54496-54498	of	_	
247-557	54499-54506	concept	_	
247-558	54507-54516	formation	_	
247-559	54518-54520	An	_	
247-560	54521-54525	FMRI	_	
247-561	54526-54531	study	_	
247-562	54532-54534	of	_	
247-563	54535-54541	number	_	
247-564	54542-54552	processing	_	
247-565	54553-54555	in	_	
247-566	54556-54564	children	_	
247-567	54565-54569	with	_	
247-568	54570-54575	fetal	_	
247-569	54576-54583	alcohol	_	
247-570	54584-54592	syndrome	_	
247-571	54593-54612	Clinically-oriented	_	
247-572	54613-54623	monitoring	_	
247-573	54624-54626	of	_	
247-574	54627-54632	acute	_	
247-575	54633-54640	effects	_	
247-576	54641-54643	of	_	
247-577	54644-54659	methylphenidate	_	
247-578	54660-54662	on	_	
247-579	54663-54671	cerebral	_	
247-580	54672-54684	hemodynamics	_	
247-581	54685-54687	in	_	
247-582	54688-54692	ADHD	_	
247-583	54693-54701	children	_	
247-584	54702-54707	using	_	
247-585	54708-54713	fNIRS	_	
247-586	54714-54719	Fetal	_	
247-587	54720-54727	Alcohol	_	
247-588	54728-54736	Spectrum	_	
247-589	54737-54746	Disorders	_	
247-590	54746-54747	:	_	
247-591	54748-54754	Recent	_	
247-592	54755-54767	Neuroimaging	_	
247-593	54768-54776	Findings	_	
247-594	54777-54786	Improving	_	
247-595	54787-54796	executive	_	
247-596	54797-54808	functioning	_	
247-597	54809-54811	in	_	
247-598	54812-54820	children	_	
247-599	54821-54825	with	_	
247-600	54826-54831	fetal	_	
247-601	54832-54839	alcohol	_	
247-602	54840-54848	spectrum	_	
247-603	54849-54858	disorders	_	
247-604	54860-54863	The	_	
247-605	54864-54872	clinical	_	
247-606	54873-54880	utility	_	
247-607	54881-54884	and	_	
247-608	54885-54896	specificity	_	
247-609	54897-54899	of	_	
247-610	54900-54906	parent	_	
247-611	54907-54913	report	_	
247-612	54914-54916	of	_	
247-613	54917-54926	executive	_	
247-614	54927-54935	function	_	
247-615	54936-54941	among	_	
247-616	54942-54950	children	_	
247-617	54951-54955	with	_	
247-618	54956-54964	prenatal	_	
247-619	54965-54972	alcohol	_	
247-620	54973-54981	exposure	_	
247-621	54982-54987	Fetal	_	
247-622	54988-54995	alcohol	_	
247-623	54996-55004	syndrome	_	
247-624	55005-55008	and	_	
247-625	55009-55012	the	_	
247-626	55013-55023	developing	_	
247-627	55024-55039	socio-emotional	_	
247-628	55040-55045	brain	_	
247-629	55046-55054	Prenatal	_	
247-630	55055-55062	alcohol	_	
247-631	55063-55071	exposure	_	
247-632	55072-55075	and	_	
247-633	55076-55082	infant	_	
247-634	55083-55091	negative	_	
247-635	55092-55098	affect	_	
247-636	55099-55101	as	_	
247-637	55102-55112	precursors	_	
247-638	55113-55115	of	_	
247-639	55116-55126	depressive	_	
247-640	55127-55135	features	_	
247-641	55136-55138	in	_	
247-642	55139-55147	children	_	
247-643	55148-55159	Psychiatric	_	
247-644	55160-55170	conditions	_	
247-645	55171-55181	associated	_	
247-646	55182-55186	with	_	
247-647	55187-55195	prenatal	_	
247-648	55196-55203	alcohol	_	
247-649	55204-55212	exposure	_	
247-650	55213-55220	Altered	_	
247-651	55221-55237	frontal-parietal	_	
247-652	55238-55249	functioning	_	
247-653	55250-55256	during	_	
247-654	55257-55263	verbal	_	
247-655	55264-55271	working	_	
247-656	55272-55278	memory	_	
247-657	55279-55281	in	_	
247-658	55282-55290	children	_	
247-659	55291-55294	and	_	
247-660	55295-55306	adolescents	_	
247-661	55307-55311	with	_	
247-662	55312-55317	heavy	_	
247-663	55318-55326	prenatal	_	
247-664	55327-55334	alcohol	_	
247-665	55335-55343	exposure	_	
247-666	55344-55357	Near-infrared	_	
247-667	55358-55370	spectroscopy	_	
247-668	55371-55373	in	_	
247-669	55374-55384	functional	_	
247-670	55385-55395	activation	_	
247-671	55396-55403	studies	_	
247-672	55403-55404	:	_	
247-673	55405-55408	Can	_	
247-674	55409-55413	NIRS	_	
247-675	55414-55425	demonstrate	_	
247-676	55426-55434	cortical	_	
247-677	55435-55445	activation	_	
247-678	55445-55446	?	_	

#Text=ADHD and FAS
#Text=Association among SNAP-25 gene DdeI and MnlI polymorphisms and hemodynamic changes during methylphenidate use: A functional near-infrared spectroscopy study
#Text=fNIRS evidence of prefrontal regulation of frustration in early childhood
#Text=Parent rating of executive function in fetal alcohol spectrum disorder: A review of the literature and new data on Aboriginal Canadian children
#Text=Vascular effects of maternal alcohol consumption
#Text=Executive functioning and working memory in fetal alcohol spectrum disorder
#Text=Executive functioning and working memory deficits on the CANTAB among children with prenatal alcohol exposure
#Text=Fetal alcohol spectrum disorders: an overview
#Text=Linking trait-based phenotypes to prefrontal cortex activation during inhibitory control
#Text=A problem-solving task specialized for functional neuroimaging: validation of the Scarborough adaptation of the Tower of London (S-TOL) using near-infrared spectroscopy
#Text=Effects of methylphenidate on olfaction and frontal and temporal brain oxygenation in children with ADHD
#Text=A review on continuous wave functional near-infrared spectroscopy and imaging instrumentation and methodology
#Text=Executive functioning predicts social skills following prenatal alcohol exposure
#Text=Behavioral regulation as a predictor of response to Children’s Friendship Training in children with fetal alcohol spectrum disorders
#Text=Development of brain vessels in human embryos and fetuses in conditions of prenatal exposure to alcohol
#Text=Functional magnetic resonance imaging of verbal learning in children with heavy prenatal alcohol exposure
#Text=Attention, distraction and reaction time at age 7 years and prenatal alcohol exposure
#Text=
#Text=Maternal drinking during pregnancy: attention and short-term memory in 14-year-old offspring–a longitudinal prospective study
#Text=Statistical analysis of fNIRS data: a comprehensive review
#Text=Comparison of social abilities of children with fetal alcohol syndrome to those of children with similar IQ scores and normal controls
#Text=The use of near-infrared spectroscopy in the study of typical and atypical development
#Text=Differences in executive functioning in children with heavy prenatal alcohol exposure or attention-deficit/hyperactivity disorder
#Text=Functional neuroimaging: Optical approaches
#Text=Neurocognitive habilitation therapy for children with fetal alcohol spectrum disorders: an adaptation of the Alert Program(R)
#Text=A review of functional near-infrared spectroscopy studies of Attention Deficit/Hyperactivity Disorder neurological activation patterns
#Text=Fetal Alcohol Spectrum Disorders: An Overview from the Glia Perspective
#Text=Global functional connectivity abnormalities in children with fetal alcohol spectrum disorders
#Text=Developmental cortical thinning in fetal alcohol spectrum disorders
#Text=Prenatal alcohol exposure alters behavioral laterality of adult offspring in rats
#Text=This figure depicts the levels of oxygenated hemoglobin (μmolar) as a function of group status and prefrontal corical area.
248-1	55447-55451	ADHD	_	
248-2	55452-55455	and	_	
248-3	55456-55459	FAS	_	
248-4	55460-55471	Association	_	
248-5	55472-55477	among	_	
248-6	55478-55482	SNAP	_	
248-7	55482-55483	-	_	
248-8	55483-55485	25	_	
248-9	55486-55490	gene	_	
248-10	55491-55495	DdeI	_	
248-11	55496-55499	and	_	
248-12	55500-55504	MnlI	_	
248-13	55505-55518	polymorphisms	_	
248-14	55519-55522	and	_	
248-15	55523-55534	hemodynamic	_	
248-16	55535-55542	changes	_	
248-17	55543-55549	during	_	
248-18	55550-55565	methylphenidate	_	
248-19	55566-55569	use	_	
248-20	55569-55570	:	_	
248-21	55571-55572	A	_	
248-22	55573-55583	functional	_	
248-23	55584-55597	near-infrared	_	
248-24	55598-55610	spectroscopy	_	
248-25	55611-55616	study	_	
248-26	55617-55622	fNIRS	_	
248-27	55623-55631	evidence	_	
248-28	55632-55634	of	_	
248-29	55635-55645	prefrontal	_	
248-30	55646-55656	regulation	_	
248-31	55657-55659	of	_	
248-32	55660-55671	frustration	_	
248-33	55672-55674	in	_	
248-34	55675-55680	early	_	
248-35	55681-55690	childhood	_	
248-36	55691-55697	Parent	_	
248-37	55698-55704	rating	_	
248-38	55705-55707	of	_	
248-39	55708-55717	executive	_	
248-40	55718-55726	function	_	
248-41	55727-55729	in	_	
248-42	55730-55735	fetal	_	
248-43	55736-55743	alcohol	_	
248-44	55744-55752	spectrum	_	
248-45	55753-55761	disorder	_	
248-46	55761-55762	:	_	
248-47	55763-55764	A	_	
248-48	55765-55771	review	_	
248-49	55772-55774	of	_	
248-50	55775-55778	the	_	
248-51	55779-55789	literature	_	
248-52	55790-55793	and	_	
248-53	55794-55797	new	_	
248-54	55798-55802	data	_	
248-55	55803-55805	on	_	
248-56	55806-55816	Aboriginal	_	
248-57	55817-55825	Canadian	_	
248-58	55826-55834	children	_	
248-59	55835-55843	Vascular	_	
248-60	55844-55851	effects	_	
248-61	55852-55854	of	_	
248-62	55855-55863	maternal	_	
248-63	55864-55871	alcohol	_	
248-64	55872-55883	consumption	_	
248-65	55884-55893	Executive	_	
248-66	55894-55905	functioning	_	
248-67	55906-55909	and	_	
248-68	55910-55917	working	_	
248-69	55918-55924	memory	_	
248-70	55925-55927	in	_	
248-71	55928-55933	fetal	_	
248-72	55934-55941	alcohol	_	
248-73	55942-55950	spectrum	_	
248-74	55951-55959	disorder	_	
248-75	55960-55969	Executive	_	
248-76	55970-55981	functioning	_	
248-77	55982-55985	and	_	
248-78	55986-55993	working	_	
248-79	55994-56000	memory	_	
248-80	56001-56009	deficits	_	
248-81	56010-56012	on	_	
248-82	56013-56016	the	_	
248-83	56017-56023	CANTAB	_	
248-84	56024-56029	among	_	
248-85	56030-56038	children	_	
248-86	56039-56043	with	_	
248-87	56044-56052	prenatal	_	
248-88	56053-56060	alcohol	_	
248-89	56061-56069	exposure	_	
248-90	56070-56075	Fetal	_	
248-91	56076-56083	alcohol	_	
248-92	56084-56092	spectrum	_	
248-93	56093-56102	disorders	_	
248-94	56102-56103	:	_	
248-95	56104-56106	an	_	
248-96	56107-56115	overview	_	
248-97	56116-56123	Linking	_	
248-98	56124-56135	trait-based	_	
248-99	56136-56146	phenotypes	_	
248-100	56147-56149	to	_	
248-101	56150-56160	prefrontal	_	
248-102	56161-56167	cortex	_	
248-103	56168-56178	activation	_	
248-104	56179-56185	during	_	
248-105	56186-56196	inhibitory	_	
248-106	56197-56204	control	_	
248-107	56205-56206	A	_	
248-108	56207-56222	problem-solving	_	
248-109	56223-56227	task	_	
248-110	56228-56239	specialized	_	
248-111	56240-56243	for	_	
248-112	56244-56254	functional	_	
248-113	56255-56267	neuroimaging	_	
248-114	56267-56268	:	_	
248-115	56269-56279	validation	_	
248-116	56280-56282	of	_	
248-117	56283-56286	the	_	
248-118	56287-56298	Scarborough	_	
248-119	56299-56309	adaptation	_	
248-120	56310-56312	of	_	
248-121	56313-56316	the	_	
248-122	56317-56322	Tower	_	
248-123	56323-56325	of	_	
248-124	56326-56332	London	_	
248-125	56333-56334	(	_	
248-126	56334-56339	S-TOL	_	
248-127	56339-56340	)	_	
248-128	56341-56346	using	_	
248-129	56347-56360	near-infrared	_	
248-130	56361-56373	spectroscopy	_	
248-131	56374-56381	Effects	_	
248-132	56382-56384	of	_	
248-133	56385-56400	methylphenidate	_	
248-134	56401-56403	on	_	
248-135	56404-56413	olfaction	_	
248-136	56414-56417	and	_	
248-137	56418-56425	frontal	_	
248-138	56426-56429	and	_	
248-139	56430-56438	temporal	_	
248-140	56439-56444	brain	_	
248-141	56445-56456	oxygenation	_	
248-142	56457-56459	in	_	
248-143	56460-56468	children	_	
248-144	56469-56473	with	_	
248-145	56474-56478	ADHD	_	
248-146	56479-56480	A	_	
248-147	56481-56487	review	_	
248-148	56488-56490	on	_	
248-149	56491-56501	continuous	_	
248-150	56502-56506	wave	_	
248-151	56507-56517	functional	_	
248-152	56518-56531	near-infrared	_	
248-153	56532-56544	spectroscopy	_	
248-154	56545-56548	and	_	
248-155	56549-56556	imaging	_	
248-156	56557-56572	instrumentation	_	
248-157	56573-56576	and	_	
248-158	56577-56588	methodology	_	
248-159	56589-56598	Executive	_	
248-160	56599-56610	functioning	_	
248-161	56611-56619	predicts	_	
248-162	56620-56626	social	_	
248-163	56627-56633	skills	_	
248-164	56634-56643	following	_	
248-165	56644-56652	prenatal	_	
248-166	56653-56660	alcohol	_	
248-167	56661-56669	exposure	_	
248-168	56670-56680	Behavioral	_	
248-169	56681-56691	regulation	_	
248-170	56692-56694	as	_	
248-171	56695-56696	a	_	
248-172	56697-56706	predictor	_	
248-173	56707-56709	of	_	
248-174	56710-56718	response	_	
248-175	56719-56721	to	_	
248-176	56722-56730	Children	_	
248-177	56730-56731	’	_	
248-178	56731-56732	s	_	
248-179	56733-56743	Friendship	_	
248-180	56744-56752	Training	_	
248-181	56753-56755	in	_	
248-182	56756-56764	children	_	
248-183	56765-56769	with	_	
248-184	56770-56775	fetal	_	
248-185	56776-56783	alcohol	_	
248-186	56784-56792	spectrum	_	
248-187	56793-56802	disorders	_	
248-188	56803-56814	Development	_	
248-189	56815-56817	of	_	
248-190	56818-56823	brain	_	
248-191	56824-56831	vessels	_	
248-192	56832-56834	in	_	
248-193	56835-56840	human	_	
248-194	56841-56848	embryos	_	
248-195	56849-56852	and	_	
248-196	56853-56860	fetuses	_	
248-197	56861-56863	in	_	
248-198	56864-56874	conditions	_	
248-199	56875-56877	of	_	
248-200	56878-56886	prenatal	_	
248-201	56887-56895	exposure	_	
248-202	56896-56898	to	_	
248-203	56899-56906	alcohol	_	
248-204	56907-56917	Functional	_	
248-205	56918-56926	magnetic	_	
248-206	56927-56936	resonance	_	
248-207	56937-56944	imaging	_	
248-208	56945-56947	of	_	
248-209	56948-56954	verbal	_	
248-210	56955-56963	learning	_	
248-211	56964-56966	in	_	
248-212	56967-56975	children	_	
248-213	56976-56980	with	_	
248-214	56981-56986	heavy	_	
248-215	56987-56995	prenatal	_	
248-216	56996-57003	alcohol	_	
248-217	57004-57012	exposure	_	
248-218	57013-57022	Attention	_	
248-219	57022-57023	,	_	
248-220	57024-57035	distraction	_	
248-221	57036-57039	and	_	
248-222	57040-57048	reaction	_	
248-223	57049-57053	time	_	
248-224	57054-57056	at	_	
248-225	57057-57060	age	_	
248-226	57061-57062	7	_	
248-227	57063-57068	years	_	
248-228	57069-57072	and	_	
248-229	57073-57081	prenatal	_	
248-230	57082-57089	alcohol	_	
248-231	57090-57098	exposure	_	
248-232	57100-57108	Maternal	_	
248-233	57109-57117	drinking	_	
248-234	57118-57124	during	_	
248-235	57125-57134	pregnancy	_	
248-236	57134-57135	:	_	
248-237	57136-57145	attention	_	
248-238	57146-57149	and	_	
248-239	57150-57160	short-term	_	
248-240	57161-57167	memory	_	
248-241	57168-57170	in	_	
248-242	57171-57173	14	_	
248-243	57173-57174	-	_	
248-244	57174-57182	year-old	_	
248-245	57183-57194	offspring–a	_	
248-246	57195-57207	longitudinal	_	
248-247	57208-57219	prospective	_	
248-248	57220-57225	study	_	
248-249	57226-57237	Statistical	_	
248-250	57238-57246	analysis	_	
248-251	57247-57249	of	_	
248-252	57250-57255	fNIRS	_	
248-253	57256-57260	data	_	
248-254	57260-57261	:	_	
248-255	57262-57263	a	_	
248-256	57264-57277	comprehensive	_	
248-257	57278-57284	review	_	
248-258	57285-57295	Comparison	_	
248-259	57296-57298	of	_	
248-260	57299-57305	social	_	
248-261	57306-57315	abilities	_	
248-262	57316-57318	of	_	
248-263	57319-57327	children	_	
248-264	57328-57332	with	_	
248-265	57333-57338	fetal	_	
248-266	57339-57346	alcohol	_	
248-267	57347-57355	syndrome	_	
248-268	57356-57358	to	_	
248-269	57359-57364	those	_	
248-270	57365-57367	of	_	
248-271	57368-57376	children	_	
248-272	57377-57381	with	_	
248-273	57382-57389	similar	_	
248-274	57390-57392	IQ	_	
248-275	57393-57399	scores	_	
248-276	57400-57403	and	_	
248-277	57404-57410	normal	_	
248-278	57411-57419	controls	_	
248-279	57420-57423	The	_	
248-280	57424-57427	use	_	
248-281	57428-57430	of	_	
248-282	57431-57444	near-infrared	_	
248-283	57445-57457	spectroscopy	_	
248-284	57458-57460	in	_	
248-285	57461-57464	the	_	
248-286	57465-57470	study	_	
248-287	57471-57473	of	_	
248-288	57474-57481	typical	_	
248-289	57482-57485	and	_	
248-290	57486-57494	atypical	_	
248-291	57495-57506	development	_	
248-292	57507-57518	Differences	_	
248-293	57519-57521	in	_	
248-294	57522-57531	executive	_	
248-295	57532-57543	functioning	_	
248-296	57544-57546	in	_	
248-297	57547-57555	children	_	
248-298	57556-57560	with	_	
248-299	57561-57566	heavy	_	
248-300	57567-57575	prenatal	_	
248-301	57576-57583	alcohol	_	
248-302	57584-57592	exposure	_	
248-303	57593-57595	or	_	
248-304	57596-57613	attention-deficit	_	
248-305	57613-57614	/	_	
248-306	57614-57627	hyperactivity	_	
248-307	57628-57636	disorder	_	
248-308	57637-57647	Functional	_	
248-309	57648-57660	neuroimaging	_	
248-310	57660-57661	:	_	
248-311	57662-57669	Optical	_	
248-312	57670-57680	approaches	_	
248-313	57681-57695	Neurocognitive	_	
248-314	57696-57708	habilitation	_	
248-315	57709-57716	therapy	_	
248-316	57717-57720	for	_	
248-317	57721-57729	children	_	
248-318	57730-57734	with	_	
248-319	57735-57740	fetal	_	
248-320	57741-57748	alcohol	_	
248-321	57749-57757	spectrum	_	
248-322	57758-57767	disorders	_	
248-323	57767-57768	:	_	
248-324	57769-57771	an	_	
248-325	57772-57782	adaptation	_	
248-326	57783-57785	of	_	
248-327	57786-57789	the	_	
248-328	57790-57795	Alert	_	
248-329	57796-57803	Program	_	
248-330	57803-57804	(	_	
248-331	57804-57805	R	_	
248-332	57805-57806	)	_	
248-333	57807-57808	A	_	
248-334	57809-57815	review	_	
248-335	57816-57818	of	_	
248-336	57819-57829	functional	_	
248-337	57830-57843	near-infrared	_	
248-338	57844-57856	spectroscopy	_	
248-339	57857-57864	studies	_	
248-340	57865-57867	of	_	
248-341	57868-57877	Attention	_	
248-342	57878-57885	Deficit	_	
248-343	57885-57886	/	_	
248-344	57886-57899	Hyperactivity	_	
248-345	57900-57908	Disorder	_	
248-346	57909-57921	neurological	_	
248-347	57922-57932	activation	_	
248-348	57933-57941	patterns	_	
248-349	57942-57947	Fetal	_	
248-350	57948-57955	Alcohol	_	
248-351	57956-57964	Spectrum	_	
248-352	57965-57974	Disorders	_	
248-353	57974-57975	:	_	
248-354	57976-57978	An	_	
248-355	57979-57987	Overview	_	
248-356	57988-57992	from	_	
248-357	57993-57996	the	_	
248-358	57997-58001	Glia	_	
248-359	58002-58013	Perspective	_	
248-360	58014-58020	Global	_	
248-361	58021-58031	functional	_	
248-362	58032-58044	connectivity	_	
248-363	58045-58058	abnormalities	_	
248-364	58059-58061	in	_	
248-365	58062-58070	children	_	
248-366	58071-58075	with	_	
248-367	58076-58081	fetal	_	
248-368	58082-58089	alcohol	_	
248-369	58090-58098	spectrum	_	
248-370	58099-58108	disorders	_	
248-371	58109-58122	Developmental	_	
248-372	58123-58131	cortical	_	
248-373	58132-58140	thinning	_	
248-374	58141-58143	in	_	
248-375	58144-58149	fetal	_	
248-376	58150-58157	alcohol	_	
248-377	58158-58166	spectrum	_	
248-378	58167-58176	disorders	_	
248-379	58177-58185	Prenatal	_	
248-380	58186-58193	alcohol	_	
248-381	58194-58202	exposure	_	
248-382	58203-58209	alters	_	
248-383	58210-58220	behavioral	_	
248-384	58221-58231	laterality	_	
248-385	58232-58234	of	_	
248-386	58235-58240	adult	_	
248-387	58241-58250	offspring	_	
248-388	58251-58253	in	_	
248-389	58254-58258	rats	_	
248-390	58259-58263	This	_	
248-391	58264-58270	figure	_	
248-392	58271-58278	depicts	_	
248-393	58279-58282	the	_	
248-394	58283-58289	levels	_	
248-395	58290-58292	of	_	
248-396	58293-58303	oxygenated	_	
248-397	58304-58314	hemoglobin	_	
248-398	58315-58316	(	_	
248-399	58316-58322	μmolar	_	
248-400	58322-58323	)	_	
248-401	58324-58326	as	_	
248-402	58327-58328	a	_	
248-403	58329-58337	function	_	
248-404	58338-58340	of	_	
248-405	58341-58346	group	_	
248-406	58347-58353	status	_	
248-407	58354-58357	and	_	
248-408	58358-58368	prefrontal	_	
248-409	58369-58376	corical	_	
248-410	58377-58381	area	_	
248-411	58381-58382	.	_	

#Text=This figure depicts the levels of deoxygenated hemoglobin (μmolar) as a function of group status and prefrontal corical area.
249-1	58383-58387	This	_	
249-2	58388-58394	figure	_	
249-3	58395-58402	depicts	_	
249-4	58403-58406	the	_	
249-5	58407-58413	levels	_	
249-6	58414-58416	of	_	
249-7	58417-58429	deoxygenated	_	
249-8	58430-58440	hemoglobin	_	
249-9	58441-58442	(	_	
249-10	58442-58448	μmolar	_	
249-11	58448-58449	)	_	
249-12	58450-58452	as	_	
249-13	58453-58454	a	_	
249-14	58455-58463	function	_	
249-15	58464-58466	of	_	
249-16	58467-58472	group	_	
249-17	58473-58479	status	_	
249-18	58480-58483	and	_	
249-19	58484-58494	prefrontal	_	
249-20	58495-58502	corical	_	
249-21	58503-58507	area	_	
249-22	58507-58508	.	_	

#Text=This figure depicts the levels of oxygenated hemoglobin (μmolar) as a function of task condition during performance by group status and prefrontal cortical area.
250-1	58509-58513	This	_	
250-2	58514-58520	figure	_	
250-3	58521-58528	depicts	_	
250-4	58529-58532	the	_	
250-5	58533-58539	levels	_	
250-6	58540-58542	of	_	
250-7	58543-58553	oxygenated	_	
250-8	58554-58564	hemoglobin	_	
250-9	58565-58566	(	_	
250-10	58566-58572	μmolar	_	
250-11	58572-58573	)	_	
250-12	58574-58576	as	_	
250-13	58577-58578	a	_	
250-14	58579-58587	function	_	
250-15	58588-58590	of	_	
250-16	58591-58595	task	_	
250-17	58596-58605	condition	_	
250-18	58606-58612	during	_	
250-19	58613-58624	performance	_	
250-20	58625-58627	by	_	
250-21	58628-58633	group	_	
250-22	58634-58640	status	_	
250-23	58641-58644	and	_	
250-24	58645-58655	prefrontal	_	
250-25	58656-58664	cortical	_	
250-26	58665-58669	area	_	
250-27	58669-58670	.	_	

#Text=This figure depicts the levels of deoxygenated hemoglobin (μmolar) as a function of task condition during performance by group status and prefrontal cortical area.
251-1	58671-58675	This	_	
251-2	58676-58682	figure	_	
251-3	58683-58690	depicts	_	
251-4	58691-58694	the	_	
251-5	58695-58701	levels	_	
251-6	58702-58704	of	_	
251-7	58705-58717	deoxygenated	_	
251-8	58718-58728	hemoglobin	_	
251-9	58729-58730	(	_	
251-10	58730-58736	μmolar	_	
251-11	58736-58737	)	_	
251-12	58738-58740	as	_	
251-13	58741-58742	a	_	
251-14	58743-58751	function	_	
251-15	58752-58754	of	_	
251-16	58755-58759	task	_	
251-17	58760-58769	condition	_	
251-18	58770-58776	during	_	
251-19	58777-58788	performance	_	
251-20	58789-58791	by	_	
251-21	58792-58797	group	_	
251-22	58798-58804	status	_	
251-23	58805-58808	and	_	
251-24	58809-58819	prefrontal	_	
251-25	58820-58828	cortical	_	
251-26	58829-58833	area	_	
251-27	58833-58834	.	_	

#Text=Sample Characteristics by Group Status
#Text=Measure\tControlsn=12\tPrenatal Alcohol-Exposedn=18\tClinical Contrastn=14\tStatistic and p-Value\t \tChild’s Age [M (SD)]\t11.4 (3.1)\t10.9 (2.6)\t10.7 (2.8)\tns\t \tChild’s Gender [n (% male)]\t6 (50)\t10 (55.6)\t7 (50.0)\tns\t \tRace [n (% African American or Mixed Race with African American)]\t12 (100)\t15 (83.3)\t14 (100)\tns\t \tEthnicity [n (% Non-Hispanic)]\t12 (100)\t15 (83.3)\t13 (92.9)\tns\t \tParental Behavioral Concern [n (% yes)]\t1 (8.3)\t12 (66.7)\t13 (92.9)\tX (2) = 19.820, p < .000\t \tDevelopmental or Learning Problem [n (% yes)]\t0 (0)\t7 (38.9)\t4 (28.6)\tX (2) = 5.947, p < .051\t \tChild Protective Service Involvement [n (% yes)]\t1 (8.3)\t5 (27.8)\t2 (14.3)\tns\t \tPlacement\t\t\t\tX (4) = 11.020, p < .026\t \t Biological Parent [n (% yes)]\t12 (100.0)\t9 (50.0)\t12 (85.7)\t\t \t Kinship Care [n (% yes)]\t0 (0.0)\t6 (33.3)\t1 (7.1)\t\t \t Legal Guardian/Adoptive Parent [n (% yes)]\t0 (0.0)\t3 (16.7)\t1 (7.1)\t\t \tDAS GCA1\t92.8 (9.1)\t87.8 (13.2)\t78.3 (12.7)\tF (2, 41) = 4.94, p < .012\t \t
#Text=DAS GCA refers to the Differential Ability Scale’s General Conceptual Ability score, which is measure of overall intelligence with a Mean of 100 and standard deviation of 15.
252-1	58835-58841	Sample	_	
252-2	58842-58857	Characteristics	_	
252-3	58858-58860	by	_	
252-4	58861-58866	Group	_	
252-5	58867-58873	Status	_	
252-6	58874-58881	Measure	_	
252-7	58882-58891	Controlsn	_	
252-8	58891-58892	=	_	
252-9	58892-58894	12	_	
252-10	58895-58903	Prenatal	_	
252-11	58904-58920	Alcohol-Exposedn	_	
252-12	58920-58921	=	_	
252-13	58921-58923	18	_	
252-14	58924-58932	Clinical	_	
252-15	58933-58942	Contrastn	_	
252-16	58942-58943	=	_	
252-17	58943-58945	14	_	
252-18	58946-58955	Statistic	_	
252-19	58956-58959	and	_	
252-20	58960-58967	p-Value	_	
252-21	58970-58975	Child	_	
252-22	58975-58976	’	_	
252-23	58976-58977	s	_	
252-24	58978-58981	Age	_	
252-25	58982-58983	[	_	
252-26	58983-58984	M	_	
252-27	58985-58986	(	_	
252-28	58986-58988	SD	_	
252-29	58988-58989	)	_	
252-30	58989-58990	]	_	
252-31	58991-58995	11.4	_	
252-32	58996-58997	(	_	
252-33	58997-59000	3.1	_	
252-34	59000-59001	)	_	
252-35	59002-59006	10.9	_	
252-36	59007-59008	(	_	
252-37	59008-59011	2.6	_	
252-38	59011-59012	)	_	
252-39	59013-59017	10.7	_	
252-40	59018-59019	(	_	
252-41	59019-59022	2.8	_	
252-42	59022-59023	)	_	
252-43	59024-59026	ns	_	
252-44	59029-59034	Child	_	
252-45	59034-59035	’	_	
252-46	59035-59036	s	_	
252-47	59037-59043	Gender	_	
252-48	59044-59045	[	_	
252-49	59045-59046	n	_	
252-50	59047-59048	(	_	
252-51	59048-59049	%	_	
252-52	59050-59054	male	_	
252-53	59054-59055	)	_	
252-54	59055-59056	]	_	
252-55	59057-59058	6	_	
252-56	59059-59060	(	_	
252-57	59060-59062	50	_	
252-58	59062-59063	)	_	
252-59	59064-59066	10	_	
252-60	59067-59068	(	_	
252-61	59068-59072	55.6	_	
252-62	59072-59073	)	_	
252-63	59074-59075	7	_	
252-64	59076-59077	(	_	
252-65	59077-59081	50.0	_	
252-66	59081-59082	)	_	
252-67	59083-59085	ns	_	
252-68	59088-59092	Race	_	
252-69	59093-59094	[	_	
252-70	59094-59095	n	_	
252-71	59096-59097	(	_	
252-72	59097-59098	%	_	
252-73	59099-59106	African	_	
252-74	59107-59115	American	_	
252-75	59116-59118	or	_	
252-76	59119-59124	Mixed	_	
252-77	59125-59129	Race	_	
252-78	59130-59134	with	_	
252-79	59135-59142	African	_	
252-80	59143-59151	American	_	
252-81	59151-59152	)	_	
252-82	59152-59153	]	_	
252-83	59154-59156	12	_	
252-84	59157-59158	(	_	
252-85	59158-59161	100	_	
252-86	59161-59162	)	_	
252-87	59163-59165	15	_	
252-88	59166-59167	(	_	
252-89	59167-59171	83.3	_	
252-90	59171-59172	)	_	
252-91	59173-59175	14	_	
252-92	59176-59177	(	_	
252-93	59177-59180	100	_	
252-94	59180-59181	)	_	
252-95	59182-59184	ns	_	
252-96	59187-59196	Ethnicity	_	
252-97	59197-59198	[	_	
252-98	59198-59199	n	_	
252-99	59200-59201	(	_	
252-100	59201-59202	%	_	
252-101	59203-59215	Non-Hispanic	_	
252-102	59215-59216	)	_	
252-103	59216-59217	]	_	
252-104	59218-59220	12	_	
252-105	59221-59222	(	_	
252-106	59222-59225	100	_	
252-107	59225-59226	)	_	
252-108	59227-59229	15	_	
252-109	59230-59231	(	_	
252-110	59231-59235	83.3	_	
252-111	59235-59236	)	_	
252-112	59237-59239	13	_	
252-113	59240-59241	(	_	
252-114	59241-59245	92.9	_	
252-115	59245-59246	)	_	
252-116	59247-59249	ns	_	
252-117	59252-59260	Parental	_	
252-118	59261-59271	Behavioral	_	
252-119	59272-59279	Concern	_	
252-120	59280-59281	[	_	
252-121	59281-59282	n	_	
252-122	59283-59284	(	_	
252-123	59284-59285	%	_	
252-124	59286-59289	yes	_	
252-125	59289-59290	)	_	
252-126	59290-59291	]	_	
252-127	59292-59293	1	_	
252-128	59294-59295	(	_	
252-129	59295-59298	8.3	_	
252-130	59298-59299	)	_	
252-131	59300-59302	12	_	
252-132	59303-59304	(	_	
252-133	59304-59308	66.7	_	
252-134	59308-59309	)	_	
252-135	59310-59312	13	_	
252-136	59313-59314	(	_	
252-137	59314-59318	92.9	_	
252-138	59318-59319	)	_	
252-139	59320-59321	X	_	
252-140	59322-59323	(	_	
252-141	59323-59324	2	_	
252-142	59324-59325	)	_	
252-143	59326-59327	=	_	
252-144	59328-59334	19.820	_	
252-145	59334-59335	,	_	
252-146	59336-59337	p	_	
252-147	59338-59339	<	_	
252-148	59340-59344	.000	_	
252-149	59347-59360	Developmental	_	
252-150	59361-59363	or	_	
252-151	59364-59372	Learning	_	
252-152	59373-59380	Problem	_	
252-153	59381-59382	[	_	
252-154	59382-59383	n	_	
252-155	59384-59385	(	_	
252-156	59385-59386	%	_	
252-157	59387-59390	yes	_	
252-158	59390-59391	)	_	
252-159	59391-59392	]	_	
252-160	59393-59394	0	_	
252-161	59395-59396	(	_	
252-162	59396-59397	0	_	
252-163	59397-59398	)	_	
252-164	59399-59400	7	_	
252-165	59401-59402	(	_	
252-166	59402-59406	38.9	_	
252-167	59406-59407	)	_	
252-168	59408-59409	4	_	
252-169	59410-59411	(	_	
252-170	59411-59415	28.6	_	
252-171	59415-59416	)	_	
252-172	59417-59418	X	_	
252-173	59419-59420	(	_	
252-174	59420-59421	2	_	
252-175	59421-59422	)	_	
252-176	59423-59424	=	_	
252-177	59425-59430	5.947	_	
252-178	59430-59431	,	_	
252-179	59432-59433	p	_	
252-180	59434-59435	<	_	
252-181	59436-59440	.051	_	
252-182	59443-59448	Child	_	
252-183	59449-59459	Protective	_	
252-184	59460-59467	Service	_	
252-185	59468-59479	Involvement	_	
252-186	59480-59481	[	_	
252-187	59481-59482	n	_	
252-188	59483-59484	(	_	
252-189	59484-59485	%	_	
252-190	59486-59489	yes	_	
252-191	59489-59490	)	_	
252-192	59490-59491	]	_	
252-193	59492-59493	1	_	
252-194	59494-59495	(	_	
252-195	59495-59498	8.3	_	
252-196	59498-59499	)	_	
252-197	59500-59501	5	_	
252-198	59502-59503	(	_	
252-199	59503-59507	27.8	_	
252-200	59507-59508	)	_	
252-201	59509-59510	2	_	
252-202	59511-59512	(	_	
252-203	59512-59516	14.3	_	
252-204	59516-59517	)	_	
252-205	59518-59520	ns	_	
252-206	59523-59532	Placement	_	
252-207	59536-59537	X	_	
252-208	59538-59539	(	_	
252-209	59539-59540	4	_	
252-210	59540-59541	)	_	
252-211	59542-59543	=	_	
252-212	59544-59550	11.020	_	
252-213	59550-59551	,	_	
252-214	59552-59553	p	_	
252-215	59554-59555	<	_	
252-216	59556-59560	.026	_	
252-217	59564-59574	Biological	_	
252-218	59575-59581	Parent	_	
252-219	59582-59583	[	_	
252-220	59583-59584	n	_	
252-221	59585-59586	(	_	
252-222	59586-59587	%	_	
252-223	59588-59591	yes	_	
252-224	59591-59592	)	_	
252-225	59592-59593	]	_	
252-226	59594-59596	12	_	
252-227	59597-59598	(	_	
252-228	59598-59603	100.0	_	
252-229	59603-59604	)	_	
252-230	59605-59606	9	_	
252-231	59607-59608	(	_	
252-232	59608-59612	50.0	_	
252-233	59612-59613	)	_	
252-234	59614-59616	12	_	
252-235	59617-59618	(	_	
252-236	59618-59622	85.7	_	
252-237	59622-59623	)	_	
252-238	59628-59635	Kinship	_	
252-239	59636-59640	Care	_	
252-240	59641-59642	[	_	
252-241	59642-59643	n	_	
252-242	59644-59645	(	_	
252-243	59645-59646	%	_	
252-244	59647-59650	yes	_	
252-245	59650-59651	)	_	
252-246	59651-59652	]	_	
252-247	59653-59654	0	_	
252-248	59655-59656	(	_	
252-249	59656-59659	0.0	_	
252-250	59659-59660	)	_	
252-251	59661-59662	6	_	
252-252	59663-59664	(	_	
252-253	59664-59668	33.3	_	
252-254	59668-59669	)	_	
252-255	59670-59671	1	_	
252-256	59672-59673	(	_	
252-257	59673-59676	7.1	_	
252-258	59676-59677	)	_	
252-259	59682-59687	Legal	_	
252-260	59688-59696	Guardian	_	
252-261	59696-59697	/	_	
252-262	59697-59705	Adoptive	_	
252-263	59706-59712	Parent	_	
252-264	59713-59714	[	_	
252-265	59714-59715	n	_	
252-266	59716-59717	(	_	
252-267	59717-59718	%	_	
252-268	59719-59722	yes	_	
252-269	59722-59723	)	_	
252-270	59723-59724	]	_	
252-271	59725-59726	0	_	
252-272	59727-59728	(	_	
252-273	59728-59731	0.0	_	
252-274	59731-59732	)	_	
252-275	59733-59734	3	_	
252-276	59735-59736	(	_	
252-277	59736-59740	16.7	_	
252-278	59740-59741	)	_	
252-279	59742-59743	1	_	
252-280	59744-59745	(	_	
252-281	59745-59748	7.1	_	
252-282	59748-59749	)	_	
252-283	59753-59756	DAS	_	
252-284	59757-59761	GCA1	_	
252-285	59762-59766	92.8	_	
252-286	59767-59768	(	_	
252-287	59768-59771	9.1	_	
252-288	59771-59772	)	_	
252-289	59773-59777	87.8	_	
252-290	59778-59779	(	_	
252-291	59779-59783	13.2	_	
252-292	59783-59784	)	_	
252-293	59785-59789	78.3	_	
252-294	59790-59791	(	_	
252-295	59791-59795	12.7	_	
252-296	59795-59796	)	_	
252-297	59797-59798	F	_	
252-298	59799-59800	(	_	
252-299	59800-59801	2	_	
252-300	59801-59802	,	_	
252-301	59803-59805	41	_	
252-302	59805-59806	)	_	
252-303	59807-59808	=	_	
252-304	59809-59813	4.94	_	
252-305	59813-59814	,	_	
252-306	59815-59816	p	_	
252-307	59817-59818	<	_	
252-308	59819-59823	.012	_	
252-309	59827-59830	DAS	_	
252-310	59831-59834	GCA	_	
252-311	59835-59841	refers	_	
252-312	59842-59844	to	_	
252-313	59845-59848	the	_	
252-314	59849-59861	Differential	_	
252-315	59862-59869	Ability	_	
252-316	59870-59875	Scale	_	
252-317	59875-59876	’	_	
252-318	59876-59877	s	_	
252-319	59878-59885	General	_	
252-320	59886-59896	Conceptual	_	
252-321	59897-59904	Ability	_	
252-322	59905-59910	score	_	
252-323	59910-59911	,	_	
252-324	59912-59917	which	_	
252-325	59918-59920	is	_	
252-326	59921-59928	measure	_	
252-327	59929-59931	of	_	
252-328	59932-59939	overall	_	
252-329	59940-59952	intelligence	_	
252-330	59953-59957	with	_	
252-331	59958-59959	a	_	
252-332	59960-59964	Mean	_	
252-333	59965-59967	of	_	
252-334	59968-59971	100	_	
252-335	59972-59975	and	_	
252-336	59976-59984	standard	_	
252-337	59985-59994	deviation	_	
252-338	59995-59997	of	_	
252-339	59998-60000	15	_	
252-340	60000-60001	.	_	

#Text=Mean and Standard Error of Change in Oxygenated Hemoglobin (HBO) by Group Status (μmolar)
#Text=\tControls\tPrenatal Alcohol-Exposed\tClinical Contrast\tStatistical effect\t \tLateral Left\t.309 (.014)\t.256 (.010)\t.282 (.012)\tF (2, 8352.206) = 5.086, p < .006PAE < Controls; Clinical Contrast= Controls, PAE\t \tLateral Right\t−.031 (.019)\t.174 (.015)\t.268 (.017)\tF (2, 9114.632) = 75.292, p < .000Controls < PAE < Clinical Contrast\t \tMedial Mean\t.218 (.016)\t.166 (.012)\t.240 (.014)\tF (2, 9107.268) = 8.699, p < .000PAE < Controls, Clinical Contrast\t \t
#Text=Mean and Standard Error of Change in Deoxygenated Hemoglobin (HBR) by Group Status (μmolar)
#Text=\tControls\tPrenatal Alcohol-Exposed\tClinical Contrast\tStatistical effect\t \tLateral Left\t−.701 (.028)\t−.572 (.021)\t−.760 (.026)\tGroup: F (2, 8009.136) = 17.465, p < .000PAE > Clinical Contrast, Controls\t \tLateral Right\t−.792 (.032)\t−.612 (.025)\t−.778 (.029)\tGroup: F (2, 8865.029) = 13.736, p < .000PAE > Clinical Contrast, Controls\t \tMedial Mean\t−.673 (.028)\t−.538 (.022)\t−.628 (.025)\tGroup: F (2, 8516.959) = 8.003, p < .000PAE > Clinical Contrast, Controls\t \t
#Text=Highlights
#Text=Prefrontal cortex (PFC) activity, using fNIRS, discriminated children with prenatal alcohol exposure (PAE) from contrast groups.
253-1	60002-60006	Mean	_	
253-2	60007-60010	and	_	
253-3	60011-60019	Standard	_	
253-4	60020-60025	Error	_	
253-5	60026-60028	of	_	
253-6	60029-60035	Change	_	
253-7	60036-60038	in	_	
253-8	60039-60049	Oxygenated	_	
253-9	60050-60060	Hemoglobin	_	
253-10	60061-60062	(	_	
253-11	60062-60065	HBO	_	
253-12	60065-60066	)	_	
253-13	60067-60069	by	_	
253-14	60070-60075	Group	_	
253-15	60076-60082	Status	_	
253-16	60083-60084	(	_	
253-17	60084-60090	μmolar	_	
253-18	60090-60091	)	_	
253-19	60093-60101	Controls	_	
253-20	60102-60110	Prenatal	_	
253-21	60111-60126	Alcohol-Exposed	_	
253-22	60127-60135	Clinical	_	
253-23	60136-60144	Contrast	_	
253-24	60145-60156	Statistical	_	
253-25	60157-60163	effect	_	
253-26	60166-60173	Lateral	_	
253-27	60174-60178	Left	_	
253-28	60179-60183	.309	_	
253-29	60184-60185	(	_	
253-30	60185-60189	.014	_	
253-31	60189-60190	)	_	
253-32	60191-60195	.256	_	
253-33	60196-60197	(	_	
253-34	60197-60201	.010	_	
253-35	60201-60202	)	_	
253-36	60203-60207	.282	_	
253-37	60208-60209	(	_	
253-38	60209-60213	.012	_	
253-39	60213-60214	)	_	
253-40	60215-60216	F	_	
253-41	60217-60218	(	_	
253-42	60218-60219	2	_	
253-43	60219-60220	,	_	
253-44	60221-60229	8352.206	_	
253-45	60229-60230	)	_	
253-46	60231-60232	=	_	
253-47	60233-60238	5.086	_	
253-48	60238-60239	,	_	
253-49	60240-60241	p	_	
253-50	60242-60243	<	_	
253-51	60244-60251	.006PAE	_	
253-52	60252-60253	<	_	
253-53	60254-60262	Controls	_	
253-54	60262-60263	;	_	
253-55	60264-60272	Clinical	_	
253-56	60273-60281	Contrast	_	
253-57	60281-60282	=	_	
253-58	60283-60291	Controls	_	
253-59	60291-60292	,	_	
253-60	60293-60296	PAE	_	
253-61	60299-60306	Lateral	_	
253-62	60307-60312	Right	_	
253-63	60313-60314	−	_	
253-64	60314-60318	.031	_	
253-65	60319-60320	(	_	
253-66	60320-60324	.019	_	
253-67	60324-60325	)	_	
253-68	60326-60330	.174	_	
253-69	60331-60332	(	_	
253-70	60332-60336	.015	_	
253-71	60336-60337	)	_	
253-72	60338-60342	.268	_	
253-73	60343-60344	(	_	
253-74	60344-60348	.017	_	
253-75	60348-60349	)	_	
253-76	60350-60351	F	_	
253-77	60352-60353	(	_	
253-78	60353-60354	2	_	
253-79	60354-60355	,	_	
253-80	60356-60364	9114.632	_	
253-81	60364-60365	)	_	
253-82	60366-60367	=	_	
253-83	60368-60374	75.292	_	
253-84	60374-60375	,	_	
253-85	60376-60377	p	_	
253-86	60378-60379	<	_	
253-87	60380-60392	.000Controls	_	
253-88	60393-60394	<	_	
253-89	60395-60398	PAE	_	
253-90	60399-60400	<	_	
253-91	60401-60409	Clinical	_	
253-92	60410-60418	Contrast	_	
253-93	60421-60427	Medial	_	
253-94	60428-60432	Mean	_	
253-95	60433-60437	.218	_	
253-96	60438-60439	(	_	
253-97	60439-60443	.016	_	
253-98	60443-60444	)	_	
253-99	60445-60449	.166	_	
253-100	60450-60451	(	_	
253-101	60451-60455	.012	_	
253-102	60455-60456	)	_	
253-103	60457-60461	.240	_	
253-104	60462-60463	(	_	
253-105	60463-60467	.014	_	
253-106	60467-60468	)	_	
253-107	60469-60470	F	_	
253-108	60471-60472	(	_	
253-109	60472-60473	2	_	
253-110	60473-60474	,	_	
253-111	60475-60483	9107.268	_	
253-112	60483-60484	)	_	
253-113	60485-60486	=	_	
253-114	60487-60492	8.699	_	
253-115	60492-60493	,	_	
253-116	60494-60495	p	_	
253-117	60496-60497	<	_	
253-118	60498-60505	.000PAE	_	
253-119	60506-60507	<	_	
253-120	60508-60516	Controls	_	
253-121	60516-60517	,	_	
253-122	60518-60526	Clinical	_	
253-123	60527-60535	Contrast	_	
253-124	60539-60543	Mean	_	
253-125	60544-60547	and	_	
253-126	60548-60556	Standard	_	
253-127	60557-60562	Error	_	
253-128	60563-60565	of	_	
253-129	60566-60572	Change	_	
253-130	60573-60575	in	_	
253-131	60576-60588	Deoxygenated	_	
253-132	60589-60599	Hemoglobin	_	
253-133	60600-60601	(	_	
253-134	60601-60604	HBR	_	
253-135	60604-60605	)	_	
253-136	60606-60608	by	_	
253-137	60609-60614	Group	_	
253-138	60615-60621	Status	_	
253-139	60622-60623	(	_	
253-140	60623-60629	μmolar	_	
253-141	60629-60630	)	_	
253-142	60632-60640	Controls	_	
253-143	60641-60649	Prenatal	_	
253-144	60650-60665	Alcohol-Exposed	_	
253-145	60666-60674	Clinical	_	
253-146	60675-60683	Contrast	_	
253-147	60684-60695	Statistical	_	
253-148	60696-60702	effect	_	
253-149	60705-60712	Lateral	_	
253-150	60713-60717	Left	_	
253-151	60718-60719	−	_	
253-152	60719-60723	.701	_	
253-153	60724-60725	(	_	
253-154	60725-60729	.028	_	
253-155	60729-60730	)	_	
253-156	60731-60732	−	_	
253-157	60732-60736	.572	_	
253-158	60737-60738	(	_	
253-159	60738-60742	.021	_	
253-160	60742-60743	)	_	
253-161	60744-60745	−	_	
253-162	60745-60749	.760	_	
253-163	60750-60751	(	_	
253-164	60751-60755	.026	_	
253-165	60755-60756	)	_	
253-166	60757-60762	Group	_	
253-167	60762-60763	:	_	
253-168	60764-60765	F	_	
253-169	60766-60767	(	_	
253-170	60767-60768	2	_	
253-171	60768-60769	,	_	
253-172	60770-60778	8009.136	_	
253-173	60778-60779	)	_	
253-174	60780-60781	=	_	
253-175	60782-60788	17.465	_	
253-176	60788-60789	,	_	
253-177	60790-60791	p	_	
253-178	60792-60793	<	_	
253-179	60794-60801	.000PAE	_	
253-180	60802-60803	>	_	
253-181	60804-60812	Clinical	_	
253-182	60813-60821	Contrast	_	
253-183	60821-60822	,	_	
253-184	60823-60831	Controls	_	
253-185	60834-60841	Lateral	_	
253-186	60842-60847	Right	_	
253-187	60848-60849	−	_	
253-188	60849-60853	.792	_	
253-189	60854-60855	(	_	
253-190	60855-60859	.032	_	
253-191	60859-60860	)	_	
253-192	60861-60862	−	_	
253-193	60862-60866	.612	_	
253-194	60867-60868	(	_	
253-195	60868-60872	.025	_	
253-196	60872-60873	)	_	
253-197	60874-60875	−	_	
253-198	60875-60879	.778	_	
253-199	60880-60881	(	_	
253-200	60881-60885	.029	_	
253-201	60885-60886	)	_	
253-202	60887-60892	Group	_	
253-203	60892-60893	:	_	
253-204	60894-60895	F	_	
253-205	60896-60897	(	_	
253-206	60897-60898	2	_	
253-207	60898-60899	,	_	
253-208	60900-60908	8865.029	_	
253-209	60908-60909	)	_	
253-210	60910-60911	=	_	
253-211	60912-60918	13.736	_	
253-212	60918-60919	,	_	
253-213	60920-60921	p	_	
253-214	60922-60923	<	_	
253-215	60924-60931	.000PAE	_	
253-216	60932-60933	>	_	
253-217	60934-60942	Clinical	_	
253-218	60943-60951	Contrast	_	
253-219	60951-60952	,	_	
253-220	60953-60961	Controls	_	
253-221	60964-60970	Medial	_	
253-222	60971-60975	Mean	_	
253-223	60976-60977	−	_	
253-224	60977-60981	.673	_	
253-225	60982-60983	(	_	
253-226	60983-60987	.028	_	
253-227	60987-60988	)	_	
253-228	60989-60990	−	_	
253-229	60990-60994	.538	_	
253-230	60995-60996	(	_	
253-231	60996-61000	.022	_	
253-232	61000-61001	)	_	
253-233	61002-61003	−	_	
253-234	61003-61007	.628	_	
253-235	61008-61009	(	_	
253-236	61009-61013	.025	_	
253-237	61013-61014	)	_	
253-238	61015-61020	Group	_	
253-239	61020-61021	:	_	
253-240	61022-61023	F	_	
253-241	61024-61025	(	_	
253-242	61025-61026	2	_	
253-243	61026-61027	,	_	
253-244	61028-61036	8516.959	_	
253-245	61036-61037	)	_	
253-246	61038-61039	=	_	
253-247	61040-61045	8.003	_	
253-248	61045-61046	,	_	
253-249	61047-61048	p	_	
253-250	61049-61050	<	_	
253-251	61051-61058	.000PAE	_	
253-252	61059-61060	>	_	
253-253	61061-61069	Clinical	_	
253-254	61070-61078	Contrast	_	
253-255	61078-61079	,	_	
253-256	61080-61088	Controls	_	
253-257	61092-61102	Highlights	_	
253-258	61103-61113	Prefrontal	_	
253-259	61114-61120	cortex	_	
253-260	61121-61122	(	_	
253-261	61122-61125	PFC	_	
253-262	61125-61126	)	_	
253-263	61127-61135	activity	_	
253-264	61135-61136	,	_	
253-265	61137-61142	using	_	
253-266	61143-61148	fNIRS	_	
253-267	61148-61149	,	_	
253-268	61150-61163	discriminated	_	
253-269	61164-61172	children	_	
253-270	61173-61177	with	_	
253-271	61178-61186	prenatal	_	
253-272	61187-61194	alcohol	_	
253-273	61195-61203	exposure	_	
253-274	61204-61205	(	_	
253-275	61205-61208	PAE	_	
253-276	61208-61209	)	_	
253-277	61210-61214	from	_	
253-278	61215-61223	contrast	_	
253-279	61224-61230	groups	_	
253-280	61230-61231	.	_	

#Text=Children with PAE had less activation in the medial PFC areas than did the contrast groups.
254-1	61232-61240	Children	_	
254-2	61241-61245	with	_	
254-3	61246-61249	PAE	_	
254-4	61250-61253	had	_	
254-5	61254-61258	less	_	
254-6	61259-61269	activation	_	
254-7	61270-61272	in	_	
254-8	61273-61276	the	_	
254-9	61277-61283	medial	_	
254-10	61284-61287	PFC	_	
254-11	61288-61293	areas	_	
254-12	61294-61298	than	_	
254-13	61299-61302	did	_	
254-14	61303-61306	the	_	
254-15	61307-61315	contrast	_	
254-16	61316-61322	groups	_	
254-17	61322-61323	.	_	

#Text=Children with PAE had greater oxygen depletion in all areas of PFC relative to the contrast groups.
255-1	61324-61332	Children	_	
255-2	61333-61337	with	_	
255-3	61338-61341	PAE	_	
255-4	61342-61345	had	_	
255-5	61346-61353	greater	_	
255-6	61354-61360	oxygen	_	
255-7	61361-61370	depletion	_	
255-8	61371-61373	in	_	
255-9	61374-61377	all	_	
255-10	61378-61383	areas	_	
255-11	61384-61386	of	_	
255-12	61387-61390	PFC	_	
255-13	61391-61399	relative	_	
255-14	61400-61402	to	_	
255-15	61403-61406	the	_	
255-16	61407-61415	contrast	_	
255-17	61416-61422	groups	_	
255-18	61422-61423	.	_	
